<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.2.475">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">


<title>Untitled</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1.6em;
  vertical-align: middle;
}
pre > code.sourceCode { white-space: pre; position: relative; }
pre > code.sourceCode > span { display: inline-block; line-height: 1.25; }
pre > code.sourceCode > span:empty { height: 1.2em; }
.sourceCode { overflow: visible; }
code.sourceCode > span { color: inherit; text-decoration: inherit; }
div.sourceCode { margin: 1em 0; }
pre.sourceCode { margin: 0; }
@media screen {
div.sourceCode { overflow: auto; }
}
@media print {
pre > code.sourceCode { white-space: pre-wrap; }
pre > code.sourceCode > span { text-indent: -5em; padding-left: 5em; }
}
pre.numberSource code
  { counter-reset: source-line 0; }
pre.numberSource code > span
  { position: relative; left: -4em; counter-increment: source-line; }
pre.numberSource code > span > a:first-child::before
  { content: counter(source-line);
    position: relative; left: -1em; text-align: right; vertical-align: baseline;
    border: none; display: inline-block;
    -webkit-touch-callout: none; -webkit-user-select: none;
    -khtml-user-select: none; -moz-user-select: none;
    -ms-user-select: none; user-select: none;
    padding: 0 4px; width: 4em;
    color: #aaaaaa;
  }
pre.numberSource { margin-left: 3em; border-left: 1px solid #aaaaaa;  padding-left: 4px; }
div.sourceCode
  {   }
@media screen {
pre > code.sourceCode > span > a:first-child::before { text-decoration: underline; }
}
code span.al { color: #ff0000; font-weight: bold; } /* Alert */
code span.an { color: #60a0b0; font-weight: bold; font-style: italic; } /* Annotation */
code span.at { color: #7d9029; } /* Attribute */
code span.bn { color: #40a070; } /* BaseN */
code span.bu { color: #008000; } /* BuiltIn */
code span.cf { color: #007020; font-weight: bold; } /* ControlFlow */
code span.ch { color: #4070a0; } /* Char */
code span.cn { color: #880000; } /* Constant */
code span.co { color: #60a0b0; font-style: italic; } /* Comment */
code span.cv { color: #60a0b0; font-weight: bold; font-style: italic; } /* CommentVar */
code span.do { color: #ba2121; font-style: italic; } /* Documentation */
code span.dt { color: #902000; } /* DataType */
code span.dv { color: #40a070; } /* DecVal */
code span.er { color: #ff0000; font-weight: bold; } /* Error */
code span.ex { } /* Extension */
code span.fl { color: #40a070; } /* Float */
code span.fu { color: #06287e; } /* Function */
code span.im { color: #008000; font-weight: bold; } /* Import */
code span.in { color: #60a0b0; font-weight: bold; font-style: italic; } /* Information */
code span.kw { color: #007020; font-weight: bold; } /* Keyword */
code span.op { color: #666666; } /* Operator */
code span.ot { color: #007020; } /* Other */
code span.pp { color: #bc7a00; } /* Preprocessor */
code span.sc { color: #4070a0; } /* SpecialChar */
code span.ss { color: #bb6688; } /* SpecialString */
code span.st { color: #4070a0; } /* String */
code span.va { color: #19177c; } /* Variable */
code span.vs { color: #4070a0; } /* VerbatimString */
code span.wa { color: #60a0b0; font-weight: bold; font-style: italic; } /* Warning */
</style>


<script src="OncologSideEffects_quarto_files/libs/clipboard/clipboard.min.js"></script>
<script src="OncologSideEffects_quarto_files/libs/quarto-html/quarto.js"></script>
<script src="OncologSideEffects_quarto_files/libs/quarto-html/popper.min.js"></script>
<script src="OncologSideEffects_quarto_files/libs/quarto-html/tippy.umd.min.js"></script>
<script src="OncologSideEffects_quarto_files/libs/quarto-html/anchor.min.js"></script>
<link href="OncologSideEffects_quarto_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="OncologSideEffects_quarto_files/libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="OncologSideEffects_quarto_files/libs/bootstrap/bootstrap.min.js"></script>
<link href="OncologSideEffects_quarto_files/libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="OncologSideEffects_quarto_files/libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">
<script src="OncologSideEffects_quarto_files/libs/htmlwidgets-1.6.2/htmlwidgets.js"></script>
<script src="OncologSideEffects_quarto_files/libs/plotly-binding-4.10.1/plotly.js"></script>
<script src="OncologSideEffects_quarto_files/libs/typedarray-0.1/typedarray.min.js"></script>
<script src="OncologSideEffects_quarto_files/libs/jquery-3.5.1/jquery.min.js"></script>
<link href="OncologSideEffects_quarto_files/libs/crosstalk-1.2.0/css/crosstalk.min.css" rel="stylesheet">
<script src="OncologSideEffects_quarto_files/libs/crosstalk-1.2.0/js/crosstalk.min.js"></script>
<link href="OncologSideEffects_quarto_files/libs/plotly-htmlwidgets-css-2.11.1/plotly-htmlwidgets.css" rel="stylesheet">
<script src="OncologSideEffects_quarto_files/libs/plotly-main-2.11.1/plotly-latest.min.js"></script>


</head>

<body class="fullcontent">

<div id="quarto-content" class="page-columns page-rows-contents page-layout-article">

<main class="content" id="quarto-document-content">

<header id="title-block-header" class="quarto-title-block default">
<div class="quarto-title">
<h1 class="title">Untitled</h1>
</div>



<div class="quarto-title-meta">

    
  
    
  </div>
  

</header>

<div class="cell">

</div>
<section id="quarto" class="level2">
<h2 class="anchored" data-anchor-id="quarto">Quarto</h2>
<p>Quarto enables you to <strong>weave</strong> together content and executable code into a finished document. To learn more about Quarto see <a href="https://quarto.org" class="uri">https://quarto.org</a>.</p>
<div class="cell">

</div>
<div class="cell">
<details>
<summary>Code</summary>
<div class="sourceCode cell-code" id="cb1"><pre class="sourceCode r code-with-copy"><code class="sourceCode r"><span id="cb1-1"><a href="#cb1-1" aria-hidden="true" tabindex="-1"></a>fig1<span class="fl">.1</span> <span class="ot">&lt;-</span> xlsx_wide <span class="sc">|&gt;</span> </span>
<span id="cb1-2"><a href="#cb1-2" aria-hidden="true" tabindex="-1"></a>   <span class="fu">left_join</span>(<span class="fu">select</span>(trials, drugs, id), <span class="at">by =</span> <span class="st">"id"</span>) <span class="sc">|&gt;</span> </span>
<span id="cb1-3"><a href="#cb1-3" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(<span class="at">greater =</span> <span class="fu">ifelse</span>(Experimental <span class="sc">&gt;</span> Control, <span class="st">"experi"</span>, <span class="st">"control"</span>), </span>
<span id="cb1-4"><a href="#cb1-4" aria-hidden="true" tabindex="-1"></a>         <span class="at">event =</span> <span class="fu">paste0</span>(drugs, <span class="st">", "</span>, adverse, <span class="st">", "</span>, starified)) <span class="sc">|&gt;</span> </span>
<span id="cb1-5"><a href="#cb1-5" aria-hidden="true" tabindex="-1"></a> </span>
<span id="cb1-6"><a href="#cb1-6" aria-hidden="true" tabindex="-1"></a>  <span class="fu">ggplot</span>(<span class="fu">aes</span>(<span class="at">y =</span> Experimental, <span class="at">x =</span> Control, <span class="at">color =</span> greater, <span class="at">key =</span> event)) <span class="sc">+</span></span>
<span id="cb1-7"><a href="#cb1-7" aria-hidden="true" tabindex="-1"></a>    <span class="fu">geom_abline</span>(<span class="at">intercept =</span> <span class="dv">0</span>, <span class="at">color =</span> <span class="st">"grey"</span>, <span class="at">linewidth =</span> <span class="dv">1</span>) <span class="sc">+</span></span>
<span id="cb1-8"><a href="#cb1-8" aria-hidden="true" tabindex="-1"></a>  <span class="fu">geom_point</span>(<span class="at">alpha =</span> <span class="fl">0.55</span>) <span class="sc">+</span></span>
<span id="cb1-9"><a href="#cb1-9" aria-hidden="true" tabindex="-1"></a>  <span class="fu">scale_color_manual</span>(<span class="at">values  =</span> <span class="fu">c</span>( <span class="st">"#373F51"</span>, <span class="st">"#E49273"</span>), </span>
<span id="cb1-10"><a href="#cb1-10" aria-hidden="true" tabindex="-1"></a>                     <span class="at">aesthetics =</span> <span class="st">"color"</span>) <span class="sc">+</span></span>
<span id="cb1-11"><a href="#cb1-11" aria-hidden="true" tabindex="-1"></a>  <span class="fu">scale_y_percent</span>(<span class="at">limits =</span> <span class="fu">c</span>(<span class="dv">0</span>,<span class="dv">1</span>))<span class="sc">+</span></span>
<span id="cb1-12"><a href="#cb1-12" aria-hidden="true" tabindex="-1"></a>  <span class="fu">scale_x_percent</span>(<span class="at">limits =</span> <span class="fu">c</span>(<span class="dv">0</span>,<span class="dv">1</span>))<span class="sc">+</span></span>
<span id="cb1-13"><a href="#cb1-13" aria-hidden="true" tabindex="-1"></a>  <span class="fu">labs</span>(<span class="at">title =</span> <span class="st">"Adverse Events, all reported"</span>) <span class="sc">+</span></span>
<span id="cb1-14"><a href="#cb1-14" aria-hidden="true" tabindex="-1"></a>  <span class="fu">theme_minimal</span>(<span class="at">base_family =</span> <span class="st">"Roboto Condensed"</span>) <span class="sc">+</span></span>
<span id="cb1-15"><a href="#cb1-15" aria-hidden="true" tabindex="-1"></a>  <span class="fu">theme</span>(<span class="at">legend.position =</span> <span class="st">"none"</span>, </span>
<span id="cb1-16"><a href="#cb1-16" aria-hidden="true" tabindex="-1"></a>        <span class="co"># axis.line.x = element_line(color = "red"), </span></span>
<span id="cb1-17"><a href="#cb1-17" aria-hidden="true" tabindex="-1"></a>        <span class="at">axis.ticks.x =</span> <span class="fu">element_blank</span>())</span>
<span id="cb1-18"><a href="#cb1-18" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb1-19"><a href="#cb1-19" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb1-20"><a href="#cb1-20" aria-hidden="true" tabindex="-1"></a><span class="fu">ggplotly</span>(fig1<span class="fl">.1</span>)</span></code><button title="Copy to Clipboard" class="code-copy-button"><i class="bi"></i></button></pre></div>
</details>
<div class="cell-output-display">
<div class="plotly html-widget html-fill-item-overflow-hidden html-fill-item" id="htmlwidget-5811bb751e27bf0cf46c" style="width:100%;height:464px;"></div>
<script type="application/json" data-for="htmlwidget-5811bb751e27bf0cf46c">{"x":{"data":[{"x":[-0.01,1.01],"y":[-0.01,1.01],"text":"intercept: 0<br />slope: 1","type":"scatter","mode":"lines","line":{"width":3.77952755905512,"color":"rgba(190,190,190,1)","dash":"solid"},"hoveron":"points","showlegend":false,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null},{"x":[0,0.005,0.01,0.01,0,0.015,0,0,0,0.003,0.005,0.6,0.33,0.27,0.54,0.16,0.14,0.29,0.38,0.16,0.24,0.21,0.44,0.42,0.009,0.011,0.005,0,0.009,0.016,0.03,0.016,0.002,0.018,0.005,0,0.009,0.21,0.03,0.02,0,0,0,0.01,0,0,0,0,0.27,0.12,0.01,0,0,0,0.3,0.18,0.33,0.21,0.05,0,0,0.009,0.013,0.018,0,0.19,0.28,0.26,0.2,0.21,0.22,0.14,0.11,0.012,0.11,0.006,0.037,0.13,0,0.009,0,0.24,0.1,0.003,0.021,0.015,0.006,0.015,0.003,0,0,0,0,0.006,0.015,0.009,0.006,0.43,0.36,0,0,0,0,0,0.45,0.24,0.14,0.57,0.18,0.3,0.04,0,0.12,0.003,0.06,0.003,0,0.43,0.18,0.11,0.06,0.018,0.029,0.02,0.018,0,0,0.003,0.006,0.014,0.13,0.23,0.29,0.017,0.006,0,0.047,0,0.05,0.38,0.57,0,0.41,0.29,0.21,0.23,0.16,0.18,0.21,0.12,0.11,0.12,0.11,0.11,0.1,0.12,0.49,0.64,0.03,0.02,0.03,0.03,0,0,0.04,0,0.02,0.02,0.21,0.01,0,0,0.01,0,0,0,0.07,0,0.02,0.03,0.04,0.01,0,0,0.05,0.05,0,0.003,0,0.001,0,0.01,0,0.01,0.01,0.01,0.01,0.01,0,0,0.01,0,0,0,0.13,0,0.58,0.44,0.33,0.27,0.26,0.06,0,0.026,0.01,0.013,0.11,0,0,0.05,0.02,0,0.03,0,0,0,0.1,0.15,0.15,0.13,0.23,0.16,0,0.003,0.003,0.009,0.09,0.006,0,0,0,0.003,0.42,0.31,0.003,0.008,0,0.01,0.29,0.2,0.16,0.17,0.16,0.12,0.21,0.12,0.015,0.012,0.035,0.004,0,0.015,0.004,0.008,0,0.4,0.24,0.07,0,0.05,0.05,0.19,0.25,0,0,0.003,0,0,0.49,0.47,0.35,0.23,0.018,0.018,0.032,0.011,0.004,0.007,0.06,0.01,0.01,0.01,0,0.25,0.32,0.18,0.01,0.032,0.021,0.025,0,0.71,0.01,0,0,0,0.01,0.14,0,0,0,0,0.047,0.023,0,0,0,0.023,0,0,0,0.019,0.01,0.01,0.004,0.01,0.004,0.036,0.005,0,0.01,0,0,0,0,0,0,0,0,0,0,0,0,0,0.11,0.01,0.03,0.049,0.003,0,0.003,0,0,0.003,0,0.01,0.003,0.16,0.14,0,0,0.011,0.004,0.004,0.005,0,0,0.019,0.006,0.003,0,0.45,0.13,0.23,0.15,0.011,0.011,0.006,0.023,0,0,0,0,0,0.036,0.027,0.009,0.3,0.71,0.46,0.24,0.013,0,0.013,0.08,0.11,0.026,0,0,0,0.001,0,0,0,0,0,0,0,0,0,0,0,0.12,0.15,0.13,0.13,0.16,0.05,0.02,0.01,0.07,0.02,0,0.01,0.02,0.01,0.26,0.13,0.34,0.14,0.2,0.34,0.32,0.28,0.18,0.43,0.19,0.02,0.1,0.02,0.01,0,0.01,0.01,0,0,0,0.01,0.01,0,0,0.09,0.14,0.43,0.38,0.02,0.04,0,0.01,0.006,0,0,0,0.02,0,0.02,0.09,0.02,0.004,0,0.01,0,0.02,0,0,0.004,0,0.004,0,0,0,0,0,0.016,0,0,0,0,0,1,0.54,0.23,0.52,0.41,0.22,0.72,0.11,0.04,0.02,0.02,0.01,0.02,0.15,0.17,0.03,0.18,0.14,0.18,0.39,0.52,0.52,0.3,0.39,0.32,0.14,0.085,0.007,0,0,0.007,0.021,0.007,0.014,0,0.028,0.014,0.014,0.035,0,0.27,0.5,0.26,0.18,0.12,0.015,0.16,0.02,0.05,0.003,0.31,0.21,0.22,0.41,0.46,0.39,0.003,0.08,0.08,0.044,0.14,0.003,0.003,0,0.006,0.003,0.01,0.04,0,0,0.32,0.15,0,0,0.032,0,0,0,0.016,0,0.47,0.09,0.25,0.21,0.15,0.14,0.004,0.023,0.015,0.008,0.015,0,0.03,0,0.023,0.023,0.004,0.008,0.24,0.2,0.13,0.22,0.43,0.11,0.007,0.013,0.007,0.013,0.007,0.007,0.007,0,0.007,0.007,0,0.07,0,0.45,0.43,0.3,0.18,0.25,0.06,0,0.025,0.007,0.021,0.032,0.014,0,0.21,0.22,0.007,0,0.017,0.026,0.006,0.006,0.28,0.35,0.19,0.2,0.26,0.19,0.19,0.27,0.3,0,0.05,0,0.005,0.014,0.09,0.005,0.005,0.048,0.13,0,0.32,0.17,0.49,0.14,0.17,0.16,0.24,0.06,0,0,0,0.026,0.05,0,0,0,0,0.038,0,0,0.41,0.23,0.006,0.006,0.009,0.009,0.57,0.58,0.33,0.44,0.42,0.16,0.11,0.058,0.4,0.48,0.15,0.15,0.2,0.18,0.14,0.23,0.11,0.088,0.19,0.53,0.029,0.029,0.036,0.022,0,0.007,0,0.007,0,0.036,0.029,0.022,0.007,0,0.015,0,0.007,0.007,0,0,0,0,0.022,0.029,0.007,0.05,0.01,0,0.34,0.22,0.12,0.34,0.19,0.019,0.008,0.042,0.004,0.42,0.27,0.18,0.005,0.025,0.005,0.023,0.007,0,0.27,0.64,0.28,0.32,0.2,0.19,0.41,0.48,0.32,0.29,0.18,0.27,0.43,0.26,0.08,0.01,0.01,0.1,0.05,0.03,0.01,0.03,0,0.03,0.02,0,0,0.01,0,0,0.34,0.19,0.17,0.11,0.34,0.32,0.019,0.011,0.011,0,0,0.008,0,0,0,0,0,0,0.006,0.003,0,0.003,0.003,0.01,0,0.006,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.003,0,0.27,0.17,0.07,0.11,0.09,0.08,0.08,0.07,0.06,0.06,0.05,0.06,0.02,0.01,0.01,0.01,0.01,0.06,0.01,0,0,0.01,0.01,0.01,0.01,0.01,0,0,0,0,0,0.01,0.01,0,0.01,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"y":[0,0,0.01,0,0,0.015,0,0,0,0.003,0,0.6,0.32,0.25,0.53,0.14,0.13,0.29,0.37,0.13,0.24,0.19,0.44,0.39,0.007,0.007,0,0,0.002,0.011,0.025,0.011,0,0.005,0.005,0,0.009,0.21,0.01,0.01,0,0,0,0.01,0,0,0,0,0.26,0.12,0,0,0,0,0.24,0.1,0.1,0.14,0.013,0,0,0.008,0,0.013,0,0.18,0.26,0.24,0.19,0.2,0.14,0.13,0.11,0.012,0.09,0.006,0.025,0.13,0,0.009,0,0.19,0.1,0,0.018,0.015,0,0.012,0,0,0,0,0,0,0.006,0.006,0,0.37,0.3,0,0,0,0,0,0.27,0.2,0.12,0.32,0.17,0.26,0.018,0,0.028,0,0.039,0.003,0,0.42,0.18,0.1,0.06,0.015,0.006,0.015,0.012,0,0,0.003,0.002,0.014,0.12,0.13,0.13,0.013,0.003,0,0,0,0,0.33,0.53,0,0.25,0.23,0.17,0.2,0.15,0.16,0.14,0.12,0.1,0.08,0.07,0.05,0.05,0.04,0.49,0.49,0.03,0,0,0.01,0,0,0.04,0,0.01,0.01,0.12,0,0,0,0.01,0,0,0,0.03,0,0,0,0.03,0,0,0,0.04,0.03,0,0.003,0,0.001,0,0.01,0,0.01,0.01,0.01,0.01,0,0,0,0,0,0,0,0.11,0,0.56,0.4,0.28,0.26,0.24,0.042,0,0.02,0.003,0.007,0.09,0,0,0.03,0.02,0,0.02,0,0,0,0.1,0.15,0.13,0.11,0.22,0.16,0,0.003,0.003,0.006,0.06,0.003,0,0,0,0.003,0.41,0.29,0,0.005,0,0.005,0.29,0.17,0.15,0.13,0.12,0.11,0.2,0.12,0.008,0.006,0.008,0.002,0,0.013,0.002,0.006,0,0.4,0.24,0.07,0,0.041,0.03,0.19,0.18,0,0,0.003,0,0,0.48,0.44,0.34,0.2,0.017,0.018,0.027,0.008,0,0.007,0.06,0.01,0.01,0.01,0,0.21,0.3,0.17,0.01,0.01,0.017,0.01,0,0.7,0.01,0,0,0,0.01,0.13,0,0,0,0,0.012,0.012,0,0,0,0.012,0,0,0,0.017,0.01,0.01,0,0.004,0,0.03,0.005,0,0.005,0,0,0,0,0,0,0,0,0,0,0,0,0,0.1,0.01,0.023,0.035,0.003,0,0,0,0,0.003,0,0.006,0.003,0.11,0.13,0,0,0.008,0,0.004,0.004,0,0,0.014,0,0.003,0,0.38,0.11,0.2,0.11,0.006,0,0.006,0.011,0,0,0,0,0,0.029,0.012,0.004,0.17,0.12,0.12,0.1,0.006,0,0.006,0.006,0,0,0,0,0,0.001,0,0,0,0,0,0,0,0,0,0,0,0.1,0.12,0.12,0.1,0.15,0.05,0.01,0.01,0.05,0.02,0,0.01,0,0.01,0.12,0.11,0.22,0.12,0.12,0.2,0.29,0.1,0.16,0.42,0.14,0,0.04,0,0,0,0,0.01,0,0,0,0,0.01,0,0,0.04,0.09,0.43,0.29,0.02,0.04,0,0.01,0,0,0,0,0.01,0,0.02,0.06,0.004,0.004,0,0.01,0,0.01,0,0,0,0,0.004,0,0,0,0,0,0.006,0,0,0,0,0,0.99,0.43,0.21,0.18,0.16,0.17,0.67,0.02,0,0.02,0.01,0,0.02,0.01,0.01,0.03,0.17,0.11,0.16,0.18,0.21,0.15,0.17,0.13,0.19,0.11,0.074,0,0,0,0,0.007,0,0.007,0,0.013,0.013,0.007,0.02,0,0.26,0.15,0.14,0.12,0.11,0.006,0.034,0.011,0.05,0,0.27,0.17,0.15,0.4,0.37,0.36,0,0.08,0.08,0.034,0.13,0.003,0.003,0,0,0.003,0.01,0.04,0,0,0.32,0.14,0,0,0.008,0,0,0,0.011,0,0.32,0.046,0.25,0.17,0.13,0.14,0.004,0.023,0.008,0.008,0.015,0,0,0,0.011,0.011,0.004,0.004,0.14,0.14,0.11,0.2,0.11,0.11,0,0,0,0.007,0.007,0,0,0,0.007,0.007,0,0.007,0,0.43,0.24,0.19,0.14,0.24,0.043,0,0.007,0.003,0,0.023,0.01,0,0.21,0.2,0,0,0.017,0.012,0.003,0.003,0.22,0.21,0.17,0.11,0.17,0.13,0.16,0.12,0.13,0,0.019,0,0,0,0.05,0,0.005,0.014,0.08,0,0.26,0.12,0.19,0.13,0.12,0.12,0.18,0.02,0,0,0,0,0.018,0,0,0,0,0.012,0,0,0.32,0.21,0.006,0.006,0.006,0.006,0.53,0.3,0.24,0.21,0.18,0.08,0.007,0.022,0.32,0.18,0.15,0.051,0.15,0.11,0.029,0.12,0.08,0.059,0.088,0.074,0.022,0.022,0.007,0.007,0,0,0,0.007,0,0.029,0.022,0.015,0.007,0,0.007,0,0,0.007,0,0,0,0,0.007,0.007,0,0.03,0.01,0,0.14,0.12,0.11,0.25,0.15,0.003,0,0.014,0,0.21,0.18,0.13,0.002,0.01,0.003,0.01,0.002,0,0.27,0.4,0.18,0.17,0.15,0.16,0.34,0.33,0.3,0.21,0.15,0.27,0.32,0.26,0.07,0.01,0.01,0.02,0.04,0.01,0,0.01,0,0.01,0,0,0,0,0,0,0.34,0.17,0.15,0.1,0.31,0.32,0.004,0,0.011,0,0,0.008,0,0,0,0,0,0,0.003,0,0,0.003,0.003,0,0,0.003,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.003,0,0.22,0.15,0.06,0.1,0.09,0.08,0.07,0.06,0.06,0.05,0.03,0.03,0.01,0.01,0.01,0.01,0.01,0.06,0.01,0,0,0.01,0.01,0.01,0.01,0.01,0,0,0,0,0,0.01,0.01,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"text":["Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: talazoparib + enzalutamide, Fatigue, Grade 4","Control: 0.005<br />Experimental: 0.000<br />greater: control<br />event: talazoparib + enzalutamide, Nausea, Grade 4","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: talazoparib + enzalutamide, Decreased appetite, Grade 3","Control: 0.010<br />Experimental: 0.000<br />greater: control<br />event: talazoparib + enzalutamide, Decreased appetite, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: talazoparib + enzalutamide, Fractures, Grade 4","Control: 0.015<br />Experimental: 0.015<br />greater: control<br />event: talazoparib + enzalutamide, Dizzy, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: talazoparib + enzalutamide, Dizzy, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: talazoparib + enzalutamide, Dysgeusiae, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: talazoparib + enzalutamide, Dysgeusiae, Grade 4","Control: 0.003<br />Experimental: 0.003<br />greater: control<br />event: olaparib + abiraterone + prednisone (or prednisolone), Nausea, Grade 3-4","Control: 0.005<br />Experimental: 0.000<br />greater: control<br />event: olaparib + abiraterone + prednisone (or prednisolone), Abdominal pain, Grade 3-4","Control: 0.600<br />Experimental: 0.600<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Neutropenia, All grades","Control: 0.330<br />Experimental: 0.320<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Thrombocytopenia, All grades","Control: 0.270<br />Experimental: 0.250<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Alanine aminotransferase increased, All grades","Control: 0.540<br />Experimental: 0.530<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Peripheral neuropathy, All grades","Control: 0.160<br />Experimental: 0.140<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Altered taste, All grades","Control: 0.140<br />Experimental: 0.130<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Headache, All grades","Control: 0.290<br />Experimental: 0.290<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Constipation, All grades","Control: 0.380<br />Experimental: 0.370<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Fatigue, All grades","Control: 0.160<br />Experimental: 0.130<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Infusion-related reaction, All grades","Control: 0.240<br />Experimental: 0.240<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Alopecia, All grades","Control: 0.210<br />Experimental: 0.190<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Musculoskeletal pain, All grades","Control: 0.440<br />Experimental: 0.440<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Lymphopenia, Grade 3-4","Control: 0.420<br />Experimental: 0.390<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Neutropenia, Grade 3-4","Control: 0.009<br />Experimental: 0.007<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Creatinine increased, Grade 3-4","Control: 0.011<br />Experimental: 0.007<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Aspartate aminotransferase increased, Grade 3-4","Control: 0.005<br />Experimental: 0.000<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Alkaline phosphatase increased, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Altered taste, Grade 3-4","Control: 0.009<br />Experimental: 0.002<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Headache, Grade 3-4","Control: 0.016<br />Experimental: 0.011<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Abdominal paind, Grade 3-4","Control: 0.030<br />Experimental: 0.025<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Fatigue, Grade 3-4","Control: 0.016<br />Experimental: 0.011<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Infusion-related reaction, Grade 3-4","Control: 0.002<br />Experimental: 0.000<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Alopecia, Grade 3-4","Control: 0.018<br />Experimental: 0.005<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Musculoskeletal pain, Grade 3-4","Control: 0.005<br />Experimental: 0.005<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Upper respiratory tract infection', Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Cough, Grade 3-4","Control: 0.009<br />Experimental: 0.009<br />greater: control<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Dyspnea, Grade 3-4","Control: 0.210<br />Experimental: 0.210<br />greater: control<br />event: sacituzumab govitecan-hziy, Decreased appetite, All grades","Control: 0.030<br />Experimental: 0.010<br />greater: control<br />event: sacituzumab govitecan-hziy, Nausea, Grade 3-4","Control: 0.020<br />Experimental: 0.010<br />greater: control<br />event: sacituzumab govitecan-hziy, Vomiting, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: sacituzumab govitecan-hziy, Abdominal Pain, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: sacituzumab govitecan-hziy, Dyspepsia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: sacituzumab govitecan-hziy, Arthralgia, Grade 3-4","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: sacituzumab govitecan-hziy, Headache, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: sacituzumab govitecan-hziy, Dyspnea, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: sacituzumab govitecan-hziy, Cough, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: sacituzumab govitecan-hziy, Alopecia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: sacituzumab govitecan-hziy, Pruritus, Grade 3-4","Control: 0.270<br />Experimental: 0.260<br />greater: control<br />event: elacestrant, Fatigue, All grades","Control: 0.120<br />Experimental: 0.120<br />greater: control<br />event: elacestrant, Headache, All grades","Control: 0.010<br />Experimental: 0.000<br />greater: control<br />event: elacestrant, Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: elacestrant, Constipation, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: elacestrant, Dyspepsia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: elacestrant, Hot flush , Grade 3-4","Control: 0.300<br />Experimental: 0.240<br />greater: control<br />event: zanubrutinib, Rash, All grades","Control: 0.180<br />Experimental: 0.100<br />greater: control<br />event: zanubrutinib, Constipation, All grades","Control: 0.330<br />Experimental: 0.100<br />greater: control<br />event: zanubrutinib, Nausea, All grades","Control: 0.210<br />Experimental: 0.140<br />greater: control<br />event: zanubrutinib, Fatigue, All grades","Control: 0.050<br />Experimental: 0.013<br />greater: control<br />event: zanubrutinib, Rash, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: zanubrutinib, Bruising, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: zanubrutinib, Coughe, Grade 3-4","Control: 0.009<br />Experimental: 0.008<br />greater: control<br />event: zanubrutinib, Diarrhea, Grade 3-4","Control: 0.013<br />Experimental: 0.000<br />greater: control<br />event: zanubrutinib, Nausea, Grade 3-4","Control: 0.018<br />Experimental: 0.013<br />greater: control<br />event: zanubrutinib, Fatigue, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: zanubrutinib, Headache, Grade 3-4","Control: 0.190<br />Experimental: 0.180<br />greater: control<br />event: zanubrutinib, Pneumonia, All grades","Control: 0.280<br />Experimental: 0.260<br />greater: control<br />event: zanubrutinib, Musculoskeletal pain, All grades","Control: 0.260<br />Experimental: 0.240<br />greater: control<br />event: zanubrutinib, Hemorrhage, All grades","Control: 0.200<br />Experimental: 0.190<br />greater: control<br />event: zanubrutinib, Hypertension, All grades","Control: 0.210<br />Experimental: 0.200<br />greater: control<br />event: zanubrutinib, Rash, All grades","Control: 0.220<br />Experimental: 0.140<br />greater: control<br />event: zanubrutinib, Diarrhea, All grades","Control: 0.140<br />Experimental: 0.130<br />greater: control<br />event: zanubrutinib, Fatigue, All grades","Control: 0.110<br />Experimental: 0.110<br />greater: control<br />event: zanubrutinib, Cough, All grades","Control: 0.012<br />Experimental: 0.012<br />greater: control<br />event: zanubrutinib, Upper respiratory tract infection, Grade 3-4","Control: 0.110<br />Experimental: 0.090<br />greater: control<br />event: zanubrutinib, Pneumonia, Grade 3-4","Control: 0.006<br />Experimental: 0.006<br />greater: control<br />event: zanubrutinib, Musculoskeletal pain, Grade 3-4","Control: 0.037<br />Experimental: 0.025<br />greater: control<br />event: zanubrutinib, Hemorrhage, Grade 3-4","Control: 0.130<br />Experimental: 0.130<br />greater: control<br />event: zanubrutinib, Hypertension, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: zanubrutinib, Bruising, Grade 3-4","Control: 0.009<br />Experimental: 0.009<br />greater: control<br />event: zanubrutinib, Fatigue, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: zanubrutinib, Dizziness, Grade 3-4","Control: 0.240<br />Experimental: 0.190<br />greater: control<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Constipation, All grades","Control: 0.100<br />Experimental: 0.100<br />greater: control<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Edema, All grades","Control: 0.003<br />Experimental: 0.000<br />greater: control<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Cough/Productive Cough/, Grade 3-4","Control: 0.021<br />Experimental: 0.018<br />greater: control<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Nausea, Grade 3-4","Control: 0.015<br />Experimental: 0.015<br />greater: control<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Diarrhea, Grade 3-4","Control: 0.006<br />Experimental: 0.000<br />greater: control<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Constipation, Grade 3-4","Control: 0.015<br />Experimental: 0.012<br />greater: control<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Vomiting, Grade 3-4","Control: 0.003<br />Experimental: 0.000<br />greater: control<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Stomatitis, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Hypothyroidism, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Alopecia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Pruritus, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Pyrexia, Grade 3-4","Control: 0.006<br />Experimental: 0.000<br />greater: control<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Edema, Grade 3-4","Control: 0.015<br />Experimental: 0.006<br />greater: control<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Musculoskeletal Pain, Grade 3-4","Control: 0.009<br />Experimental: 0.006<br />greater: control<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Upper respiratory tract infections, Grade 3-4","Control: 0.006<br />Experimental: 0.000<br />greater: control<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Headachek, Grade 3-4","Control: 0.430<br />Experimental: 0.370<br />greater: control<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Alopecia, All grades","Control: 0.360<br />Experimental: 0.300<br />greater: control<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Musculoskeletal pain, All grades","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Alopecia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Nausea, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Vomiting, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Peripheral neuropath, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Insomnia, Grade 3-4","Control: 0.450<br />Experimental: 0.270<br />greater: control<br />event: tremelimumab + durvalumab, Diarrhea, All grades","Control: 0.240<br />Experimental: 0.200<br />greater: control<br />event: tremelimumab + durvalumab, Abdominal pain, All grades","Control: 0.140<br />Experimental: 0.120<br />greater: control<br />event: tremelimumab + durvalumab, Nausea, All grades","Control: 0.570<br />Experimental: 0.320<br />greater: control<br />event: tremelimumab + durvalumab, Rash, All grades","Control: 0.180<br />Experimental: 0.170<br />greater: control<br />event: tremelimumab + durvalumab, Decreased appetite, All grades","Control: 0.300<br />Experimental: 0.260<br />greater: control<br />event: tremelimumab + durvalumab, Fatigue, All grades","Control: 0.040<br />Experimental: 0.018<br />greater: control<br />event: tremelimumab + durvalumab, Abdominal pain, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tremelimumab + durvalumab, Nausea, Grade 3-4","Control: 0.120<br />Experimental: 0.028<br />greater: control<br />event: tremelimumab + durvalumab, Rash, Grade 3-4","Control: 0.003<br />Experimental: 0.000<br />greater: control<br />event: tremelimumab + durvalumab, Pruritus, Grade 3-4","Control: 0.060<br />Experimental: 0.039<br />greater: control<br />event: tremelimumab + durvalumab, Fatigue, Grade 3-4","Control: 0.003<br />Experimental: 0.003<br />greater: control<br />event: tremelimumab + durvalumab, Pyrexia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tremelimumab + durvalumab, Hypothyroidisml, Grade 3-4","Control: 0.430<br />Experimental: 0.420<br />greater: control<br />event: durvalumab + gemcitabine + cisplatin, Fatigue, All grades","Control: 0.180<br />Experimental: 0.180<br />greater: control<br />event: durvalumab + gemcitabine + cisplatin, Vomiting, All grades","Control: 0.110<br />Experimental: 0.100<br />greater: control<br />event: durvalumab + gemcitabine + cisplatin, Insomnia, All grades","Control: 0.060<br />Experimental: 0.060<br />greater: control<br />event: durvalumab + gemcitabine + cisplatin, Fatigue, Grade 3-4","Control: 0.018<br />Experimental: 0.015<br />greater: control<br />event: durvalumab + gemcitabine + cisplatin, Nausea, Grade 3-4","Control: 0.029<br />Experimental: 0.006<br />greater: control<br />event: durvalumab + gemcitabine + cisplatin, Abdominal pain, Grade 3-4","Control: 0.020<br />Experimental: 0.015<br />greater: control<br />event: durvalumab + gemcitabine + cisplatin, Vomiting, Grade 3-4","Control: 0.018<br />Experimental: 0.012<br />greater: control<br />event: durvalumab + gemcitabine + cisplatin, Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: durvalumab + gemcitabine + cisplatin, Pruritus, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: durvalumab + gemcitabine + cisplatin, Insomnia, Grade 3-4","Control: 0.003<br />Experimental: 0.003<br />greater: control<br />event: darolutamide + docetaxel, Constipation, Grade 3-4","Control: 0.006<br />Experimental: 0.002<br />greater: control<br />event: darolutamide + docetaxel, Decreased Appetite, Grade 3-4","Control: 0.014<br />Experimental: 0.014<br />greater: control<br />event: darolutamide + docetaxel, Hemorrhage, Grade 3-4","Control: 0.130<br />Experimental: 0.120<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Pyrexia, All grades","Control: 0.230<br />Experimental: 0.130<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Rashid, All grades","Control: 0.290<br />Experimental: 0.130<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Peripheral neuropathy, All grades","Control: 0.017<br />Experimental: 0.013<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Diarrhea, Grade 3-4","Control: 0.006<br />Experimental: 0.003<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Stomatitisb, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Alopecia, Grade 3-4","Control: 0.047<br />Experimental: 0.000<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Rashid, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Hemorrhage, Grade 3-4","Control: 0.050<br />Experimental: 0.000<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Peripheral neuropathy, Grade 3-4","Control: 0.380<br />Experimental: 0.330<br />greater: control<br />event: lisocabtagene maraleucel, Thrombocytopenia, Grade 1–2","Control: 0.570<br />Experimental: 0.530<br />greater: control<br />event: lisocabtagene maraleucel, Nausea, Grade 1–2","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: lisocabtagene maraleucel, Prolonged cytopeniat, Grade 1–2","Control: 0.410<br />Experimental: 0.250<br />greater: control<br />event: lisocabtagene maraleucel, Diarrhoea, Grade 1–2","Control: 0.290<br />Experimental: 0.230<br />greater: control<br />event: lisocabtagene maraleucel, Decreased appetite, Grade 1–2","Control: 0.210<br />Experimental: 0.170<br />greater: control<br />event: lisocabtagene maraleucel, Hypokalaemia, Grade 1–2","Control: 0.230<br />Experimental: 0.200<br />greater: control<br />event: lisocabtagene maraleucel, Vomiting, Grade 1–2","Control: 0.160<br />Experimental: 0.150<br />greater: control<br />event: lisocabtagene maraleucel, Back pain, Grade 1–2","Control: 0.180<br />Experimental: 0.160<br />greater: control<br />event: lisocabtagene maraleucel, Peripheral oedema, Grade 1–2","Control: 0.210<br />Experimental: 0.140<br />greater: control<br />event: lisocabtagene maraleucel, Hypomagnesaemia, Grade 1–2","Control: 0.120<br />Experimental: 0.120<br />greater: control<br />event: lisocabtagene maraleucel, Abdominal pain, Grade 1–2","Control: 0.110<br />Experimental: 0.100<br />greater: control<br />event: lisocabtagene maraleucel, Tachycardia, Grade 1–2","Control: 0.120<br />Experimental: 0.080<br />greater: control<br />event: lisocabtagene maraleucel, Peripheral sensory neuropathy, Grade 1–2","Control: 0.110<br />Experimental: 0.070<br />greater: control<br />event: lisocabtagene maraleucel, Hypophosphataemia, Grade 1–2","Control: 0.110<br />Experimental: 0.050<br />greater: control<br />event: lisocabtagene maraleucel, Dyspepsia, Grade 1–2","Control: 0.100<br />Experimental: 0.050<br />greater: control<br />event: lisocabtagene maraleucel, Stomatitis, Grade 1–2","Control: 0.120<br />Experimental: 0.040<br />greater: control<br />event: lisocabtagene maraleucel, Mucosal inflammation, Grade 1–2","Control: 0.490<br />Experimental: 0.490<br />greater: control<br />event: lisocabtagene maraleucel, Anaemia, Grade ≥ 3","Control: 0.640<br />Experimental: 0.490<br />greater: control<br />event: lisocabtagene maraleucel, Thrombocytopenia, Grade ≥ 3","Control: 0.030<br />Experimental: 0.030<br />greater: control<br />event: lisocabtagene maraleucel, Nausea, Grade ≥ 3","Control: 0.020<br />Experimental: 0.000<br />greater: control<br />event: lisocabtagene maraleucel, Fatigue, Grade ≥ 3","Control: 0.030<br />Experimental: 0.000<br />greater: control<br />event: lisocabtagene maraleucel, Diarrhoea, Grade ≥ 3","Control: 0.030<br />Experimental: 0.010<br />greater: control<br />event: lisocabtagene maraleucel, Decreased appetite, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: lisocabtagene maraleucel, Pyrexia, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: lisocabtagene maraleucel, Dizziness, Grade ≥ 3","Control: 0.040<br />Experimental: 0.040<br />greater: control<br />event: lisocabtagene maraleucel, Hypokalaemia, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: lisocabtagene maraleucel, Insomnia, Grade ≥ 3","Control: 0.020<br />Experimental: 0.010<br />greater: control<br />event: lisocabtagene maraleucel, Vomiting, Grade ≥ 3","Control: 0.020<br />Experimental: 0.010<br />greater: control<br />event: lisocabtagene maraleucel, Back pain, Grade ≥ 3","Control: 0.210<br />Experimental: 0.120<br />greater: control<br />event: lisocabtagene maraleucel, Febrile neutropenia, Grade ≥ 3","Control: 0.010<br />Experimental: 0.000<br />greater: control<br />event: lisocabtagene maraleucel, Hypomagnesaemia, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: lisocabtagene maraleucel, Arthralg ia, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: lisocabtagene maraleucel, Cough, Grade ≥ 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: lisocabtagene maraleucel, Dyspnoea, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: lisocabtagene maraleucel, Bone pain, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: lisocabtagene maraleucel, Tachycardia, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: lisocabtagene maraleucel, Peripheral sensory neuropathy, Grade ≥ 3","Control: 0.070<br />Experimental: 0.030<br />greater: control<br />event: lisocabtagene maraleucel, Hypophosphataemia, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: lisocabtagene maraleucel, Dyspepsia, Grade ≥ 3","Control: 0.020<br />Experimental: 0.000<br />greater: control<br />event: lisocabtagene maraleucel, Stomatitis, Grade ≥ 3","Control: 0.030<br />Experimental: 0.000<br />greater: control<br />event: lisocabtagene maraleucel, Mucosal inflammation, Grade ≥ 3","Control: 0.040<br />Experimental: 0.030<br />greater: control<br />event: ivosidenib + azacitidine, Nausea, Grade ≥ 3","Control: 0.010<br />Experimental: 0.000<br />greater: control<br />event: ivosidenib + azacitidine, Vomiting, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ivosidenib + azacitidine, Leukocytosis, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ivosidenib + azacitidine, Hematoma, Grade ≥ 3","Control: 0.050<br />Experimental: 0.040<br />greater: control<br />event: ivosidenib + azacitidine, Hypertension, Grade ≥ 3","Control: 0.050<br />Experimental: 0.030<br />greater: control<br />event: ivosidenib + azacitidine, Dyspnea, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ivosidenib + azacitidine, Headache, Grade ≥ 3","Control: 0.003<br />Experimental: 0.003<br />greater: control<br />event: olaparib, Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: olaparib, Dysgeusia, Grade 3-4","Control: 0.001<br />Experimental: 0.001<br />greater: control<br />event: olaparib, Dizziness, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Hypothyroidism, Grade ≥ 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: pembrolizumab, Diarrhoea, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Nausea, Grade ≥ 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: pembrolizumab, Increased alanine aminotransferase, Grade ≥ 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: pembrolizumab, Increased aspartate aminotransferase, Grade ≥ 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: pembrolizumab, Rash, Grade ≥ 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: pembrolizumab, Infusion reactions, Adverse events of interest: Any grade","Control: 0.010<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Myocarditis, Adverse events of interest: Any grade","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Hypothyroidism, Adverse events of interest: Grade ≥3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Infusion reactions, Adverse events of interest: Grade ≥3","Control: 0.010<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Myocarditis, Adverse events of interest: Grade ≥3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Sarcoidosis, Adverse events of interest: Grade ≥3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Thyroiditis, Adverse events of interest: Grade ≥3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Uveitis, Adverse events of interest: Grade ≥3","Control: 0.130<br />Experimental: 0.110<br />greater: control<br />event: pembrolizumab, Abdominal, All grades","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Cough, Grade 3-4","Control: 0.580<br />Experimental: 0.560<br />greater: control<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Alopecia, All grades","Control: 0.440<br />Experimental: 0.400<br />greater: control<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Nausea, All grades","Control: 0.330<br />Experimental: 0.280<br />greater: control<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Constipation, All grades","Control: 0.270<br />Experimental: 0.260<br />greater: control<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Vomiting, All grades","Control: 0.260<br />Experimental: 0.240<br />greater: control<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Urinary tract infection, All grades","Control: 0.060<br />Experimental: 0.042<br />greater: control<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Peripheral neuropathy, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Alopecia, Grade 3-4","Control: 0.026<br />Experimental: 0.020<br />greater: control<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Diarrhea, Grade 3-4","Control: 0.010<br />Experimental: 0.003<br />greater: control<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Constipation, Grade 3-4","Control: 0.013<br />Experimental: 0.007<br />greater: control<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Arthralgia, Grade 3-4","Control: 0.110<br />Experimental: 0.090<br />greater: control<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Hypertension, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: cabozantinib, Dysgeusia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: cabozantinib, Dysphonia, Grade 3-4","Control: 0.050<br />Experimental: 0.030<br />greater: control<br />event: ivosidenib, Fatigue, Grade ≥ 3","Control: 0.020<br />Experimental: 0.020<br />greater: control<br />event: ivosidenib, Nausea, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ivosidenib, Diarrhea, Grade ≥ 3","Control: 0.030<br />Experimental: 0.020<br />greater: control<br />event: ivosidenib, Abdominal pain, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ivosidenib, Cough, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ivosidenib, Headache, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ivosidenib, Neuropathy, Grade ≥ 3","Control: 0.100<br />Experimental: 0.100<br />greater: control<br />event: nivolumab, Prexia, All grades","Control: 0.150<br />Experimental: 0.150<br />greater: control<br />event: nivolumab, Abdominal pain, All grades","Control: 0.150<br />Experimental: 0.130<br />greater: control<br />event: nivolumab, Constipation, All grades","Control: 0.130<br />Experimental: 0.110<br />greater: control<br />event: nivolumab, Arthralgia, All grades","Control: 0.230<br />Experimental: 0.220<br />greater: control<br />event: nivolumab, Urinary tract infection, All grades","Control: 0.160<br />Experimental: 0.160<br />greater: control<br />event: nivolumab, Upper respiratory tract infection, All grades","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: nivolumab, Pruritus, Grade 3-4","Control: 0.003<br />Experimental: 0.003<br />greater: control<br />event: nivolumab, Prexia, Grade 3-4","Control: 0.003<br />Experimental: 0.003<br />greater: control<br />event: nivolumab, Constipation, Grade 3-4","Control: 0.009<br />Experimental: 0.006<br />greater: control<br />event: nivolumab, Musculoskeletal pain, Grade 3-4","Control: 0.090<br />Experimental: 0.060<br />greater: control<br />event: nivolumab, Urinary tract infection, Grade 3-4","Control: 0.006<br />Experimental: 0.003<br />greater: control<br />event: nivolumab, Upper respiratory tract infection, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: nivolumab, Hyperthyroidism, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: nivolumab, Hypothyroidism, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: nivolumab, Cough, Grade 3-4","Control: 0.003<br />Experimental: 0.003<br />greater: control<br />event: nivolumab, Dyspnea, Grade 3-4","Control: 0.420<br />Experimental: 0.410<br />greater: control<br />event: pembrolizumab + chemotherapy, Peripheral neuropathy, All grades","Control: 0.310<br />Experimental: 0.290<br />greater: control<br />event: pembrolizumab + chemotherapy, Arthralgia , All grades","Control: 0.003<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab + chemotherapy, Constipation, Grade 3-4","Control: 0.008<br />Experimental: 0.005<br />greater: control<br />event: pembrolizumab + chemotherapy, Abdominal pain, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab + chemotherapy, Alopecia, Grade 3-4","Control: 0.010<br />Experimental: 0.005<br />greater: control<br />event: pembrolizumab + chemotherapy, Headache, Grade 3-4","Control: 0.290<br />Experimental: 0.290<br />greater: control<br />event: nivolumab, Diarrhea, All grades","Control: 0.200<br />Experimental: 0.170<br />greater: control<br />event: nivolumab, Abdominal Pain, All grades","Control: 0.160<br />Experimental: 0.150<br />greater: control<br />event: nivolumab, Vomiting, All grades","Control: 0.170<br />Experimental: 0.130<br />greater: control<br />event: nivolumab, Dysphagia, All grades","Control: 0.160<br />Experimental: 0.120<br />greater: control<br />event: nivolumab, Dyspepsia, All grades","Control: 0.120<br />Experimental: 0.110<br />greater: control<br />event: nivolumab, Constipation, All grades","Control: 0.210<br />Experimental: 0.200<br />greater: control<br />event: nivolumab, cough, All grades","Control: 0.120<br />Experimental: 0.120<br />greater: control<br />event: nivolumab, Dyspnea, All grades","Control: 0.015<br />Experimental: 0.008<br />greater: control<br />event: nivolumab, Abdominal Pain, Grade 3-4","Control: 0.012<br />Experimental: 0.006<br />greater: control<br />event: nivolumab, Vomiting, Grade 3-4","Control: 0.035<br />Experimental: 0.008<br />greater: control<br />event: nivolumab, Dysphagia, Grade 3-4","Control: 0.004<br />Experimental: 0.002<br />greater: control<br />event: nivolumab, Dyspepsia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: nivolumab, Constipation, Grade 3-4","Control: 0.015<br />Experimental: 0.013<br />greater: control<br />event: nivolumab, Fatigue, Grade 3-4","Control: 0.004<br />Experimental: 0.002<br />greater: control<br />event: nivolumab, cough, Grade 3-4","Control: 0.008<br />Experimental: 0.006<br />greater: control<br />event: nivolumab, Musculoskeletal pain, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: nivolumab, Hypothyroidism, Grade 3-4","Control: 0.400<br />Experimental: 0.400<br />greater: control<br />event: pembrolizumab + chemotherapy, Constipation, All grades","Control: 0.240<br />Experimental: 0.240<br />greater: control<br />event: pembrolizumab + chemotherapy, Weight loss, All grades","Control: 0.070<br />Experimental: 0.070<br />greater: control<br />event: pembrolizumab + chemotherapy, Nausea, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab + chemotherapy, Constipation, Grade 3-4","Control: 0.050<br />Experimental: 0.041<br />greater: control<br />event: pembrolizumab + chemotherapy, Decreased appetite, Grade 3-4","Control: 0.050<br />Experimental: 0.030<br />greater: control<br />event: pembrolizumab + chemotherapy, Weight loss, Grade 3-4","Control: 0.190<br />Experimental: 0.190<br />greater: control<br />event: osimertinib, Cough, All grades","Control: 0.250<br />Experimental: 0.180<br />greater: control<br />event: osimertinib, Musculoskeletal Pain, All grades","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: osimertinib, Pruritus, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: osimertinib, Cough, Grade ≥ 3","Control: 0.003<br />Experimental: 0.003<br />greater: control<br />event: osimertinib, Musculoskeletal Pain, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: osimertinib, Nasopharyngitis, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: osimertinib, Dizziness, Grade ≥ 3","Control: 0.490<br />Experimental: 0.480<br />greater: control<br />event: pembrolizumab + chemotherapy, Fatigue, All grades","Control: 0.470<br />Experimental: 0.440<br />greater: control<br />event: pembrolizumab + chemotherapy, Nausea, All grades","Control: 0.350<br />Experimental: 0.340<br />greater: control<br />event: pembrolizumab + chemotherapy, Alopecia, All grades","Control: 0.230<br />Experimental: 0.200<br />greater: control<br />event: pembrolizumab + chemotherapy, Headache, All grades","Control: 0.018<br />Experimental: 0.017<br />greater: control<br />event: pembrolizumab + chemotherapy, Nausea, Grade 3-4","Control: 0.018<br />Experimental: 0.018<br />greater: control<br />event: pembrolizumab + chemotherapy, Diarrhea, Grade 3-4","Control: 0.032<br />Experimental: 0.027<br />greater: control<br />event: pembrolizumab + chemotherapy, Vomiting, Grade 3-4","Control: 0.011<br />Experimental: 0.008<br />greater: control<br />event: pembrolizumab + chemotherapy, Alopecia, Grade 3-4","Control: 0.004<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab + chemotherapy, Cough, Grade 3-4","Control: 0.007<br />Experimental: 0.007<br />greater: control<br />event: pembrolizumab + chemotherapy, Headache, Grade 3-4","Control: 0.060<br />Experimental: 0.060<br />greater: control<br />event: venetoclax + azacitidine, Urinary tract infection, Grade 3-4","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: venetoclax + azacitidine, Dizziness, Grade 3-4","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: azacitidine, Arthralgia, TYPO","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: azacitidine, Decreased appetite, TYPO","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: azacitidine, Dizziness, TYPO","Control: 0.250<br />Experimental: 0.210<br />greater: control<br />event: atezolizumab +  cobimetinib + vemurafenib, Photosensitivity reaction, All grades","Control: 0.320<br />Experimental: 0.300<br />greater: control<br />event: atezolizumab +  cobimetinib + vemurafenib, Nausea, All grades","Control: 0.180<br />Experimental: 0.170<br />greater: control<br />event: atezolizumab +  cobimetinib + vemurafenib, Hypertension, All grades","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: atezolizumab +  cobimetinib + vemurafenib, Pruritus, Grade 3-4","Control: 0.032<br />Experimental: 0.010<br />greater: control<br />event: atezolizumab +  cobimetinib + vemurafenib, Photosensitivity reaction, Grade 3-4","Control: 0.021<br />Experimental: 0.017<br />greater: control<br />event: atezolizumab +  cobimetinib + vemurafenib, Pyrexia, Grade 3-4","Control: 0.025<br />Experimental: 0.010<br />greater: control<br />event: atezolizumab +  cobimetinib + vemurafenib, Nausea, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: atezolizumab +  cobimetinib + vemurafenib, Hypothyroidism, Grade 3-4","Control: 0.710<br />Experimental: 0.700<br />greater: control<br />event: ramucirumab + erlotinib, Diarrhea, All grades","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: ramucirumab + erlotinib, Gastrointestinal hemorrhage, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ramucirumab + erlotinib, Gingival bleeding, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ramucirumab + erlotinib, Alopecia, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ramucirumab + erlotinib, Epistaxis, Grade ≥ 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: ramucirumab + erlotinib, Pulmonary hemorrhageq, Grade ≥ 3","Control: 0.140<br />Experimental: 0.130<br />greater: control<br />event: ripretinib, Asthenia, Grades 1-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ripretinib, Alopecia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ripretinib, Palmar-plantar erythrodysesthesia syndrome, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ripretinib, Dry skin, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ripretinib, Pruritus, Grade 3-4","Control: 0.047<br />Experimental: 0.012<br />greater: control<br />event: ripretinib, Asthenia, Grade 3-4","Control: 0.023<br />Experimental: 0.012<br />greater: control<br />event: ripretinib, Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ripretinib, Stomatitis, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ripretinib, Arthralgia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ripretinib, Muscle spasms, Grade 3-4","Control: 0.023<br />Experimental: 0.012<br />greater: control<br />event: ripretinib, Decreased appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ripretinib, Decreased weight, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ripretinib, Headache, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ripretinib, Dyspnea, Grade 3-4","Control: 0.019<br />Experimental: 0.017<br />greater: control<br />event: olaparib + bevacizumab, Vomiting, TYPO","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: niraparib, Nausea, Grade 3-4","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: niraparib, Vomiting, Grade 3-4","Control: 0.004<br />Experimental: 0.000<br />greater: control<br />event: niraparib, Dizziness, Grade 3-4","Control: 0.010<br />Experimental: 0.004<br />greater: control<br />event: niraparib, Dyspnea, Grade 3-4","Control: 0.004<br />Experimental: 0.000<br />greater: control<br />event: niraparib, Cough, Grade 3-4","Control: 0.036<br />Experimental: 0.030<br />greater: control<br />event: tucatinib + trastuzumab + capecitabine, Vomiting, Grade 3","Control: 0.005<br />Experimental: 0.005<br />greater: control<br />event: tucatinib + trastuzumab + capecitabine, Arthralgia, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tucatinib + trastuzumab + capecitabine, Creatinine increased, Grade 3","Control: 0.010<br />Experimental: 0.005<br />greater: control<br />event: tucatinib + trastuzumab + capecitabine, Peripheral neuropathy, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tucatinib + trastuzumab + capecitabine, Epistaxis, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tucatinib + trastuzumab + capecitabine, Nausea, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tucatinib + trastuzumab + capecitabine, Vomiting, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tucatinib + trastuzumab + capecitabine, Stomatitis, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tucatinib + trastuzumab + capecitabine, Palmar-plantar erythrodysesthesia syndrome, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tucatinib + trastuzumab + capecitabine, Rash, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tucatinib + trastuzumab + capecitabine, Decreased appetite, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tucatinib + trastuzumab + capecitabine, Anemia, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tucatinib + trastuzumab + capecitabine, Arthralgia, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tucatinib + trastuzumab + capecitabine, Creatinine increased, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tucatinib + trastuzumab + capecitabine, Weight decreased, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tucatinib + trastuzumab + capecitabine, Peripheral neuropathy, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tucatinib + trastuzumab + capecitabine, Epistaxis, Grade 4","Control: 0.110<br />Experimental: 0.100<br />greater: control<br />event: nivolumab + chemotherapy, Alopecia, All grades","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: nivolumab + chemotherapy, Constipation, Grade 3-4","Control: 0.030<br />Experimental: 0.023<br />greater: control<br />event: nivolumab + chemotherapy, Vomiting, Grade 3-4","Control: 0.049<br />Experimental: 0.035<br />greater: control<br />event: nivolumab + chemotherapy, Fatigue, Grade 3-4","Control: 0.003<br />Experimental: 0.003<br />greater: control<br />event: nivolumab + chemotherapy, Pyrexiad, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: nivolumab + chemotherapy, Edemae, Grade 3-4","Control: 0.003<br />Experimental: 0.000<br />greater: control<br />event: nivolumab + chemotherapy, Insomnia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: nivolumab + chemotherapy, Pruritus, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: nivolumab + chemotherapy, Alopecia, Grade 3-4","Control: 0.003<br />Experimental: 0.003<br />greater: control<br />event: nivolumab + chemotherapy, Cough, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: nivolumab + chemotherapy, Hypothyroidism, Grade 3-4","Control: 0.010<br />Experimental: 0.006<br />greater: control<br />event: nivolumab + chemotherapy, Weight decreased, Grade 3-4","Control: 0.003<br />Experimental: 0.003<br />greater: control<br />event: nivolumab + chemotherapy, Musculoskeletal pain, Grade 3-4","Control: 0.160<br />Experimental: 0.110<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Epistaxis, All grades","Control: 0.140<br />Experimental: 0.130<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Peripheral neuropathy, All grades","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Constipation, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Dyspepsia, Grade 3-4","Control: 0.011<br />Experimental: 0.008<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Respiratory infectiong, Grade 3-4","Control: 0.004<br />Experimental: 0.000<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Epistaxis, Grade 3-4","Control: 0.004<br />Experimental: 0.004<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Peripheral neuropathy, Grade 3-4","Control: 0.005<br />Experimental: 0.004<br />greater: control<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Peripheral edema, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Dry mouth, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Dysgeusia, Grade 3-4","Control: 0.019<br />Experimental: 0.014<br />greater: control<br />event: relatlimab-rmbw +nivolumab, Rash, Grade 3-4","Control: 0.006<br />Experimental: 0.000<br />greater: control<br />event: relatlimab-rmbw +nivolumab, Pruritus, Grade 3-4","Control: 0.003<br />Experimental: 0.003<br />greater: control<br />event: relatlimab-rmbw +nivolumab, Headache, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: relatlimab-rmbw +nivolumab, Hypothyroidisma, Grade 3-4","Control: 0.450<br />Experimental: 0.380<br />greater: control<br />event: nivolumab + platinum-doublet chemotherapy, Nausea, All grades","Control: 0.130<br />Experimental: 0.110<br />greater: control<br />event: nivolumab + platinum-doublet chemotherapy, Vomiting, All grades","Control: 0.230<br />Experimental: 0.200<br />greater: control<br />event: nivolumab + platinum-doublet chemotherapy, Decreased appetite, All grades","Control: 0.150<br />Experimental: 0.110<br />greater: control<br />event: nivolumab + platinum-doublet chemotherapy, Alopecia, All grades","Control: 0.011<br />Experimental: 0.006<br />greater: control<br />event: nivolumab + platinum-doublet chemotherapy, Nausea, Grade 3-4","Control: 0.011<br />Experimental: 0.000<br />greater: control<br />event: nivolumab + platinum-doublet chemotherapy, Constipation, Grade 3-4","Control: 0.006<br />Experimental: 0.006<br />greater: control<br />event: nivolumab + platinum-doublet chemotherapy, Malaise, Grade 3-4","Control: 0.023<br />Experimental: 0.011<br />greater: control<br />event: nivolumab + platinum-doublet chemotherapy, Decreased appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: nivolumab + platinum-doublet chemotherapy, Alopecia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: nivolumab + platinum-doublet chemotherapy, Peripheral neuropathy, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tebentafusp-tebn, Dry skin, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tebentafusp-tebn, Erythema, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: tebentafusp-tebn, Edemab, Grade 3-4","Control: 0.036<br />Experimental: 0.029<br />greater: control<br />event: tebentafusp-tebn, Abdominal pain, Grade 3-4","Control: 0.027<br />Experimental: 0.012<br />greater: control<br />event: tebentafusp-tebn, Diarrhea, Grade 3-4","Control: 0.009<br />Experimental: 0.004<br />greater: control<br />event: tebentafusp-tebn, Headache, Grade 3-4","Control: 0.300<br />Experimental: 0.170<br />greater: control<br />event: asciminib, Rash, All grades","Control: 0.710<br />Experimental: 0.120<br />greater: control<br />event: asciminib, Diarrhea, All grades","Control: 0.460<br />Experimental: 0.120<br />greater: control<br />event: asciminib, Nausea, All grades","Control: 0.240<br />Experimental: 0.100<br />greater: control<br />event: asciminib, Abdominal pain, All grades","Control: 0.013<br />Experimental: 0.006<br />greater: control<br />event: asciminib, Upper respiratory tract infection, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: asciminib, Arthralgia, Grade 3-4","Control: 0.013<br />Experimental: 0.006<br />greater: control<br />event: asciminib, Fatigue, Grade 3-4","Control: 0.080<br />Experimental: 0.006<br />greater: control<br />event: asciminib, Rash, Grade 3-4","Control: 0.110<br />Experimental: 0.000<br />greater: control<br />event: asciminib, Diarrhea, Grade 3-4","Control: 0.026<br />Experimental: 0.000<br />greater: control<br />event: asciminib, Abdominal pain, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: atezolizumab, Pruritus, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: atezolizumab, Hypothyroidism, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: atezolizumab, Cough, Grade 3-4","Control: 0.001<br />Experimental: 0.001<br />greater: control<br />event: abemaciclib + endocrine therapy, Dizziness, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: abemaciclib + endocrine therapy, Alopecia, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: abemaciclib + endocrine therapy, Diarrhea, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: abemaciclib + endocrine therapy, Nausea, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: abemaciclib + endocrine therapy, Vomiting, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: abemaciclib + endocrine therapy, Stomatitis, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: abemaciclib + endocrine therapy, Fatigue, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: abemaciclib + endocrine therapy, Headache, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: abemaciclib + endocrine therapy, Dizziness, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: abemaciclib + endocrine therapy, Decreased appetite, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: abemaciclib + endocrine therapy, Rash, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: abemaciclib + endocrine therapy, Alopecia, Grade 4","Control: 0.120<br />Experimental: 0.100<br />greater: control<br />event: ruxolitinib, Edema, All grades","Control: 0.150<br />Experimental: 0.120<br />greater: control<br />event: ruxolitinib, Hemorrhage, All grades","Control: 0.130<br />Experimental: 0.120<br />greater: control<br />event: ruxolitinib, Nausea, All grades","Control: 0.130<br />Experimental: 0.100<br />greater: control<br />event: ruxolitinib, Diarrhea, All grades","Control: 0.160<br />Experimental: 0.150<br />greater: control<br />event: ruxolitinib, Infections (pathogen not specified), Grade ≥ 3","Control: 0.050<br />Experimental: 0.050<br />greater: control<br />event: ruxolitinib, Viral infections, Grade ≥ 3","Control: 0.020<br />Experimental: 0.010<br />greater: control<br />event: ruxolitinib, Fatigue, Grade ≥ 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: ruxolitinib, Edema, Grade ≥ 3","Control: 0.070<br />Experimental: 0.050<br />greater: control<br />event: ruxolitinib, Hypertension, Grade ≥ 3","Control: 0.020<br />Experimental: 0.020<br />greater: control<br />event: ruxolitinib, Hemorrhage, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: ruxolitinib, Cough, Grade ≥ 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: ruxolitinib, Dyspnea, Grade ≥ 3","Control: 0.020<br />Experimental: 0.000<br />greater: control<br />event: ruxolitinib, Nausea, Grade ≥ 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: ruxolitinib, Diarrhea, Grade ≥ 3","Control: 0.260<br />Experimental: 0.120<br />greater: control<br />event: zanubrutinib, Pneumonia, All grades","Control: 0.130<br />Experimental: 0.110<br />greater: control<br />event: zanubrutinib, Urinary tract infection, All grades","Control: 0.340<br />Experimental: 0.220<br />greater: control<br />event: zanubrutinib, Diarrhea, All grades","Control: 0.140<br />Experimental: 0.120<br />greater: control<br />event: zanubrutinib, Vomiting, All grades","Control: 0.200<br />Experimental: 0.120<br />greater: control<br />event: zanubrutinib, Edema peripheral, All grades","Control: 0.340<br />Experimental: 0.200<br />greater: control<br />event: zanubrutinib, Bruising, All grades","Control: 0.320<br />Experimental: 0.290<br />greater: control<br />event: zanubrutinib, Rash, All grades","Control: 0.280<br />Experimental: 0.100<br />greater: control<br />event: zanubrutinib, Muscle spasms, All grades","Control: 0.180<br />Experimental: 0.160<br />greater: control<br />event: zanubrutinib, Cough, All grades","Control: 0.430<br />Experimental: 0.420<br />greater: control<br />event: zanubrutinib, Hemorrhage, All grades","Control: 0.190<br />Experimental: 0.140<br />greater: control<br />event: zanubrutinib, Hypertension, All grades","Control: 0.020<br />Experimental: 0.000<br />greater: control<br />event: zanubrutinib, Upper respiratory tract infection, Grade 3-4","Control: 0.100<br />Experimental: 0.040<br />greater: control<br />event: zanubrutinib, Pneumonia, Grade 3-4","Control: 0.020<br />Experimental: 0.000<br />greater: control<br />event: zanubrutinib, Urinary tract infection, Grade 3-4","Control: 0.010<br />Experimental: 0.000<br />greater: control<br />event: zanubrutinib, Nausea, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: zanubrutinib, Constipation, Grade 3-4","Control: 0.010<br />Experimental: 0.000<br />greater: control<br />event: zanubrutinib, Vomiting, Grade 3-4","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: zanubrutinib, Fatigue, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: zanubrutinib, Edema peripheral, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: zanubrutinib, Bruising, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: zanubrutinib, Rash, Grade 3-4","Control: 0.010<br />Experimental: 0.000<br />greater: control<br />event: zanubrutinib, Muscle spasms, Grade 3-4","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: zanubrutinib, Headache, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: zanubrutinib, Cough, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: zanubrutinib, Dyspnea, Grade 3-4","Control: 0.090<br />Experimental: 0.040<br />greater: control<br />event: zanubrutinib, Hemorrhage, Grade 3-4","Control: 0.140<br />Experimental: 0.090<br />greater: control<br />event: zanubrutinib, Hypertension, Grade 3-4","Control: 0.430<br />Experimental: 0.430<br />greater: control<br />event: lenvatinib + pembrolizumab, Stomatitis, All Grades","Control: 0.380<br />Experimental: 0.290<br />greater: control<br />event: lenvatinib + pembrolizumab, Palmar-plantar erythrodysaesthesia syndrome, All Grades","Control: 0.020<br />Experimental: 0.020<br />greater: control<br />event: lenvatinib + pembrolizumab, Stomatitis, Grade 3-4","Control: 0.040<br />Experimental: 0.040<br />greater: control<br />event: lenvatinib + pembrolizumab, Palmar-plantar erythrodysaesthesia syndrome, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: lenvatinib + pembrolizumab, Dysphonia, Grade 3-4","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: lenvatinib + pembrolizumab, Headache, Grade 3-4","Control: 0.006<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab + lenvatinib, Constipation, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab + lenvatinib, Dysphonia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Pyrexia, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Edema peripheral, Grade ≥ 3","Control: 0.020<br />Experimental: 0.010<br />greater: control<br />event: daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Upper respiratory infection, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Cough, Grade ≥ 3","Control: 0.020<br />Experimental: 0.020<br />greater: control<br />event: sacituzumab govitecan, Lymphopenia, Grade 3-4","Control: 0.090<br />Experimental: 0.060<br />greater: control<br />event: sacituzumab govitecan, Fatigue, Grade 3-4","Control: 0.020<br />Experimental: 0.004<br />greater: control<br />event: sacituzumab govitecan, Pyrexia, Grade 3-4","Control: 0.004<br />Experimental: 0.004<br />greater: control<br />event: sacituzumab govitecan, Urinary tract infection, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: sacituzumab govitecan, Upper respiratory tract infection, Grade 3-4","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: sacituzumab govitecan, Alanine aminotransferase increased, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: sacituzumab govitecan, Hypomagnesaemia, Grade 3-4","Control: 0.020<br />Experimental: 0.010<br />greater: control<br />event: sacituzumab govitecan, Back pain, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: sacituzumab govitecan, Dizziness, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: sacituzumab govitecan, Insomnia, Grade 3-4","Control: 0.004<br />Experimental: 0.000<br />greater: control<br />event: sacituzumab govitecan, Cough, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: sacituzumab govitecan, Alopecia, Grade 3-4","Control: 0.004<br />Experimental: 0.004<br />greater: control<br />event: sacituzumab govitecan, Rash, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: sacituzumab govitecan, Pruritus, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Cough, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Infusion-related reaction, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Upper respiratory tract infection, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Bronchitis, Grade 4","Control: 0.016<br />Experimental: 0.006<br />greater: control<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Hypertension, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Dyspnea, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Cough, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Diarrhea, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Vomiting, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Fatigue, Grade 4","Control: 1.000<br />Experimental: 0.990<br />greater: control<br />event: tivozanib, Any, All Grades","Control: 0.540<br />Experimental: 0.430<br />greater: control<br />event: tivozanib, Diarrhea, All Grades","Control: 0.230<br />Experimental: 0.210<br />greater: control<br />event: tivozanib, Stomatitis, All Grades","Control: 0.520<br />Experimental: 0.180<br />greater: control<br />event: tivozanib, Rash, All Grades","Control: 0.410<br />Experimental: 0.160<br />greater: control<br />event: tivozanib, Palmar-plantar erythrodysesthesia syndrome, All Grades","Control: 0.220<br />Experimental: 0.170<br />greater: control<br />event: tivozanib, Weight decreased, All Grades","Control: 0.720<br />Experimental: 0.670<br />greater: control<br />event: tivozanib, Any, Grade 3-4","Control: 0.110<br />Experimental: 0.020<br />greater: control<br />event: tivozanib, Diarrhea, Grade 3-4","Control: 0.040<br />Experimental: 0.000<br />greater: control<br />event: tivozanib, Nausea, Grade 3-4","Control: 0.020<br />Experimental: 0.020<br />greater: control<br />event: tivozanib, Stomatitis, Grade 3-4","Control: 0.020<br />Experimental: 0.010<br />greater: control<br />event: tivozanib, Vomiting, Grade 3-4","Control: 0.010<br />Experimental: 0.000<br />greater: control<br />event: tivozanib, Cough, Grade 3-4","Control: 0.020<br />Experimental: 0.020<br />greater: control<br />event: tivozanib, Back pain, Grade 3-4","Control: 0.150<br />Experimental: 0.010<br />greater: control<br />event: tivozanib, Rash, Grade 3-4","Control: 0.170<br />Experimental: 0.010<br />greater: control<br />event: tivozanib, Palmar-plantar erythrodysesthesia syndrome, Grade 3-4","Control: 0.030<br />Experimental: 0.030<br />greater: control<br />event: tivozanib, Weight decreased, Grade 3-4","Control: 0.180<br />Experimental: 0.170<br />greater: control<br />event: lorlatinib, Headache, All Grades","Control: 0.140<br />Experimental: 0.110<br />greater: control<br />event: lorlatinib, Dizziness, All Grades","Control: 0.180<br />Experimental: 0.160<br />greater: control<br />event: lorlatinib, Cough, All Grades","Control: 0.390<br />Experimental: 0.180<br />greater: control<br />event: lorlatinib, Vision disorder, All Grades","Control: 0.520<br />Experimental: 0.210<br />greater: control<br />event: lorlatinib, Diarrhea, All Grades","Control: 0.520<br />Experimental: 0.150<br />greater: control<br />event: lorlatinib, Nausea, All Grades","Control: 0.300<br />Experimental: 0.170<br />greater: control<br />event: lorlatinib, Constipation, All Grades","Control: 0.390<br />Experimental: 0.130<br />greater: control<br />event: lorlatinib, Vomiting, All Grades","Control: 0.320<br />Experimental: 0.190<br />greater: control<br />event: lorlatinib, Fatigue, All Grades","Control: 0.140<br />Experimental: 0.110<br />greater: control<br />event: lorlatinib, Chest pain, All Grades","Control: 0.085<br />Experimental: 0.074<br />greater: control<br />event: lorlatinib, Pneumonia, All Grades","Control: 0.007<br />Experimental: 0.000<br />greater: control<br />event: lorlatinib, Headache, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: lorlatinib, Dizziness, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: lorlatinib, Cough, Grade 3-4","Control: 0.007<br />Experimental: 0.000<br />greater: control<br />event: lorlatinib, Vision disorder, Grade 3-4","Control: 0.021<br />Experimental: 0.007<br />greater: control<br />event: lorlatinib, Nausea, Grade 3-4","Control: 0.007<br />Experimental: 0.000<br />greater: control<br />event: lorlatinib, Constipation, Grade 3-4","Control: 0.014<br />Experimental: 0.007<br />greater: control<br />event: lorlatinib, Vomiting, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: lorlatinib, Pain in extremity, Grade 3-4","Control: 0.028<br />Experimental: 0.013<br />greater: control<br />event: lorlatinib, Fatigue, Grade 3-4","Control: 0.014<br />Experimental: 0.013<br />greater: control<br />event: lorlatinib, Pyrexia, Grade 3-4","Control: 0.014<br />Experimental: 0.007<br />greater: control<br />event: lorlatinib, Upper respiratory tract infection, Grade 3-4","Control: 0.035<br />Experimental: 0.020<br />greater: control<br />event: lorlatinib, Pneumonia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: lorlatinib, Rash, Grade 3-4","Control: 0.270<br />Experimental: 0.260<br />greater: control<br />event: cemiplimab-rwlc, Musculoskeletal paina, All Grades","Control: 0.500<br />Experimental: 0.150<br />greater: control<br />event: cemiplimab-rwlc, Anemia, All Grades","Control: 0.260<br />Experimental: 0.140<br />greater: control<br />event: cemiplimab-rwlc, Fatigue, All Grades","Control: 0.180<br />Experimental: 0.120<br />greater: control<br />event: cemiplimab-rwlc, Decreased appetite, All Grades","Control: 0.120<br />Experimental: 0.110<br />greater: control<br />event: cemiplimab-rwlc, Pneumonia, All Grades","Control: 0.015<br />Experimental: 0.006<br />greater: control<br />event: cemiplimab-rwlc, Musculoskeletal paina, Grade 3-4","Control: 0.160<br />Experimental: 0.034<br />greater: control<br />event: cemiplimab-rwlc, Anemia, Grade 3-4","Control: 0.020<br />Experimental: 0.011<br />greater: control<br />event: cemiplimab-rwlc, Fatigue, Grade 3-4","Control: 0.050<br />Experimental: 0.050<br />greater: control<br />event: cemiplimab-rwlc, Pneumonia, Grade 3-4","Control: 0.003<br />Experimental: 0.000<br />greater: control<br />event: cemiplimab-rwlc, Cough, Grade 3-4","Control: 0.310<br />Experimental: 0.270<br />greater: control<br />event: nivolumab + cabozantinib, Nausea, Grades 1-4","Control: 0.210<br />Experimental: 0.170<br />greater: control<br />event: nivolumab + cabozantinib, Vomiting, Grades 1-4","Control: 0.220<br />Experimental: 0.150<br />greater: control<br />event: nivolumab + cabozantinib, Dyspepsia, Grades 1-4","Control: 0.410<br />Experimental: 0.400<br />greater: control<br />event: nivolumab + cabozantinib, Palmar-plantar erythrodysesthesia, Grades 1-4","Control: 0.460<br />Experimental: 0.370<br />greater: control<br />event: nivolumab + cabozantinib, Stomatitis, Grades 1-4","Control: 0.390<br />Experimental: 0.360<br />greater: control<br />event: nivolumab + cabozantinib, Hypertension, Grades 1-4","Control: 0.003<br />Experimental: 0.000<br />greater: control<br />event: nivolumab + cabozantinib, Dyspepsia, Grade 3-4","Control: 0.080<br />Experimental: 0.080<br />greater: control<br />event: nivolumab + cabozantinib, Fatigue, Grade 3-4","Control: 0.080<br />Experimental: 0.080<br />greater: control<br />event: nivolumab + cabozantinib, Palmar-plantar erythrodysesthesia, Grade 3-4","Control: 0.044<br />Experimental: 0.034<br />greater: control<br />event: nivolumab + cabozantinib, Stomatitis, Grade 3-4","Control: 0.140<br />Experimental: 0.130<br />greater: control<br />event: nivolumab + cabozantinib, Hypertension, Grade 3-4","Control: 0.003<br />Experimental: 0.003<br />greater: control<br />event: nivolumab + cabozantinib, Hypothyroidism, Grade 3-4","Control: 0.003<br />Experimental: 0.003<br />greater: control<br />event: nivolumab + cabozantinib, Arthralgia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: nivolumab + cabozantinib, Dysgeusia, Grade 3-4","Control: 0.006<br />Experimental: 0.000<br />greater: control<br />event: nivolumab + cabozantinib, Headache, Grade 3-4","Control: 0.003<br />Experimental: 0.003<br />greater: control<br />event: nivolumab + cabozantinib, Upper respiratory tract infection, Grade 3-4","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Upper respiratory tract infection, Grade 3-4","Control: 0.040<br />Experimental: 0.040<br />greater: control<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Dyspnea, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Arthralgia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Injection site reactions, Grade 3-4","Control: 0.320<br />Experimental: 0.320<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Diarrhea, All Grades","Control: 0.150<br />Experimental: 0.140<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Abdominal pain, All Grades","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Vomiting, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Constipation, Grade 3-4","Control: 0.032<br />Experimental: 0.008<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Abdominal pain, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Pyrexia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Edema peripheral, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: fam-trastuzumab deruxtecan-nxki, Alopecia, Grade 3-4","Control: 0.016<br />Experimental: 0.011<br />greater: control<br />event: relugolix, Musculoskeletal pain, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: relugolix, Constipation, Grade 3-4","Control: 0.470<br />Experimental: 0.320<br />greater: control<br />event: selinexor + bortezomib + dexamethasone, Peripheral neuropathy, All Grades","Control: 0.090<br />Experimental: 0.046<br />greater: control<br />event: selinexor + bortezomib + dexamethasone, Peripheral neuropathy, Grade 3-4","Control: 0.250<br />Experimental: 0.250<br />greater: control<br />event: margetuximab + chemotherapy, Diarrhea, All Grades","Control: 0.210<br />Experimental: 0.170<br />greater: control<br />event: margetuximab + chemotherapy, Abdominal paina, All Grades","Control: 0.150<br />Experimental: 0.130<br />greater: control<br />event: margetuximab + chemotherapy, Palmar-plantar erythrodysesthesia, All Grades","Control: 0.140<br />Experimental: 0.140<br />greater: control<br />event: margetuximab + chemotherapy, Decreased appetite, All Grades","Control: 0.004<br />Experimental: 0.004<br />greater: control<br />event: margetuximab + chemotherapy, Pyrexia, Grade 3-4","Control: 0.023<br />Experimental: 0.023<br />greater: control<br />event: margetuximab + chemotherapy, Diarrhea, Grade 3-4","Control: 0.015<br />Experimental: 0.008<br />greater: control<br />event: margetuximab + chemotherapy, Vomiting, Grade 3-4","Control: 0.008<br />Experimental: 0.008<br />greater: control<br />event: margetuximab + chemotherapy, Constipation, Grade 3-4","Control: 0.015<br />Experimental: 0.015<br />greater: control<br />event: margetuximab + chemotherapy, Abdominal paina, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: margetuximab + chemotherapy, Alopecia, Grade 3-4","Control: 0.030<br />Experimental: 0.000<br />greater: control<br />event: margetuximab + chemotherapy, Palmar-plantar erythrodysesthesia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: margetuximab + chemotherapy, Headache, Grade 3-4","Control: 0.023<br />Experimental: 0.011<br />greater: control<br />event: margetuximab + chemotherapy, Peripheral neuropathy, Grade 3-4","Control: 0.023<br />Experimental: 0.011<br />greater: control<br />event: margetuximab + chemotherapy, Dyspnea, Grade 3-4","Control: 0.004<br />Experimental: 0.004<br />greater: control<br />event: margetuximab + chemotherapy, Decreased appetite, Grade 3-4","Control: 0.008<br />Experimental: 0.004<br />greater: control<br />event: margetuximab + chemotherapy, Arthralgia/Myalgia, Grade 3-4","Control: 0.240<br />Experimental: 0.140<br />greater: control<br />event: pembrolizumab, Nausea, All Grades","Control: 0.200<br />Experimental: 0.140<br />greater: control<br />event: pembrolizumab, Vomiting, All Grades","Control: 0.130<br />Experimental: 0.110<br />greater: control<br />event: pembrolizumab, Abdominal, All Grades","Control: 0.220<br />Experimental: 0.200<br />greater: control<br />event: pembrolizumab, Fatigue, All Grades","Control: 0.430<br />Experimental: 0.110<br />greater: control<br />event: pembrolizumab, Peripheral neuropathyø, All Grades","Control: 0.110<br />Experimental: 0.110<br />greater: control<br />event: pembrolizumab, Headache, All Grades","Control: 0.007<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Urinary tract infection, Grade 3-4","Control: 0.013<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Musculoskeletal pain, Grade 3-4","Control: 0.007<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Nausea, Grade 3-4","Control: 0.013<br />Experimental: 0.007<br />greater: control<br />event: pembrolizumab, Abdominal, Grade 3-4","Control: 0.007<br />Experimental: 0.007<br />greater: control<br />event: pembrolizumab, pyrexia, Grade 3-4","Control: 0.007<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Fatigue, Grade 3-4","Control: 0.007<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Rash, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Pruritus, Grade 3-4","Control: 0.007<br />Experimental: 0.007<br />greater: control<br />event: pembrolizumab, Cough, Grade 3-4","Control: 0.007<br />Experimental: 0.007<br />greater: control<br />event: pembrolizumab, Dyspnea, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Hypothyroidism, Grade 3-4","Control: 0.070<br />Experimental: 0.007<br />greater: control<br />event: pembrolizumab, Peripheral neuropathyø, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Headache, Grade 3-4","Control: 0.450<br />Experimental: 0.430<br />greater: control<br />event: nivolumab + ipilimumab, Fatigue, All Grades","Control: 0.430<br />Experimental: 0.240<br />greater: control<br />event: nivolumab + ipilimumab, Nausea, All Grades","Control: 0.300<br />Experimental: 0.190<br />greater: control<br />event: nivolumab + ipilimumab, Consti ation, All Grades","Control: 0.180<br />Experimental: 0.140<br />greater: control<br />event: nivolumab + ipilimumab, Vomiting, All Grades","Control: 0.250<br />Experimental: 0.240<br />greater: control<br />event: nivolumab + ipilimumab, Decreased appetite, All Grades","Control: 0.060<br />Experimental: 0.043<br />greater: control<br />event: nivolumab + ipilimumab, Fatigue, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: nivolumab + ipilimumab, Edema, Grade 3-4","Control: 0.025<br />Experimental: 0.007<br />greater: control<br />event: nivolumab + ipilimumab, Nausea, Grade 3-4","Control: 0.007<br />Experimental: 0.003<br />greater: control<br />event: nivolumab + ipilimumab, Consti ation, Grade 3-4","Control: 0.021<br />Experimental: 0.000<br />greater: control<br />event: nivolumab + ipilimumab, Vomiting, Grade 3-4","Control: 0.032<br />Experimental: 0.023<br />greater: control<br />event: nivolumab + ipilimumab, Dyspnea, Grade 3-4","Control: 0.014<br />Experimental: 0.010<br />greater: control<br />event: nivolumab + ipilimumab, Decreased appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: nivolumab + ipilimumab, Hypothyroidism, Grade 3-4","Control: 0.210<br />Experimental: 0.210<br />greater: control<br />event: carfilzomib + daratumumab + dexamethasone, Cough, All Grades","Control: 0.220<br />Experimental: 0.200<br />greater: control<br />event: carfilzomib + daratumumab + dexamethasone, Dyspnea, All Grades","Control: 0.007<br />Experimental: 0.000<br />greater: control<br />event: carfilzomib + daratumumab + dexamethasone, Nausea, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: carfilzomib + daratumumab + dexamethasone, Cough, Grade 3-4","Control: 0.017<br />Experimental: 0.017<br />greater: control<br />event: avelumab, Fatigue, Grade 3-4","Control: 0.026<br />Experimental: 0.012<br />greater: control<br />event: avelumab, Musculoskeletal pain, Grade 3-4","Control: 0.006<br />Experimental: 0.003<br />greater: control<br />event: avelumab, Nausea, Grade 3-4","Control: 0.006<br />Experimental: 0.003<br />greater: control<br />event: avelumab, Decreased appetite, Grade 3-4","Control: 0.280<br />Experimental: 0.220<br />greater: control<br />event: nivolumab, Rash, All Grades","Control: 0.350<br />Experimental: 0.210<br />greater: control<br />event: nivolumab, Decreased appetite, All Grades","Control: 0.190<br />Experimental: 0.170<br />greater: control<br />event: nivolumab, Constipation, All Grades","Control: 0.200<br />Experimental: 0.110<br />greater: control<br />event: nivolumab, Nausea, All Grades","Control: 0.260<br />Experimental: 0.170<br />greater: control<br />event: nivolumab, Musculoskeletal pain, All Grades","Control: 0.190<br />Experimental: 0.130<br />greater: control<br />event: nivolumab, Pneumonia, All Grades","Control: 0.190<br />Experimental: 0.160<br />greater: control<br />event: nivolumab, Pyrexia, All Grades","Control: 0.270<br />Experimental: 0.120<br />greater: control<br />event: nivolumab, Fatigue, All Grades","Control: 0.300<br />Experimental: 0.130<br />greater: control<br />event: nivolumab, Anemia, All Grades","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: nivolumab, Pruritus, Grade 3-4","Control: 0.050<br />Experimental: 0.019<br />greater: control<br />event: nivolumab, Decreased appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: nivolumab, Constipation, Grade 3-4","Control: 0.005<br />Experimental: 0.000<br />greater: control<br />event: nivolumab, Nausea, Grade 3-4","Control: 0.014<br />Experimental: 0.000<br />greater: control<br />event: nivolumab, Musculoskeletal pain, Grade 3-4","Control: 0.090<br />Experimental: 0.050<br />greater: control<br />event: nivolumab, Pneumonia, Grade 3-4","Control: 0.005<br />Experimental: 0.000<br />greater: control<br />event: nivolumab, Cough, Grade 3-4","Control: 0.005<br />Experimental: 0.005<br />greater: control<br />event: nivolumab, Pyrexia, Grade 3-4","Control: 0.048<br />Experimental: 0.014<br />greater: control<br />event: nivolumab, Fatigue, Grade 3-4","Control: 0.130<br />Experimental: 0.080<br />greater: control<br />event: nivolumab, Anemia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: nivolumab, Hypothyroidism, Grade 3-4","Control: 0.320<br />Experimental: 0.260<br />greater: control<br />event: atezolizumab + bevacizumab, Fatigue/asthenia, All Grades","Control: 0.170<br />Experimental: 0.120<br />greater: control<br />event: atezolizumab + bevacizumab, Rash, All Grades","Control: 0.490<br />Experimental: 0.190<br />greater: control<br />event: atezolizumab + bevacizumab, Diarrhea, All Grades","Control: 0.140<br />Experimental: 0.130<br />greater: control<br />event: atezolizumab + bevacizumab, Constipation, All Grades","Control: 0.170<br />Experimental: 0.120<br />greater: control<br />event: atezolizumab + bevacizumab, Abdominal Pain, All Grades","Control: 0.160<br />Experimental: 0.120<br />greater: control<br />event: atezolizumab + bevacizumab, Nausea, All Grades","Control: 0.240<br />Experimental: 0.180<br />greater: control<br />event: atezolizumab + bevacizumab, Decreased Appetite, All Grades","Control: 0.060<br />Experimental: 0.020<br />greater: control<br />event: atezolizumab + bevacizumab, Fatigue/asthenia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: atezolizumab + bevacizumab, Pyrexia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: atezolizumab + bevacizumab, Weight Decreased, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: atezolizumab + bevacizumab, Pruritus, Grade 3-4","Control: 0.026<br />Experimental: 0.000<br />greater: control<br />event: atezolizumab + bevacizumab, Rash, Grade 3-4","Control: 0.050<br />Experimental: 0.018<br />greater: control<br />event: atezolizumab + bevacizumab, Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: atezolizumab + bevacizumab, Constipation, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: atezolizumab + bevacizumab, Abdominal Pain, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: atezolizumab + bevacizumab, Nausea, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: atezolizumab + bevacizumab, Vomiting, Grade 3-4","Control: 0.038<br />Experimental: 0.012<br />greater: control<br />event: atezolizumab + bevacizumab, Decreased Appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: atezolizumab + bevacizumab, Cough, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: atezolizumab + bevacizumab, Epistaxis, Grade 3-4","Control: 0.410<br />Experimental: 0.320<br />greater: control<br />event: nivolumab + ipilimumab + chemotherapy, Nausea, All Grades","Control: 0.230<br />Experimental: 0.210<br />greater: control<br />event: nivolumab + ipilimumab + chemotherapy, Constipation, All Grades","Control: 0.006<br />Experimental: 0.006<br />greater: control<br />event: nivolumab + ipilimumab + chemotherapy, Pyrexia, Grade 3-4","Control: 0.006<br />Experimental: 0.006<br />greater: control<br />event: nivolumab + ipilimumab + chemotherapy, Constipation, Grade 3-4","Control: 0.009<br />Experimental: 0.006<br />greater: control<br />event: nivolumab + ipilimumab + chemotherapy, Abdominal pain, Grade 3-4","Control: 0.009<br />Experimental: 0.006<br />greater: control<br />event: nivolumab + ipilimumab + chemotherapy, Cough, Grade 3-4","Control: 0.570<br />Experimental: 0.530<br />greater: control<br />event: brigatinib, Diarrhea, All Grades","Control: 0.580<br />Experimental: 0.300<br />greater: control<br />event: brigatinib, Nausea, All Grades","Control: 0.330<br />Experimental: 0.240<br />greater: control<br />event: brigatinib, Abdominal pain, All Grades","Control: 0.440<br />Experimental: 0.210<br />greater: control<br />event: brigatinib, Vomiting, All Grades","Control: 0.420<br />Experimental: 0.180<br />greater: control<br />event: brigatinib, Constipation, All Grades","Control: 0.160<br />Experimental: 0.080<br />greater: control<br />event: brigatinib, Dyspepsia, All Grades","Control: 0.110<br />Experimental: 0.007<br />greater: control<br />event: brigatinib, Gastroesophageal reflux disease, All Grades","Control: 0.058<br />Experimental: 0.022<br />greater: control<br />event: brigatinib, Pulmonary embolism, All Grades","Control: 0.400<br />Experimental: 0.320<br />greater: control<br />event: brigatinib, Fatigue, All Grades","Control: 0.480<br />Experimental: 0.180<br />greater: control<br />event: brigatinib, Edema, All Grades","Control: 0.150<br />Experimental: 0.150<br />greater: control<br />event: brigatinib, Pyrexia, All Grades","Control: 0.150<br />Experimental: 0.051<br />greater: control<br />event: brigatinib, Pain in extremity, All Grades","Control: 0.200<br />Experimental: 0.150<br />greater: control<br />event: brigatinib, Dizziness, All Grades","Control: 0.180<br />Experimental: 0.110<br />greater: control<br />event: brigatinib, Peripheral neuropathy, All Grades","Control: 0.140<br />Experimental: 0.029<br />greater: control<br />event: brigatinib, Dysgeusia, All Grades","Control: 0.230<br />Experimental: 0.120<br />greater: control<br />event: brigatinib, Bradycardia, All Grades","Control: 0.110<br />Experimental: 0.080<br />greater: control<br />event: brigatinib, Nasopharyngitis, All Grades","Control: 0.088<br />Experimental: 0.059<br />greater: control<br />event: brigatinib, Urinary tract infection, All Grades","Control: 0.190<br />Experimental: 0.088<br />greater: control<br />event: brigatinib, Decreased Appetite, All Grades","Control: 0.530<br />Experimental: 0.074<br />greater: control<br />event: brigatinib, Visual Disturbance0e, All Grades","Control: 0.029<br />Experimental: 0.022<br />greater: control<br />event: brigatinib, Diarrhea, Grade 3-4","Control: 0.029<br />Experimental: 0.022<br />greater: control<br />event: brigatinib, Nausea, Grade 3-4","Control: 0.036<br />Experimental: 0.007<br />greater: control<br />event: brigatinib, Abdominal pain, Grade 3-4","Control: 0.022<br />Experimental: 0.007<br />greater: control<br />event: brigatinib, Vomiting, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: brigatinib, Constipation, Grade 3-4","Control: 0.007<br />Experimental: 0.000<br />greater: control<br />event: brigatinib, Dyspepsia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: brigatinib, Gastroesophageal reflux disease, Grade 3-4","Control: 0.007<br />Experimental: 0.007<br />greater: control<br />event: brigatinib, Pruritus, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: brigatinib, Cough, Grade 3-4","Control: 0.036<br />Experimental: 0.029<br />greater: control<br />event: brigatinib, Dyspnea, Grade 3-4","Control: 0.029<br />Experimental: 0.022<br />greater: control<br />event: brigatinib, Pulmonary embolism, Grade 3-4","Control: 0.022<br />Experimental: 0.015<br />greater: control<br />event: brigatinib, Fatigue, Grade 3-4","Control: 0.007<br />Experimental: 0.007<br />greater: control<br />event: brigatinib, Edema, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: brigatinib, Myalgia, Grade 3-4","Control: 0.015<br />Experimental: 0.007<br />greater: control<br />event: brigatinib, Back pain, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: brigatinib, Arthralgia, Grade 3-4","Control: 0.007<br />Experimental: 0.000<br />greater: control<br />event: brigatinib, Pain in extremity, Grade 3-4","Control: 0.007<br />Experimental: 0.007<br />greater: control<br />event: brigatinib, Dizziness, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: brigatinib, Dysgeusia, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: brigatinib, Increased Blood cholesterol, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: brigatinib, Upper respiratory tract infection, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: brigatinib, Nasopharyngitis, Grade 3-4","Control: 0.022<br />Experimental: 0.007<br />greater: control<br />event: brigatinib, Urinary tract infection, Grade 3-4","Control: 0.029<br />Experimental: 0.007<br />greater: control<br />event: brigatinib, Decreased Appetite, Grade 3-4","Control: 0.007<br />Experimental: 0.000<br />greater: control<br />event: brigatinib, Visual Disturbance0e, Grade 3-4","Control: 0.050<br />Experimental: 0.030<br />greater: control<br />event: olaparib, Fatigue (including asthenia), Grade 3-4","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: olaparib, Decreased appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: olaparib, Cough, Grade 3-4","Control: 0.340<br />Experimental: 0.140<br />greater: control<br />event: atezolizumab, Nausea, All Grades","Control: 0.220<br />Experimental: 0.120<br />greater: control<br />event: atezolizumab, Constipation, All Grades","Control: 0.120<br />Experimental: 0.110<br />greater: control<br />event: atezolizumab, Diarrhea, All Grades","Control: 0.340<br />Experimental: 0.250<br />greater: control<br />event: atezolizumab, Fatigue/asthenia, All Grades","Control: 0.190<br />Experimental: 0.150<br />greater: control<br />event: atezolizumab, Decreased appetite, All Grades","Control: 0.019<br />Experimental: 0.003<br />greater: control<br />event: atezolizumab, Nausea, Grade 3-4","Control: 0.008<br />Experimental: 0.000<br />greater: control<br />event: atezolizumab, Diarrhea, Grade 3-4","Control: 0.042<br />Experimental: 0.014<br />greater: control<br />event: atezolizumab, Fatigue/asthenia, Grade 3-4","Control: 0.004<br />Experimental: 0.000<br />greater: control<br />event: atezolizumab, Pyrexia, Grade 3-4","Control: 0.420<br />Experimental: 0.210<br />greater: control<br />event: nivolumab + ipilimumab, Nausea, All Grades","Control: 0.270<br />Experimental: 0.180<br />greater: control<br />event: nivolumab + ipilimumab, Constipation, All Grades","Control: 0.180<br />Experimental: 0.130<br />greater: control<br />event: nivolumab + ipilimumab, Vomiting, All Grades","Control: 0.005<br />Experimental: 0.002<br />greater: control<br />event: nivolumab + ipilimumab, Edema, Grade 3-4","Control: 0.025<br />Experimental: 0.010<br />greater: control<br />event: nivolumab + ipilimumab, Nausea, Grade 3-4","Control: 0.005<br />Experimental: 0.003<br />greater: control<br />event: nivolumab + ipilimumab, Constipation, Grade 3-4","Control: 0.023<br />Experimental: 0.010<br />greater: control<br />event: nivolumab + ipilimumab, Vomiting, Grade 3-4","Control: 0.007<br />Experimental: 0.002<br />greater: control<br />event: nivolumab + ipilimumab, Abdominal pain, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: nivolumab + ipilimumab, Hyperthyroidism, Grade 3-4","Control: 0.270<br />Experimental: 0.270<br />greater: control<br />event: ibrutinib + rituximab, Pyrexia, All Grades","Control: 0.640<br />Experimental: 0.400<br />greater: control<br />event: ibrutinib + rituximab, Nausea, All Grades","Control: 0.280<br />Experimental: 0.180<br />greater: control<br />event: ibrutinib + rituximab, Vomiting, All Grades","Control: 0.320<br />Experimental: 0.170<br />greater: control<br />event: ibrutinib + rituximab, Constipation, All Grades","Control: 0.200<br />Experimental: 0.150<br />greater: control<br />event: ibrutinib + rituximab, Decreased appetite, All Grades","Control: 0.190<br />Experimental: 0.160<br />greater: control<br />event: ibrutinib + rituximab, Insomnia, All Grades","Control: 0.410<br />Experimental: 0.340<br />greater: control<br />event: encorafenib + cetuximab, Nausea, All Grades","Control: 0.480<br />Experimental: 0.330<br />greater: control<br />event: encorafenib + cetuximab, Diarrhea, All Grades","Control: 0.320<br />Experimental: 0.300<br />greater: control<br />event: encorafenib + cetuximab, Abdominal pain, All Grades","Control: 0.290<br />Experimental: 0.210<br />greater: control<br />event: encorafenib + cetuximab, Vomiting, All Grades","Control: 0.180<br />Experimental: 0.150<br />greater: control<br />event: encorafenib + cetuximab, Constipation, All Grades","Control: 0.270<br />Experimental: 0.270<br />greater: control<br />event: encorafenib + cetuximab, Decreased appetite, All Grades","Control: 0.430<br />Experimental: 0.320<br />greater: control<br />event: encorafenib + cetuximab, Dermatitis acneiform, All Grades","Control: 0.260<br />Experimental: 0.260<br />greater: control<br />event: encorafenib + cetuximab, Rash, All Grades","Control: 0.080<br />Experimental: 0.070<br />greater: control<br />event: encorafenib + cetuximab, Fatigue, Grade ≥ 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: encorafenib + cetuximab, Pyrexia, Grade ≥ 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: encorafenib + cetuximab, Nausea, Grade ≥ 3","Control: 0.100<br />Experimental: 0.020<br />greater: control<br />event: encorafenib + cetuximab, Diarrhea, Grade ≥ 3","Control: 0.050<br />Experimental: 0.040<br />greater: control<br />event: encorafenib + cetuximab, Abdominal pain, Grade ≥ 3","Control: 0.030<br />Experimental: 0.010<br />greater: control<br />event: encorafenib + cetuximab, Vomiting, Grade ≥ 3","Control: 0.010<br />Experimental: 0.000<br />greater: control<br />event: encorafenib + cetuximab, Constipation, Grade ≥ 3","Control: 0.030<br />Experimental: 0.010<br />greater: control<br />event: encorafenib + cetuximab, Decreased appetite, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: encorafenib + cetuximab, Pain in extremity, Grade ≥ 3","Control: 0.030<br />Experimental: 0.010<br />greater: control<br />event: encorafenib + cetuximab, Dermatitis acneiform, Grade ≥ 3","Control: 0.020<br />Experimental: 0.000<br />greater: control<br />event: encorafenib + cetuximab, Rash, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: encorafenib + cetuximab, Pruritus, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: encorafenib + cetuximab, Melanocytic nevus, Grade ≥ 3","Control: 0.010<br />Experimental: 0.000<br />greater: control<br />event: encorafenib + cetuximab, Dry skin, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: encorafenib + cetuximab, Headache, Grade ≥ 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: encorafenib + cetuximab, Insomnia, Grade ≥ 3","Control: 0.340<br />Experimental: 0.340<br />greater: control<br />event: durvalumab + Etoposide + either Carboplatin or Cisplatin , Nausea, All Grades","Control: 0.190<br />Experimental: 0.170<br />greater: control<br />event: durvalumab + Etoposide + either Carboplatin or Cisplatin , Constipation, All Grades","Control: 0.170<br />Experimental: 0.150<br />greater: control<br />event: durvalumab + Etoposide + either Carboplatin or Cisplatin , Vomiting, All Grades","Control: 0.110<br />Experimental: 0.100<br />greater: control<br />event: durvalumab + Etoposide + either Carboplatin or Cisplatin , Diarrhea, All Grades","Control: 0.340<br />Experimental: 0.310<br />greater: control<br />event: durvalumab + Etoposide + either Carboplatin or Cisplatin , Alopecia, All Grades","Control: 0.320<br />Experimental: 0.320<br />greater: control<br />event: durvalumab + Etoposide + either Carboplatin or Cisplatin , Fatigue/Asthenia, All Grades","Control: 0.019<br />Experimental: 0.004<br />greater: control<br />event: durvalumab + Etoposide + either Carboplatin or Cisplatin , Nausea, Grade 3-4","Control: 0.011<br />Experimental: 0.000<br />greater: control<br />event: durvalumab + Etoposide + either Carboplatin or Cisplatin , Vomiting, Grade 3-4","Control: 0.011<br />Experimental: 0.011<br />greater: control<br />event: durvalumab + Etoposide + either Carboplatin or Cisplatin , Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: durvalumab + Etoposide + either Carboplatin or Cisplatin , Hyperthyroidisma, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: durvalumab + Etoposide + either Carboplatin or Cisplatin , Rash, Grade 3-4","Control: 0.008<br />Experimental: 0.008<br />greater: control<br />event: durvalumab + Etoposide + either Carboplatin or Cisplatin , Decreased appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: isatuximab-irfc, Nausea, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: isatuximab-irfc, Upper respiratory tract infection, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: isatuximab-irfc, Dyspnea, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: isatuximab-irfc, Diarrhea, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: isatuximab-irfc, Nausea, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: isatuximab-irfc, Vomiting, Grade 4","Control: 0.006<br />Experimental: 0.003<br />greater: control<br />event: neratinib +  Capecitabine, Abdominal distension, Grade 3","Control: 0.003<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Malaise, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Influenza like illness, Grade 3","Control: 0.003<br />Experimental: 0.003<br />greater: control<br />event: neratinib +  Capecitabine, Upper respiratory tract infection, Grade 3","Control: 0.003<br />Experimental: 0.003<br />greater: control<br />event: neratinib +  Capecitabine, Back Pain, Grade 3","Control: 0.010<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Arthralgia, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Muscle spasms, Grade 3","Control: 0.006<br />Experimental: 0.003<br />greater: control<br />event: neratinib +  Capecitabine, Dizziness, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Dysuria, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Diarrhea, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Nausea, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Vomiting, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Constipation, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Abdominal distension, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Fatigue/asthenia, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Malaise, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Influenza like illness, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Urinary tract infection, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Upper respiratory tract infection, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Decreased appetite, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Back Pain, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Arthralgia, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Muscle spasms, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Dizziness, Grade 4","Control: 0.003<br />Experimental: 0.003<br />greater: control<br />event: neratinib +  Capecitabine, Renal impairment, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: neratinib +  Capecitabine, Dysuria, Grade 4","Control: 0.270<br />Experimental: 0.220<br />greater: control<br />event: pembrolizumab, Increased bodyweight, Grade 1–2","Control: 0.170<br />Experimental: 0.150<br />greater: control<br />event: pembrolizumab, Cough, Grade 1–2","Control: 0.070<br />Experimental: 0.060<br />greater: control<br />event: pembrolizumab, Hypertension, Grade 1–2","Control: 0.110<br />Experimental: 0.100<br />greater: control<br />event: pembrolizumab, Dyspnoea, Grade 1–2","Control: 0.090<br />Experimental: 0.090<br />greater: control<br />event: pembrolizumab, Upper respiratory tract infection, Grade 1–2","Control: 0.080<br />Experimental: 0.080<br />greater: control<br />event: pembrolizumab, Back pain, Grade 1–2","Control: 0.080<br />Experimental: 0.070<br />greater: control<br />event: pembrolizumab, Headache, Grade 1–2","Control: 0.070<br />Experimental: 0.060<br />greater: control<br />event: pembrolizumab, Constipation, Grade 1–2","Control: 0.060<br />Experimental: 0.060<br />greater: control<br />event: pembrolizumab, Influenza-like illness, Grade 1–2","Control: 0.060<br />Experimental: 0.050<br />greater: control<br />event: pembrolizumab, Pyrexia, Grade 1–2","Control: 0.050<br />Experimental: 0.030<br />greater: control<br />event: pembrolizumab, Pain in extremity, Grade 1–2","Control: 0.060<br />Experimental: 0.030<br />greater: control<br />event: pembrolizumab, Paraesthesia, Grade 1–2","Control: 0.020<br />Experimental: 0.010<br />greater: control<br />event: pembrolizumab, Increased bodyweight, Grade 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: pembrolizumab, Pruritus, Grade 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: pembrolizumab, Arthralgia, Grade 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: pembrolizumab, Diarrhoea, Grade 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: pembrolizumab, Fatigue, Grade 3","Control: 0.060<br />Experimental: 0.060<br />greater: control<br />event: pembrolizumab, Hypertension, Grade 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: pembrolizumab, Dyspnoea, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Upper respiratory tract infection, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Nasopharyngitis, Grade 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: pembrolizumab, Increased alanine aminotransferase, Grade 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: pembrolizumab, Headache, Grade 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: pembrolizumab, Asthenia, Grade 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: pembrolizumab, Increased aspartate aminotransferase, Grade 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: pembrolizumab, Decreased appetite, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Decreased bodyweight, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Increased blood creatinine, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Productive cough, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Constipation, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Influenza-like illness, Grade 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: pembrolizumab, Pneumonitis, Grade 3","Control: 0.010<br />Experimental: 0.010<br />greater: control<br />event: pembrolizumab, Pyrexia, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Dry skin, Grade 3","Control: 0.010<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Pain in extremity, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Paraesthesia, Grade 3","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Increased bodyweight, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Pruritus, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Hypothyroidism, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Arthralgia, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Diarrhoea, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Fatigue, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Cough, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Hypertension, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Dyspnoea, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Hyperthyroidism, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Upper respiratory tract infection, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Nausea, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Nasopharyngitis, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Rash, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Increased alanine aminotransferase, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Back pain, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Headache, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Asthenia, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Maculopapular rash, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Increased aspartate aminotransferase, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Decreased appetite, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Decreased bodyweight, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Increased blood creatinine, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Myalgia, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Productive cough, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Constipation, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Influenza-like illness, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Pyrexia, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Dry skin, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Pain in extremity, Grade 4","Control: 0.000<br />Experimental: 0.000<br />greater: control<br />event: pembrolizumab, Paraesthesia, Grade 4"],"key":["talazoparib + enzalutamide, Fatigue, Grade 4","talazoparib + enzalutamide, Nausea, Grade 4","talazoparib + enzalutamide, Decreased appetite, Grade 3","talazoparib + enzalutamide, Decreased appetite, Grade 4","talazoparib + enzalutamide, Fractures, Grade 4","talazoparib + enzalutamide, Dizzy, Grade 3","talazoparib + enzalutamide, Dizzy, Grade 4","talazoparib + enzalutamide, Dysgeusiae, Grade 3","talazoparib + enzalutamide, Dysgeusiae, Grade 4","olaparib + abiraterone + prednisone (or prednisolone), Nausea, Grade 3-4","olaparib + abiraterone + prednisone (or prednisolone), Abdominal pain, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Neutropenia, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Thrombocytopenia, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Alanine aminotransferase increased, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Peripheral neuropathy, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Altered taste, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Headache, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Constipation, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Fatigue, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Infusion-related reaction, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Alopecia, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Musculoskeletal pain, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Lymphopenia, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Neutropenia, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Creatinine increased, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Aspartate aminotransferase increased, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Alkaline phosphatase increased, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Altered taste, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Headache, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Abdominal paind, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Fatigue, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Infusion-related reaction, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Alopecia, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Musculoskeletal pain, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Upper respiratory tract infection', Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Cough, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Dyspnea, Grade 3-4","sacituzumab govitecan-hziy, Decreased appetite, All grades","sacituzumab govitecan-hziy, Nausea, Grade 3-4","sacituzumab govitecan-hziy, Vomiting, Grade 3-4","sacituzumab govitecan-hziy, Abdominal Pain, Grade 3-4","sacituzumab govitecan-hziy, Dyspepsia, Grade 3-4","sacituzumab govitecan-hziy, Arthralgia, Grade 3-4","sacituzumab govitecan-hziy, Headache, Grade 3-4","sacituzumab govitecan-hziy, Dyspnea, Grade 3-4","sacituzumab govitecan-hziy, Cough, Grade 3-4","sacituzumab govitecan-hziy, Alopecia, Grade 3-4","sacituzumab govitecan-hziy, Pruritus, Grade 3-4","elacestrant, Fatigue, All grades","elacestrant, Headache, All grades","elacestrant, Diarrhea, Grade 3-4","elacestrant, Constipation, Grade 3-4","elacestrant, Dyspepsia, Grade 3-4","elacestrant, Hot flush , Grade 3-4","zanubrutinib, Rash, All grades","zanubrutinib, Constipation, All grades","zanubrutinib, Nausea, All grades","zanubrutinib, Fatigue, All grades","zanubrutinib, Rash, Grade 3-4","zanubrutinib, Bruising, Grade 3-4","zanubrutinib, Coughe, Grade 3-4","zanubrutinib, Diarrhea, Grade 3-4","zanubrutinib, Nausea, Grade 3-4","zanubrutinib, Fatigue, Grade 3-4","zanubrutinib, Headache, Grade 3-4","zanubrutinib, Pneumonia, All grades","zanubrutinib, Musculoskeletal pain, All grades","zanubrutinib, Hemorrhage, All grades","zanubrutinib, Hypertension, All grades","zanubrutinib, Rash, All grades","zanubrutinib, Diarrhea, All grades","zanubrutinib, Fatigue, All grades","zanubrutinib, Cough, All grades","zanubrutinib, Upper respiratory tract infection, Grade 3-4","zanubrutinib, Pneumonia, Grade 3-4","zanubrutinib, Musculoskeletal pain, Grade 3-4","zanubrutinib, Hemorrhage, Grade 3-4","zanubrutinib, Hypertension, Grade 3-4","zanubrutinib, Bruising, Grade 3-4","zanubrutinib, Fatigue, Grade 3-4","zanubrutinib, Dizziness, Grade 3-4","tremelimumab + durvalumab + platinum-based chemotherapy, Constipation, All grades","tremelimumab + durvalumab + platinum-based chemotherapy, Edema, All grades","tremelimumab + durvalumab + platinum-based chemotherapy, Cough/Productive Cough/, Grade 3-4","tremelimumab + durvalumab + platinum-based chemotherapy, Nausea, Grade 3-4","tremelimumab + durvalumab + platinum-based chemotherapy, Diarrhea, Grade 3-4","tremelimumab + durvalumab + platinum-based chemotherapy, Constipation, Grade 3-4","tremelimumab + durvalumab + platinum-based chemotherapy, Vomiting, Grade 3-4","tremelimumab + durvalumab + platinum-based chemotherapy, Stomatitis, Grade 3-4","tremelimumab + durvalumab + platinum-based chemotherapy, Hypothyroidism, Grade 3-4","tremelimumab + durvalumab + platinum-based chemotherapy, Alopecia, Grade 3-4","tremelimumab + durvalumab + platinum-based chemotherapy, Pruritus, Grade 3-4","tremelimumab + durvalumab + platinum-based chemotherapy, Pyrexia, Grade 3-4","tremelimumab + durvalumab + platinum-based chemotherapy, Edema, Grade 3-4","tremelimumab + durvalumab + platinum-based chemotherapy, Musculoskeletal Pain, Grade 3-4","tremelimumab + durvalumab + platinum-based chemotherapy, Upper respiratory tract infections, Grade 3-4","tremelimumab + durvalumab + platinum-based chemotherapy, Headachek, Grade 3-4","cemiplimab-rwlc + platinum-based chemotherapy, Alopecia, All grades","cemiplimab-rwlc + platinum-based chemotherapy, Musculoskeletal pain, All grades","cemiplimab-rwlc + platinum-based chemotherapy, Alopecia, Grade 3-4","cemiplimab-rwlc + platinum-based chemotherapy, Nausea, Grade 3-4","cemiplimab-rwlc + platinum-based chemotherapy, Vomiting, Grade 3-4","cemiplimab-rwlc + platinum-based chemotherapy, Peripheral neuropath, Grade 3-4","cemiplimab-rwlc + platinum-based chemotherapy, Insomnia, Grade 3-4","tremelimumab + durvalumab, Diarrhea, All grades","tremelimumab + durvalumab, Abdominal pain, All grades","tremelimumab + durvalumab, Nausea, All grades","tremelimumab + durvalumab, Rash, All grades","tremelimumab + durvalumab, Decreased appetite, All grades","tremelimumab + durvalumab, Fatigue, All grades","tremelimumab + durvalumab, Abdominal pain, Grade 3-4","tremelimumab + durvalumab, Nausea, Grade 3-4","tremelimumab + durvalumab, Rash, Grade 3-4","tremelimumab + durvalumab, Pruritus, Grade 3-4","tremelimumab + durvalumab, Fatigue, Grade 3-4","tremelimumab + durvalumab, Pyrexia, Grade 3-4","tremelimumab + durvalumab, Hypothyroidisml, Grade 3-4","durvalumab + gemcitabine + cisplatin, Fatigue, All grades","durvalumab + gemcitabine + cisplatin, Vomiting, All grades","durvalumab + gemcitabine + cisplatin, Insomnia, All grades","durvalumab + gemcitabine + cisplatin, Fatigue, Grade 3-4","durvalumab + gemcitabine + cisplatin, Nausea, Grade 3-4","durvalumab + gemcitabine + cisplatin, Abdominal pain, Grade 3-4","durvalumab + gemcitabine + cisplatin, Vomiting, Grade 3-4","durvalumab + gemcitabine + cisplatin, Diarrhea, Grade 3-4","durvalumab + gemcitabine + cisplatin, Pruritus, Grade 3-4","durvalumab + gemcitabine + cisplatin, Insomnia, Grade 3-4","darolutamide + docetaxel, Constipation, Grade 3-4","darolutamide + docetaxel, Decreased Appetite, Grade 3-4","darolutamide + docetaxel, Hemorrhage, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Pyrexia, All grades","fam-trastuzumab deruxtecan-nxki, Rashid, All grades","fam-trastuzumab deruxtecan-nxki, Peripheral neuropathy, All grades","fam-trastuzumab deruxtecan-nxki, Diarrhea, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Stomatitisb, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Alopecia, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Rashid, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Hemorrhage, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Peripheral neuropathy, Grade 3-4","lisocabtagene maraleucel, Thrombocytopenia, Grade 1–2","lisocabtagene maraleucel, Nausea, Grade 1–2","lisocabtagene maraleucel, Prolonged cytopeniat, Grade 1–2","lisocabtagene maraleucel, Diarrhoea, Grade 1–2","lisocabtagene maraleucel, Decreased appetite, Grade 1–2","lisocabtagene maraleucel, Hypokalaemia, Grade 1–2","lisocabtagene maraleucel, Vomiting, Grade 1–2","lisocabtagene maraleucel, Back pain, Grade 1–2","lisocabtagene maraleucel, Peripheral oedema, Grade 1–2","lisocabtagene maraleucel, Hypomagnesaemia, Grade 1–2","lisocabtagene maraleucel, Abdominal pain, Grade 1–2","lisocabtagene maraleucel, Tachycardia, Grade 1–2","lisocabtagene maraleucel, Peripheral sensory neuropathy, Grade 1–2","lisocabtagene maraleucel, Hypophosphataemia, Grade 1–2","lisocabtagene maraleucel, Dyspepsia, Grade 1–2","lisocabtagene maraleucel, Stomatitis, Grade 1–2","lisocabtagene maraleucel, Mucosal inflammation, Grade 1–2","lisocabtagene maraleucel, Anaemia, Grade ≥ 3","lisocabtagene maraleucel, Thrombocytopenia, Grade ≥ 3","lisocabtagene maraleucel, Nausea, Grade ≥ 3","lisocabtagene maraleucel, Fatigue, Grade ≥ 3","lisocabtagene maraleucel, Diarrhoea, Grade ≥ 3","lisocabtagene maraleucel, Decreased appetite, Grade ≥ 3","lisocabtagene maraleucel, Pyrexia, Grade ≥ 3","lisocabtagene maraleucel, Dizziness, Grade ≥ 3","lisocabtagene maraleucel, Hypokalaemia, Grade ≥ 3","lisocabtagene maraleucel, Insomnia, Grade ≥ 3","lisocabtagene maraleucel, Vomiting, Grade ≥ 3","lisocabtagene maraleucel, Back pain, Grade ≥ 3","lisocabtagene maraleucel, Febrile neutropenia, Grade ≥ 3","lisocabtagene maraleucel, Hypomagnesaemia, Grade ≥ 3","lisocabtagene maraleucel, Arthralg ia, Grade ≥ 3","lisocabtagene maraleucel, Cough, Grade ≥ 3","lisocabtagene maraleucel, Dyspnoea, Grade ≥ 3","lisocabtagene maraleucel, Bone pain, Grade ≥ 3","lisocabtagene maraleucel, Tachycardia, Grade ≥ 3","lisocabtagene maraleucel, Peripheral sensory neuropathy, Grade ≥ 3","lisocabtagene maraleucel, Hypophosphataemia, Grade ≥ 3","lisocabtagene maraleucel, Dyspepsia, Grade ≥ 3","lisocabtagene maraleucel, Stomatitis, Grade ≥ 3","lisocabtagene maraleucel, Mucosal inflammation, Grade ≥ 3","ivosidenib + azacitidine, Nausea, Grade ≥ 3","ivosidenib + azacitidine, Vomiting, Grade ≥ 3","ivosidenib + azacitidine, Leukocytosis, Grade ≥ 3","ivosidenib + azacitidine, Hematoma, Grade ≥ 3","ivosidenib + azacitidine, Hypertension, Grade ≥ 3","ivosidenib + azacitidine, Dyspnea, Grade ≥ 3","ivosidenib + azacitidine, Headache, Grade ≥ 3","olaparib, Diarrhea, Grade 3-4","olaparib, Dysgeusia, Grade 3-4","olaparib, Dizziness, Grade 3-4","pembrolizumab, Hypothyroidism, Grade ≥ 3","pembrolizumab, Diarrhoea, Grade ≥ 3","pembrolizumab, Nausea, Grade ≥ 3","pembrolizumab, Increased alanine aminotransferase, Grade ≥ 3","pembrolizumab, Increased aspartate aminotransferase, Grade ≥ 3","pembrolizumab, Rash, Grade ≥ 3","pembrolizumab, Infusion reactions, Adverse events of interest: Any grade","pembrolizumab, Myocarditis, Adverse events of interest: Any grade","pembrolizumab, Hypothyroidism, Adverse events of interest: Grade ≥3","pembrolizumab, Infusion reactions, Adverse events of interest: Grade ≥3","pembrolizumab, Myocarditis, Adverse events of interest: Grade ≥3","pembrolizumab, Sarcoidosis, Adverse events of interest: Grade ≥3","pembrolizumab, Thyroiditis, Adverse events of interest: Grade ≥3","pembrolizumab, Uveitis, Adverse events of interest: Grade ≥3","pembrolizumab, Abdominal, All grades","pembrolizumab, Cough, Grade 3-4","pembrolizumab + chemotherapy + (bevacizumab?), Alopecia, All grades","pembrolizumab + chemotherapy + (bevacizumab?), Nausea, All grades","pembrolizumab + chemotherapy + (bevacizumab?), Constipation, All grades","pembrolizumab + chemotherapy + (bevacizumab?), Vomiting, All grades","pembrolizumab + chemotherapy + (bevacizumab?), Urinary tract infection, All grades","pembrolizumab + chemotherapy + (bevacizumab?), Peripheral neuropathy, Grade 3-4","pembrolizumab + chemotherapy + (bevacizumab?), Alopecia, Grade 3-4","pembrolizumab + chemotherapy + (bevacizumab?), Diarrhea, Grade 3-4","pembrolizumab + chemotherapy + (bevacizumab?), Constipation, Grade 3-4","pembrolizumab + chemotherapy + (bevacizumab?), Arthralgia, Grade 3-4","pembrolizumab + chemotherapy + (bevacizumab?), Hypertension, Grade 3-4","cabozantinib, Dysgeusia, Grade 3-4","cabozantinib, Dysphonia, Grade 3-4","ivosidenib, Fatigue, Grade ≥ 3","ivosidenib, Nausea, Grade ≥ 3","ivosidenib, Diarrhea, Grade ≥ 3","ivosidenib, Abdominal pain, Grade ≥ 3","ivosidenib, Cough, Grade ≥ 3","ivosidenib, Headache, Grade ≥ 3","ivosidenib, Neuropathy, Grade ≥ 3","nivolumab, Prexia, All grades","nivolumab, Abdominal pain, All grades","nivolumab, Constipation, All grades","nivolumab, Arthralgia, All grades","nivolumab, Urinary tract infection, All grades","nivolumab, Upper respiratory tract infection, All grades","nivolumab, Pruritus, Grade 3-4","nivolumab, Prexia, Grade 3-4","nivolumab, Constipation, Grade 3-4","nivolumab, Musculoskeletal pain, Grade 3-4","nivolumab, Urinary tract infection, Grade 3-4","nivolumab, Upper respiratory tract infection, Grade 3-4","nivolumab, Hyperthyroidism, Grade 3-4","nivolumab, Hypothyroidism, Grade 3-4","nivolumab, Cough, Grade 3-4","nivolumab, Dyspnea, Grade 3-4","pembrolizumab + chemotherapy, Peripheral neuropathy, All grades","pembrolizumab + chemotherapy, Arthralgia , All grades","pembrolizumab + chemotherapy, Constipation, Grade 3-4","pembrolizumab + chemotherapy, Abdominal pain, Grade 3-4","pembrolizumab + chemotherapy, Alopecia, Grade 3-4","pembrolizumab + chemotherapy, Headache, Grade 3-4","nivolumab, Diarrhea, All grades","nivolumab, Abdominal Pain, All grades","nivolumab, Vomiting, All grades","nivolumab, Dysphagia, All grades","nivolumab, Dyspepsia, All grades","nivolumab, Constipation, All grades","nivolumab, cough, All grades","nivolumab, Dyspnea, All grades","nivolumab, Abdominal Pain, Grade 3-4","nivolumab, Vomiting, Grade 3-4","nivolumab, Dysphagia, Grade 3-4","nivolumab, Dyspepsia, Grade 3-4","nivolumab, Constipation, Grade 3-4","nivolumab, Fatigue, Grade 3-4","nivolumab, cough, Grade 3-4","nivolumab, Musculoskeletal pain, Grade 3-4","nivolumab, Hypothyroidism, Grade 3-4","pembrolizumab + chemotherapy, Constipation, All grades","pembrolizumab + chemotherapy, Weight loss, All grades","pembrolizumab + chemotherapy, Nausea, Grade 3-4","pembrolizumab + chemotherapy, Constipation, Grade 3-4","pembrolizumab + chemotherapy, Decreased appetite, Grade 3-4","pembrolizumab + chemotherapy, Weight loss, Grade 3-4","osimertinib, Cough, All grades","osimertinib, Musculoskeletal Pain, All grades","osimertinib, Pruritus, Grade ≥ 3","osimertinib, Cough, Grade ≥ 3","osimertinib, Musculoskeletal Pain, Grade ≥ 3","osimertinib, Nasopharyngitis, Grade ≥ 3","osimertinib, Dizziness, Grade ≥ 3","pembrolizumab + chemotherapy, Fatigue, All grades","pembrolizumab + chemotherapy, Nausea, All grades","pembrolizumab + chemotherapy, Alopecia, All grades","pembrolizumab + chemotherapy, Headache, All grades","pembrolizumab + chemotherapy, Nausea, Grade 3-4","pembrolizumab + chemotherapy, Diarrhea, Grade 3-4","pembrolizumab + chemotherapy, Vomiting, Grade 3-4","pembrolizumab + chemotherapy, Alopecia, Grade 3-4","pembrolizumab + chemotherapy, Cough, Grade 3-4","pembrolizumab + chemotherapy, Headache, Grade 3-4","venetoclax + azacitidine, Urinary tract infection, Grade 3-4","venetoclax + azacitidine, Dizziness, Grade 3-4","azacitidine, Arthralgia, TYPO","azacitidine, Decreased appetite, TYPO","azacitidine, Dizziness, TYPO","atezolizumab +  cobimetinib + vemurafenib, Photosensitivity reaction, All grades","atezolizumab +  cobimetinib + vemurafenib, Nausea, All grades","atezolizumab +  cobimetinib + vemurafenib, Hypertension, All grades","atezolizumab +  cobimetinib + vemurafenib, Pruritus, Grade 3-4","atezolizumab +  cobimetinib + vemurafenib, Photosensitivity reaction, Grade 3-4","atezolizumab +  cobimetinib + vemurafenib, Pyrexia, Grade 3-4","atezolizumab +  cobimetinib + vemurafenib, Nausea, Grade 3-4","atezolizumab +  cobimetinib + vemurafenib, Hypothyroidism, Grade 3-4","ramucirumab + erlotinib, Diarrhea, All grades","ramucirumab + erlotinib, Gastrointestinal hemorrhage, Grade ≥ 3","ramucirumab + erlotinib, Gingival bleeding, Grade ≥ 3","ramucirumab + erlotinib, Alopecia, Grade ≥ 3","ramucirumab + erlotinib, Epistaxis, Grade ≥ 3","ramucirumab + erlotinib, Pulmonary hemorrhageq, Grade ≥ 3","ripretinib, Asthenia, Grades 1-4","ripretinib, Alopecia, Grade 3-4","ripretinib, Palmar-plantar erythrodysesthesia syndrome, Grade 3-4","ripretinib, Dry skin, Grade 3-4","ripretinib, Pruritus, Grade 3-4","ripretinib, Asthenia, Grade 3-4","ripretinib, Diarrhea, Grade 3-4","ripretinib, Stomatitis, Grade 3-4","ripretinib, Arthralgia, Grade 3-4","ripretinib, Muscle spasms, Grade 3-4","ripretinib, Decreased appetite, Grade 3-4","ripretinib, Decreased weight, Grade 3-4","ripretinib, Headache, Grade 3-4","ripretinib, Dyspnea, Grade 3-4","olaparib + bevacizumab, Vomiting, TYPO","niraparib, Nausea, Grade 3-4","niraparib, Vomiting, Grade 3-4","niraparib, Dizziness, Grade 3-4","niraparib, Dyspnea, Grade 3-4","niraparib, Cough, Grade 3-4","tucatinib + trastuzumab + capecitabine, Vomiting, Grade 3","tucatinib + trastuzumab + capecitabine, Arthralgia, Grade 3","tucatinib + trastuzumab + capecitabine, Creatinine increased, Grade 3","tucatinib + trastuzumab + capecitabine, Peripheral neuropathy, Grade 3","tucatinib + trastuzumab + capecitabine, Epistaxis, Grade 3","tucatinib + trastuzumab + capecitabine, Nausea, Grade 4","tucatinib + trastuzumab + capecitabine, Vomiting, Grade 4","tucatinib + trastuzumab + capecitabine, Stomatitis, Grade 4","tucatinib + trastuzumab + capecitabine, Palmar-plantar erythrodysesthesia syndrome, Grade 4","tucatinib + trastuzumab + capecitabine, Rash, Grade 4","tucatinib + trastuzumab + capecitabine, Decreased appetite, Grade 4","tucatinib + trastuzumab + capecitabine, Anemia, Grade 4","tucatinib + trastuzumab + capecitabine, Arthralgia, Grade 4","tucatinib + trastuzumab + capecitabine, Creatinine increased, Grade 4","tucatinib + trastuzumab + capecitabine, Weight decreased, Grade 4","tucatinib + trastuzumab + capecitabine, Peripheral neuropathy, Grade 4","tucatinib + trastuzumab + capecitabine, Epistaxis, Grade 4","nivolumab + chemotherapy, Alopecia, All grades","nivolumab + chemotherapy, Constipation, Grade 3-4","nivolumab + chemotherapy, Vomiting, Grade 3-4","nivolumab + chemotherapy, Fatigue, Grade 3-4","nivolumab + chemotherapy, Pyrexiad, Grade 3-4","nivolumab + chemotherapy, Edemae, Grade 3-4","nivolumab + chemotherapy, Insomnia, Grade 3-4","nivolumab + chemotherapy, Pruritus, Grade 3-4","nivolumab + chemotherapy, Alopecia, Grade 3-4","nivolumab + chemotherapy, Cough, Grade 3-4","nivolumab + chemotherapy, Hypothyroidism, Grade 3-4","nivolumab + chemotherapy, Weight decreased, Grade 3-4","nivolumab + chemotherapy, Musculoskeletal pain, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Epistaxis, All grades","fam-trastuzumab deruxtecan-nxki, Peripheral neuropathy, All grades","fam-trastuzumab deruxtecan-nxki, Constipation, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Dyspepsia, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Respiratory infectiong, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Epistaxis, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Peripheral neuropathy, Grade 3-4","lutetium Lu 177 vipivotide tetraxetan + standard of care, Peripheral edema, Grade 3-4","lutetium Lu 177 vipivotide tetraxetan + standard of care, Dry mouth, Grade 3-4","lutetium Lu 177 vipivotide tetraxetan + standard of care, Dysgeusia, Grade 3-4","relatlimab-rmbw +nivolumab, Rash, Grade 3-4","relatlimab-rmbw +nivolumab, Pruritus, Grade 3-4","relatlimab-rmbw +nivolumab, Headache, Grade 3-4","relatlimab-rmbw +nivolumab, Hypothyroidisma, Grade 3-4","nivolumab + platinum-doublet chemotherapy, Nausea, All grades","nivolumab + platinum-doublet chemotherapy, Vomiting, All grades","nivolumab + platinum-doublet chemotherapy, Decreased appetite, All grades","nivolumab + platinum-doublet chemotherapy, Alopecia, All grades","nivolumab + platinum-doublet chemotherapy, Nausea, Grade 3-4","nivolumab + platinum-doublet chemotherapy, Constipation, Grade 3-4","nivolumab + platinum-doublet chemotherapy, Malaise, Grade 3-4","nivolumab + platinum-doublet chemotherapy, Decreased appetite, Grade 3-4","nivolumab + platinum-doublet chemotherapy, Alopecia, Grade 3-4","nivolumab + platinum-doublet chemotherapy, Peripheral neuropathy, Grade 3-4","tebentafusp-tebn, Dry skin, Grade 3-4","tebentafusp-tebn, Erythema, Grade 3-4","tebentafusp-tebn, Edemab, Grade 3-4","tebentafusp-tebn, Abdominal pain, Grade 3-4","tebentafusp-tebn, Diarrhea, Grade 3-4","tebentafusp-tebn, Headache, Grade 3-4","asciminib, Rash, All grades","asciminib, Diarrhea, All grades","asciminib, Nausea, All grades","asciminib, Abdominal pain, All grades","asciminib, Upper respiratory tract infection, Grade 3-4","asciminib, Arthralgia, Grade 3-4","asciminib, Fatigue, Grade 3-4","asciminib, Rash, Grade 3-4","asciminib, Diarrhea, Grade 3-4","asciminib, Abdominal pain, Grade 3-4","atezolizumab, Pruritus, Grade 3-4","atezolizumab, Hypothyroidism, Grade 3-4","atezolizumab, Cough, Grade 3-4","abemaciclib + endocrine therapy, Dizziness, Grade 3","abemaciclib + endocrine therapy, Alopecia, Grade 3","abemaciclib + endocrine therapy, Diarrhea, Grade 4","abemaciclib + endocrine therapy, Nausea, Grade 4","abemaciclib + endocrine therapy, Vomiting, Grade 4","abemaciclib + endocrine therapy, Stomatitis, Grade 4","abemaciclib + endocrine therapy, Fatigue, Grade 4","abemaciclib + endocrine therapy, Headache, Grade 4","abemaciclib + endocrine therapy, Dizziness, Grade 4","abemaciclib + endocrine therapy, Decreased appetite, Grade 4","abemaciclib + endocrine therapy, Rash, Grade 4","abemaciclib + endocrine therapy, Alopecia, Grade 4","ruxolitinib, Edema, All grades","ruxolitinib, Hemorrhage, All grades","ruxolitinib, Nausea, All grades","ruxolitinib, Diarrhea, All grades","ruxolitinib, Infections (pathogen not specified), Grade ≥ 3","ruxolitinib, Viral infections, Grade ≥ 3","ruxolitinib, Fatigue, Grade ≥ 3","ruxolitinib, Edema, Grade ≥ 3","ruxolitinib, Hypertension, Grade ≥ 3","ruxolitinib, Hemorrhage, Grade ≥ 3","ruxolitinib, Cough, Grade ≥ 3","ruxolitinib, Dyspnea, Grade ≥ 3","ruxolitinib, Nausea, Grade ≥ 3","ruxolitinib, Diarrhea, Grade ≥ 3","zanubrutinib, Pneumonia, All grades","zanubrutinib, Urinary tract infection, All grades","zanubrutinib, Diarrhea, All grades","zanubrutinib, Vomiting, All grades","zanubrutinib, Edema peripheral, All grades","zanubrutinib, Bruising, All grades","zanubrutinib, Rash, All grades","zanubrutinib, Muscle spasms, All grades","zanubrutinib, Cough, All grades","zanubrutinib, Hemorrhage, All grades","zanubrutinib, Hypertension, All grades","zanubrutinib, Upper respiratory tract infection, Grade 3-4","zanubrutinib, Pneumonia, Grade 3-4","zanubrutinib, Urinary tract infection, Grade 3-4","zanubrutinib, Nausea, Grade 3-4","zanubrutinib, Constipation, Grade 3-4","zanubrutinib, Vomiting, Grade 3-4","zanubrutinib, Fatigue, Grade 3-4","zanubrutinib, Edema peripheral, Grade 3-4","zanubrutinib, Bruising, Grade 3-4","zanubrutinib, Rash, Grade 3-4","zanubrutinib, Muscle spasms, Grade 3-4","zanubrutinib, Headache, Grade 3-4","zanubrutinib, Cough, Grade 3-4","zanubrutinib, Dyspnea, Grade 3-4","zanubrutinib, Hemorrhage, Grade 3-4","zanubrutinib, Hypertension, Grade 3-4","lenvatinib + pembrolizumab, Stomatitis, All Grades","lenvatinib + pembrolizumab, Palmar-plantar erythrodysaesthesia syndrome, All Grades","lenvatinib + pembrolizumab, Stomatitis, Grade 3-4","lenvatinib + pembrolizumab, Palmar-plantar erythrodysaesthesia syndrome, Grade 3-4","lenvatinib + pembrolizumab, Dysphonia, Grade 3-4","lenvatinib + pembrolizumab, Headache, Grade 3-4","pembrolizumab + lenvatinib, Constipation, Grade 3-4","pembrolizumab + lenvatinib, Dysphonia, Grade 3-4","daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Pyrexia, Grade ≥ 3","daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Edema peripheral, Grade ≥ 3","daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Upper respiratory infection, Grade ≥ 3","daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Cough, Grade ≥ 3","sacituzumab govitecan, Lymphopenia, Grade 3-4","sacituzumab govitecan, Fatigue, Grade 3-4","sacituzumab govitecan, Pyrexia, Grade 3-4","sacituzumab govitecan, Urinary tract infection, Grade 3-4","sacituzumab govitecan, Upper respiratory tract infection, Grade 3-4","sacituzumab govitecan, Alanine aminotransferase increased, Grade 3-4","sacituzumab govitecan, Hypomagnesaemia, Grade 3-4","sacituzumab govitecan, Back pain, Grade 3-4","sacituzumab govitecan, Dizziness, Grade 3-4","sacituzumab govitecan, Insomnia, Grade 3-4","sacituzumab govitecan, Cough, Grade 3-4","sacituzumab govitecan, Alopecia, Grade 3-4","sacituzumab govitecan, Rash, Grade 3-4","sacituzumab govitecan, Pruritus, Grade 3-4","isatuximab-irfc + Carfilzomib + Dexamethasone, Cough, Grade 3","isatuximab-irfc + Carfilzomib + Dexamethasone, Infusion-related reaction, Grade 4","isatuximab-irfc + Carfilzomib + Dexamethasone, Upper respiratory tract infection, Grade 4","isatuximab-irfc + Carfilzomib + Dexamethasone, Bronchitis, Grade 4","isatuximab-irfc + Carfilzomib + Dexamethasone, Hypertension, Grade 4","isatuximab-irfc + Carfilzomib + Dexamethasone, Dyspnea, Grade 4","isatuximab-irfc + Carfilzomib + Dexamethasone, Cough, Grade 4","isatuximab-irfc + Carfilzomib + Dexamethasone, Diarrhea, Grade 4","isatuximab-irfc + Carfilzomib + Dexamethasone, Vomiting, Grade 4","isatuximab-irfc + Carfilzomib + Dexamethasone, Fatigue, Grade 4","tivozanib, Any, All Grades","tivozanib, Diarrhea, All Grades","tivozanib, Stomatitis, All Grades","tivozanib, Rash, All Grades","tivozanib, Palmar-plantar erythrodysesthesia syndrome, All Grades","tivozanib, Weight decreased, All Grades","tivozanib, Any, Grade 3-4","tivozanib, Diarrhea, Grade 3-4","tivozanib, Nausea, Grade 3-4","tivozanib, Stomatitis, Grade 3-4","tivozanib, Vomiting, Grade 3-4","tivozanib, Cough, Grade 3-4","tivozanib, Back pain, Grade 3-4","tivozanib, Rash, Grade 3-4","tivozanib, Palmar-plantar erythrodysesthesia syndrome, Grade 3-4","tivozanib, Weight decreased, Grade 3-4","lorlatinib, Headache, All Grades","lorlatinib, Dizziness, All Grades","lorlatinib, Cough, All Grades","lorlatinib, Vision disorder, All Grades","lorlatinib, Diarrhea, All Grades","lorlatinib, Nausea, All Grades","lorlatinib, Constipation, All Grades","lorlatinib, Vomiting, All Grades","lorlatinib, Fatigue, All Grades","lorlatinib, Chest pain, All Grades","lorlatinib, Pneumonia, All Grades","lorlatinib, Headache, Grade 3-4","lorlatinib, Dizziness, Grade 3-4","lorlatinib, Cough, Grade 3-4","lorlatinib, Vision disorder, Grade 3-4","lorlatinib, Nausea, Grade 3-4","lorlatinib, Constipation, Grade 3-4","lorlatinib, Vomiting, Grade 3-4","lorlatinib, Pain in extremity, Grade 3-4","lorlatinib, Fatigue, Grade 3-4","lorlatinib, Pyrexia, Grade 3-4","lorlatinib, Upper respiratory tract infection, Grade 3-4","lorlatinib, Pneumonia, Grade 3-4","lorlatinib, Rash, Grade 3-4","cemiplimab-rwlc, Musculoskeletal paina, All Grades","cemiplimab-rwlc, Anemia, All Grades","cemiplimab-rwlc, Fatigue, All Grades","cemiplimab-rwlc, Decreased appetite, All Grades","cemiplimab-rwlc, Pneumonia, All Grades","cemiplimab-rwlc, Musculoskeletal paina, Grade 3-4","cemiplimab-rwlc, Anemia, Grade 3-4","cemiplimab-rwlc, Fatigue, Grade 3-4","cemiplimab-rwlc, Pneumonia, Grade 3-4","cemiplimab-rwlc, Cough, Grade 3-4","nivolumab + cabozantinib, Nausea, Grades 1-4","nivolumab + cabozantinib, Vomiting, Grades 1-4","nivolumab + cabozantinib, Dyspepsia, Grades 1-4","nivolumab + cabozantinib, Palmar-plantar erythrodysesthesia, Grades 1-4","nivolumab + cabozantinib, Stomatitis, Grades 1-4","nivolumab + cabozantinib, Hypertension, Grades 1-4","nivolumab + cabozantinib, Dyspepsia, Grade 3-4","nivolumab + cabozantinib, Fatigue, Grade 3-4","nivolumab + cabozantinib, Palmar-plantar erythrodysesthesia, Grade 3-4","nivolumab + cabozantinib, Stomatitis, Grade 3-4","nivolumab + cabozantinib, Hypertension, Grade 3-4","nivolumab + cabozantinib, Hypothyroidism, Grade 3-4","nivolumab + cabozantinib, Arthralgia, Grade 3-4","nivolumab + cabozantinib, Dysgeusia, Grade 3-4","nivolumab + cabozantinib, Headache, Grade 3-4","nivolumab + cabozantinib, Upper respiratory tract infection, Grade 3-4","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Upper respiratory tract infection, Grade 3-4","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Dyspnea, Grade 3-4","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Arthralgia, Grade 3-4","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Injection site reactions, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Diarrhea, All Grades","fam-trastuzumab deruxtecan-nxki, Abdominal pain, All Grades","fam-trastuzumab deruxtecan-nxki, Vomiting, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Constipation, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Abdominal pain, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Pyrexia, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Edema peripheral, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Alopecia, Grade 3-4","relugolix, Musculoskeletal pain, Grade 3-4","relugolix, Constipation, Grade 3-4","selinexor + bortezomib + dexamethasone, Peripheral neuropathy, All Grades","selinexor + bortezomib + dexamethasone, Peripheral neuropathy, Grade 3-4","margetuximab + chemotherapy, Diarrhea, All Grades","margetuximab + chemotherapy, Abdominal paina, All Grades","margetuximab + chemotherapy, Palmar-plantar erythrodysesthesia, All Grades","margetuximab + chemotherapy, Decreased appetite, All Grades","margetuximab + chemotherapy, Pyrexia, Grade 3-4","margetuximab + chemotherapy, Diarrhea, Grade 3-4","margetuximab + chemotherapy, Vomiting, Grade 3-4","margetuximab + chemotherapy, Constipation, Grade 3-4","margetuximab + chemotherapy, Abdominal paina, Grade 3-4","margetuximab + chemotherapy, Alopecia, Grade 3-4","margetuximab + chemotherapy, Palmar-plantar erythrodysesthesia, Grade 3-4","margetuximab + chemotherapy, Headache, Grade 3-4","margetuximab + chemotherapy, Peripheral neuropathy, Grade 3-4","margetuximab + chemotherapy, Dyspnea, Grade 3-4","margetuximab + chemotherapy, Decreased appetite, Grade 3-4","margetuximab + chemotherapy, Arthralgia/Myalgia, Grade 3-4","pembrolizumab, Nausea, All Grades","pembrolizumab, Vomiting, All Grades","pembrolizumab, Abdominal, All Grades","pembrolizumab, Fatigue, All Grades","pembrolizumab, Peripheral neuropathyø, All Grades","pembrolizumab, Headache, All Grades","pembrolizumab, Urinary tract infection, Grade 3-4","pembrolizumab, Musculoskeletal pain, Grade 3-4","pembrolizumab, Nausea, Grade 3-4","pembrolizumab, Abdominal, Grade 3-4","pembrolizumab, pyrexia, Grade 3-4","pembrolizumab, Fatigue, Grade 3-4","pembrolizumab, Rash, Grade 3-4","pembrolizumab, Pruritus, Grade 3-4","pembrolizumab, Cough, Grade 3-4","pembrolizumab, Dyspnea, Grade 3-4","pembrolizumab, Hypothyroidism, Grade 3-4","pembrolizumab, Peripheral neuropathyø, Grade 3-4","pembrolizumab, Headache, Grade 3-4","nivolumab + ipilimumab, Fatigue, All Grades","nivolumab + ipilimumab, Nausea, All Grades","nivolumab + ipilimumab, Consti ation, All Grades","nivolumab + ipilimumab, Vomiting, All Grades","nivolumab + ipilimumab, Decreased appetite, All Grades","nivolumab + ipilimumab, Fatigue, Grade 3-4","nivolumab + ipilimumab, Edema, Grade 3-4","nivolumab + ipilimumab, Nausea, Grade 3-4","nivolumab + ipilimumab, Consti ation, Grade 3-4","nivolumab + ipilimumab, Vomiting, Grade 3-4","nivolumab + ipilimumab, Dyspnea, Grade 3-4","nivolumab + ipilimumab, Decreased appetite, Grade 3-4","nivolumab + ipilimumab, Hypothyroidism, Grade 3-4","carfilzomib + daratumumab + dexamethasone, Cough, All Grades","carfilzomib + daratumumab + dexamethasone, Dyspnea, All Grades","carfilzomib + daratumumab + dexamethasone, Nausea, Grade 3-4","carfilzomib + daratumumab + dexamethasone, Cough, Grade 3-4","avelumab, Fatigue, Grade 3-4","avelumab, Musculoskeletal pain, Grade 3-4","avelumab, Nausea, Grade 3-4","avelumab, Decreased appetite, Grade 3-4","nivolumab, Rash, All Grades","nivolumab, Decreased appetite, All Grades","nivolumab, Constipation, All Grades","nivolumab, Nausea, All Grades","nivolumab, Musculoskeletal pain, All Grades","nivolumab, Pneumonia, All Grades","nivolumab, Pyrexia, All Grades","nivolumab, Fatigue, All Grades","nivolumab, Anemia, All Grades","nivolumab, Pruritus, Grade 3-4","nivolumab, Decreased appetite, Grade 3-4","nivolumab, Constipation, Grade 3-4","nivolumab, Nausea, Grade 3-4","nivolumab, Musculoskeletal pain, Grade 3-4","nivolumab, Pneumonia, Grade 3-4","nivolumab, Cough, Grade 3-4","nivolumab, Pyrexia, Grade 3-4","nivolumab, Fatigue, Grade 3-4","nivolumab, Anemia, Grade 3-4","nivolumab, Hypothyroidism, Grade 3-4","atezolizumab + bevacizumab, Fatigue/asthenia, All Grades","atezolizumab + bevacizumab, Rash, All Grades","atezolizumab + bevacizumab, Diarrhea, All Grades","atezolizumab + bevacizumab, Constipation, All Grades","atezolizumab + bevacizumab, Abdominal Pain, All Grades","atezolizumab + bevacizumab, Nausea, All Grades","atezolizumab + bevacizumab, Decreased Appetite, All Grades","atezolizumab + bevacizumab, Fatigue/asthenia, Grade 3-4","atezolizumab + bevacizumab, Pyrexia, Grade 3-4","atezolizumab + bevacizumab, Weight Decreased, Grade 3-4","atezolizumab + bevacizumab, Pruritus, Grade 3-4","atezolizumab + bevacizumab, Rash, Grade 3-4","atezolizumab + bevacizumab, Diarrhea, Grade 3-4","atezolizumab + bevacizumab, Constipation, Grade 3-4","atezolizumab + bevacizumab, Abdominal Pain, Grade 3-4","atezolizumab + bevacizumab, Nausea, Grade 3-4","atezolizumab + bevacizumab, Vomiting, Grade 3-4","atezolizumab + bevacizumab, Decreased Appetite, Grade 3-4","atezolizumab + bevacizumab, Cough, Grade 3-4","atezolizumab + bevacizumab, Epistaxis, Grade 3-4","nivolumab + ipilimumab + chemotherapy, Nausea, All Grades","nivolumab + ipilimumab + chemotherapy, Constipation, All Grades","nivolumab + ipilimumab + chemotherapy, Pyrexia, Grade 3-4","nivolumab + ipilimumab + chemotherapy, Constipation, Grade 3-4","nivolumab + ipilimumab + chemotherapy, Abdominal pain, Grade 3-4","nivolumab + ipilimumab + chemotherapy, Cough, Grade 3-4","brigatinib, Diarrhea, All Grades","brigatinib, Nausea, All Grades","brigatinib, Abdominal pain, All Grades","brigatinib, Vomiting, All Grades","brigatinib, Constipation, All Grades","brigatinib, Dyspepsia, All Grades","brigatinib, Gastroesophageal reflux disease, All Grades","brigatinib, Pulmonary embolism, All Grades","brigatinib, Fatigue, All Grades","brigatinib, Edema, All Grades","brigatinib, Pyrexia, All Grades","brigatinib, Pain in extremity, All Grades","brigatinib, Dizziness, All Grades","brigatinib, Peripheral neuropathy, All Grades","brigatinib, Dysgeusia, All Grades","brigatinib, Bradycardia, All Grades","brigatinib, Nasopharyngitis, All Grades","brigatinib, Urinary tract infection, All Grades","brigatinib, Decreased Appetite, All Grades","brigatinib, Visual Disturbance0e, All Grades","brigatinib, Diarrhea, Grade 3-4","brigatinib, Nausea, Grade 3-4","brigatinib, Abdominal pain, Grade 3-4","brigatinib, Vomiting, Grade 3-4","brigatinib, Constipation, Grade 3-4","brigatinib, Dyspepsia, Grade 3-4","brigatinib, Gastroesophageal reflux disease, Grade 3-4","brigatinib, Pruritus, Grade 3-4","brigatinib, Cough, Grade 3-4","brigatinib, Dyspnea, Grade 3-4","brigatinib, Pulmonary embolism, Grade 3-4","brigatinib, Fatigue, Grade 3-4","brigatinib, Edema, Grade 3-4","brigatinib, Myalgia, Grade 3-4","brigatinib, Back pain, Grade 3-4","brigatinib, Arthralgia, Grade 3-4","brigatinib, Pain in extremity, Grade 3-4","brigatinib, Dizziness, Grade 3-4","brigatinib, Dysgeusia, Grade 3-4","brigatinib, Increased Blood cholesterol, Grade 3-4","brigatinib, Upper respiratory tract infection, Grade 3-4","brigatinib, Nasopharyngitis, Grade 3-4","brigatinib, Urinary tract infection, Grade 3-4","brigatinib, Decreased Appetite, Grade 3-4","brigatinib, Visual Disturbance0e, Grade 3-4","olaparib, Fatigue (including asthenia), Grade 3-4","olaparib, Decreased appetite, Grade 3-4","olaparib, Cough, Grade 3-4","atezolizumab, Nausea, All Grades","atezolizumab, Constipation, All Grades","atezolizumab, Diarrhea, All Grades","atezolizumab, Fatigue/asthenia, All Grades","atezolizumab, Decreased appetite, All Grades","atezolizumab, Nausea, Grade 3-4","atezolizumab, Diarrhea, Grade 3-4","atezolizumab, Fatigue/asthenia, Grade 3-4","atezolizumab, Pyrexia, Grade 3-4","nivolumab + ipilimumab, Nausea, All Grades","nivolumab + ipilimumab, Constipation, All Grades","nivolumab + ipilimumab, Vomiting, All Grades","nivolumab + ipilimumab, Edema, Grade 3-4","nivolumab + ipilimumab, Nausea, Grade 3-4","nivolumab + ipilimumab, Constipation, Grade 3-4","nivolumab + ipilimumab, Vomiting, Grade 3-4","nivolumab + ipilimumab, Abdominal pain, Grade 3-4","nivolumab + ipilimumab, Hyperthyroidism, Grade 3-4","ibrutinib + rituximab, Pyrexia, All Grades","ibrutinib + rituximab, Nausea, All Grades","ibrutinib + rituximab, Vomiting, All Grades","ibrutinib + rituximab, Constipation, All Grades","ibrutinib + rituximab, Decreased appetite, All Grades","ibrutinib + rituximab, Insomnia, All Grades","encorafenib + cetuximab, Nausea, All Grades","encorafenib + cetuximab, Diarrhea, All Grades","encorafenib + cetuximab, Abdominal pain, All Grades","encorafenib + cetuximab, Vomiting, All Grades","encorafenib + cetuximab, Constipation, All Grades","encorafenib + cetuximab, Decreased appetite, All Grades","encorafenib + cetuximab, Dermatitis acneiform, All Grades","encorafenib + cetuximab, Rash, All Grades","encorafenib + cetuximab, Fatigue, Grade ≥ 3","encorafenib + cetuximab, Pyrexia, Grade ≥ 3","encorafenib + cetuximab, Nausea, Grade ≥ 3","encorafenib + cetuximab, Diarrhea, Grade ≥ 3","encorafenib + cetuximab, Abdominal pain, Grade ≥ 3","encorafenib + cetuximab, Vomiting, Grade ≥ 3","encorafenib + cetuximab, Constipation, Grade ≥ 3","encorafenib + cetuximab, Decreased appetite, Grade ≥ 3","encorafenib + cetuximab, Pain in extremity, Grade ≥ 3","encorafenib + cetuximab, Dermatitis acneiform, Grade ≥ 3","encorafenib + cetuximab, Rash, Grade ≥ 3","encorafenib + cetuximab, Pruritus, Grade ≥ 3","encorafenib + cetuximab, Melanocytic nevus, Grade ≥ 3","encorafenib + cetuximab, Dry skin, Grade ≥ 3","encorafenib + cetuximab, Headache, Grade ≥ 3","encorafenib + cetuximab, Insomnia, Grade ≥ 3","durvalumab + Etoposide + either Carboplatin or Cisplatin , Nausea, All Grades","durvalumab + Etoposide + either Carboplatin or Cisplatin , Constipation, All Grades","durvalumab + Etoposide + either Carboplatin or Cisplatin , Vomiting, All Grades","durvalumab + Etoposide + either Carboplatin or Cisplatin , Diarrhea, All Grades","durvalumab + Etoposide + either Carboplatin or Cisplatin , Alopecia, All Grades","durvalumab + Etoposide + either Carboplatin or Cisplatin , Fatigue/Asthenia, All Grades","durvalumab + Etoposide + either Carboplatin or Cisplatin , Nausea, Grade 3-4","durvalumab + Etoposide + either Carboplatin or Cisplatin , Vomiting, Grade 3-4","durvalumab + Etoposide + either Carboplatin or Cisplatin , Diarrhea, Grade 3-4","durvalumab + Etoposide + either Carboplatin or Cisplatin , Hyperthyroidisma, Grade 3-4","durvalumab + Etoposide + either Carboplatin or Cisplatin , Rash, Grade 3-4","durvalumab + Etoposide + either Carboplatin or Cisplatin , Decreased appetite, Grade 3-4","isatuximab-irfc, Nausea, Grade 3","isatuximab-irfc, Upper respiratory tract infection, Grade 4","isatuximab-irfc, Dyspnea, Grade 4","isatuximab-irfc, Diarrhea, Grade 4","isatuximab-irfc, Nausea, Grade 4","isatuximab-irfc, Vomiting, Grade 4","neratinib +  Capecitabine, Abdominal distension, Grade 3","neratinib +  Capecitabine, Malaise, Grade 3","neratinib +  Capecitabine, Influenza like illness, Grade 3","neratinib +  Capecitabine, Upper respiratory tract infection, Grade 3","neratinib +  Capecitabine, Back Pain, Grade 3","neratinib +  Capecitabine, Arthralgia, Grade 3","neratinib +  Capecitabine, Muscle spasms, Grade 3","neratinib +  Capecitabine, Dizziness, Grade 3","neratinib +  Capecitabine, Dysuria, Grade 3","neratinib +  Capecitabine, Diarrhea, Grade 4","neratinib +  Capecitabine, Nausea, Grade 4","neratinib +  Capecitabine, Vomiting, Grade 4","neratinib +  Capecitabine, Constipation, Grade 4","neratinib +  Capecitabine, Abdominal distension, Grade 4","neratinib +  Capecitabine, Fatigue/asthenia, Grade 4","neratinib +  Capecitabine, Malaise, Grade 4","neratinib +  Capecitabine, Influenza like illness, Grade 4","neratinib +  Capecitabine, Urinary tract infection, Grade 4","neratinib +  Capecitabine, Upper respiratory tract infection, Grade 4","neratinib +  Capecitabine, Decreased appetite, Grade 4","neratinib +  Capecitabine, Back Pain, Grade 4","neratinib +  Capecitabine, Arthralgia, Grade 4","neratinib +  Capecitabine, Muscle spasms, Grade 4","neratinib +  Capecitabine, Dizziness, Grade 4","neratinib +  Capecitabine, Renal impairment, Grade 4","neratinib +  Capecitabine, Dysuria, Grade 4","pembrolizumab, Increased bodyweight, Grade 1–2","pembrolizumab, Cough, Grade 1–2","pembrolizumab, Hypertension, Grade 1–2","pembrolizumab, Dyspnoea, Grade 1–2","pembrolizumab, Upper respiratory tract infection, Grade 1–2","pembrolizumab, Back pain, Grade 1–2","pembrolizumab, Headache, Grade 1–2","pembrolizumab, Constipation, Grade 1–2","pembrolizumab, Influenza-like illness, Grade 1–2","pembrolizumab, Pyrexia, Grade 1–2","pembrolizumab, Pain in extremity, Grade 1–2","pembrolizumab, Paraesthesia, Grade 1–2","pembrolizumab, Increased bodyweight, Grade 3","pembrolizumab, Pruritus, Grade 3","pembrolizumab, Arthralgia, Grade 3","pembrolizumab, Diarrhoea, Grade 3","pembrolizumab, Fatigue, Grade 3","pembrolizumab, Hypertension, Grade 3","pembrolizumab, Dyspnoea, Grade 3","pembrolizumab, Upper respiratory tract infection, Grade 3","pembrolizumab, Nasopharyngitis, Grade 3","pembrolizumab, Increased alanine aminotransferase, Grade 3","pembrolizumab, Headache, Grade 3","pembrolizumab, Asthenia, Grade 3","pembrolizumab, Increased aspartate aminotransferase, Grade 3","pembrolizumab, Decreased appetite, Grade 3","pembrolizumab, Decreased bodyweight, Grade 3","pembrolizumab, Increased blood creatinine, Grade 3","pembrolizumab, Productive cough, Grade 3","pembrolizumab, Constipation, Grade 3","pembrolizumab, Influenza-like illness, Grade 3","pembrolizumab, Pneumonitis, Grade 3","pembrolizumab, Pyrexia, Grade 3","pembrolizumab, Dry skin, Grade 3","pembrolizumab, Pain in extremity, Grade 3","pembrolizumab, Paraesthesia, Grade 3","pembrolizumab, Increased bodyweight, Grade 4","pembrolizumab, Pruritus, Grade 4","pembrolizumab, Hypothyroidism, Grade 4","pembrolizumab, Arthralgia, Grade 4","pembrolizumab, Diarrhoea, Grade 4","pembrolizumab, Fatigue, Grade 4","pembrolizumab, Cough, Grade 4","pembrolizumab, Hypertension, Grade 4","pembrolizumab, Dyspnoea, Grade 4","pembrolizumab, Hyperthyroidism, Grade 4","pembrolizumab, Upper respiratory tract infection, Grade 4","pembrolizumab, Nausea, Grade 4","pembrolizumab, Nasopharyngitis, Grade 4","pembrolizumab, Rash, Grade 4","pembrolizumab, Increased alanine aminotransferase, Grade 4","pembrolizumab, Back pain, Grade 4","pembrolizumab, Headache, Grade 4","pembrolizumab, Asthenia, Grade 4","pembrolizumab, Maculopapular rash, Grade 4","pembrolizumab, Increased aspartate aminotransferase, Grade 4","pembrolizumab, Decreased appetite, Grade 4","pembrolizumab, Decreased bodyweight, Grade 4","pembrolizumab, Increased blood creatinine, Grade 4","pembrolizumab, Myalgia, Grade 4","pembrolizumab, Productive cough, Grade 4","pembrolizumab, Constipation, Grade 4","pembrolizumab, Influenza-like illness, Grade 4","pembrolizumab, Pyrexia, Grade 4","pembrolizumab, Dry skin, Grade 4","pembrolizumab, Pain in extremity, Grade 4","pembrolizumab, Paraesthesia, Grade 4"],"type":"scatter","mode":"markers","marker":{"autocolorscale":false,"color":"rgba(55,63,81,1)","opacity":0.55,"size":5.66929133858268,"symbol":"circle","line":{"width":1.88976377952756,"color":"rgba(55,63,81,1)"}},"hoveron":"points","name":"control","legendgroup":"control","showlegend":true,"xaxis":"x","yaxis":"y","hoverinfo":"text","_isNestedKey":false,"frame":null},{"x":[0.4,0.01,0.17,0.01,0.14,0.1,0.015,0.09,0.045,0.18,0.06,0.3,0.14,0.1,0.07,0.07,0.07,0.033,0.018,0.015,0.003,0,0,0.77,0.67,0.09,0.64,0.23,0.22,0.17,0.12,0.37,0.2,0.19,0.14,0.14,0.13,0.11,0.11,0.16,0.14,0.14,0.1,0.11,0.06,0.09,0.005,0.16,0.002,0.011,0.005,0.018,0.002,0.005,0.007,0,0.002,0,0.007,0.23,0.35,0.25,0.16,0.14,0.06,0.51,0.04,0.12,0.15,0.17,0.07,0.19,0.02,0.01,0,0.04,0,0,0.39,0.19,0.09,0.1,0.06,0.1,0.026,0.1,0.08,0.01,0.009,0,0.009,0.01,0.004,0,0.17,0.15,0.08,0.04,0.05,0.026,0.1,0.12,0.013,0.08,0.05,0.004,0.009,0.04,0.004,0.026,0,0.004,0,0.22,0.1,0.14,0.07,0.046,0.009,0.009,0,0.08,0.37,0.15,0.14,0.06,0.021,0.1,0.06,0.045,0.32,0.08,0.22,0.25,0.12,0.09,0.08,0.006,0.045,0.012,0.042,0.06,0.16,0.11,0.1,0.07,0.18,0.19,0.12,0.08,0.07,0.07,0,0,0,0,0.02,0,0,0.007,0.06,0.09,0.043,0.06,0.17,0.043,0.008,0,0.008,0.16,0.34,0.29,0.23,0.15,0.23,0.14,0.08,0.006,0.003,0.009,0,0.2,0.13,0.15,0.13,0.16,0.09,0.002,0.012,0.037,0.3,0.13,0.22,0.22,0.13,0.12,0.48,0.33,0.27,0.19,0.31,0.08,0.035,0.06,0.06,0.05,0.006,0.09,0,0,0,0,0.047,0,0.05,0.012,0.006,0,0,0,0,0,0.012,0.19,0.37,0,0.21,0.37,0.24,0.23,0.04,0.14,0.12,0.04,0.07,0.03,0.1,0.09,0.08,0.1,0,0.04,0.09,0.07,0.51,0,0.03,0.01,0,0.09,0,0,0.12,0.01,0,0,0,0.01,0.38,0.27,0.07,0.12,0.08,0.01,0.04,0.08,0.08,0.15,0.03,0.03,0,0.08,0.01,0.23,0.08,0.14,0.045,0.28,0.039,0.06,0.07,0.17,0.048,0.07,0.06,0,0,0,0.007,0.003,0.003,0.008,0.001,0,0.02,0.01,0.1,0.06,0.18,0.08,0.07,0.03,0.04,0.02,0.1,0.06,0.02,0,0,0,0,0,0,0,0.03,0.01,0.01,0,0.01,0,0,0,0,0,0,0.01,0,0.01,0.01,0,0,0,0,0,0.01,0,0,0,0,0,0,0,0.01,0,0.36,0.31,0.15,0.13,0.23,0.1,0.036,0.002,0.12,0.13,0.07,0.1,0.006,0.002,0.004,0,0.002,0,0.002,0,0,0,0.006,0.002,0.57,0.15,0.46,0.3,0.26,0.23,0.003,0.06,0.016,0.019,0.08,0.03,0.02,0.08,0.03,0.02,0.23,0.16,0,0.05,0.05,0,0.02,0.02,0,0.03,0,0,0,0,0,0,0,0,0.03,0,0,0,0,0.31,0.29,0.17,0.22,0.15,0.2,0.09,0.19,0.05,0.07,0.07,0,0.07,0,0,0,0,0.19,0.16,0.32,0.27,0.13,0.24,0.011,0.023,0.16,0.11,0.06,0.07,0.09,0.08,0.003,0.003,0.017,0,0.006,0,0.009,0.003,0,0.006,0.66,0.19,0.66,0.39,0.34,0.29,0.28,0.23,0.58,0.41,0.29,0.19,0.24,0.17,0.19,0.039,0.003,0.018,0.018,0.01,0.015,0.005,0.023,0.003,0,0,0.003,0,0.21,0.29,0.1,0.06,0.09,0.2,0.08,0.1,0.015,0.008,0,0.004,0.004,0,0,0,0.008,0.63,0.33,0.32,0.26,0.46,0.38,0.03,0.05,0.038,0.09,0.2,0.07,0.07,0.19,0.038,0.07,0.09,0.1,0.1,0.07,0.09,0.09,0.038,0.003,0,0,0,0,0,0,0,0.003,0,0.23,0.27,0.22,0.16,0.2,0.14,0.043,0.004,0,0.004,0.35,0.33,0.23,0.13,0.13,0.19,0.28,0.23,0.19,0.24,0.08,0.17,0.15,0.16,0.09,0.1,0.08,0.01,0.03,0.01,0,0,0.19,0.01,0.02,0,0.03,0.03,0.01,0,0.14,0.02,0.24,0.1,0.21,0.24,0.13,0.25,0.17,0.1,0.05,0.06,0.08,0.09,0.01,0,0.01,0,0.01,0.01,0.05,0,0.08,0.72,0.17,0.45,0.35,0.21,0.36,0.15,0.48,0.1,0.08,0.08,0.06,0.23,0.018,0,0.13,0.01,0.032,0,0.01,0.01,0.07,0.76,0.12,0.36,0.03,0.01,0.08,0.2,0.12,0.02,0.04,0.07,0.07,0.05,0.01,0.01,0,0,0,0.047,0,0.07,0.047,0.23,0.07,0.12,0.3,0.19,0.14,0.07,0,0.12,0.047,0.047,0.21,0.12,0.047,0.047,0,0.023,0,0,0.047,0,0,0,0,0.32,0.22,0.11,0.1,0.09,0.1,0.015,0.007,0.004,0.011,0.015,0.05,0.18,0.08,0.09,0.28,0.2,0.12,0.41,0.07,0.08,0.38,0.15,0.13,0.15,0.05,0.13,0.15,0.07,0.004,0.02,0.01,0.004,0.004,0.01,0.008,0,0,0,0.004,0,0.01,0.53,0.44,0.25,0.21,0.53,0.15,0.24,0.2,0.13,0.046,0.015,0.06,0.07,0.05,0.09,0.03,0.005,0.09,0.005,0.036,0,0.025,0.005,0,0,0.56,0.43,0.35,0.2,0.19,0.12,0.11,0.5,0.41,0.12,0.13,0.13,0.1,0.07,0.036,0.13,0.1,0.003,0.11,0.08,0.026,0.03,0.02,0.049,0.007,0.06,0.01,0,0.026,0.3,0.1,0.2,0.07,0.08,0.05,0.06,0.35,0.17,0.031,0.25,0.17,0.06,0.12,0.1,0.019,0.16,0.08,0.004,0.008,0.004,0.004,0,0.008,0.06,0,0.004,0.004,0.004,0,0,0,0,0.23,0.15,0.09,0.07,0.034,0.005,0.17,0.11,0.06,0.029,0.06,0.13,0.044,0.01,0.06,0.044,0.02,0.015,0.015,0.005,0,0,0.005,0.005,0.005,0.005,0.005,0.049,0.01,0.005,0.029,0,0,0.31,0.29,0.21,0.17,0.17,0.14,0.12,0.14,0.07,0.11,0.017,0.006,0.014,0,0.003,0,0.32,0.23,0.14,0.07,0.06,0.006,0.011,0,0.027,0.28,0.23,0.036,0.05,0.009,0,0.07,0.42,0.036,0.1,0.26,0.33,0.09,0.2,0.027,0.1,0.16,0,0,0,0.009,0.009,0,0.009,0,0,0,0.12,0.16,0.039,0.15,0.11,0.05,0.013,0,0.039,0,0.014,0.006,0.006,0.11,0.022,0.05,0.07,0.09,0.06,0,0.002,0.002,0.002,0.002,0,0.09,0.09,0.046,0.05,0.39,0.18,0.15,0.07,0.024,0.045,0.027,0.002,0.001,0.001,0,0.027,0.001,0.002,0.001,0,0.001,0.44,0.23,0.13,0.09,0.1,0.13,0.08,0.08,0,0.01,0.4,0.13,0.07,0.25,0.13,0.06,0.39,0.14,0.12,0.07,0.02,0.02,0,0.01,0,0.56,0.5,0.33,0.18,0.2,0.19,0.41,0.32,0.43,0.26,0.31,0.17,0.04,0.13,0.16,0.09,0.21,0.16,0.08,0.06,0.01,0.01,0.01,0,0.03,0,0.2,0.04,0.01,0.01,0.03,0.02,0,0.05,0.009,0.06,0.15,0.54,0.2,0.47,0.21,0.26,0.21,0.25,0.27,0.21,0.06,0.034,0.13,0.09,0.006,0.009,0.049,0,0.025,0.009,0.06,0.028,0.015,0.022,0.012,0.012,0.006,0,0.003,0.003,0.012,0.003,0,0,0.39,0.14,0.09,0.27,0.22,0.14,0.08,0.05,0.17,0.01,0.46,0.06,0.44,0.34,0.29,0.24,0.21,0.13,0.4,0.11,0.08,0.26,0.09,0.15,0.08,0.05,0.14,0.044,0.12,0.09,0.07,0.44,0.28,0.12,0.06,0.17,0.26,0.16,0.23,0.12,0.13,0.5,0.14,0.08,0.03,0.1,0.21,0.13,0.06,0.14,0.07,0.13,0.07,0.05,0.18,0.16,0.05,0.03,0.34,0.06,0.06,0.01,0.004,0.01,0,0.01,0.01,0.01,0.004,0,0.004,0.033,0.57,0.3,0.13,0.32,0.24,0.15,0.29,0.09,0.32,0,0.07,0.15,0.008,0.18,0.008,0.025,0.008,0.033,0.025,0.48,0.31,0.12,0.18,0.17,0.3,0.09,0.15,0.11,0.11,0.16,0.12,0.17,0.01,0.04,0,0.01,0,0.05,0.15,0.06,0.1,0.16,0,0.021,0.11,0.07,0.11,0.08,0.4,0.13,0.13,0.077,0.021,0.085,0,0.007,0,0,0.021,0,0,0.007,0,0,0,0.014,0.021,0.007,0,0.06,0.08,0,0.003,0.47,0.15,0.5,0.26,0.14,0.044,0.3,0.29,0.09,0.2,0.22,0.12,0.17,0.034,0.08,0.044,0.003,0.003,0.003,0.05,0,0,0.031,0.013,0,0,0.21,0.09,0.3,0.29,0.2,0.2,0.11,0.06,0.05,0.05,0.05,0,0.05,0.04,0,0.02,0,0,0,0.02,0.47,0.08,0.23,0.048,0.45,0.032,0.31,0.032,0.44,0.16,0,0.15,0,0.016,0.016,0.016,0,0.13,0.016,0.23,0.032,0.048,0,0.016,0.52,0.29,0.24,0.07,0.1,0,0,0,0.1,0.25,0.044,0.21,0.11,0.05,0.12,0.039,0.22,0.06,0.06,0,0.01,0,0.05,0.01,0,0.01,0,0.015,0.015,0,0.47,0.14,0.32,0.14,0.17,0.15,0.16,0.15,0.12,0.11,0.12,0.09,0.03,0.045,0.004,0,0,0,0.24,0.03,0.29,0.17,0.13,0.19,0.12,0.14,0.03,0.07,0.03,0,0.013,0,0.013,0.046,0.08,0.17,0.011,0.11,0.014,0.12,0.1,0.16,0.09,0.014,0.07,0.042,0.007,0.011,0,0.004,0,0.011,0.007,0,0,0.021,0.28,0.28,0.15,0.29,0.12,0.12,0.3,0.31,0.14,0.13,0.28,0.11,0.1,0.05,0.08,0.007,0.033,0.09,0.013,0.16,0.14,0.007,0.13,0.026,0.02,0.013,0.13,0.035,0.15,0.06,0.023,0.017,0.11,0.049,0.09,0.06,0.035,0.046,0.07,0.006,0,0,0,0,0,0.038,0.003,0,0.006,0,0,0,0.07,0.17,0.14,0.14,0.014,0.01,0.014,0,0.24,0.1,0.07,0.1,0.1,0.08,0.1,0.045,0,0.12,0.006,0,0.4,0.1,0.27,0.18,0.17,0.11,0.1,0.029,0.1,0.22,0.15,0.14,0.034,0.07,0.06,0.049,0.02,0.009,0.017,0.014,0.003,0,0.006,0.017,0.032,0,0,0,0.088,0.17,0.058,0.2,0.22,0.022,0.08,0.23,0.17,0.12,0.17,0.007,0.066,0.1,0,0,0.007,0.029,0,0,0,0,0.029,0.15,0.03,0.19,0.07,0.12,0.32,0.18,0.02,0.03,0.05,0,0,0,0.01,0,0.09,0.1,0.1,0.008,0,0,0,0.42,0.11,0.12,0.1,0.033,0.26,0.16,0.025,0.16,0.09,0.16,0.13,0.1,0.012,0.005,0.08,0.06,0.044,0.004,0.004,0,0.014,0.007,0.002,0.009,0.021,0,0.012,0,0.04,0,0.78,0.17,0.08,0.35,0.1,0.27,0.08,0.1,0.29,0.04,0.22,0.08,0.27,0.13,0.13,0.25,0.21,0.19,0.03,0.04,0.5,0.15,0.03,0.04,0.01,0.06,0,0.12,0.03,0.06,0.09,0.06,0,0,0,0,0.09,0.004,0.06,0.17,0,0,0.008,0.023,0,0.23,0.42,0.02,0.12,0.19,0.09,0.034,0,0.16,0.034,0.013,0.013,0.007,0,0,0.027,0.007,0.66,0.42,0.31,0.13,0.032,0.4,0.023,0.013,0.042,0.045,0.22,0.08,0.06,0.019,0.1,0.01,0.019,0.13,0.029,0.019,0,0.045,0.006,0.023,0,0.12,0.05,0.13,0.14,0.15,0.03,0.06,0.06,0.05,0.05,0.05,0.03,0.05,0.04,0.04,0.06,0.03,0.03,0.02,0.04,0,0,0,0,0,0,0,0,0],"y":[0.49,0.04,0.21,0.02,0.2,0.14,0.03,0.13,0.1,0.48,0.14,0.38,0.3,0.19,0.13,0.16,0.14,0.16,0.05,0.023,0.01,0.01,0.003,0.8,0.68,0.15,0.66,0.26,0.23,0.19,0.13,0.42,0.31,0.22,0.16,0.15,0.16,0.14,0.13,0.17,0.17,0.15,0.13,0.14,0.08,0.15,0.014,0.18,0.009,0.016,0.011,0.039,0.011,0.014,0.011,0.014,0.005,0.007,0.011,0.62,0.59,0.34,0.23,0.2,0.11,0.6,0.1,0.15,0.16,0.2,0.12,0.48,0.12,0.1,0.01,0.08,0.02,0.02,0.41,0.35,0.19,0.13,0.12,0.11,0.1,0.15,0.11,0.07,0.025,0.008,0.01,0.02,0.008,0.02,0.33,0.28,0.13,0.27,0.14,0.24,0.15,0.14,0.13,0.12,0.11,0.017,0.013,0.05,0.04,0.07,0.004,0.06,0.008,0.27,0.14,0.16,0.1,0.07,0.012,0.015,0.003,0.12,0.42,0.22,0.18,0.1,0.13,0.27,0.1,0.11,0.36,0.19,0.29,0.28,0.17,0.15,0.11,0.024,0.05,0.015,0.08,0.13,0.25,0.14,0.12,0.11,0.23,0.23,0.17,0.11,0.13,0.11,0.013,0.016,0.003,0.013,0.038,0.01,0.013,0.022,0.23,0.13,0.1,0.14,0.22,0.06,0.013,0.003,0.026,0.2,0.4,0.32,0.24,0.17,0.26,0.23,0.11,0.015,0.006,0.021,0.009,0.23,0.19,0.19,0.18,0.18,0.14,0.018,0.021,0.07,0.76,0.4,0.34,0.27,0.18,0.13,0.54,0.4,0.39,0.32,0.32,0.16,0.16,0.15,0.11,0.14,0.12,0.1,0.046,0.016,0.008,0.005,0.09,0.003,0.1,0.024,0.013,0.003,0.003,0.005,0.003,0.013,0.013,0.47,0.39,0.49,0.42,0.39,0.34,0.29,0.09,0.22,0.21,0.2,0.1,0.04,0.14,0.14,0.13,0.13,0.12,0.12,0.1,0.1,0.8,0.01,0.43,0.04,0.02,0.25,0.03,0.01,0.15,0.03,0.01,0.01,0.01,0.04,0.42,0.41,0.2,0.18,0.15,0.13,0.15,0.13,0.3,0.2,0.11,0.1,0.01,0.1,0.04,0.57,0.23,0.18,0.1,0.42,0.24,0.17,0.16,0.2,0.12,0.11,0.13,0.008,0.007,0.001,0.018,0.09,0.03,0.05,0.002,0.002,0.14,0.1,0.18,0.08,0.2,0.09,0.14,0.06,0.07,0.06,0.23,0.16,0.07,0.01,0.01,0.01,0.01,0.01,0.01,0.01,0.16,0.1,0.04,0.02,0.02,0.02,0.01,0.01,0.01,0.01,0.01,0.02,0.01,0.03,0.02,0.01,0.01,0.01,0.02,0.01,0.02,0.01,0.01,0.01,0.01,0.01,0.01,0.01,0.03,0.01,0.41,0.4,0.3,0.23,0.27,0.16,0.21,0.12,0.17,0.15,0.14,0.13,0.012,0.012,0.014,0.002,0.027,0.004,0.004,0.002,0.002,0.002,0.037,0.012,0.58,0.22,0.47,0.36,0.27,0.24,0.036,0.07,0.02,0.026,0.09,0.51,0.24,0.14,0.26,0.1,0.42,0.23,0.46,0.3,0.18,0.1,0.1,0.1,0.05,0.15,0.07,0.03,0.01,0.05,0.01,0.1,0.03,0.1,0.1,0.01,0.02,0.02,0.01,0.43,0.41,0.35,0.35,0.23,0.23,0.27,0.24,0.18,0.15,0.13,0.11,0.09,0.02,0.02,0.07,0.01,0.36,0.3,0.36,0.3,0.16,0.28,0.11,0.11,0.17,0.14,0.11,0.13,0.11,0.11,0.017,0.011,0.028,0.006,0.009,0.003,0.017,0.009,0.003,0.04,0.7,0.28,0.67,0.42,0.41,0.34,0.31,0.24,0.61,0.52,0.3,0.2,0.26,0.23,0.21,0.08,0.013,0.037,0.032,0.027,0.027,0.05,0.033,0.005,0.005,0.001,0.009,0.005,0.23,0.34,0.21,0.13,0.13,0.21,0.1,0.15,0.11,0.009,0.008,0.008,0.009,0.004,0.004,0.002,0.009,0.67,0.36,0.34,0.27,0.57,0.44,0.041,0.07,0.06,0.12,0.47,0.32,0.12,0.4,0.37,0.29,0.19,0.14,0.13,0.1,0.13,0.1,0.13,0.024,0.018,0.003,0.006,0.009,0.003,0.006,0.003,0.006,0.006,0.28,0.28,0.26,0.26,0.23,0.21,0.05,0.005,0.02,0.008,0.44,0.43,0.3,0.18,0.18,0.42,0.36,0.31,0.27,0.27,0.12,0.25,0.25,0.22,0.16,0.18,0.17,0.02,0.05,0.02,0.01,0.01,0.42,0.02,0.06,0.01,0.07,0.05,0.04,0.01,0.22,0.04,0.65,0.6,0.5,0.39,0.22,0.44,0.27,0.14,0.11,0.13,0.12,0.11,0.03,0.03,0.05,0.01,0.02,0.04,0.09,0.01,0.11,0.75,0.26,0.51,0.49,0.26,0.5,0.23,0.62,0.22,0.18,0.1,0.12,0.27,0.03,0.01,0.21,0.013,0.043,0.01,0.026,0.013,0.1,0.81,0.45,0.42,0.1,0.09,0.34,0.34,0.34,0.07,0.23,0.15,0.17,0.24,0.07,0.02,0.03,0.01,0.01,0.52,0.21,0.13,0.11,0.42,0.17,0.39,0.36,0.34,0.28,0.21,0.11,0.32,0.18,0.15,0.27,0.19,0.19,0.14,0.13,0.035,0.012,0.035,0.07,0.012,0.035,0.012,0.07,0.53,0.53,0.22,0.41,0.24,0.18,0.05,0.024,0.17,0.07,0.019,0.66,0.64,0.42,0.28,0.57,0.4,0.22,0.51,0.14,0.19,0.39,0.26,0.19,0.25,0.12,0.22,0.18,0.18,0.39,0.31,0.21,0.05,0.01,0.03,0.03,0.01,0.01,0.004,0.01,0.002,0.06,0.81,0.58,0.36,0.32,0.63,0.2,0.42,0.25,0.21,0.15,0.14,0.13,0.13,0.12,0.12,0.037,0.025,0.13,0.007,0.09,0.005,0.037,0.01,0.005,0.002,0.65,0.44,0.44,0.29,0.23,0.14,0.13,0.51,0.47,0.19,0.16,0.18,0.16,0.16,0.11,0.16,0.13,0.07,0.12,0.11,0.042,0.09,0.029,0.07,0.019,0.07,0.013,0.006,0.05,0.76,0.49,0.34,0.29,0.21,0.2,0.11,0.49,0.33,0.37,0.31,0.29,0.17,0.22,0.11,0.11,0.22,0.13,0.07,0.016,0.012,0.008,0.008,0.06,0.07,0.004,0.012,0.016,0.012,0.004,0.008,0.004,0.004,0.43,0.21,0.11,0.1,0.07,0.39,0.35,0.2,0.19,0.19,0.11,0.32,0.17,0.12,0.09,0.08,0.07,0.07,0.06,0.019,0.004,0.004,0.013,0.011,0.009,0.008,0.011,0.13,0.08,0.038,0.032,0.009,0.008,0.45,0.39,0.28,0.25,0.24,0.17,0.18,0.17,0.15,0.15,0.042,0.02,0.02,0.006,0.006,0.003,0.34,0.26,0.15,0.2,0.13,0.011,0.023,0.023,0.89,0.83,0.69,0.31,0.28,0.24,0.2,0.76,0.64,0.48,0.45,0.49,0.45,0.3,0.25,0.39,0.31,0.22,0.008,0.18,0.045,0.037,0.06,0.004,0.02,0.012,0.033,0.008,0.26,0.22,0.12,0.19,0.17,0.13,0.026,0.019,0.06,0.006,0.17,0.1,0.14,0.16,0.14,0.14,0.12,0.14,0.11,0.012,0.008,0.006,0.004,0.008,0.006,0.84,0.3,0.18,0.14,0.51,0.41,0.2,0.11,0.12,0.11,0.11,0.08,0.005,0.005,0.001,0.049,0.029,0.003,0.006,0.004,0.006,0.45,0.28,0.18,0.16,0.13,0.16,0.13,0.11,0.01,0.02,0.44,0.18,0.16,0.31,0.16,0.11,0.45,0.18,0.13,0.14,0.03,0.04,0.01,0.09,0.01,0.63,0.62,0.36,0.27,0.26,0.25,0.58,0.57,0.56,0.27,0.41,0.37,0.3,0.3,0.21,0.3,0.25,0.23,0.09,0.1,0.03,0.02,0.03,0.01,0.04,0.01,0.29,0.05,0.04,0.05,0.08,0.05,0.08,0.09,0.67,0.67,0.25,0.58,0.55,0.49,0.37,0.35,0.34,0.27,0.53,0.44,0.34,0.29,0.31,0.26,0.22,0.23,0.2,0.009,0.39,0.026,0.11,0.08,0.029,0.023,0.026,0.026,0.05,0.07,0.1,0.06,0.05,0.006,0.029,0.023,0.46,0.19,0.15,0.38,0.36,0.22,0.13,0.13,0.23,0.05,0.53,0.11,0.48,0.39,0.31,0.27,0.25,0.17,0.44,0.19,0.12,0.29,0.14,0.17,0.14,0.12,0.2,0.18,0.13,0.13,0.1,0.64,0.4,0.17,0.1,0.59,0.57,0.33,0.37,0.3,0.17,0.65,0.15,0.13,0.12,0.11,0.28,0.16,0.12,0.16,0.12,0.18,0.1,0.11,0.24,0.47,0.12,0.1,0.52,0.09,0.11,0.11,0.03,0.02,0.004,0.03,0.02,0.02,0.03,0.004,0.008,0.46,0.67,0.36,0.24,0.37,0.29,0.23,0.36,0.15,0.42,0.006,0.09,0.19,0.023,0.2,0.05,0.028,0.011,0.05,0.034,0.67,0.44,0.17,0.3,0.18,0.39,0.27,0.22,0.15,0.24,0.19,0.13,0.24,0.03,0.05,0.01,0.03,0.01,0.16,0.34,0.21,0.11,0.2,0.027,0.18,0.19,0.15,0.15,0.17,0.56,0.38,0.17,0.11,0.067,0.11,0.02,0.02,0.02,0.013,0.027,0.02,0.1,0.013,0.007,0.007,0.007,0.04,0.17,0.013,0.02,0.15,0.11,0.014,0.006,0.64,0.22,0.51,0.44,0.36,0.19,0.34,0.33,0.18,0.28,0.24,0.16,0.2,0.17,0.2,0.07,0.006,0.019,0.019,0.11,0.031,0.003,0.038,0.019,0.003,0.003,0.4,0.15,0.36,0.34,0.31,0.26,0.2,0.12,0.1,0.1,0.11,0.11,0.1,0.06,0.02,0.03,0.01,0.02,0.01,0.04,0.63,0.26,0.24,0.11,0.6,0.06,0.58,0.048,0.55,0.24,0.1,0.22,0.1,0.08,0.048,0.024,0.016,0.17,0.024,0.38,0.048,0.09,0.024,0.032,0.54,0.3,0.26,0.12,0.12,0.006,0.003,0.002,0.5,0.32,0.21,0.59,0.15,0.35,0.26,0.12,0.29,0.22,0.13,0.08,0.06,0.041,0.28,0.015,0.036,0.021,0.01,0.036,0.09,0.01,0.57,0.19,0.33,0.21,0.19,0.18,0.19,0.16,0.14,0.13,0.14,0.11,0.13,0.07,0.011,0.004,0.008,0.015,0.41,0.11,0.32,0.22,0.2,0.2,0.18,0.2,0.11,0.11,0.19,0.014,0.027,0.014,0.05,0.18,0.17,0.38,0.13,0.34,0.21,0.32,0.15,0.27,0.23,0.15,0.12,0.1,0.013,0.033,0.01,0.027,0.01,0.06,0.01,0.007,0.003,0.04,0.41,0.32,0.2,0.4,0.18,0.17,0.37,0.33,0.32,0.18,0.31,0.18,0.16,0.12,0.11,0.019,0.07,0.13,0.026,0.25,0.17,0.039,0.18,0.039,0.039,0.019,0.35,0.15,0.24,0.16,0.2,0.17,0.2,0.17,0.16,0.16,0.13,0.14,0.14,0.12,0.1,0.003,0.006,0.012,0.003,0.06,0.006,0.006,0.012,0.003,0.003,0.009,0.12,0.18,0.17,0.16,0.11,0.019,0.019,0.01,0.3,0.18,0.2,0.11,0.19,0.1,0.12,0.1,0.11,0.15,0.03,0.024,0.49,0.14,0.39,0.31,0.18,0.12,0.3,0.21,0.11,0.28,0.19,0.18,0.19,0.11,0.11,0.05,0.045,0.017,0.06,0.02,0.047,0.008,0.008,0.02,0.047,0.003,0.006,0.006,0.13,0.4,0.2,0.35,0.25,0.051,0.32,0.28,0.21,0.14,0.22,0.13,0.15,0.12,0.007,0.029,0.029,0.13,0.007,0.022,0.007,0.007,0.051,0.46,0.12,0.41,0.21,0.18,0.41,0.3,0.11,0.1,0.21,0.04,0.01,0.01,0.02,0.02,0.14,0.14,0.12,0.01,0.007,0.007,0.003,0.44,0.18,0.14,0.34,0.21,0.31,0.27,0.13,0.26,0.1,0.26,0.23,0.21,0.16,0.1,0.13,0.11,0.06,0.005,0.047,0.005,0.023,0.019,0.009,0.036,0.043,0.002,0.09,0.005,0.07,0.005,0.8,0.28,0.23,0.61,0.41,0.53,0.22,0.19,0.49,0.36,0.42,0.31,0.4,0.21,0.19,0.32,0.22,0.29,0.16,0.19,0.51,0.17,0.27,0.15,0.1,0.14,0.14,0.13,0.2,0.12,0.19,0.13,0.01,0.01,0.01,0.02,0.15,0.1,0.11,0.18,0.008,0.008,0.011,0.034,0.38,0.31,0.57,0.12,0.17,0.26,0.15,0.12,0.013,0.22,0.09,0.11,0.05,0.02,0.013,0.013,0.033,0.013,0.83,0.53,0.46,0.31,0.08,0.45,0.043,0.04,0.09,0.08,0.35,0.1,0.1,0.05,0.14,0.07,0.046,0.25,0.043,0.04,0.01,0.06,0.007,0.026,0.02,0.21,0.21,0.18,0.17,0.16,0.11,0.09,0.09,0.08,0.07,0.07,0.07,0.07,0.07,0.07,0.07,0.06,0.06,0.05,0.05,0.01,0.01,0.01,0.01,0.01,0.01,0.01,0.01,0.01],"text":["Control: 0.400<br />Experimental: 0.490<br />greater: experi<br />event: talazoparib + enzalutamide, Fatigue, Grades 1-4","Control: 0.010<br />Experimental: 0.040<br />greater: experi<br />event: talazoparib + enzalutamide, Fatigue, Grade 3","Control: 0.170<br />Experimental: 0.210<br />greater: experi<br />event: talazoparib + enzalutamide, Nausea, Grades 1-4","Control: 0.010<br />Experimental: 0.020<br />greater: experi<br />event: talazoparib + enzalutamide, Nausea, Grade 3","Control: 0.140<br />Experimental: 0.200<br />greater: experi<br />event: talazoparib + enzalutamide, Decreased appetite, Grades 1-4","Control: 0.100<br />Experimental: 0.140<br />greater: experi<br />event: talazoparib + enzalutamide, Fractures, Grades 1-4","Control: 0.015<br />Experimental: 0.030<br />greater: experi<br />event: talazoparib + enzalutamide, Fractures, Grade 3","Control: 0.090<br />Experimental: 0.130<br />greater: experi<br />event: talazoparib + enzalutamide, Dizzy, Grades 1-4","Control: 0.045<br />Experimental: 0.100<br />greater: experi<br />event: talazoparib + enzalutamide, Dysgeusiae, Grades 1-4","Control: 0.180<br />Experimental: 0.480<br />greater: experi<br />event: olaparib + abiraterone + prednisone (or prednisolone), Anemia, Grades 1-4","Control: 0.060<br />Experimental: 0.140<br />greater: experi<br />event: olaparib + abiraterone + prednisone (or prednisolone), Lymphopenia, Grades 1-4","Control: 0.300<br />Experimental: 0.380<br />greater: experi<br />event: olaparib + abiraterone + prednisone (or prednisolone), Fatigue (includes asthenia), Grades 1-4","Control: 0.140<br />Experimental: 0.300<br />greater: experi<br />event: olaparib + abiraterone + prednisone (or prednisolone), Nausea, Grades 1-4","Control: 0.100<br />Experimental: 0.190<br />greater: experi<br />event: olaparib + abiraterone + prednisone (or prednisolone), Diarrhea, Grades 1-4","Control: 0.070<br />Experimental: 0.130<br />greater: experi<br />event: olaparib + abiraterone + prednisone (or prednisolone), Abdominal pain, Grades 1-4","Control: 0.070<br />Experimental: 0.160<br />greater: experi<br />event: olaparib + abiraterone + prednisone (or prednisolone), Decreased appetite, Grades 1-4","Control: 0.070<br />Experimental: 0.140<br />greater: experi<br />event: olaparib + abiraterone + prednisone (or prednisolone), Dizziness, Grades 1-4","Control: 0.033<br />Experimental: 0.160<br />greater: experi<br />event: olaparib + abiraterone + prednisone (or prednisolone), Anemia, Grade 3-4","Control: 0.018<br />Experimental: 0.050<br />greater: experi<br />event: olaparib + abiraterone + prednisone (or prednisolone), Lymphopenia, Grade 3-4","Control: 0.015<br />Experimental: 0.023<br />greater: experi<br />event: olaparib + abiraterone + prednisone (or prednisolone), Fatigue (includes asthenia), Grade 3-4","Control: 0.003<br />Experimental: 0.010<br />greater: experi<br />event: olaparib + abiraterone + prednisone (or prednisolone), Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: olaparib + abiraterone + prednisone (or prednisolone), Decreased appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: olaparib + abiraterone + prednisone (or prednisolone), Dizziness, Grade 3-4","Control: 0.770<br />Experimental: 0.800<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Lymphopenia, All grades","Control: 0.670<br />Experimental: 0.680<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Anemia, All grades","Control: 0.090<br />Experimental: 0.150<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Febrile neutropeniaa, All grades","Control: 0.640<br />Experimental: 0.660<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Creatinine increased, All grades","Control: 0.230<br />Experimental: 0.260<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Aspartate aminotransferase increased, All grades","Control: 0.220<br />Experimental: 0.230<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Alkaline phosphatase increased, All grades","Control: 0.170<br />Experimental: 0.190<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Uric acid increased, All grades","Control: 0.120<br />Experimental: 0.130<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Weight decreased, All grades","Control: 0.370<br />Experimental: 0.420<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Nausea, All grades","Control: 0.200<br />Experimental: 0.310<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Diarrhea, All grades","Control: 0.190<br />Experimental: 0.220<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Mucositis, All grades","Control: 0.140<br />Experimental: 0.160<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Abdominal paind, All grades","Control: 0.140<br />Experimental: 0.150<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Vomiting, All grades","Control: 0.130<br />Experimental: 0.160<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Pyrexia, All grades","Control: 0.110<br />Experimental: 0.140<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Edemae, All grades","Control: 0.110<br />Experimental: 0.130<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Rash, All grades","Control: 0.160<br />Experimental: 0.170<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Upper respiratory tract infection', All grades","Control: 0.140<br />Experimental: 0.170<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Decreased appetite, All grades","Control: 0.140<br />Experimental: 0.150<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Cough, All grades","Control: 0.100<br />Experimental: 0.130<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Dyspnea, All grades","Control: 0.110<br />Experimental: 0.140<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Anemia, Grade 3-4","Control: 0.060<br />Experimental: 0.080<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Thrombocytopenia, Grade 3-4","Control: 0.090<br />Experimental: 0.150<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Febrile neutropeniaa, Grade 3-4","Control: 0.005<br />Experimental: 0.014<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Alanine aminotransferase increased, Grade 3-4","Control: 0.160<br />Experimental: 0.180<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Uric acid increased, Grade 3-4","Control: 0.002<br />Experimental: 0.009<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Weight decreased, Grade 3-4","Control: 0.011<br />Experimental: 0.016<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Peripheral neuropathy, Grade 3-4","Control: 0.005<br />Experimental: 0.011<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Nausea, Grade 3-4","Control: 0.018<br />Experimental: 0.039<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Diarrhea, Grade 3-4","Control: 0.002<br />Experimental: 0.011<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Constipation, Grade 3-4","Control: 0.005<br />Experimental: 0.014<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Mucositis, Grade 3-4","Control: 0.007<br />Experimental: 0.011<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Vomiting, Grade 3-4","Control: 0.000<br />Experimental: 0.014<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Pyrexia, Grade 3-4","Control: 0.002<br />Experimental: 0.005<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Edemae, Grade 3-4","Control: 0.000<br />Experimental: 0.007<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Rash, Grade 3-4","Control: 0.007<br />Experimental: 0.011<br />greater: experi<br />event: polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Decreased appetite, Grade 3-4","Control: 0.230<br />Experimental: 0.620<br />greater: experi<br />event: sacituzumab govitecan-hziy, Diarrhea, All grades","Control: 0.350<br />Experimental: 0.590<br />greater: experi<br />event: sacituzumab govitecan-hziy, Nausea, All grades","Control: 0.250<br />Experimental: 0.340<br />greater: experi<br />event: sacituzumab govitecan-hziy, Constipation, All grades","Control: 0.160<br />Experimental: 0.230<br />greater: experi<br />event: sacituzumab govitecan-hziy, Vomiting, All grades","Control: 0.140<br />Experimental: 0.200<br />greater: experi<br />event: sacituzumab govitecan-hziy, Abdominal Pain, All grades","Control: 0.060<br />Experimental: 0.110<br />greater: experi<br />event: sacituzumab govitecan-hziy, Dyspepsia, All grades","Control: 0.510<br />Experimental: 0.600<br />greater: experi<br />event: sacituzumab govitecan-hziy, Fatigue, All grades","Control: 0.040<br />Experimental: 0.100<br />greater: experi<br />event: sacituzumab govitecan-hziy, Hypokalemia, All grades","Control: 0.120<br />Experimental: 0.150<br />greater: experi<br />event: sacituzumab govitecan-hziy, Arthralgia, All grades","Control: 0.150<br />Experimental: 0.160<br />greater: experi<br />event: sacituzumab govitecan-hziy, Headache, All grades","Control: 0.170<br />Experimental: 0.200<br />greater: experi<br />event: sacituzumab govitecan-hziy, Dyspnea, All grades","Control: 0.070<br />Experimental: 0.120<br />greater: experi<br />event: sacituzumab govitecan-hziy, Cough, All grades","Control: 0.190<br />Experimental: 0.480<br />greater: experi<br />event: sacituzumab govitecan-hziy, Alopecia, All grades","Control: 0.020<br />Experimental: 0.120<br />greater: experi<br />event: sacituzumab govitecan-hziy, Pruritus, All grades","Control: 0.010<br />Experimental: 0.100<br />greater: experi<br />event: sacituzumab govitecan-hziy, Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: sacituzumab govitecan-hziy, Constipation, Grade 3-4","Control: 0.040<br />Experimental: 0.080<br />greater: experi<br />event: sacituzumab govitecan-hziy, Fatigue, Grade 3-4","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: sacituzumab govitecan-hziy, Decreased appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: sacituzumab govitecan-hziy, Hypokalemia, Grade 3-4","Control: 0.390<br />Experimental: 0.410<br />greater: experi<br />event: elacestrant, Musculoskeletal pain, All grades","Control: 0.190<br />Experimental: 0.350<br />greater: experi<br />event: elacestrant, Nausea, All grades","Control: 0.090<br />Experimental: 0.190<br />greater: experi<br />event: elacestrant, Vomiting, All grades","Control: 0.100<br />Experimental: 0.130<br />greater: experi<br />event: elacestrant, Diarrhea, All grades","Control: 0.060<br />Experimental: 0.120<br />greater: experi<br />event: elacestrant, Constipation, All grades","Control: 0.100<br />Experimental: 0.110<br />greater: experi<br />event: elacestrant, Abdominal pain, All grades","Control: 0.026<br />Experimental: 0.100<br />greater: experi<br />event: elacestrant, Dyspepsia, All grades","Control: 0.100<br />Experimental: 0.150<br />greater: experi<br />event: elacestrant, Decreased appetite , All grades","Control: 0.080<br />Experimental: 0.110<br />greater: experi<br />event: elacestrant, Hot flush , All grades","Control: 0.010<br />Experimental: 0.070<br />greater: experi<br />event: elacestrant, Musculoskeletal pain, Grade 3-4","Control: 0.009<br />Experimental: 0.025<br />greater: experi<br />event: elacestrant, Nausea, Grade 3-4","Control: 0.000<br />Experimental: 0.008<br />greater: experi<br />event: elacestrant, Vomiting, Grade 3-4","Control: 0.009<br />Experimental: 0.010<br />greater: experi<br />event: elacestrant, Abdominal pain, Grade 3-4","Control: 0.010<br />Experimental: 0.020<br />greater: experi<br />event: elacestrant, Fatigue, Grade 3-4","Control: 0.004<br />Experimental: 0.008<br />greater: experi<br />event: elacestrant, Decreased appetite , Grade 3-4","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: elacestrant, Headache, Grade 3-4","Control: 0.170<br />Experimental: 0.330<br />greater: experi<br />event: zanubrutinib, Musculoskeletal pain, All grades","Control: 0.150<br />Experimental: 0.280<br />greater: experi<br />event: zanubrutinib, Upper respiratory tract infection, All grades","Control: 0.080<br />Experimental: 0.130<br />greater: experi<br />event: zanubrutinib, Pneumonia, All grades","Control: 0.040<br />Experimental: 0.270<br />greater: experi<br />event: zanubrutinib, Hemorrhage, All grades","Control: 0.050<br />Experimental: 0.140<br />greater: experi<br />event: zanubrutinib, Hypertension, All grades","Control: 0.026<br />Experimental: 0.240<br />greater: experi<br />event: zanubrutinib, Bruising, All grades","Control: 0.100<br />Experimental: 0.150<br />greater: experi<br />event: zanubrutinib, Coughe, All grades","Control: 0.120<br />Experimental: 0.140<br />greater: experi<br />event: zanubrutinib, Diarrhea, All grades","Control: 0.013<br />Experimental: 0.130<br />greater: experi<br />event: zanubrutinib, Second primary malignancyl, All grades","Control: 0.080<br />Experimental: 0.120<br />greater: experi<br />event: zanubrutinib, Headache, All grades","Control: 0.050<br />Experimental: 0.110<br />greater: experi<br />event: zanubrutinib, Dizziness, All grades","Control: 0.004<br />Experimental: 0.017<br />greater: experi<br />event: zanubrutinib, Musculoskeletal pain, Grade 3-4","Control: 0.009<br />Experimental: 0.013<br />greater: experi<br />event: zanubrutinib, Upper respiratory tract infection, Grade 3-4","Control: 0.040<br />Experimental: 0.050<br />greater: experi<br />event: zanubrutinib, Pneumonia, Grade 3-4","Control: 0.004<br />Experimental: 0.040<br />greater: experi<br />event: zanubrutinib, Hemorrhage, Grade 3-4","Control: 0.026<br />Experimental: 0.070<br />greater: experi<br />event: zanubrutinib, Hypertension, Grade 3-4","Control: 0.000<br />Experimental: 0.004<br />greater: experi<br />event: zanubrutinib, Constipation, Grade 3-4","Control: 0.004<br />Experimental: 0.060<br />greater: experi<br />event: zanubrutinib, Second primary malignancyl, Grade 3-4","Control: 0.000<br />Experimental: 0.008<br />greater: experi<br />event: zanubrutinib, Dizziness, Grade 3-4","Control: 0.220<br />Experimental: 0.270<br />greater: experi<br />event: zanubrutinib, Upper respiratory tract infection, All grades","Control: 0.100<br />Experimental: 0.140<br />greater: experi<br />event: zanubrutinib, COVID-19, All grades","Control: 0.140<br />Experimental: 0.160<br />greater: experi<br />event: zanubrutinib, Bruising, All grades","Control: 0.070<br />Experimental: 0.100<br />greater: experi<br />event: zanubrutinib, Dizziness, All grades","Control: 0.046<br />Experimental: 0.070<br />greater: experi<br />event: zanubrutinib, COVID-19, Grade 3-4","Control: 0.009<br />Experimental: 0.012<br />greater: experi<br />event: zanubrutinib, Rash, Grade 3-4","Control: 0.009<br />Experimental: 0.015<br />greater: experi<br />event: zanubrutinib, Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: zanubrutinib, Cough, Grade 3-4","Control: 0.080<br />Experimental: 0.120<br />greater: experi<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Cough/Productive Cough/, All grades","Control: 0.370<br />Experimental: 0.420<br />greater: experi<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Nausea, All grades","Control: 0.150<br />Experimental: 0.220<br />greater: experi<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Diarrhea, All grades","Control: 0.140<br />Experimental: 0.180<br />greater: experi<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Vomiting, All grades","Control: 0.060<br />Experimental: 0.100<br />greater: experi<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Stomatitis, All grades","Control: 0.021<br />Experimental: 0.130<br />greater: experi<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Hypothyroidism, All grades","Control: 0.100<br />Experimental: 0.270<br />greater: experi<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Rash, All grades","Control: 0.060<br />Experimental: 0.100<br />greater: experi<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Alopecia, All grades","Control: 0.045<br />Experimental: 0.110<br />greater: experi<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Pruritus, All grades","Control: 0.320<br />Experimental: 0.360<br />greater: experi<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Fatigue/Asthenia, All grades","Control: 0.080<br />Experimental: 0.190<br />greater: experi<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Pyrexia, All grades","Control: 0.220<br />Experimental: 0.290<br />greater: experi<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Musculoskeletal Pain, All grades","Control: 0.250<br />Experimental: 0.280<br />greater: experi<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Decreased appetite, All grades","Control: 0.120<br />Experimental: 0.170<br />greater: experi<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Pneumonia, All grades","Control: 0.090<br />Experimental: 0.150<br />greater: experi<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Upper respiratory tract infections, All grades","Control: 0.080<br />Experimental: 0.110<br />greater: experi<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Headachek, All grades","Control: 0.006<br />Experimental: 0.024<br />greater: experi<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Rash, Grade 3-4","Control: 0.045<br />Experimental: 0.050<br />greater: experi<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Fatigue/Asthenia, Grade 3-4","Control: 0.012<br />Experimental: 0.015<br />greater: experi<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Decreased appetite, Grade 3-4","Control: 0.042<br />Experimental: 0.080<br />greater: experi<br />event: tremelimumab + durvalumab + platinum-based chemotherapy, Pneumonia, Grade 3-4","Control: 0.060<br />Experimental: 0.130<br />greater: experi<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Rasha, All grades","Control: 0.160<br />Experimental: 0.250<br />greater: experi<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Nausea, All grades","Control: 0.110<br />Experimental: 0.140<br />greater: experi<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Constipation, All grades","Control: 0.100<br />Experimental: 0.120<br />greater: experi<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Vomiting, All grades","Control: 0.070<br />Experimental: 0.110<br />greater: experi<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Diarrhea, All grades","Control: 0.180<br />Experimental: 0.230<br />greater: experi<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Fatigue, All grades","Control: 0.190<br />Experimental: 0.230<br />greater: experi<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Peripheral neuropath, All grades","Control: 0.120<br />Experimental: 0.170<br />greater: experi<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Decreased appetite, All grades","Control: 0.080<br />Experimental: 0.110<br />greater: experi<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Weight decreased, All grades","Control: 0.070<br />Experimental: 0.130<br />greater: experi<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Dyspneae, All grades","Control: 0.070<br />Experimental: 0.110<br />greater: experi<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Insomnia, All grades","Control: 0.000<br />Experimental: 0.013<br />greater: experi<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Rasha, Grade 3-4","Control: 0.000<br />Experimental: 0.016<br />greater: experi<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Musculoskeletal pain, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Constipation, Grade 3-4","Control: 0.000<br />Experimental: 0.013<br />greater: experi<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Diarrhea, Grade 3-4","Control: 0.020<br />Experimental: 0.038<br />greater: experi<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Fatigue, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Decreased appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.013<br />greater: experi<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Weight decreased, Grade 3-4","Control: 0.007<br />Experimental: 0.022<br />greater: experi<br />event: cemiplimab-rwlc + platinum-based chemotherapy, Dyspneae, Grade 3-4","Control: 0.060<br />Experimental: 0.230<br />greater: experi<br />event: tremelimumab + durvalumab, Pruritus, All grades","Control: 0.090<br />Experimental: 0.130<br />greater: experi<br />event: tremelimumab + durvalumab, Pyrexia, All grades","Control: 0.043<br />Experimental: 0.100<br />greater: experi<br />event: tremelimumab + durvalumab, Insomnia, All grades","Control: 0.060<br />Experimental: 0.140<br />greater: experi<br />event: tremelimumab + durvalumab, Hypothyroidisml, All grades","Control: 0.170<br />Experimental: 0.220<br />greater: experi<br />event: tremelimumab + durvalumab, Musculoskeletal pain, All grades","Control: 0.043<br />Experimental: 0.060<br />greater: experi<br />event: tremelimumab + durvalumab, Diarrhea, Grade 3-4","Control: 0.008<br />Experimental: 0.013<br />greater: experi<br />event: tremelimumab + durvalumab, Decreased appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: tremelimumab + durvalumab, Insomnia, Grade 3-4","Control: 0.008<br />Experimental: 0.026<br />greater: experi<br />event: tremelimumab + durvalumab, Musculoskeletal pain, Grade 3-4","Control: 0.160<br />Experimental: 0.200<br />greater: experi<br />event: durvalumab + gemcitabine + cisplatin, Pyrexia, All grades","Control: 0.340<br />Experimental: 0.400<br />greater: experi<br />event: durvalumab + gemcitabine + cisplatin, Nausea, All grades","Control: 0.290<br />Experimental: 0.320<br />greater: experi<br />event: durvalumab + gemcitabine + cisplatin, Constipation, All grades","Control: 0.230<br />Experimental: 0.240<br />greater: experi<br />event: durvalumab + gemcitabine + cisplatin, Abdominal pain, All grades","Control: 0.150<br />Experimental: 0.170<br />greater: experi<br />event: durvalumab + gemcitabine + cisplatin, Diarrhea, All grades","Control: 0.230<br />Experimental: 0.260<br />greater: experi<br />event: durvalumab + gemcitabine + cisplatin, Decreased appetite, All grades","Control: 0.140<br />Experimental: 0.230<br />greater: experi<br />event: durvalumab + gemcitabine + cisplatin, Rash, All grades","Control: 0.080<br />Experimental: 0.110<br />greater: experi<br />event: durvalumab + gemcitabine + cisplatin, Pruritus, All grades","Control: 0.006<br />Experimental: 0.015<br />greater: experi<br />event: durvalumab + gemcitabine + cisplatin, Pyrexia, Grade 3-4","Control: 0.003<br />Experimental: 0.006<br />greater: experi<br />event: durvalumab + gemcitabine + cisplatin, Constipation, Grade 3-4","Control: 0.009<br />Experimental: 0.021<br />greater: experi<br />event: durvalumab + gemcitabine + cisplatin, Decreased appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.009<br />greater: experi<br />event: durvalumab + gemcitabine + cisplatin, Rash, Grade 3-4","Control: 0.200<br />Experimental: 0.230<br />greater: experi<br />event: darolutamide + docetaxel, Constipation, All grades","Control: 0.130<br />Experimental: 0.190<br />greater: experi<br />event: darolutamide + docetaxel, Decreased Appetite, All grades","Control: 0.150<br />Experimental: 0.190<br />greater: experi<br />event: darolutamide + docetaxel, Rash, All grades","Control: 0.130<br />Experimental: 0.180<br />greater: experi<br />event: darolutamide + docetaxel, Hemorrhage, All grades","Control: 0.160<br />Experimental: 0.180<br />greater: experi<br />event: darolutamide + docetaxel, Weight Increased, All grades","Control: 0.090<br />Experimental: 0.140<br />greater: experi<br />event: darolutamide + docetaxel, Hypertension, All grades","Control: 0.002<br />Experimental: 0.018<br />greater: experi<br />event: darolutamide + docetaxel, Rash, Grade 3-4","Control: 0.012<br />Experimental: 0.021<br />greater: experi<br />event: darolutamide + docetaxel, Weight Increased, Grade 3-4","Control: 0.037<br />Experimental: 0.070<br />greater: experi<br />event: darolutamide + docetaxel, Hypertension, Grade 3-4","Control: 0.300<br />Experimental: 0.760<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Nausea, All grades","Control: 0.130<br />Experimental: 0.400<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Vomiting, All grades","Control: 0.220<br />Experimental: 0.340<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Constipation, All grades","Control: 0.220<br />Experimental: 0.270<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Diarrhea, All grades","Control: 0.130<br />Experimental: 0.180<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Abdominal pain, All grades","Control: 0.120<br />Experimental: 0.130<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Stomatitisb, All grades","Control: 0.480<br />Experimental: 0.540<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Fatigue, All grades","Control: 0.330<br />Experimental: 0.400<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Alopecia, All grades","Control: 0.270<br />Experimental: 0.390<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Anemia, All grades","Control: 0.190<br />Experimental: 0.320<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Decreased appetite, All grades","Control: 0.310<br />Experimental: 0.320<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Musculoskeletal pain, All grades","Control: 0.080<br />Experimental: 0.160<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Decreased weight, All grades","Control: 0.035<br />Experimental: 0.160<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Hemorrhage, All grades","Control: 0.060<br />Experimental: 0.150<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Headache, All grades","Control: 0.060<br />Experimental: 0.110<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Dizziness, All grades","Control: 0.050<br />Experimental: 0.140<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Upper respiratory tract infection, All grades","Control: 0.006<br />Experimental: 0.120<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Interstitial lung disease, All grades","Control: 0.090<br />Experimental: 0.100<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Dyspnea, All grades","Control: 0.000<br />Experimental: 0.046<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Nausea, Grade 3-4","Control: 0.000<br />Experimental: 0.016<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Vomiting, Grade 3-4","Control: 0.000<br />Experimental: 0.008<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Constipation, Grade 3-4","Control: 0.000<br />Experimental: 0.005<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Abdominal pain, Grade 3-4","Control: 0.047<br />Experimental: 0.090<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Fatigue, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Pyrexia, Grade 3-4","Control: 0.050<br />Experimental: 0.100<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Anemia, Grade 3-4","Control: 0.012<br />Experimental: 0.024<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Decreased appetite, Grade 3-4","Control: 0.006<br />Experimental: 0.013<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Musculoskeletal pain, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Decreased weight, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Headache, Grade 3-4","Control: 0.000<br />Experimental: 0.005<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Dizziness, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Upper respiratory tract infection, Grade 3-4","Control: 0.000<br />Experimental: 0.013<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Interstitial lung disease, Grade 3-4","Control: 0.012<br />Experimental: 0.013<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Dyspnea, Grade 3-4","Control: 0.190<br />Experimental: 0.470<br />greater: experi<br />event: lisocabtagene maraleucel, Neutropenia, Grade 1–2","Control: 0.370<br />Experimental: 0.390<br />greater: experi<br />event: lisocabtagene maraleucel, Anaemia, Grade 1–2","Control: 0.000<br />Experimental: 0.490<br />greater: experi<br />event: lisocabtagene maraleucel, Cytokine release syndrome, Grade 1–2","Control: 0.210<br />Experimental: 0.420<br />greater: experi<br />event: lisocabtagene maraleucel, Headache, Grade 1–2","Control: 0.370<br />Experimental: 0.390<br />greater: experi<br />event: lisocabtagene maraleucel, Fatigue, Grade 1–2","Control: 0.240<br />Experimental: 0.340<br />greater: experi<br />event: lisocabtagene maraleucel, Constipation, Grade 1–2","Control: 0.230<br />Experimental: 0.290<br />greater: experi<br />event: lisocabtagene maraleucel, Pyrexia, Grade 1–2","Control: 0.040<br />Experimental: 0.090<br />greater: experi<br />event: lisocabtagene maraleucel, Lymphopenia, Grade 1–2","Control: 0.140<br />Experimental: 0.220<br />greater: experi<br />event: lisocabtagene maraleucel, Dizziness, Grade 1–2","Control: 0.120<br />Experimental: 0.210<br />greater: experi<br />event: lisocabtagene maraleucel, Insomnia, Grade 1–2","Control: 0.040<br />Experimental: 0.200<br />greater: experi<br />event: lisocabtagene maraleucel, Hypotension, Grade 1–2","Control: 0.070<br />Experimental: 0.100<br />greater: experi<br />event: lisocabtagene maraleucel, Leukopenia, Grade 1–2","Control: 0.030<br />Experimental: 0.040<br />greater: experi<br />event: lisocabtagene maraleucel, Febrile neutropenia, Grade 1–2","Control: 0.100<br />Experimental: 0.140<br />greater: experi<br />event: lisocabtagene maraleucel, Arthralg ia, Grade 1–2","Control: 0.090<br />Experimental: 0.140<br />greater: experi<br />event: lisocabtagene maraleucel, Cough, Grade 1–2","Control: 0.080<br />Experimental: 0.130<br />greater: experi<br />event: lisocabtagene maraleucel, Dyspnoea, Grade 1–2","Control: 0.100<br />Experimental: 0.130<br />greater: experi<br />event: lisocabtagene maraleucel, Bone pain, Grade 1–2","Control: 0.000<br />Experimental: 0.120<br />greater: experi<br />event: lisocabtagene maraleucel, Tremor, Grade 1–2","Control: 0.040<br />Experimental: 0.120<br />greater: experi<br />event: lisocabtagene maraleucel, Myalgia, Grade 1–2","Control: 0.090<br />Experimental: 0.100<br />greater: experi<br />event: lisocabtagene maraleucel, Asthenia, Grade 1–2","Control: 0.070<br />Experimental: 0.100<br />greater: experi<br />event: lisocabtagene maraleucel, Hypertension, Grade 1–2","Control: 0.510<br />Experimental: 0.800<br />greater: experi<br />event: lisocabtagene maraleucel, Neutropenia, Grade ≥ 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: lisocabtagene maraleucel, Cytokine release syndrome, Grade ≥ 3","Control: 0.030<br />Experimental: 0.430<br />greater: experi<br />event: lisocabtagene maraleucel, Prolonged cytopeniat, Grade ≥ 3","Control: 0.010<br />Experimental: 0.040<br />greater: experi<br />event: lisocabtagene maraleucel, Headache, Grade ≥ 3","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: lisocabtagene maraleucel, Constipation, Grade ≥ 3","Control: 0.090<br />Experimental: 0.250<br />greater: experi<br />event: lisocabtagene maraleucel, Lymphopenia, Grade ≥ 3","Control: 0.000<br />Experimental: 0.030<br />greater: experi<br />event: lisocabtagene maraleucel, Hypotension, Grade ≥ 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: lisocabtagene maraleucel, Peripheral oedema, Grade ≥ 3","Control: 0.120<br />Experimental: 0.150<br />greater: experi<br />event: lisocabtagene maraleucel, Leukopenia, Grade ≥ 3","Control: 0.010<br />Experimental: 0.030<br />greater: experi<br />event: lisocabtagene maraleucel, Abdominal pain, Grade ≥ 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: lisocabtagene maraleucel, Tremor, Grade ≥ 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: lisocabtagene maraleucel, Myalgia, Grade ≥ 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: lisocabtagene maraleucel, Asthenia, Grade ≥ 3","Control: 0.010<br />Experimental: 0.040<br />greater: experi<br />event: lisocabtagene maraleucel, Hypertension, Grade ≥ 3","Control: 0.380<br />Experimental: 0.420<br />greater: experi<br />event: ivosidenib + azacitidine, Nausea, All grades","Control: 0.270<br />Experimental: 0.410<br />greater: experi<br />event: ivosidenib + azacitidine, Vomiting, All grades","Control: 0.070<br />Experimental: 0.200<br />greater: experi<br />event: ivosidenib + azacitidine, Electrocardiogram QT prolonged, All grades","Control: 0.120<br />Experimental: 0.180<br />greater: experi<br />event: ivosidenib + azacitidine, Insomnia, All grades","Control: 0.080<br />Experimental: 0.150<br />greater: experi<br />event: ivosidenib + azacitidine, Differentiation Syndrome, All grades","Control: 0.010<br />Experimental: 0.130<br />greater: experi<br />event: ivosidenib + azacitidine, Leukocytosis, All grades","Control: 0.040<br />Experimental: 0.150<br />greater: experi<br />event: ivosidenib + azacitidine, Hematoma, All grades","Control: 0.080<br />Experimental: 0.130<br />greater: experi<br />event: ivosidenib + azacitidine, Hypertension, All grades","Control: 0.080<br />Experimental: 0.300<br />greater: experi<br />event: ivosidenib + azacitidine, Arthralgia, All grades","Control: 0.150<br />Experimental: 0.200<br />greater: experi<br />event: ivosidenib + azacitidine, Dyspnea, All grades","Control: 0.030<br />Experimental: 0.110<br />greater: experi<br />event: ivosidenib + azacitidine, Headache, All grades","Control: 0.030<br />Experimental: 0.100<br />greater: experi<br />event: ivosidenib + azacitidine, Electrocardiogram QT prolonged, Grade ≥ 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: ivosidenib + azacitidine, Insomnia, Grade ≥ 3","Control: 0.080<br />Experimental: 0.100<br />greater: experi<br />event: ivosidenib + azacitidine, Differentiation Syndrome, Grade ≥ 3","Control: 0.010<br />Experimental: 0.040<br />greater: experi<br />event: ivosidenib + azacitidine, Arthralgia, Grade ≥ 3","Control: 0.230<br />Experimental: 0.570<br />greater: experi<br />event: olaparib, Nausea, Grades 1-4","Control: 0.080<br />Experimental: 0.230<br />greater: experi<br />event: olaparib, Vomitin, Grades 1-4","Control: 0.140<br />Experimental: 0.180<br />greater: experi<br />event: olaparib, Diarrhea, Grades 1-4","Control: 0.045<br />Experimental: 0.100<br />greater: experi<br />event: olaparib, Stomatitis, Grades 1-4","Control: 0.280<br />Experimental: 0.420<br />greater: experi<br />event: olaparib, Fatigue (including asthenia) , Grades 1-4","Control: 0.039<br />Experimental: 0.240<br />greater: experi<br />event: olaparib, Anemia, Grades 1-4","Control: 0.060<br />Experimental: 0.170<br />greater: experi<br />event: olaparib, Leukopenia, Grades 1-4","Control: 0.070<br />Experimental: 0.160<br />greater: experi<br />event: olaparib, Neutropenia, Grades 1-4","Control: 0.170<br />Experimental: 0.200<br />greater: experi<br />event: olaparib, Headache, Grades 1-4","Control: 0.048<br />Experimental: 0.120<br />greater: experi<br />event: olaparib, Dysgeusia, Grades 1-4","Control: 0.070<br />Experimental: 0.110<br />greater: experi<br />event: olaparib, Dizziness, Grades 1-4","Control: 0.060<br />Experimental: 0.130<br />greater: experi<br />event: olaparib, Decreased appetite, Grades 1-4","Control: 0.000<br />Experimental: 0.008<br />greater: experi<br />event: olaparib, Nausea, Grade 3-4","Control: 0.000<br />Experimental: 0.007<br />greater: experi<br />event: olaparib, Vomitin, Grade 3-4","Control: 0.000<br />Experimental: 0.001<br />greater: experi<br />event: olaparib, Stomatitis, Grade 3-4","Control: 0.007<br />Experimental: 0.018<br />greater: experi<br />event: olaparib, Fatigue (including asthenia) , Grade 3-4","Control: 0.003<br />Experimental: 0.090<br />greater: experi<br />event: olaparib, Anemia, Grade 3-4","Control: 0.003<br />Experimental: 0.030<br />greater: experi<br />event: olaparib, Leukopenia, Grade 3-4","Control: 0.008<br />Experimental: 0.050<br />greater: experi<br />event: olaparib, Neutropenia, Grade 3-4","Control: 0.001<br />Experimental: 0.002<br />greater: experi<br />event: olaparib, Headache, Grade 3-4","Control: 0.000<br />Experimental: 0.002<br />greater: experi<br />event: olaparib, Decreased appetite, Grade 3-4","Control: 0.020<br />Experimental: 0.140<br />greater: experi<br />event: pembrolizumab, Hypothyroidism, All grades","Control: 0.010<br />Experimental: 0.100<br />greater: experi<br />event: pembrolizumab, Hyperthyroidism, All grades","Control: 0.100<br />Experimental: 0.180<br />greater: experi<br />event: pembrolizumab, Diarrhoea, All grades","Control: 0.060<br />Experimental: 0.080<br />greater: experi<br />event: pembrolizumab, Nausea, All grades","Control: 0.180<br />Experimental: 0.200<br />greater: experi<br />event: pembrolizumab, Fatigue, All grades","Control: 0.080<br />Experimental: 0.090<br />greater: experi<br />event: pembrolizumab, Asthenia, All grades","Control: 0.070<br />Experimental: 0.140<br />greater: experi<br />event: pembrolizumab, Arthralgia, All grades","Control: 0.030<br />Experimental: 0.060<br />greater: experi<br />event: pembrolizumab, Myalgia, All grades","Control: 0.040<br />Experimental: 0.070<br />greater: experi<br />event: pembrolizumab, Increased alanine aminotransferase, All grades","Control: 0.020<br />Experimental: 0.060<br />greater: experi<br />event: pembrolizumab, Increased aspartate aminotransferase, All grades","Control: 0.100<br />Experimental: 0.230<br />greater: experi<br />event: pembrolizumab, Pruritus, All grades","Control: 0.060<br />Experimental: 0.160<br />greater: experi<br />event: pembrolizumab, Rash, All grades","Control: 0.020<br />Experimental: 0.070<br />greater: experi<br />event: pembrolizumab, Rash maculopapular, All grades","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Hyperthyroidism, Grade ≥ 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Fatigue, Grade ≥ 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Asthenia, Grade ≥ 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Arthralgia, Grade ≥ 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Myalgia, Grade ≥ 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Pruritus, Grade ≥ 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Rash maculopapular, Grade ≥ 3","Control: 0.030<br />Experimental: 0.160<br />greater: experi<br />event: pembrolizumab, Hypothyroidism, Adverse events of interest: Any grade","Control: 0.010<br />Experimental: 0.100<br />greater: experi<br />event: pembrolizumab, Hyperthyroidism, Adverse events of interest: Any grade","Control: 0.010<br />Experimental: 0.040<br />greater: experi<br />event: pembrolizumab, Colitis, Adverse events of interest: Any grade","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: pembrolizumab, Adrenal insufficiency, Adverse events of interest: Any grade","Control: 0.010<br />Experimental: 0.020<br />greater: experi<br />event: pembrolizumab, Hepatitis, Adverse events of interest: Any grade","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: pembrolizumab, Hypophysitis, Adverse events of interest: Any grade","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Myasthenic syndrome, Adverse events of interest: Any grade","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Myelitis, Adverse events of interest: Any grade","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Myositis, Adverse events of interest: Any grade","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Nephritis, Adverse events of interest: Any grade","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Pancreatitis, Adverse events of interest: Any grade","Control: 0.010<br />Experimental: 0.020<br />greater: experi<br />event: pembrolizumab, Pneumonitis, Adverse events of interest: Any grade","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Sarcoidosis, Adverse events of interest: Any grade","Control: 0.010<br />Experimental: 0.030<br />greater: experi<br />event: pembrolizumab, Severe skin reactions, Adverse events of interest: Any grade","Control: 0.010<br />Experimental: 0.020<br />greater: experi<br />event: pembrolizumab, Thyroiditis, Adverse events of interest: Any grade","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Type 1 diabetes, Adverse events of interest: Any grade","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Uveitis, Adverse events of interest: Any grade","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Hyperthyroidism, Adverse events of interest: Grade ≥3","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: pembrolizumab, Colitis, Adverse events of interest: Grade ≥3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Adrenal insufficiency, Adverse events of interest: Grade ≥3","Control: 0.010<br />Experimental: 0.020<br />greater: experi<br />event: pembrolizumab, Hepatitis, Adverse events of interest: Grade ≥3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Hypophysitis, Adverse events of interest: Grade ≥3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Myasthenic syndrome, Adverse events of interest: Grade ≥3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Myelitis, Adverse events of interest: Grade ≥3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Myositis, Adverse events of interest: Grade ≥3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Nephritis, Adverse events of interest: Grade ≥3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Pancreatitis, Adverse events of interest: Grade ≥3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Pneumonitis, Adverse events of interest: Grade ≥3","Control: 0.010<br />Experimental: 0.030<br />greater: experi<br />event: pembrolizumab, Severe skin reactions, Adverse events of interest: Grade ≥3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Type 1 diabetes, Adverse events of interest: Grade ≥3","Control: 0.360<br />Experimental: 0.410<br />greater: experi<br />event: pembrolizumab, Musculoskeletal pain, All grades","Control: 0.310<br />Experimental: 0.400<br />greater: experi<br />event: pembrolizumab, Fatigue, All grades","Control: 0.150<br />Experimental: 0.300<br />greater: experi<br />event: pembrolizumab, Rash, All grades","Control: 0.130<br />Experimental: 0.230<br />greater: experi<br />event: pembrolizumab, Pruritus, All grades","Control: 0.230<br />Experimental: 0.270<br />greater: experi<br />event: pembrolizumab, Diarrhea, All grades","Control: 0.100<br />Experimental: 0.160<br />greater: experi<br />event: pembrolizumab, Nausea, All grades","Control: 0.036<br />Experimental: 0.210<br />greater: experi<br />event: pembrolizumab, Hypothyroidism, All grades","Control: 0.002<br />Experimental: 0.120<br />greater: experi<br />event: pembrolizumab, Hyperthyroidism , All grades","Control: 0.120<br />Experimental: 0.170<br />greater: experi<br />event: pembrolizumab, Cough, All grades","Control: 0.130<br />Experimental: 0.150<br />greater: experi<br />event: pembrolizumab, Headache, All grades","Control: 0.070<br />Experimental: 0.140<br />greater: experi<br />event: pembrolizumab, Hepatotoxicity, All grades","Control: 0.100<br />Experimental: 0.130<br />greater: experi<br />event: pembrolizumab, Acute kidney injury, All grades","Control: 0.006<br />Experimental: 0.012<br />greater: experi<br />event: pembrolizumab, Musculoskeletal pain, Grade 3-4","Control: 0.002<br />Experimental: 0.012<br />greater: experi<br />event: pembrolizumab, Fatigue, Grade 3-4","Control: 0.004<br />Experimental: 0.014<br />greater: experi<br />event: pembrolizumab, Rash, Grade 3-4","Control: 0.000<br />Experimental: 0.002<br />greater: experi<br />event: pembrolizumab, Pruritus, Grade 3-4","Control: 0.002<br />Experimental: 0.027<br />greater: experi<br />event: pembrolizumab, Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.004<br />greater: experi<br />event: pembrolizumab, Nausea, Grade 3-4","Control: 0.002<br />Experimental: 0.004<br />greater: experi<br />event: pembrolizumab, Abdominal, Grade 3-4","Control: 0.000<br />Experimental: 0.002<br />greater: experi<br />event: pembrolizumab, Hypothyroidism, Grade 3-4","Control: 0.000<br />Experimental: 0.002<br />greater: experi<br />event: pembrolizumab, Hyperthyroidism , Grade 3-4","Control: 0.000<br />Experimental: 0.002<br />greater: experi<br />event: pembrolizumab, Headache, Grade 3-4","Control: 0.006<br />Experimental: 0.037<br />greater: experi<br />event: pembrolizumab, Hepatotoxicity, Grade 3-4","Control: 0.002<br />Experimental: 0.012<br />greater: experi<br />event: pembrolizumab, Acute kidney injury, Grade 3-4","Control: 0.570<br />Experimental: 0.580<br />greater: experi<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Peripheral neuropathy, All grades","Control: 0.150<br />Experimental: 0.220<br />greater: experi<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Rash, All grades","Control: 0.460<br />Experimental: 0.470<br />greater: experi<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Fatigue, All grades","Control: 0.300<br />Experimental: 0.360<br />greater: experi<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Diarrhea, All grades","Control: 0.260<br />Experimental: 0.270<br />greater: experi<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Arthralgia, All grades","Control: 0.230<br />Experimental: 0.240<br />greater: experi<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Hypertension, All grades","Control: 0.003<br />Experimental: 0.036<br />greater: experi<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Rash, Grade 3-4","Control: 0.060<br />Experimental: 0.070<br />greater: experi<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Fatigue, Grade 3-4","Control: 0.016<br />Experimental: 0.020<br />greater: experi<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Nausea, Grade 3-4","Control: 0.019<br />Experimental: 0.026<br />greater: experi<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Vomiting, Grade 3-4","Control: 0.080<br />Experimental: 0.090<br />greater: experi<br />event: pembrolizumab + chemotherapy + (bevacizumab?), Urinary tract infection, Grade 3-4","Control: 0.030<br />Experimental: 0.510<br />greater: experi<br />event: cabozantinib, Diarrhea, All grades","Control: 0.020<br />Experimental: 0.240<br />greater: experi<br />event: cabozantinib, Nausea, All grades","Control: 0.080<br />Experimental: 0.140<br />greater: experi<br />event: cabozantinib, Vomitin, All grades","Control: 0.030<br />Experimental: 0.260<br />greater: experi<br />event: cabozantinib, Stomatitis, All grades","Control: 0.020<br />Experimental: 0.100<br />greater: experi<br />event: cabozantinib, Dry mouth, All grades","Control: 0.230<br />Experimental: 0.420<br />greater: experi<br />event: cabozantinib, Fatigue, All grades","Control: 0.160<br />Experimental: 0.230<br />greater: experi<br />event: cabozantinib, Decreased appetite, All grades","Control: 0.000<br />Experimental: 0.460<br />greater: experi<br />event: cabozantinib, Palmar-plantar erythrodysesthesia, All grades","Control: 0.050<br />Experimental: 0.300<br />greater: experi<br />event: cabozantinib, Hypertension, All grades","Control: 0.050<br />Experimental: 0.180<br />greater: experi<br />event: cabozantinib, Weight decreased, All grades","Control: 0.000<br />Experimental: 0.100<br />greater: experi<br />event: cabozantinib, Dysgeusia, All grades","Control: 0.020<br />Experimental: 0.100<br />greater: experi<br />event: cabozantinib, Headache, All grades","Control: 0.020<br />Experimental: 0.100<br />greater: experi<br />event: cabozantinib, Dysphonia, All grades","Control: 0.000<br />Experimental: 0.050<br />greater: experi<br />event: cabozantinib, Pulmonary embolism, All grades","Control: 0.030<br />Experimental: 0.150<br />greater: experi<br />event: cabozantinib, Proteinuria, All grades","Control: 0.000<br />Experimental: 0.070<br />greater: experi<br />event: cabozantinib, Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.030<br />greater: experi<br />event: cabozantinib, Nausea, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: cabozantinib, Vomitin, Grade 3-4","Control: 0.000<br />Experimental: 0.050<br />greater: experi<br />event: cabozantinib, Stomatitis, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: cabozantinib, Dry mouth, Grade 3-4","Control: 0.000<br />Experimental: 0.100<br />greater: experi<br />event: cabozantinib, Fatigue, Grade 3-4","Control: 0.000<br />Experimental: 0.030<br />greater: experi<br />event: cabozantinib, Decreased appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.100<br />greater: experi<br />event: cabozantinib, Palmar-plantar erythrodysesthesia, Grade 3-4","Control: 0.030<br />Experimental: 0.100<br />greater: experi<br />event: cabozantinib, Hypertension, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: cabozantinib, Weight decreased, Grade 3-4","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: cabozantinib, Headache, Grade 3-4","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: cabozantinib, Pulmonary embolism, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: cabozantinib, Proteinuria, Grade 3-4","Control: 0.310<br />Experimental: 0.430<br />greater: experi<br />event: ivosidenib, Fatigue, All grades","Control: 0.290<br />Experimental: 0.410<br />greater: experi<br />event: ivosidenib, Nausea, All grades","Control: 0.170<br />Experimental: 0.350<br />greater: experi<br />event: ivosidenib, Diarrhea, All grades","Control: 0.220<br />Experimental: 0.350<br />greater: experi<br />event: ivosidenib, Abdominal pain, All grades","Control: 0.150<br />Experimental: 0.230<br />greater: experi<br />event: ivosidenib, Ascites, All grades","Control: 0.200<br />Experimental: 0.230<br />greater: experi<br />event: ivosidenib, Vomiting, All grades","Control: 0.090<br />Experimental: 0.270<br />greater: experi<br />event: ivosidenib, Cough, All grades","Control: 0.190<br />Experimental: 0.240<br />greater: experi<br />event: ivosidenib, Decreased appetite, All grades","Control: 0.050<br />Experimental: 0.180<br />greater: experi<br />event: ivosidenib, Anemia, All grades","Control: 0.070<br />Experimental: 0.150<br />greater: experi<br />event: ivosidenib, Rash, All grades","Control: 0.070<br />Experimental: 0.130<br />greater: experi<br />event: ivosidenib, Headache, All grades","Control: 0.000<br />Experimental: 0.110<br />greater: experi<br />event: ivosidenib, Neuropathy, All grades","Control: 0.070<br />Experimental: 0.090<br />greater: experi<br />event: ivosidenib, Ascites, Grade ≥ 3","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: ivosidenib, Vomiting, Grade ≥ 3","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: ivosidenib, Decreased appetite, Grade ≥ 3","Control: 0.000<br />Experimental: 0.070<br />greater: experi<br />event: ivosidenib, Anemia, Grade ≥ 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: ivosidenib, Rash, Grade ≥ 3","Control: 0.190<br />Experimental: 0.360<br />greater: experi<br />event: nivolumab, Rash, All grades","Control: 0.160<br />Experimental: 0.300<br />greater: experi<br />event: nivolumab, Pruritus, All grades","Control: 0.320<br />Experimental: 0.360<br />greater: experi<br />event: nivolumab, Fatigue/Asthenia, All grades","Control: 0.270<br />Experimental: 0.300<br />greater: experi<br />event: nivolumab, Diarrhea, All grades","Control: 0.130<br />Experimental: 0.160<br />greater: experi<br />event: nivolumab, Nausea, All grades","Control: 0.240<br />Experimental: 0.280<br />greater: experi<br />event: nivolumab, Musculoskeletal pain, All grades","Control: 0.011<br />Experimental: 0.110<br />greater: experi<br />event: nivolumab, Hyperthyroidism, All grades","Control: 0.023<br />Experimental: 0.110<br />greater: experi<br />event: nivolumab, Hypothyroidism, All grades","Control: 0.160<br />Experimental: 0.170<br />greater: experi<br />event: nivolumab, Renal dysfunction, All grades","Control: 0.110<br />Experimental: 0.140<br />greater: experi<br />event: nivolumab, Cough, All grades","Control: 0.060<br />Experimental: 0.110<br />greater: experi<br />event: nivolumab, Dyspnea, All grades","Control: 0.070<br />Experimental: 0.130<br />greater: experi<br />event: nivolumab, Decreased appetite, All grades","Control: 0.090<br />Experimental: 0.110<br />greater: experi<br />event: nivolumab, Dizziness, All grades","Control: 0.080<br />Experimental: 0.110<br />greater: experi<br />event: nivolumab, Hepatitis, All grades","Control: 0.003<br />Experimental: 0.017<br />greater: experi<br />event: nivolumab, Rash, Grade 3-4","Control: 0.003<br />Experimental: 0.011<br />greater: experi<br />event: nivolumab, Fatigue/Asthenia, Grade 3-4","Control: 0.017<br />Experimental: 0.028<br />greater: experi<br />event: nivolumab, Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.006<br />greater: experi<br />event: nivolumab, Nausea, Grade 3-4","Control: 0.006<br />Experimental: 0.009<br />greater: experi<br />event: nivolumab, Abdominal pain, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: nivolumab, Arthralgia, Grade 3-4","Control: 0.009<br />Experimental: 0.017<br />greater: experi<br />event: nivolumab, Renal dysfunction, Grade 3-4","Control: 0.003<br />Experimental: 0.009<br />greater: experi<br />event: nivolumab, Decreased appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: nivolumab, Dizziness, Grade 3-4","Control: 0.006<br />Experimental: 0.040<br />greater: experi<br />event: nivolumab, Hepatitis, Grade 3-4","Control: 0.660<br />Experimental: 0.700<br />greater: experi<br />event: pembrolizumab + chemotherapy, Fatigue, All grades","Control: 0.190<br />Experimental: 0.280<br />greater: experi<br />event: pembrolizumab + chemotherapy, Pyrexia, All grades","Control: 0.660<br />Experimental: 0.670<br />greater: experi<br />event: pembrolizumab + chemotherapy, Nausea, All grades","Control: 0.390<br />Experimental: 0.420<br />greater: experi<br />event: pembrolizumab + chemotherapy, Constipation, All grades","Control: 0.340<br />Experimental: 0.410<br />greater: experi<br />event: pembrolizumab + chemotherapy, Diarrhea, All grades","Control: 0.290<br />Experimental: 0.340<br />greater: experi<br />event: pembrolizumab + chemotherapy, Stomatitis, All grades","Control: 0.280<br />Experimental: 0.310<br />greater: experi<br />event: pembrolizumab + chemotherapy, Vomiting, All grades","Control: 0.230<br />Experimental: 0.240<br />greater: experi<br />event: pembrolizumab + chemotherapy, Abdominal pain, All grades","Control: 0.580<br />Experimental: 0.610<br />greater: experi<br />event: pembrolizumab + chemotherapy, Alopecia, All grades","Control: 0.410<br />Experimental: 0.520<br />greater: experi<br />event: pembrolizumab + chemotherapy, Rash, All grades","Control: 0.290<br />Experimental: 0.300<br />greater: experi<br />event: pembrolizumab + chemotherapy, Headache, All grades","Control: 0.190<br />Experimental: 0.200<br />greater: experi<br />event: pembrolizumab + chemotherapy, Myalgia, All grades","Control: 0.240<br />Experimental: 0.260<br />greater: experi<br />event: pembrolizumab + chemotherapy, Cough, All grades","Control: 0.170<br />Experimental: 0.230<br />greater: experi<br />event: pembrolizumab + chemotherapy, Decreased appetite , All grades","Control: 0.190<br />Experimental: 0.210<br />greater: experi<br />event: pembrolizumab + chemotherapy, Insomnia, All grades","Control: 0.039<br />Experimental: 0.080<br />greater: experi<br />event: pembrolizumab + chemotherapy, Fatigue, Grade 3-4","Control: 0.003<br />Experimental: 0.013<br />greater: experi<br />event: pembrolizumab + chemotherapy, Pyrexia, Grade 3-4","Control: 0.018<br />Experimental: 0.037<br />greater: experi<br />event: pembrolizumab + chemotherapy, Nausea, Grade 3-4","Control: 0.018<br />Experimental: 0.032<br />greater: experi<br />event: pembrolizumab + chemotherapy, Diarrhea, Grade 3-4","Control: 0.010<br />Experimental: 0.027<br />greater: experi<br />event: pembrolizumab + chemotherapy, Stomatitis, Grade 3-4","Control: 0.015<br />Experimental: 0.027<br />greater: experi<br />event: pembrolizumab + chemotherapy, Vomiting, Grade 3-4","Control: 0.005<br />Experimental: 0.050<br />greater: experi<br />event: pembrolizumab + chemotherapy, Rash, Grade 3-4","Control: 0.023<br />Experimental: 0.033<br />greater: experi<br />event: pembrolizumab + chemotherapy, Peripheral neuropathy, Grade 3-4","Control: 0.003<br />Experimental: 0.005<br />greater: experi<br />event: pembrolizumab + chemotherapy, Arthralgia , Grade 3-4","Control: 0.000<br />Experimental: 0.005<br />greater: experi<br />event: pembrolizumab + chemotherapy, Myalgia, Grade 3-4","Control: 0.000<br />Experimental: 0.001<br />greater: experi<br />event: pembrolizumab + chemotherapy, Cough, Grade 3-4","Control: 0.003<br />Experimental: 0.009<br />greater: experi<br />event: pembrolizumab + chemotherapy, Decreased appetite , Grade 3-4","Control: 0.000<br />Experimental: 0.005<br />greater: experi<br />event: pembrolizumab + chemotherapy, Insomnia, Grade 3-4","Control: 0.210<br />Experimental: 0.230<br />greater: experi<br />event: nivolumab, Nausea, All grades","Control: 0.290<br />Experimental: 0.340<br />greater: experi<br />event: nivolumab, Fatigue, All grades","Control: 0.100<br />Experimental: 0.210<br />greater: experi<br />event: nivolumab, Rash, All grades","Control: 0.060<br />Experimental: 0.130<br />greater: experi<br />event: nivolumab, Pruritus, All grades","Control: 0.090<br />Experimental: 0.130<br />greater: experi<br />event: nivolumab, Weight decreased, All grades","Control: 0.200<br />Experimental: 0.210<br />greater: experi<br />event: nivolumab, Musculoskeletal pain, All grades","Control: 0.080<br />Experimental: 0.100<br />greater: experi<br />event: nivolumab, Arthralgia, All grades","Control: 0.100<br />Experimental: 0.150<br />greater: experi<br />event: nivolumab, Decreased appetite, All grades","Control: 0.015<br />Experimental: 0.110<br />greater: experi<br />event: nivolumab, Hypothyroidism, All grades","Control: 0.008<br />Experimental: 0.009<br />greater: experi<br />event: nivolumab, Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.008<br />greater: experi<br />event: nivolumab, Nausea, Grade 3-4","Control: 0.004<br />Experimental: 0.008<br />greater: experi<br />event: nivolumab, Dyspnea, Grade 3-4","Control: 0.004<br />Experimental: 0.009<br />greater: experi<br />event: nivolumab, Rash, Grade 3-4","Control: 0.000<br />Experimental: 0.004<br />greater: experi<br />event: nivolumab, Pruritus, Grade 3-4","Control: 0.000<br />Experimental: 0.004<br />greater: experi<br />event: nivolumab, Weight decreased, Grade 3-4","Control: 0.000<br />Experimental: 0.002<br />greater: experi<br />event: nivolumab, Arthralgia, Grade 3-4","Control: 0.008<br />Experimental: 0.009<br />greater: experi<br />event: nivolumab, Decreased appetite, Grade 3-4","Control: 0.630<br />Experimental: 0.670<br />greater: experi<br />event: pembrolizumab + chemotherapy, Nausea, All grades","Control: 0.330<br />Experimental: 0.360<br />greater: experi<br />event: pembrolizumab + chemotherapy, Diarrhea, All grades","Control: 0.320<br />Experimental: 0.340<br />greater: experi<br />event: pembrolizumab + chemotherapy, Vomiting, All grades","Control: 0.260<br />Experimental: 0.270<br />greater: experi<br />event: pembrolizumab + chemotherapy, Stomatitis, All grades","Control: 0.460<br />Experimental: 0.570<br />greater: experi<br />event: pembrolizumab + chemotherapy, Fatigue, All grades","Control: 0.380<br />Experimental: 0.440<br />greater: experi<br />event: pembrolizumab + chemotherapy, Decreased appetite, All grades","Control: 0.030<br />Experimental: 0.041<br />greater: experi<br />event: pembrolizumab + chemotherapy, Diarrhea, Grade 3-4","Control: 0.050<br />Experimental: 0.070<br />greater: experi<br />event: pembrolizumab + chemotherapy, Vomiting, Grade 3-4","Control: 0.038<br />Experimental: 0.060<br />greater: experi<br />event: pembrolizumab + chemotherapy, Stomatitis, Grade 3-4","Control: 0.090<br />Experimental: 0.120<br />greater: experi<br />event: pembrolizumab + chemotherapy, Fatigue, Grade 3-4","Control: 0.200<br />Experimental: 0.470<br />greater: experi<br />event: osimertinib, Diarrhea, All grades","Control: 0.070<br />Experimental: 0.320<br />greater: experi<br />event: osimertinib, Stomatitis, All grades","Control: 0.070<br />Experimental: 0.120<br />greater: experi<br />event: osimertinib, Abdominal Pain, All grades","Control: 0.190<br />Experimental: 0.400<br />greater: experi<br />event: osimertinib, Rash, All grades","Control: 0.038<br />Experimental: 0.370<br />greater: experi<br />event: osimertinib, Nail toxicity, All grades","Control: 0.070<br />Experimental: 0.290<br />greater: experi<br />event: osimertinib, Dry skin, All grades","Control: 0.090<br />Experimental: 0.190<br />greater: experi<br />event: osimertinib, Pruritus, All grades","Control: 0.100<br />Experimental: 0.140<br />greater: experi<br />event: osimertinib, Nasopharyngitis, All grades","Control: 0.100<br />Experimental: 0.130<br />greater: experi<br />event: osimertinib, Upper respiratory tract infection, All grades","Control: 0.070<br />Experimental: 0.100<br />greater: experi<br />event: osimertinib, Urinary Tract Infection, All grades","Control: 0.090<br />Experimental: 0.130<br />greater: experi<br />event: osimertinib, Fatigue, All grades","Control: 0.090<br />Experimental: 0.100<br />greater: experi<br />event: osimertinib, Dizziness, All grades","Control: 0.038<br />Experimental: 0.130<br />greater: experi<br />event: osimertinib, Decreased appetite, All grades","Control: 0.003<br />Experimental: 0.024<br />greater: experi<br />event: osimertinib, Diarrhea, Grade ≥ 3","Control: 0.000<br />Experimental: 0.018<br />greater: experi<br />event: osimertinib, Stomatitis, Grade ≥ 3","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: osimertinib, Abdominal Pain, Grade ≥ 3","Control: 0.000<br />Experimental: 0.006<br />greater: experi<br />event: osimertinib, Rash, Grade ≥ 3","Control: 0.000<br />Experimental: 0.009<br />greater: experi<br />event: osimertinib, Nail toxicity, Grade ≥ 3","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: osimertinib, Dry skin, Grade ≥ 3","Control: 0.000<br />Experimental: 0.006<br />greater: experi<br />event: osimertinib, Upper respiratory tract infection, Grade ≥ 3","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: osimertinib, Urinary Tract Infection, Grade ≥ 3","Control: 0.003<br />Experimental: 0.006<br />greater: experi<br />event: osimertinib, Fatigue, Grade ≥ 3","Control: 0.000<br />Experimental: 0.006<br />greater: experi<br />event: osimertinib, Decreased appetite, Grade ≥ 3","Control: 0.230<br />Experimental: 0.280<br />greater: experi<br />event: pembrolizumab + chemotherapy, Diarrhea, All grades","Control: 0.270<br />Experimental: 0.280<br />greater: experi<br />event: pembrolizumab + chemotherapy, Constipation, All grades","Control: 0.220<br />Experimental: 0.260<br />greater: experi<br />event: pembrolizumab + chemotherapy, Vomiting, All grades","Control: 0.160<br />Experimental: 0.260<br />greater: experi<br />event: pembrolizumab + chemotherapy, Rash, All grades","Control: 0.200<br />Experimental: 0.230<br />greater: experi<br />event: pembrolizumab + chemotherapy, Cough, All grades","Control: 0.140<br />Experimental: 0.210<br />greater: experi<br />event: pembrolizumab + chemotherapy, Decreased appetite, All grades","Control: 0.043<br />Experimental: 0.050<br />greater: experi<br />event: pembrolizumab + chemotherapy, Fatigue, Grade 3-4","Control: 0.004<br />Experimental: 0.005<br />greater: experi<br />event: pembrolizumab + chemotherapy, Constipation, Grade 3-4","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: pembrolizumab + chemotherapy, Rash, Grade 3-4","Control: 0.004<br />Experimental: 0.008<br />greater: experi<br />event: pembrolizumab + chemotherapy, Decreased appetite, Grade 3-4","Control: 0.350<br />Experimental: 0.440<br />greater: experi<br />event: venetoclax + azacitidine, Nausea, All grades","Control: 0.330<br />Experimental: 0.430<br />greater: experi<br />event: venetoclax + azacitidine, Diarrhea, All grades","Control: 0.230<br />Experimental: 0.300<br />greater: experi<br />event: venetoclax + azacitidine, Vomiting, All grades","Control: 0.130<br />Experimental: 0.180<br />greater: experi<br />event: venetoclax + azacitidine, Stomatitis, All grades","Control: 0.130<br />Experimental: 0.180<br />greater: experi<br />event: venetoclax + azacitidine, Abdominal pain, All grades","Control: 0.190<br />Experimental: 0.420<br />greater: experi<br />event: venetoclax + azacitidine, Febrile neutropenia, All grades","Control: 0.280<br />Experimental: 0.360<br />greater: experi<br />event: venetoclax + azacitidine, Musculoskeletal pain, All grades","Control: 0.230<br />Experimental: 0.310<br />greater: experi<br />event: venetoclax + azacitidine, Fatigue, All grades","Control: 0.190<br />Experimental: 0.270<br />greater: experi<br />event: venetoclax + azacitidine, Edemag, All grades","Control: 0.240<br />Experimental: 0.270<br />greater: experi<br />event: venetoclax + azacitidine, Hemorrhage, All grades","Control: 0.080<br />Experimental: 0.120<br />greater: experi<br />event: venetoclax + azacitidine, Hypotension, All grades","Control: 0.170<br />Experimental: 0.250<br />greater: experi<br />event: venetoclax + azacitidine, Decreased appetite, All grades","Control: 0.150<br />Experimental: 0.250<br />greater: experi<br />event: venetoclax + azacitidine, Rash, All grades","Control: 0.160<br />Experimental: 0.220<br />greater: experi<br />event: venetoclax + azacitidine, Sepsis (excluding fungal), All grades","Control: 0.090<br />Experimental: 0.160<br />greater: experi<br />event: venetoclax + azacitidine, Urinary tract infection, All grades","Control: 0.100<br />Experimental: 0.180<br />greater: experi<br />event: venetoclax + azacitidine, Dyspnean, All grades","Control: 0.080<br />Experimental: 0.170<br />greater: experi<br />event: venetoclax + azacitidine, Dizziness, All grades","Control: 0.010<br />Experimental: 0.020<br />greater: experi<br />event: venetoclax + azacitidine, Nausea, Grade 3-4","Control: 0.030<br />Experimental: 0.050<br />greater: experi<br />event: venetoclax + azacitidine, Diarrhea, Grade 3-4","Control: 0.010<br />Experimental: 0.020<br />greater: experi<br />event: venetoclax + azacitidine, Vomiting, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: venetoclax + azacitidine, Stomatitis, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: venetoclax + azacitidine, Abdominal pain, Grade 3-4","Control: 0.190<br />Experimental: 0.420<br />greater: experi<br />event: venetoclax + azacitidine, Febrile neutropenia, Grade 3-4","Control: 0.010<br />Experimental: 0.020<br />greater: experi<br />event: venetoclax + azacitidine, Musculoskeletal pain, Grade 3-4","Control: 0.020<br />Experimental: 0.060<br />greater: experi<br />event: venetoclax + azacitidine, Fatigue, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: venetoclax + azacitidine, Edemag, Grade 3-4","Control: 0.030<br />Experimental: 0.070<br />greater: experi<br />event: venetoclax + azacitidine, Hemorrhage, Grade 3-4","Control: 0.030<br />Experimental: 0.050<br />greater: experi<br />event: venetoclax + azacitidine, Hypotension, Grade 3-4","Control: 0.010<br />Experimental: 0.040<br />greater: experi<br />event: venetoclax + azacitidine, Decreased appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: venetoclax + azacitidine, Rash, Grade 3-4","Control: 0.140<br />Experimental: 0.220<br />greater: experi<br />event: venetoclax + azacitidine, Sepsis (excluding fungal), Grade 3-4","Control: 0.020<br />Experimental: 0.040<br />greater: experi<br />event: venetoclax + azacitidine, Dyspnean, Grade 3-4","Control: 0.240<br />Experimental: 0.650<br />greater: experi<br />event: azacitidine, Nausea, All grades","Control: 0.100<br />Experimental: 0.600<br />greater: experi<br />event: azacitidine, Vomiting, All grades","Control: 0.210<br />Experimental: 0.500<br />greater: experi<br />event: azacitidine, Diarrhea, All grades","Control: 0.240<br />Experimental: 0.390<br />greater: experi<br />event: azacitidine, Constipation, All grades","Control: 0.130<br />Experimental: 0.220<br />greater: experi<br />event: azacitidine, Abdominal pain, All grades","Control: 0.250<br />Experimental: 0.440<br />greater: experi<br />event: azacitidine, Fatigue / astheniab, All grades","Control: 0.170<br />Experimental: 0.270<br />greater: experi<br />event: azacitidine, Pneumoniac, All grades","Control: 0.100<br />Experimental: 0.140<br />greater: experi<br />event: azacitidine, Arthralgia, All grades","Control: 0.050<br />Experimental: 0.110<br />greater: experi<br />event: azacitidine, Pain in extremity, All grades","Control: 0.060<br />Experimental: 0.130<br />greater: experi<br />event: azacitidine, Decreased appetite, All grades","Control: 0.080<br />Experimental: 0.120<br />greater: experi<br />event: azacitidine, Febrile neutropenia, All grades","Control: 0.090<br />Experimental: 0.110<br />greater: experi<br />event: azacitidine, Dizziness, All grades","Control: 0.010<br />Experimental: 0.030<br />greater: experi<br />event: azacitidine, Nausea, TYPO","Control: 0.000<br />Experimental: 0.030<br />greater: experi<br />event: azacitidine, Vomiting, TYPO","Control: 0.010<br />Experimental: 0.050<br />greater: experi<br />event: azacitidine, Diarrhea, TYPO","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: azacitidine, Constipation, TYPO","Control: 0.010<br />Experimental: 0.020<br />greater: experi<br />event: azacitidine, Abdominal pain, TYPO","Control: 0.010<br />Experimental: 0.040<br />greater: experi<br />event: azacitidine, Fatigue / astheniab, TYPO","Control: 0.050<br />Experimental: 0.090<br />greater: experi<br />event: azacitidine, Pneumoniac, TYPO","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: azacitidine, Pain in extremity, TYPO","Control: 0.080<br />Experimental: 0.110<br />greater: experi<br />event: azacitidine, Febrile neutropenia, TYPO","Control: 0.720<br />Experimental: 0.750<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Rash, All grades","Control: 0.170<br />Experimental: 0.260<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Pruritus, All grades","Control: 0.450<br />Experimental: 0.510<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Fatigue, All grades","Control: 0.350<br />Experimental: 0.490<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Pyrexia, All grades","Control: 0.210<br />Experimental: 0.260<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Edema, All grades","Control: 0.360<br />Experimental: 0.500<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Hepatotoxicity, All grades","Control: 0.150<br />Experimental: 0.230<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Stomatitis, All grades","Control: 0.480<br />Experimental: 0.620<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Musculoskeletal pain, All grades","Control: 0.100<br />Experimental: 0.220<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Hypothyroidism, All grades","Control: 0.080<br />Experimental: 0.180<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Hyperthyroidism, All grades","Control: 0.080<br />Experimental: 0.100<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Infusion related reaction, All grades","Control: 0.060<br />Experimental: 0.120<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Pneumonitis, All grades","Control: 0.230<br />Experimental: 0.270<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Rash, Grade 3-4","Control: 0.018<br />Experimental: 0.030<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Fatigue, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Edema, Grade 3-4","Control: 0.130<br />Experimental: 0.210<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Hepatotoxicity, Grade 3-4","Control: 0.010<br />Experimental: 0.013<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Stomatitis, Grade 3-4","Control: 0.032<br />Experimental: 0.043<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Musculoskeletal pain, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Hyperthyroidism, Grade 3-4","Control: 0.010<br />Experimental: 0.026<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Infusion related reaction, Grade 3-4","Control: 0.010<br />Experimental: 0.013<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Pneumonitis, Grade 3-4","Control: 0.070<br />Experimental: 0.100<br />greater: experi<br />event: atezolizumab +  cobimetinib + vemurafenib, Hypertension, Grade 3-4","Control: 0.760<br />Experimental: 0.810<br />greater: experi<br />event: ramucirumab + erlotinib, Infectionsa b, All grades","Control: 0.120<br />Experimental: 0.450<br />greater: experi<br />event: ramucirumab + erlotinib, Hypertension, All grades","Control: 0.360<br />Experimental: 0.420<br />greater: experi<br />event: ramucirumab + erlotinib, Stomatitis, All grades","Control: 0.030<br />Experimental: 0.100<br />greater: experi<br />event: ramucirumab + erlotinib, Gastrointestinal hemorrhage, All grades","Control: 0.010<br />Experimental: 0.090<br />greater: experi<br />event: ramucirumab + erlotinib, Gingival bleeding, All grades","Control: 0.080<br />Experimental: 0.340<br />greater: experi<br />event: ramucirumab + erlotinib, Proteinuria, All grades","Control: 0.200<br />Experimental: 0.340<br />greater: experi<br />event: ramucirumab + erlotinib, Alopecia, All grades","Control: 0.120<br />Experimental: 0.340<br />greater: experi<br />event: ramucirumab + erlotinib, Epistaxis, All grades","Control: 0.020<br />Experimental: 0.070<br />greater: experi<br />event: ramucirumab + erlotinib, Pulmonary hemorrhageq, All grades","Control: 0.040<br />Experimental: 0.230<br />greater: experi<br />event: ramucirumab + erlotinib, Peripheral edema, All grades","Control: 0.070<br />Experimental: 0.150<br />greater: experi<br />event: ramucirumab + erlotinib, Headache, All grades","Control: 0.070<br />Experimental: 0.170<br />greater: experi<br />event: ramucirumab + erlotinib, Infectionsa b, Grade ≥ 3","Control: 0.050<br />Experimental: 0.240<br />greater: experi<br />event: ramucirumab + erlotinib, Hypertension, Grade ≥ 3","Control: 0.010<br />Experimental: 0.070<br />greater: experi<br />event: ramucirumab + erlotinib, Diarrhea, Grade ≥ 3","Control: 0.010<br />Experimental: 0.020<br />greater: experi<br />event: ramucirumab + erlotinib, Stomatitis, Grade ≥ 3","Control: 0.000<br />Experimental: 0.030<br />greater: experi<br />event: ramucirumab + erlotinib, Proteinuria, Grade ≥ 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: ramucirumab + erlotinib, Peripheral edema, Grade ≥ 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: ramucirumab + erlotinib, Headache, Grade ≥ 3","Control: 0.047<br />Experimental: 0.520<br />greater: experi<br />event: ripretinib, Alopecia, Grades 1-4","Control: 0.000<br />Experimental: 0.210<br />greater: experi<br />event: ripretinib, Palmar-plantar erythrodysesthesia syndrome, Grades 1-4","Control: 0.070<br />Experimental: 0.130<br />greater: experi<br />event: ripretinib, Dry skin, Grades 1-4","Control: 0.047<br />Experimental: 0.110<br />greater: experi<br />event: ripretinib, Pruritus, Grades 1-4","Control: 0.230<br />Experimental: 0.420<br />greater: experi<br />event: ripretinib, Fatigue, Grades 1-4","Control: 0.070<br />Experimental: 0.170<br />greater: experi<br />event: ripretinib, Peripheral edema, Grades 1-4","Control: 0.120<br />Experimental: 0.390<br />greater: experi<br />event: ripretinib, Nausea, Grades 1-4","Control: 0.300<br />Experimental: 0.360<br />greater: experi<br />event: ripretinib, Abdominal pain, Grades 1-4","Control: 0.190<br />Experimental: 0.340<br />greater: experi<br />event: ripretinib, Constipation, Grades 1-4","Control: 0.140<br />Experimental: 0.280<br />greater: experi<br />event: ripretinib, Diarrhea, Grades 1-4","Control: 0.070<br />Experimental: 0.210<br />greater: experi<br />event: ripretinib, Vomiting, Grades 1-4","Control: 0.000<br />Experimental: 0.110<br />greater: experi<br />event: ripretinib, Stomatitis, Grades 1-4","Control: 0.120<br />Experimental: 0.320<br />greater: experi<br />event: ripretinib, Myalgia, Grades 1-4","Control: 0.047<br />Experimental: 0.180<br />greater: experi<br />event: ripretinib, Arthralgia, Grades 1-4","Control: 0.047<br />Experimental: 0.150<br />greater: experi<br />event: ripretinib, Muscle spasms, Grades 1-4","Control: 0.210<br />Experimental: 0.270<br />greater: experi<br />event: ripretinib, Decreased appetite, Grades 1-4","Control: 0.120<br />Experimental: 0.190<br />greater: experi<br />event: ripretinib, Decreased weight, Grades 1-4","Control: 0.047<br />Experimental: 0.190<br />greater: experi<br />event: ripretinib, Headache, Grades 1-4","Control: 0.047<br />Experimental: 0.140<br />greater: experi<br />event: ripretinib, Hypertension, Grades 1-4","Control: 0.000<br />Experimental: 0.130<br />greater: experi<br />event: ripretinib, Dyspnea, Grades 1-4","Control: 0.023<br />Experimental: 0.035<br />greater: experi<br />event: ripretinib, Fatigue, Grade 3-4","Control: 0.000<br />Experimental: 0.012<br />greater: experi<br />event: ripretinib, Peripheral edema, Grade 3-4","Control: 0.000<br />Experimental: 0.035<br />greater: experi<br />event: ripretinib, Nausea, Grade 3-4","Control: 0.047<br />Experimental: 0.070<br />greater: experi<br />event: ripretinib, Abdominal pain, Grade 3-4","Control: 0.000<br />Experimental: 0.012<br />greater: experi<br />event: ripretinib, Constipation, Grade 3-4","Control: 0.000<br />Experimental: 0.035<br />greater: experi<br />event: ripretinib, Vomiting, Grade 3-4","Control: 0.000<br />Experimental: 0.012<br />greater: experi<br />event: ripretinib, Myalgia, Grade 3-4","Control: 0.000<br />Experimental: 0.070<br />greater: experi<br />event: ripretinib, Hypertension, Grade 3-4","Control: 0.320<br />Experimental: 0.530<br />greater: experi<br />event: olaparib + bevacizumab, Fatigue (including asthenia), Grades 1-4","Control: 0.220<br />Experimental: 0.530<br />greater: experi<br />event: olaparib + bevacizumab, Nausea, Grades 1-4","Control: 0.110<br />Experimental: 0.220<br />greater: experi<br />event: olaparib + bevacizumab, Vomiting, Grades 1-4","Control: 0.100<br />Experimental: 0.410<br />greater: experi<br />event: olaparib + bevacizumab, Anemia, Grades 1-4","Control: 0.090<br />Experimental: 0.240<br />greater: experi<br />event: olaparib + bevacizumab, Lymphopenia, Grades 1-4","Control: 0.100<br />Experimental: 0.180<br />greater: experi<br />event: olaparib + bevacizumab, Leukopenia, Grades 1-4","Control: 0.015<br />Experimental: 0.050<br />greater: experi<br />event: olaparib + bevacizumab, Fatigue (including asthenia), TYPO","Control: 0.007<br />Experimental: 0.024<br />greater: experi<br />event: olaparib + bevacizumab, Nausea, TYPO","Control: 0.004<br />Experimental: 0.170<br />greater: experi<br />event: olaparib + bevacizumab, Anemia, TYPO","Control: 0.011<br />Experimental: 0.070<br />greater: experi<br />event: olaparib + bevacizumab, Lymphopenia, TYPO","Control: 0.015<br />Experimental: 0.019<br />greater: experi<br />event: olaparib + bevacizumab, Leukopenia, TYPO","Control: 0.050<br />Experimental: 0.660<br />greater: experi<br />event: niraparib, Thrombocytopenia, Grades 1-4","Control: 0.180<br />Experimental: 0.640<br />greater: experi<br />event: niraparib, Anemia, Grades 1-4","Control: 0.080<br />Experimental: 0.420<br />greater: experi<br />event: niraparib, Neutropenia, Grades 1-4","Control: 0.090<br />Experimental: 0.280<br />greater: experi<br />event: niraparib, Leukopenia, Grades 1-4","Control: 0.280<br />Experimental: 0.570<br />greater: experi<br />event: niraparib, Nausea, Grades 1-4","Control: 0.200<br />Experimental: 0.400<br />greater: experi<br />event: niraparib, Constipation, Grades 1-4","Control: 0.120<br />Experimental: 0.220<br />greater: experi<br />event: niraparib, Vomiting, Grades 1-4","Control: 0.410<br />Experimental: 0.510<br />greater: experi<br />event: niraparib, Fatigue, Grades 1-4","Control: 0.070<br />Experimental: 0.140<br />greater: experi<br />event: niraparib, AST/ALT elevation, Grades 1-4","Control: 0.080<br />Experimental: 0.190<br />greater: experi<br />event: niraparib, Decreased appetite, Grades 1-4","Control: 0.380<br />Experimental: 0.390<br />greater: experi<br />event: niraparib, Musculoskeletal pain, Grades 1-4","Control: 0.150<br />Experimental: 0.260<br />greater: experi<br />event: niraparib, Headache, Grades 1-4","Control: 0.130<br />Experimental: 0.190<br />greater: experi<br />event: niraparib, Dizziness, Grades 1-4","Control: 0.150<br />Experimental: 0.250<br />greater: experi<br />event: niraparib, Insomnia, Grades 1-4","Control: 0.050<br />Experimental: 0.120<br />greater: experi<br />event: niraparib, Acute kidney injury, Grades 1-4","Control: 0.130<br />Experimental: 0.220<br />greater: experi<br />event: niraparib, Dyspnea, Grades 1-4","Control: 0.150<br />Experimental: 0.180<br />greater: experi<br />event: niraparib, Cough, Grades 1-4","Control: 0.070<br />Experimental: 0.180<br />greater: experi<br />event: niraparib, Hypertension, Grades 1-4","Control: 0.004<br />Experimental: 0.390<br />greater: experi<br />event: niraparib, Thrombocytopenia, Grade 3-4","Control: 0.020<br />Experimental: 0.310<br />greater: experi<br />event: niraparib, Anemia, Grade 3-4","Control: 0.010<br />Experimental: 0.210<br />greater: experi<br />event: niraparib, Neutropenia, Grade 3-4","Control: 0.004<br />Experimental: 0.050<br />greater: experi<br />event: niraparib, Leukopenia, Grade 3-4","Control: 0.004<br />Experimental: 0.010<br />greater: experi<br />event: niraparib, Constipation, Grade 3-4","Control: 0.010<br />Experimental: 0.030<br />greater: experi<br />event: niraparib, Fatigue, Grade 3-4","Control: 0.008<br />Experimental: 0.030<br />greater: experi<br />event: niraparib, AST/ALT elevation, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: niraparib, Decreased appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: niraparib, Musculoskeletal pain, Grade 3-4","Control: 0.000<br />Experimental: 0.004<br />greater: experi<br />event: niraparib, Headache, Grade 3-4","Control: 0.004<br />Experimental: 0.010<br />greater: experi<br />event: niraparib, Insomnia, Grade 3-4","Control: 0.000<br />Experimental: 0.002<br />greater: experi<br />event: niraparib, Acute kidney injury, Grade 3-4","Control: 0.010<br />Experimental: 0.060<br />greater: experi<br />event: niraparib, Hypertension, Grade 3-4","Control: 0.530<br />Experimental: 0.810<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Diarrhea, All grades","Control: 0.440<br />Experimental: 0.580<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Nausea, All grades","Control: 0.250<br />Experimental: 0.360<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Vomiting, All grades","Control: 0.210<br />Experimental: 0.320<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Stomatitis, All grades","Control: 0.530<br />Experimental: 0.630<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Palmar-plantar erythrodysesthesia syndrome, All grades","Control: 0.150<br />Experimental: 0.200<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Rash, All grades","Control: 0.240<br />Experimental: 0.420<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Hepatotoxicity, All grades","Control: 0.200<br />Experimental: 0.250<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Decreased appetite, All grades","Control: 0.130<br />Experimental: 0.210<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Anemia, All grades","Control: 0.046<br />Experimental: 0.150<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Arthralgia, All grades","Control: 0.015<br />Experimental: 0.140<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Creatinine increased, All grades","Control: 0.060<br />Experimental: 0.130<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Weight decreased, All grades","Control: 0.070<br />Experimental: 0.130<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Peripheral neuropathy, All grades","Control: 0.050<br />Experimental: 0.120<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Epistaxis, All grades","Control: 0.090<br />Experimental: 0.120<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Diarrhea, Grade 3","Control: 0.030<br />Experimental: 0.037<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Nausea, Grade 3","Control: 0.005<br />Experimental: 0.025<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Stomatitis, Grade 3","Control: 0.090<br />Experimental: 0.130<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Palmar-plantar erythrodysesthesia syndrome, Grade 3","Control: 0.005<br />Experimental: 0.007<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Rash, Grade 3","Control: 0.036<br />Experimental: 0.090<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Hepatotoxicity, Grade 3","Control: 0.000<br />Experimental: 0.005<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Decreased appetite, Grade 3","Control: 0.025<br />Experimental: 0.037<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Anemia, Grade 3","Control: 0.005<br />Experimental: 0.010<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Weight decreased, Grade 3","Control: 0.000<br />Experimental: 0.005<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Diarrhea, Grade 4","Control: 0.000<br />Experimental: 0.002<br />greater: experi<br />event: tucatinib + trastuzumab + capecitabine, Hepatotoxicity, Grade 4","Control: 0.560<br />Experimental: 0.650<br />greater: experi<br />event: nivolumab + chemotherapy, Nausea, All grades","Control: 0.430<br />Experimental: 0.440<br />greater: experi<br />event: nivolumab + chemotherapy, Constipation, All grades","Control: 0.350<br />Experimental: 0.440<br />greater: experi<br />event: nivolumab + chemotherapy, Stomatitis, All grades","Control: 0.200<br />Experimental: 0.290<br />greater: experi<br />event: nivolumab + chemotherapy, Diarrhea, All grades","Control: 0.190<br />Experimental: 0.230<br />greater: experi<br />event: nivolumab + chemotherapy, Vomiting, All grades","Control: 0.120<br />Experimental: 0.140<br />greater: experi<br />event: nivolumab + chemotherapy, Dysphagia, All grades","Control: 0.110<br />Experimental: 0.130<br />greater: experi<br />event: nivolumab + chemotherapy, Abdominal pain, All grades","Control: 0.500<br />Experimental: 0.510<br />greater: experi<br />event: nivolumab + chemotherapy, Decreased appetite, All grades","Control: 0.410<br />Experimental: 0.470<br />greater: experi<br />event: nivolumab + chemotherapy, Fatigue, All grades","Control: 0.120<br />Experimental: 0.190<br />greater: experi<br />event: nivolumab + chemotherapy, Pyrexiad, All grades","Control: 0.130<br />Experimental: 0.160<br />greater: experi<br />event: nivolumab + chemotherapy, Edemae, All grades","Control: 0.130<br />Experimental: 0.180<br />greater: experi<br />event: nivolumab + chemotherapy, Peripheral neuropathy, All grades","Control: 0.100<br />Experimental: 0.160<br />greater: experi<br />event: nivolumab + chemotherapy, Insomnia, All grades","Control: 0.070<br />Experimental: 0.160<br />greater: experi<br />event: nivolumab + chemotherapy, Rash, All grades","Control: 0.036<br />Experimental: 0.110<br />greater: experi<br />event: nivolumab + chemotherapy, Pruritus, All grades","Control: 0.130<br />Experimental: 0.160<br />greater: experi<br />event: nivolumab + chemotherapy, Cough, All grades","Control: 0.100<br />Experimental: 0.130<br />greater: experi<br />event: nivolumab + chemotherapy, Pneumonial, All grades","Control: 0.003<br />Experimental: 0.070<br />greater: experi<br />event: nivolumab + chemotherapy, Hypothyroidism, All grades","Control: 0.110<br />Experimental: 0.120<br />greater: experi<br />event: nivolumab + chemotherapy, Weight decreased, All grades","Control: 0.080<br />Experimental: 0.110<br />greater: experi<br />event: nivolumab + chemotherapy, Musculoskeletal pain, All grades","Control: 0.026<br />Experimental: 0.042<br />greater: experi<br />event: nivolumab + chemotherapy, Nausea, Grade 3-4","Control: 0.030<br />Experimental: 0.090<br />greater: experi<br />event: nivolumab + chemotherapy, Stomatitis, Grade 3-4","Control: 0.020<br />Experimental: 0.029<br />greater: experi<br />event: nivolumab + chemotherapy, Diarrhea, Grade 3-4","Control: 0.049<br />Experimental: 0.070<br />greater: experi<br />event: nivolumab + chemotherapy, Dysphagia, Grade 3-4","Control: 0.007<br />Experimental: 0.019<br />greater: experi<br />event: nivolumab + chemotherapy, Abdominal pain, Grade 3-4","Control: 0.060<br />Experimental: 0.070<br />greater: experi<br />event: nivolumab + chemotherapy, Decreased appetite, Grade 3-4","Control: 0.010<br />Experimental: 0.013<br />greater: experi<br />event: nivolumab + chemotherapy, Peripheral neuropathy, Grade 3-4","Control: 0.000<br />Experimental: 0.006<br />greater: experi<br />event: nivolumab + chemotherapy, Rash, Grade 3-4","Control: 0.026<br />Experimental: 0.050<br />greater: experi<br />event: nivolumab + chemotherapy, Pneumonial, Grade 3-4","Control: 0.300<br />Experimental: 0.760<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Nausea, All grades","Control: 0.100<br />Experimental: 0.490<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Vomiting, All grades","Control: 0.200<br />Experimental: 0.340<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Constipation, All grades","Control: 0.070<br />Experimental: 0.290<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Diarrhea, All grades","Control: 0.080<br />Experimental: 0.210<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Abdominal paina, All grades","Control: 0.050<br />Experimental: 0.200<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Stomatitisb, All grades","Control: 0.060<br />Experimental: 0.110<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Dyspepsia, All grades","Control: 0.350<br />Experimental: 0.490<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Fatigue, All grades","Control: 0.170<br />Experimental: 0.330<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Anemia, All grades","Control: 0.031<br />Experimental: 0.370<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Alopeciae, All grades","Control: 0.250<br />Experimental: 0.310<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Musculoskeletal pain, All grades","Control: 0.170<br />Experimental: 0.290<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Decreased appetite, All grades","Control: 0.060<br />Experimental: 0.170<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Decreased weight, All grades","Control: 0.120<br />Experimental: 0.220<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Respiratory infectiong, All grades","Control: 0.100<br />Experimental: 0.110<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Cough, All grades","Control: 0.019<br />Experimental: 0.110<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Interstitial lung disease, All grades","Control: 0.160<br />Experimental: 0.220<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Headache, All grades","Control: 0.080<br />Experimental: 0.130<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Dizziness, All grades","Control: 0.004<br />Experimental: 0.070<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Nausea, Grade 3-4","Control: 0.008<br />Experimental: 0.016<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Vomiting, Grade 3-4","Control: 0.004<br />Experimental: 0.012<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Diarrhea, Grade 3-4","Control: 0.004<br />Experimental: 0.008<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Abdominal paina, Grade 3-4","Control: 0.000<br />Experimental: 0.008<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Stomatitisb, Grade 3-4","Control: 0.008<br />Experimental: 0.060<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Fatigue, Grade 3-4","Control: 0.060<br />Experimental: 0.070<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Anemia, Grade 3-4","Control: 0.000<br />Experimental: 0.004<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Alopeciae, Grade 3-4","Control: 0.004<br />Experimental: 0.012<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Musculoskeletal pain, Grade 3-4","Control: 0.004<br />Experimental: 0.016<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Decreased appetite, Grade 3-4","Control: 0.004<br />Experimental: 0.012<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Decreased weight, Grade 3-4","Control: 0.000<br />Experimental: 0.004<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Cough, Grade 3-4","Control: 0.000<br />Experimental: 0.008<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Interstitial lung disease, Grade 3-4","Control: 0.000<br />Experimental: 0.004<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Headache, Grade 3-4","Control: 0.000<br />Experimental: 0.004<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Dizziness, Grade 3-4","Control: 0.230<br />Experimental: 0.430<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Fatigue, All grades","Control: 0.150<br />Experimental: 0.210<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Decreased appetite, All grades","Control: 0.090<br />Experimental: 0.110<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Weight decreased, All grades","Control: 0.070<br />Experimental: 0.100<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Peripheral edema, All grades","Control: 0.034<br />Experimental: 0.070<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Pyrexia, All grades","Control: 0.005<br />Experimental: 0.390<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Dry mouth, All grades","Control: 0.170<br />Experimental: 0.350<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Nausea, All grades","Control: 0.110<br />Experimental: 0.200<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Constipation, All grades","Control: 0.060<br />Experimental: 0.190<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Vomiting, All grades","Control: 0.029<br />Experimental: 0.190<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Diarrhea, All grades","Control: 0.060<br />Experimental: 0.110<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Abdominal pain, All grades","Control: 0.130<br />Experimental: 0.320<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Anemia, All grades","Control: 0.044<br />Experimental: 0.170<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Thrombocytopenia, All grades","Control: 0.010<br />Experimental: 0.120<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Urinary tract infection, All grades","Control: 0.060<br />Experimental: 0.090<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Acute kidney injury, All grades","Control: 0.044<br />Experimental: 0.080<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Dizziness, All grades","Control: 0.020<br />Experimental: 0.070<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Headache, All grades","Control: 0.015<br />Experimental: 0.070<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Dysgeusia, All grades","Control: 0.015<br />Experimental: 0.060<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Fatigue, Grade 3-4","Control: 0.005<br />Experimental: 0.019<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Decreased appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.004<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Weight decreased, Grade 3-4","Control: 0.000<br />Experimental: 0.004<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Pyrexia, Grade 3-4","Control: 0.005<br />Experimental: 0.013<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Nausea, Grade 3-4","Control: 0.005<br />Experimental: 0.011<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Constipation, Grade 3-4","Control: 0.005<br />Experimental: 0.009<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Vomiting, Grade 3-4","Control: 0.005<br />Experimental: 0.008<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Diarrhea, Grade 3-4","Control: 0.005<br />Experimental: 0.011<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Abdominal pain, Grade 3-4","Control: 0.049<br />Experimental: 0.130<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Anemia, Grade 3-4","Control: 0.010<br />Experimental: 0.080<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Thrombocytopenia, Grade 3-4","Control: 0.005<br />Experimental: 0.038<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Urinary tract infection, Grade 3-4","Control: 0.029<br />Experimental: 0.032<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Acute kidney injury, Grade 3-4","Control: 0.000<br />Experimental: 0.009<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Dizziness, Grade 3-4","Control: 0.000<br />Experimental: 0.008<br />greater: experi<br />event: lutetium Lu 177 vipivotide tetraxetan + standard of care, Headache, Grade 3-4","Control: 0.310<br />Experimental: 0.450<br />greater: experi<br />event: relatlimab-rmbw +nivolumab, Musculoskeletal pain, All grades","Control: 0.290<br />Experimental: 0.390<br />greater: experi<br />event: relatlimab-rmbw +nivolumab, Fatigue, All grades","Control: 0.210<br />Experimental: 0.280<br />greater: experi<br />event: relatlimab-rmbw +nivolumab, Rash, All grades","Control: 0.170<br />Experimental: 0.250<br />greater: experi<br />event: relatlimab-rmbw +nivolumab, Pruritus, All grades","Control: 0.170<br />Experimental: 0.240<br />greater: experi<br />event: relatlimab-rmbw +nivolumab, Diarrhea, All grades","Control: 0.140<br />Experimental: 0.170<br />greater: experi<br />event: relatlimab-rmbw +nivolumab, Nausea, All grades","Control: 0.120<br />Experimental: 0.180<br />greater: experi<br />event: relatlimab-rmbw +nivolumab, Headache, All grades","Control: 0.140<br />Experimental: 0.170<br />greater: experi<br />event: relatlimab-rmbw +nivolumab, Hypothyroidisma, All grades","Control: 0.070<br />Experimental: 0.150<br />greater: experi<br />event: relatlimab-rmbw +nivolumab, Decreased appetite, All grades","Control: 0.110<br />Experimental: 0.150<br />greater: experi<br />event: relatlimab-rmbw +nivolumab, Cough, All grades","Control: 0.017<br />Experimental: 0.042<br />greater: experi<br />event: relatlimab-rmbw +nivolumab, Musculoskeletal pain, Grade 3-4","Control: 0.006<br />Experimental: 0.020<br />greater: experi<br />event: relatlimab-rmbw +nivolumab, Fatigue, Grade 3-4","Control: 0.014<br />Experimental: 0.020<br />greater: experi<br />event: relatlimab-rmbw +nivolumab, Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.006<br />greater: experi<br />event: relatlimab-rmbw +nivolumab, Nausea, Grade 3-4","Control: 0.003<br />Experimental: 0.006<br />greater: experi<br />event: relatlimab-rmbw +nivolumab, Decreased appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: relatlimab-rmbw +nivolumab, Cough, Grade 3-4","Control: 0.320<br />Experimental: 0.340<br />greater: experi<br />event: nivolumab + platinum-doublet chemotherapy, Constipation, All grades","Control: 0.230<br />Experimental: 0.260<br />greater: experi<br />event: nivolumab + platinum-doublet chemotherapy, Fatigue, All grades","Control: 0.140<br />Experimental: 0.150<br />greater: experi<br />event: nivolumab + platinum-doublet chemotherapy, Malaise, All grades","Control: 0.070<br />Experimental: 0.200<br />greater: experi<br />event: nivolumab + platinum-doublet chemotherapy, Rash, All grades","Control: 0.060<br />Experimental: 0.130<br />greater: experi<br />event: nivolumab + platinum-doublet chemotherapy, Peripheral neuropathy, All grades","Control: 0.006<br />Experimental: 0.011<br />greater: experi<br />event: nivolumab + platinum-doublet chemotherapy, Vomiting, Grade 3-4","Control: 0.011<br />Experimental: 0.023<br />greater: experi<br />event: nivolumab + platinum-doublet chemotherapy, Fatigue, Grade 3-4","Control: 0.000<br />Experimental: 0.023<br />greater: experi<br />event: nivolumab + platinum-doublet chemotherapy, Rash, Grade 3-4","Control: 0.027<br />Experimental: 0.890<br />greater: experi<br />event: tebentafusp-tebn, Cytokine release syndrome, All grades","Control: 0.280<br />Experimental: 0.830<br />greater: experi<br />event: tebentafusp-tebn, Rash, All grades","Control: 0.230<br />Experimental: 0.690<br />greater: experi<br />event: tebentafusp-tebn, Pruritus, All grades","Control: 0.036<br />Experimental: 0.310<br />greater: experi<br />event: tebentafusp-tebn, Dry skin, All grades","Control: 0.050<br />Experimental: 0.280<br />greater: experi<br />event: tebentafusp-tebn, Skin Hypopigmentation, All grades","Control: 0.009<br />Experimental: 0.240<br />greater: experi<br />event: tebentafusp-tebn, Erythema, All grades","Control: 0.000<br />Experimental: 0.200<br />greater: experi<br />event: tebentafusp-tebn, Hair color changes, All grades","Control: 0.070<br />Experimental: 0.760<br />greater: experi<br />event: tebentafusp-tebn, Pyrexia, All grades","Control: 0.420<br />Experimental: 0.640<br />greater: experi<br />event: tebentafusp-tebn, Fatigue, All grades","Control: 0.036<br />Experimental: 0.480<br />greater: experi<br />event: tebentafusp-tebn, Chills, All grades","Control: 0.100<br />Experimental: 0.450<br />greater: experi<br />event: tebentafusp-tebn, Edemab, All grades","Control: 0.260<br />Experimental: 0.490<br />greater: experi<br />event: tebentafusp-tebn, Nausea, All grades","Control: 0.330<br />Experimental: 0.450<br />greater: experi<br />event: tebentafusp-tebn, Abdominal pain, All grades","Control: 0.090<br />Experimental: 0.300<br />greater: experi<br />event: tebentafusp-tebn, Vomiting, All grades","Control: 0.200<br />Experimental: 0.250<br />greater: experi<br />event: tebentafusp-tebn, Diarrhea, All grades","Control: 0.027<br />Experimental: 0.390<br />greater: experi<br />event: tebentafusp-tebn, Hypotension, All grades","Control: 0.100<br />Experimental: 0.310<br />greater: experi<br />event: tebentafusp-tebn, Headache, All grades","Control: 0.160<br />Experimental: 0.220<br />greater: experi<br />event: tebentafusp-tebn, Arthralgia, All grades","Control: 0.000<br />Experimental: 0.008<br />greater: experi<br />event: tebentafusp-tebn, Cytokine release syndrome, Grade 3-4","Control: 0.000<br />Experimental: 0.180<br />greater: experi<br />event: tebentafusp-tebn, Rash, Grade 3-4","Control: 0.000<br />Experimental: 0.045<br />greater: experi<br />event: tebentafusp-tebn, Pruritus, Grade 3-4","Control: 0.009<br />Experimental: 0.037<br />greater: experi<br />event: tebentafusp-tebn, Pyrexia, Grade 3-4","Control: 0.009<br />Experimental: 0.060<br />greater: experi<br />event: tebentafusp-tebn, Fatigue, Grade 3-4","Control: 0.000<br />Experimental: 0.004<br />greater: experi<br />event: tebentafusp-tebn, Chills, Grade 3-4","Control: 0.009<br />Experimental: 0.020<br />greater: experi<br />event: tebentafusp-tebn, Nausea, Grade 3-4","Control: 0.000<br />Experimental: 0.012<br />greater: experi<br />event: tebentafusp-tebn, Vomiting, Grade 3-4","Control: 0.000<br />Experimental: 0.033<br />greater: experi<br />event: tebentafusp-tebn, Hypotension, Grade 3-4","Control: 0.000<br />Experimental: 0.008<br />greater: experi<br />event: tebentafusp-tebn, Arthralgia, Grade 3-4","Control: 0.120<br />Experimental: 0.260<br />greater: experi<br />event: asciminib, Upper respiratory tract infection, All grades","Control: 0.160<br />Experimental: 0.220<br />greater: experi<br />event: asciminib, Musculoskeletal pain, All grades","Control: 0.039<br />Experimental: 0.120<br />greater: experi<br />event: asciminib, Arthralgia, All grades","Control: 0.150<br />Experimental: 0.190<br />greater: experi<br />event: asciminib, Headache, All grades","Control: 0.110<br />Experimental: 0.170<br />greater: experi<br />event: asciminib, Fatigue, All grades","Control: 0.050<br />Experimental: 0.130<br />greater: experi<br />event: asciminib, Hypertension, All grades","Control: 0.013<br />Experimental: 0.026<br />greater: experi<br />event: asciminib, Musculoskeletal pain, Grade 3-4","Control: 0.000<br />Experimental: 0.019<br />greater: experi<br />event: asciminib, Headache, Grade 3-4","Control: 0.039<br />Experimental: 0.060<br />greater: experi<br />event: asciminib, Hypertension, Grade 3-4","Control: 0.000<br />Experimental: 0.006<br />greater: experi<br />event: asciminib, Nausea, Grade 3-4","Control: 0.014<br />Experimental: 0.170<br />greater: experi<br />event: atezolizumab, Rash, All grades","Control: 0.006<br />Experimental: 0.100<br />greater: experi<br />event: atezolizumab, Pruritus, All grades","Control: 0.006<br />Experimental: 0.140<br />greater: experi<br />event: atezolizumab, Hypothyroidism, All grades","Control: 0.110<br />Experimental: 0.160<br />greater: experi<br />event: atezolizumab, Cough, All grades","Control: 0.022<br />Experimental: 0.140<br />greater: experi<br />event: atezolizumab, Pyrexia, All grades","Control: 0.050<br />Experimental: 0.140<br />greater: experi<br />event: atezolizumab, Fatigue, All grades","Control: 0.070<br />Experimental: 0.120<br />greater: experi<br />event: atezolizumab, Peripheral neuropathy, All grades","Control: 0.090<br />Experimental: 0.140<br />greater: experi<br />event: atezolizumab, Musculoskeletal pain, All grades","Control: 0.060<br />Experimental: 0.110<br />greater: experi<br />event: atezolizumab, Arthralgia, All grades","Control: 0.000<br />Experimental: 0.012<br />greater: experi<br />event: atezolizumab, Rash, Grade 3-4","Control: 0.002<br />Experimental: 0.008<br />greater: experi<br />event: atezolizumab, Pyrexia, Grade 3-4","Control: 0.002<br />Experimental: 0.006<br />greater: experi<br />event: atezolizumab, Fatigue, Grade 3-4","Control: 0.002<br />Experimental: 0.004<br />greater: experi<br />event: atezolizumab, Peripheral neuropathy, Grade 3-4","Control: 0.002<br />Experimental: 0.008<br />greater: experi<br />event: atezolizumab, Musculoskeletal pain, Grade 3-4","Control: 0.000<br />Experimental: 0.006<br />greater: experi<br />event: atezolizumab, Arthralgia, Grade 3-4","Control: 0.090<br />Experimental: 0.840<br />greater: experi<br />event: abemaciclib + endocrine therapy, Diarrhea, All grades","Control: 0.090<br />Experimental: 0.300<br />greater: experi<br />event: abemaciclib + endocrine therapy, Nausea, All grades","Control: 0.046<br />Experimental: 0.180<br />greater: experi<br />event: abemaciclib + endocrine therapy, Vomiting, All grades","Control: 0.050<br />Experimental: 0.140<br />greater: experi<br />event: abemaciclib + endocrine therapy, Stomatitis, All grades","Control: 0.390<br />Experimental: 0.510<br />greater: experi<br />event: abemaciclib + endocrine therapy, Infections, All grades","Control: 0.180<br />Experimental: 0.410<br />greater: experi<br />event: abemaciclib + endocrine therapy, Fatigue, All grades","Control: 0.150<br />Experimental: 0.200<br />greater: experi<br />event: abemaciclib + endocrine therapy, Headache, All grades","Control: 0.070<br />Experimental: 0.110<br />greater: experi<br />event: abemaciclib + endocrine therapy, Dizziness, All grades","Control: 0.024<br />Experimental: 0.120<br />greater: experi<br />event: abemaciclib + endocrine therapy, Decreased appetite, All grades","Control: 0.045<br />Experimental: 0.110<br />greater: experi<br />event: abemaciclib + endocrine therapy, Rash, All grades","Control: 0.027<br />Experimental: 0.110<br />greater: experi<br />event: abemaciclib + endocrine therapy, Alopecia, All grades","Control: 0.002<br />Experimental: 0.080<br />greater: experi<br />event: abemaciclib + endocrine therapy, Diarrhea, Grade 3","Control: 0.001<br />Experimental: 0.005<br />greater: experi<br />event: abemaciclib + endocrine therapy, Nausea, Grade 3","Control: 0.001<br />Experimental: 0.005<br />greater: experi<br />event: abemaciclib + endocrine therapy, Vomiting, Grade 3","Control: 0.000<br />Experimental: 0.001<br />greater: experi<br />event: abemaciclib + endocrine therapy, Stomatitis, Grade 3","Control: 0.027<br />Experimental: 0.049<br />greater: experi<br />event: abemaciclib + endocrine therapy, Infections, Grade 3","Control: 0.001<br />Experimental: 0.029<br />greater: experi<br />event: abemaciclib + endocrine therapy, Fatigue, Grade 3","Control: 0.002<br />Experimental: 0.003<br />greater: experi<br />event: abemaciclib + endocrine therapy, Headache, Grade 3","Control: 0.001<br />Experimental: 0.006<br />greater: experi<br />event: abemaciclib + endocrine therapy, Decreased appetite, Grade 3","Control: 0.000<br />Experimental: 0.004<br />greater: experi<br />event: abemaciclib + endocrine therapy, Rash, Grade 3","Control: 0.001<br />Experimental: 0.006<br />greater: experi<br />event: abemaciclib + endocrine therapy, Infections, Grade 4","Control: 0.440<br />Experimental: 0.450<br />greater: experi<br />event: ruxolitinib, Infections (pathogen not specified), All grades","Control: 0.230<br />Experimental: 0.280<br />greater: experi<br />event: ruxolitinib, Viral infections, All grades","Control: 0.130<br />Experimental: 0.180<br />greater: experi<br />event: ruxolitinib, Musculoskeletal pain, All grades","Control: 0.090<br />Experimental: 0.160<br />greater: experi<br />event: ruxolitinib, Pyrexia, All grades","Control: 0.100<br />Experimental: 0.130<br />greater: experi<br />event: ruxolitinib, Fatigue, All grades","Control: 0.130<br />Experimental: 0.160<br />greater: experi<br />event: ruxolitinib, Hypertension, All grades","Control: 0.080<br />Experimental: 0.130<br />greater: experi<br />event: ruxolitinib, Cough, All grades","Control: 0.080<br />Experimental: 0.110<br />greater: experi<br />event: ruxolitinib, Dyspnea, All grades","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: ruxolitinib, Musculoskeletal pain, Grade ≥ 3","Control: 0.010<br />Experimental: 0.020<br />greater: experi<br />event: ruxolitinib, Pyrexia, Grade ≥ 3","Control: 0.400<br />Experimental: 0.440<br />greater: experi<br />event: zanubrutinib, Upper respiratory tract infection, All grades","Control: 0.130<br />Experimental: 0.180<br />greater: experi<br />event: zanubrutinib, Nausea, All grades","Control: 0.070<br />Experimental: 0.160<br />greater: experi<br />event: zanubrutinib, Constipation, All grades","Control: 0.250<br />Experimental: 0.310<br />greater: experi<br />event: zanubrutinib, Fatigue, All grades","Control: 0.130<br />Experimental: 0.160<br />greater: experi<br />event: zanubrutinib, Pyrexia, All grades","Control: 0.060<br />Experimental: 0.110<br />greater: experi<br />event: zanubrutinib, Pruritus, All grades","Control: 0.390<br />Experimental: 0.450<br />greater: experi<br />event: zanubrutinib, Musculoskeletal am, All grades","Control: 0.140<br />Experimental: 0.180<br />greater: experi<br />event: zanubrutinib, Headache, All grades","Control: 0.120<br />Experimental: 0.130<br />greater: experi<br />event: zanubrutinib, Dizziness, All grades","Control: 0.070<br />Experimental: 0.140<br />greater: experi<br />event: zanubrutinib, Dyspnea, All grades","Control: 0.020<br />Experimental: 0.030<br />greater: experi<br />event: zanubrutinib, Diarrhea, Grade 3-4","Control: 0.020<br />Experimental: 0.040<br />greater: experi<br />event: zanubrutinib, Pyrexia, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: zanubrutinib, Pruritus, Grade 3-4","Control: 0.010<br />Experimental: 0.090<br />greater: experi<br />event: zanubrutinib, Musculoskeletal am, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: zanubrutinib, Dizziness, Grade 3-4","Control: 0.560<br />Experimental: 0.630<br />greater: experi<br />event: lenvatinib + pembrolizumab, Fatigue, All Grades","Control: 0.500<br />Experimental: 0.620<br />greater: experi<br />event: lenvatinib + pembrolizumab, Diarrhea, All Grades","Control: 0.330<br />Experimental: 0.360<br />greater: experi<br />event: lenvatinib + pembrolizumab, Nausea, All Grades","Control: 0.180<br />Experimental: 0.270<br />greater: experi<br />event: lenvatinib + pembrolizumab, Abdominal pain, All Grades","Control: 0.200<br />Experimental: 0.260<br />greater: experi<br />event: lenvatinib + pembrolizumab, Vomiting, All Grades","Control: 0.190<br />Experimental: 0.250<br />greater: experi<br />event: lenvatinib + pembrolizumab, Constipation, All Grades","Control: 0.410<br />Experimental: 0.580<br />greater: experi<br />event: lenvatinib + pembrolizumab, Musculoskeletal pain, All Grades","Control: 0.320<br />Experimental: 0.570<br />greater: experi<br />event: lenvatinib + pembrolizumab, Hypothyroidism, All Grades","Control: 0.430<br />Experimental: 0.560<br />greater: experi<br />event: lenvatinib + pembrolizumab, Hypertension, All Grades","Control: 0.260<br />Experimental: 0.270<br />greater: experi<br />event: lenvatinib + pembrolizumab, Hemorrhagic events, All Grades","Control: 0.310<br />Experimental: 0.410<br />greater: experi<br />event: lenvatinib + pembrolizumab, Decreased appetite, All Grades","Control: 0.170<br />Experimental: 0.370<br />greater: experi<br />event: lenvatinib + pembrolizumab, Rash, All Grades","Control: 0.040<br />Experimental: 0.300<br />greater: experi<br />event: lenvatinib + pembrolizumab, Dysphonia, All Grades","Control: 0.130<br />Experimental: 0.300<br />greater: experi<br />event: lenvatinib + pembrolizumab, Proteinuria, All Grades","Control: 0.160<br />Experimental: 0.210<br />greater: experi<br />event: lenvatinib + pembrolizumab, Acute kidney injury, All Grades","Control: 0.090<br />Experimental: 0.300<br />greater: experi<br />event: lenvatinib + pembrolizumab, Weight decreased , All Grades","Control: 0.210<br />Experimental: 0.250<br />greater: experi<br />event: lenvatinib + pembrolizumab, Hepatotoxicity, All Grades","Control: 0.160<br />Experimental: 0.230<br />greater: experi<br />event: lenvatinib + pembrolizumab, Headache, All Grades","Control: 0.080<br />Experimental: 0.090<br />greater: experi<br />event: lenvatinib + pembrolizumab, Fatigue, Grade 3-4","Control: 0.060<br />Experimental: 0.100<br />greater: experi<br />event: lenvatinib + pembrolizumab, Diarrhea, Grade 3-4","Control: 0.010<br />Experimental: 0.030<br />greater: experi<br />event: lenvatinib + pembrolizumab, Nausea, Grade 3-4","Control: 0.010<br />Experimental: 0.020<br />greater: experi<br />event: lenvatinib + pembrolizumab, Abdominal pain, Grade 3-4","Control: 0.010<br />Experimental: 0.030<br />greater: experi<br />event: lenvatinib + pembrolizumab, Vomiting, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: lenvatinib + pembrolizumab, Constipation, Grade 3-4","Control: 0.030<br />Experimental: 0.040<br />greater: experi<br />event: lenvatinib + pembrolizumab, Musculoskeletal pain, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: lenvatinib + pembrolizumab, Hypothyroidism, Grade 3-4","Control: 0.200<br />Experimental: 0.290<br />greater: experi<br />event: lenvatinib + pembrolizumab, Hypertension, Grade 3-4","Control: 0.040<br />Experimental: 0.050<br />greater: experi<br />event: lenvatinib + pembrolizumab, Hemorrhagic events, Grade 3-4","Control: 0.010<br />Experimental: 0.040<br />greater: experi<br />event: lenvatinib + pembrolizumab, Decreased appetite, Grade 3-4","Control: 0.010<br />Experimental: 0.050<br />greater: experi<br />event: lenvatinib + pembrolizumab, Rash, Grade 3-4","Control: 0.030<br />Experimental: 0.080<br />greater: experi<br />event: lenvatinib + pembrolizumab, Proteinuria, Grade 3-4","Control: 0.020<br />Experimental: 0.050<br />greater: experi<br />event: lenvatinib + pembrolizumab, Acute kidney injury, Grade 3-4","Control: 0.000<br />Experimental: 0.080<br />greater: experi<br />event: lenvatinib + pembrolizumab, Weight decreased , Grade 3-4","Control: 0.050<br />Experimental: 0.090<br />greater: experi<br />event: lenvatinib + pembrolizumab, Hepatotoxicity, Grade 3-4","Control: 0.009<br />Experimental: 0.670<br />greater: experi<br />event: pembrolizumab + lenvatinib, Hypothyroidism, All Grades","Control: 0.060<br />Experimental: 0.670<br />greater: experi<br />event: pembrolizumab + lenvatinib, Hypertension, All Grades","Control: 0.150<br />Experimental: 0.250<br />greater: experi<br />event: pembrolizumab + lenvatinib, Hemorrhagic events, All Grades","Control: 0.540<br />Experimental: 0.580<br />greater: experi<br />event: pembrolizumab + lenvatinib, Fatigue, All Grades","Control: 0.200<br />Experimental: 0.550<br />greater: experi<br />event: pembrolizumab + lenvatinib, Diarrhea, All Grades","Control: 0.470<br />Experimental: 0.490<br />greater: experi<br />event: pembrolizumab + lenvatinib, Nausea, All Grades","Control: 0.210<br />Experimental: 0.370<br />greater: experi<br />event: pembrolizumab + lenvatinib, Vomiting, All Grades","Control: 0.260<br />Experimental: 0.350<br />greater: experi<br />event: pembrolizumab + lenvatinib, Stomatitis, All Grades","Control: 0.210<br />Experimental: 0.340<br />greater: experi<br />event: pembrolizumab + lenvatinib, Abdominal pain, All Grades","Control: 0.250<br />Experimental: 0.270<br />greater: experi<br />event: pembrolizumab + lenvatinib, Constipation, All Grades","Control: 0.270<br />Experimental: 0.530<br />greater: experi<br />event: pembrolizumab + lenvatinib, Musculoskeletal disorders, All Grades","Control: 0.210<br />Experimental: 0.440<br />greater: experi<br />event: pembrolizumab + lenvatinib, Decreased appetite, All Grades","Control: 0.060<br />Experimental: 0.340<br />greater: experi<br />event: pembrolizumab + lenvatinib, Decreased weight, All Grades","Control: 0.034<br />Experimental: 0.290<br />greater: experi<br />event: pembrolizumab + lenvatinib, Proteinuria, All Grades","Control: 0.130<br />Experimental: 0.310<br />greater: experi<br />event: pembrolizumab + lenvatinib, Urinary tract infection, All Grades","Control: 0.090<br />Experimental: 0.260<br />greater: experi<br />event: pembrolizumab + lenvatinib, Headache, All Grades","Control: 0.006<br />Experimental: 0.220<br />greater: experi<br />event: pembrolizumab + lenvatinib, Dysphonia, All Grades","Control: 0.009<br />Experimental: 0.230<br />greater: experi<br />event: pembrolizumab + lenvatinib, Palmar-plantar erythrodysesthesia, All Grades","Control: 0.049<br />Experimental: 0.200<br />greater: experi<br />event: pembrolizumab + lenvatinib, Rash, All Grades","Control: 0.000<br />Experimental: 0.009<br />greater: experi<br />event: pembrolizumab + lenvatinib, Hypothyroidism, Grade 3-4","Control: 0.025<br />Experimental: 0.390<br />greater: experi<br />event: pembrolizumab + lenvatinib, Hypertension, Grade 3-4","Control: 0.009<br />Experimental: 0.026<br />greater: experi<br />event: pembrolizumab + lenvatinib, Hemorrhagic events, Grade 3-4","Control: 0.060<br />Experimental: 0.110<br />greater: experi<br />event: pembrolizumab + lenvatinib, Fatigue, Grade 3-4","Control: 0.028<br />Experimental: 0.080<br />greater: experi<br />event: pembrolizumab + lenvatinib, Diarrhea, Grade 3-4","Control: 0.015<br />Experimental: 0.029<br />greater: experi<br />event: pembrolizumab + lenvatinib, Nausea, Grade 3-4","Control: 0.022<br />Experimental: 0.023<br />greater: experi<br />event: pembrolizumab + lenvatinib, Vomiting, Grade 3-4","Control: 0.012<br />Experimental: 0.026<br />greater: experi<br />event: pembrolizumab + lenvatinib, Stomatitis, Grade 3-4","Control: 0.012<br />Experimental: 0.026<br />greater: experi<br />event: pembrolizumab + lenvatinib, Abdominal pain, Grade 3-4","Control: 0.006<br />Experimental: 0.050<br />greater: experi<br />event: pembrolizumab + lenvatinib, Musculoskeletal disorders, Grade 3-4","Control: 0.000<br />Experimental: 0.070<br />greater: experi<br />event: pembrolizumab + lenvatinib, Decreased appetite, Grade 3-4","Control: 0.003<br />Experimental: 0.100<br />greater: experi<br />event: pembrolizumab + lenvatinib, Decreased weight, Grade 3-4","Control: 0.003<br />Experimental: 0.060<br />greater: experi<br />event: pembrolizumab + lenvatinib, Proteinuria, Grade 3-4","Control: 0.012<br />Experimental: 0.050<br />greater: experi<br />event: pembrolizumab + lenvatinib, Urinary tract infection, Grade 3-4","Control: 0.003<br />Experimental: 0.006<br />greater: experi<br />event: pembrolizumab + lenvatinib, Headache, Grade 3-4","Control: 0.000<br />Experimental: 0.029<br />greater: experi<br />event: pembrolizumab + lenvatinib, Palmar-plantar erythrodysesthesia, Grade 3-4","Control: 0.000<br />Experimental: 0.023<br />greater: experi<br />event: pembrolizumab + lenvatinib, Rash, Grade 3-4","Control: 0.390<br />Experimental: 0.460<br />greater: experi<br />event: daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Fatigue, All Grades","Control: 0.140<br />Experimental: 0.190<br />greater: experi<br />event: daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Pyrexia, All Grades","Control: 0.090<br />Experimental: 0.150<br />greater: experi<br />event: daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Edema peripheral, All Grades","Control: 0.270<br />Experimental: 0.380<br />greater: experi<br />event: daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Pneumonia, All Grades","Control: 0.220<br />Experimental: 0.360<br />greater: experi<br />event: daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Upper respiratory infection, All Grades","Control: 0.140<br />Experimental: 0.220<br />greater: experi<br />event: daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Diarrhea, All Grades","Control: 0.080<br />Experimental: 0.130<br />greater: experi<br />event: daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Cough, All Grades","Control: 0.050<br />Experimental: 0.130<br />greater: experi<br />event: daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Fatigue, Grade ≥ 3","Control: 0.170<br />Experimental: 0.230<br />greater: experi<br />event: daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Pneumonia, Grade ≥ 3","Control: 0.010<br />Experimental: 0.050<br />greater: experi<br />event: daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Diarrhea, Grade ≥ 3","Control: 0.460<br />Experimental: 0.530<br />greater: experi<br />event: nivolumab + chemotherapy, Peripheral neuropathy, All Grades","Control: 0.060<br />Experimental: 0.110<br />greater: experi<br />event: nivolumab + chemotherapy, Headache, All Grades","Control: 0.440<br />Experimental: 0.480<br />greater: experi<br />event: nivolumab + chemotherapy, Nausea, All Grades","Control: 0.340<br />Experimental: 0.390<br />greater: experi<br />event: nivolumab + chemotherapy, Diarrhea, All Grades","Control: 0.290<br />Experimental: 0.310<br />greater: experi<br />event: nivolumab + chemotherapy, Vomiting, All Grades","Control: 0.240<br />Experimental: 0.270<br />greater: experi<br />event: nivolumab + chemotherapy, Abdominal pain, All Grades","Control: 0.210<br />Experimental: 0.250<br />greater: experi<br />event: nivolumab + chemotherapy, Constipation, All Grades","Control: 0.130<br />Experimental: 0.170<br />greater: experi<br />event: nivolumab + chemotherapy, Stomatitisc, All Grades","Control: 0.400<br />Experimental: 0.440<br />greater: experi<br />event: nivolumab + chemotherapy, Fatigue, All Grades","Control: 0.110<br />Experimental: 0.190<br />greater: experi<br />event: nivolumab + chemotherapy, Pyrexia, All Grades","Control: 0.080<br />Experimental: 0.120<br />greater: experi<br />event: nivolumab + chemotherapy, Edema, All Grades","Control: 0.260<br />Experimental: 0.290<br />greater: experi<br />event: nivolumab + chemotherapy, Decreased appetite, All Grades","Control: 0.090<br />Experimental: 0.140<br />greater: experi<br />event: nivolumab + chemotherapy, Hypoalbuminemia, All Grades","Control: 0.150<br />Experimental: 0.170<br />greater: experi<br />event: nivolumab + chemotherapy, Weight decreased, All Grades","Control: 0.080<br />Experimental: 0.140<br />greater: experi<br />event: nivolumab + chemotherapy, Increased lipase, All Grades","Control: 0.050<br />Experimental: 0.120<br />greater: experi<br />event: nivolumab + chemotherapy, Increased amylase, All Grades","Control: 0.140<br />Experimental: 0.200<br />greater: experi<br />event: nivolumab + chemotherapy, Musculoskeletal pain, All Grades","Control: 0.044<br />Experimental: 0.180<br />greater: experi<br />event: nivolumab + chemotherapy, Rash, All Grades","Control: 0.120<br />Experimental: 0.130<br />greater: experi<br />event: nivolumab + chemotherapy, Palmar-plantar erythrodysesthesia syndrome, All Grades","Control: 0.090<br />Experimental: 0.130<br />greater: experi<br />event: nivolumab + chemotherapy, Cough, All Grades","Control: 0.070<br />Experimental: 0.100<br />greater: experi<br />event: nivolumab + chemotherapy, Upper respiratory tract infection, All Grades","Control: 0.440<br />Experimental: 0.640<br />greater: experi<br />event: sacituzumab govitecan, Neutropenia, All Grades","Control: 0.280<br />Experimental: 0.400<br />greater: experi<br />event: sacituzumab govitecan, Anemia, All Grades","Control: 0.120<br />Experimental: 0.170<br />greater: experi<br />event: sacituzumab govitecan, Leukopenia, All Grades","Control: 0.060<br />Experimental: 0.100<br />greater: experi<br />event: sacituzumab govitecan, Lymphopenia, All Grades","Control: 0.170<br />Experimental: 0.590<br />greater: experi<br />event: sacituzumab govitecan, Diarrhea, All Grades","Control: 0.260<br />Experimental: 0.570<br />greater: experi<br />event: sacituzumab govitecan, Nausea, All Grades","Control: 0.160<br />Experimental: 0.330<br />greater: experi<br />event: sacituzumab govitecan, Vomiting, All Grades","Control: 0.230<br />Experimental: 0.370<br />greater: experi<br />event: sacituzumab govitecan, Constipation, All Grades","Control: 0.120<br />Experimental: 0.300<br />greater: experi<br />event: sacituzumab govitecan, Abdominal Pain, All Grades","Control: 0.130<br />Experimental: 0.170<br />greater: experi<br />event: sacituzumab govitecan, Stomatitisv, All Grades","Control: 0.500<br />Experimental: 0.650<br />greater: experi<br />event: sacituzumab govitecan, Fatigue, All Grades","Control: 0.140<br />Experimental: 0.150<br />greater: experi<br />event: sacituzumab govitecan, Pyrexia, All Grades","Control: 0.080<br />Experimental: 0.130<br />greater: experi<br />event: sacituzumab govitecan, Urinary tract infection, All Grades","Control: 0.030<br />Experimental: 0.120<br />greater: experi<br />event: sacituzumab govitecan, Upper respiratory tract infection, All Grades","Control: 0.100<br />Experimental: 0.110<br />greater: experi<br />event: sacituzumab govitecan, Alanine aminotransferase increased, All Grades","Control: 0.210<br />Experimental: 0.280<br />greater: experi<br />event: sacituzumab govitecan, Decreased appetite, All Grades","Control: 0.130<br />Experimental: 0.160<br />greater: experi<br />event: sacituzumab govitecan, Hypokalemia, All Grades","Control: 0.060<br />Experimental: 0.120<br />greater: experi<br />event: sacituzumab govitecan, Hypomagnesaemia, All Grades","Control: 0.140<br />Experimental: 0.160<br />greater: experi<br />event: sacituzumab govitecan, Back pain, All Grades","Control: 0.070<br />Experimental: 0.120<br />greater: experi<br />event: sacituzumab govitecan, Arthralgia, All Grades","Control: 0.130<br />Experimental: 0.180<br />greater: experi<br />event: sacituzumab govitecan, Headache, All Grades","Control: 0.070<br />Experimental: 0.100<br />greater: experi<br />event: sacituzumab govitecan, Dizziness, All Grades","Control: 0.050<br />Experimental: 0.110<br />greater: experi<br />event: sacituzumab govitecan, Insomnia, All Grades","Control: 0.180<br />Experimental: 0.240<br />greater: experi<br />event: sacituzumab govitecan, Cough, All Grades","Control: 0.160<br />Experimental: 0.470<br />greater: experi<br />event: sacituzumab govitecan, Alopecia, All Grades","Control: 0.050<br />Experimental: 0.120<br />greater: experi<br />event: sacituzumab govitecan, Rash, All Grades","Control: 0.030<br />Experimental: 0.100<br />greater: experi<br />event: sacituzumab govitecan, Pruritus, All Grades","Control: 0.340<br />Experimental: 0.520<br />greater: experi<br />event: sacituzumab govitecan, Neutropenia, Grade 3-4","Control: 0.060<br />Experimental: 0.090<br />greater: experi<br />event: sacituzumab govitecan, Anemia, Grade 3-4","Control: 0.060<br />Experimental: 0.110<br />greater: experi<br />event: sacituzumab govitecan, Leukopenia, Grade 3-4","Control: 0.010<br />Experimental: 0.110<br />greater: experi<br />event: sacituzumab govitecan, Diarrhea, Grade 3-4","Control: 0.004<br />Experimental: 0.030<br />greater: experi<br />event: sacituzumab govitecan, Nausea, Grade 3-4","Control: 0.010<br />Experimental: 0.020<br />greater: experi<br />event: sacituzumab govitecan, Vomiting, Grade 3-4","Control: 0.000<br />Experimental: 0.004<br />greater: experi<br />event: sacituzumab govitecan, Constipation, Grade 3-4","Control: 0.010<br />Experimental: 0.030<br />greater: experi<br />event: sacituzumab govitecan, Abdominal Pain, Grade 3-4","Control: 0.010<br />Experimental: 0.020<br />greater: experi<br />event: sacituzumab govitecan, Stomatitisv, Grade 3-4","Control: 0.010<br />Experimental: 0.020<br />greater: experi<br />event: sacituzumab govitecan, Decreased appetite, Grade 3-4","Control: 0.004<br />Experimental: 0.030<br />greater: experi<br />event: sacituzumab govitecan, Hypokalemia, Grade 3-4","Control: 0.000<br />Experimental: 0.004<br />greater: experi<br />event: sacituzumab govitecan, Arthralgia, Grade 3-4","Control: 0.004<br />Experimental: 0.008<br />greater: experi<br />event: sacituzumab govitecan, Headache, Grade 3-4","Control: 0.033<br />Experimental: 0.460<br />greater: experi<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Infusion-related reaction, All Grades","Control: 0.570<br />Experimental: 0.670<br />greater: experi<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Upper respiratory tract infection, All Grades","Control: 0.300<br />Experimental: 0.360<br />greater: experi<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Pneumonia, All Grades","Control: 0.130<br />Experimental: 0.240<br />greater: experi<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Bronchitis, All Grades","Control: 0.320<br />Experimental: 0.370<br />greater: experi<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Hypertension, All Grades","Control: 0.240<br />Experimental: 0.290<br />greater: experi<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Dyspnea, All Grades","Control: 0.150<br />Experimental: 0.230<br />greater: experi<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Cough, All Grades","Control: 0.290<br />Experimental: 0.360<br />greater: experi<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Diarrhea, All Grades","Control: 0.090<br />Experimental: 0.150<br />greater: experi<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Vomiting, All Grades","Control: 0.320<br />Experimental: 0.420<br />greater: experi<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Fatigue, All Grades","Control: 0.000<br />Experimental: 0.006<br />greater: experi<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Infusion-related reaction, Grade 3","Control: 0.070<br />Experimental: 0.090<br />greater: experi<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Upper respiratory tract infection, Grade 3","Control: 0.150<br />Experimental: 0.190<br />greater: experi<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Pneumonia, Grade 3","Control: 0.008<br />Experimental: 0.023<br />greater: experi<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Bronchitis, Grade 3","Control: 0.180<br />Experimental: 0.200<br />greater: experi<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Hypertension, Grade 3","Control: 0.008<br />Experimental: 0.050<br />greater: experi<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Dyspnea, Grade 3","Control: 0.025<br />Experimental: 0.028<br />greater: experi<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Diarrhea, Grade 3","Control: 0.008<br />Experimental: 0.011<br />greater: experi<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Vomiting, Grade 3","Control: 0.033<br />Experimental: 0.050<br />greater: experi<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Fatigue, Grade 3","Control: 0.025<br />Experimental: 0.034<br />greater: experi<br />event: isatuximab-irfc + Carfilzomib + Dexamethasone, Pneumonia, Grade 4","Control: 0.480<br />Experimental: 0.670<br />greater: experi<br />event: tivozanib, Fatigue, All Grades","Control: 0.310<br />Experimental: 0.440<br />greater: experi<br />event: tivozanib, Hypertension, All Grades","Control: 0.120<br />Experimental: 0.170<br />greater: experi<br />event: tivozanib, Bleeding, All Grades","Control: 0.180<br />Experimental: 0.300<br />greater: experi<br />event: tivozanib, Nausea, All Grades","Control: 0.170<br />Experimental: 0.180<br />greater: experi<br />event: tivozanib, Vomiting, All Grades","Control: 0.300<br />Experimental: 0.390<br />greater: experi<br />event: tivozanib, Decreased appetite, All Grades","Control: 0.090<br />Experimental: 0.270<br />greater: experi<br />event: tivozanib, Dysphonia, All Grades","Control: 0.150<br />Experimental: 0.220<br />greater: experi<br />event: tivozanib, Cough, All Grades","Control: 0.110<br />Experimental: 0.150<br />greater: experi<br />event: tivozanib, Dyspnea, All Grades","Control: 0.110<br />Experimental: 0.240<br />greater: experi<br />event: tivozanib, Hypothyroidism, All Grades","Control: 0.160<br />Experimental: 0.190<br />greater: experi<br />event: tivozanib, Back pain, All Grades","Control: 0.120<br />Experimental: 0.130<br />greater: experi<br />event: tivozanib, Fatigue, Grade 3-4","Control: 0.170<br />Experimental: 0.240<br />greater: experi<br />event: tivozanib, Hypertension, Grade 3-4","Control: 0.010<br />Experimental: 0.030<br />greater: experi<br />event: tivozanib, Bleeding, Grade 3-4","Control: 0.040<br />Experimental: 0.050<br />greater: experi<br />event: tivozanib, Decreased appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: tivozanib, Dysphonia, Grade 3-4","Control: 0.010<br />Experimental: 0.030<br />greater: experi<br />event: tivozanib, Dyspnea, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: tivozanib, Hypothyroidism, Grade 3-4","Control: 0.050<br />Experimental: 0.160<br />greater: experi<br />event: lorlatinib, Mood effects, All Grades","Control: 0.150<br />Experimental: 0.340<br />greater: experi<br />event: lorlatinib, Peripheral neuropathy, All Grades","Control: 0.060<br />Experimental: 0.210<br />greater: experi<br />event: lorlatinib, Cognitive effects, All Grades","Control: 0.100<br />Experimental: 0.110<br />greater: experi<br />event: lorlatinib, Sleep effects, All Grades","Control: 0.160<br />Experimental: 0.200<br />greater: experi<br />event: lorlatinib, Dyspnea, All Grades","Control: 0.000<br />Experimental: 0.027<br />greater: experi<br />event: lorlatinib, Respiratory failure, All Grades","Control: 0.021<br />Experimental: 0.180<br />greater: experi<br />event: lorlatinib, Hypertension, All Grades","Control: 0.110<br />Experimental: 0.190<br />greater: experi<br />event: lorlatinib, Arthralgia, All Grades","Control: 0.070<br />Experimental: 0.150<br />greater: experi<br />event: lorlatinib, Myalgia, All Grades","Control: 0.110<br />Experimental: 0.150<br />greater: experi<br />event: lorlatinib, Back pain, All Grades","Control: 0.080<br />Experimental: 0.170<br />greater: experi<br />event: lorlatinib, Pain in extremity, All Grades","Control: 0.400<br />Experimental: 0.560<br />greater: experi<br />event: lorlatinib, Edema, All Grades","Control: 0.130<br />Experimental: 0.380<br />greater: experi<br />event: lorlatinib, Weight gain, All Grades","Control: 0.130<br />Experimental: 0.170<br />greater: experi<br />event: lorlatinib, Pyrexia, All Grades","Control: 0.077<br />Experimental: 0.110<br />greater: experi<br />event: lorlatinib, Upper respiratory tract infection, All Grades","Control: 0.021<br />Experimental: 0.067<br />greater: experi<br />event: lorlatinib, Bronchitis, All Grades","Control: 0.085<br />Experimental: 0.110<br />greater: experi<br />event: lorlatinib, Rash, All Grades","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: lorlatinib, Mood effects, Grade 3-4","Control: 0.007<br />Experimental: 0.020<br />greater: experi<br />event: lorlatinib, Peripheral neuropathy, Grade 3-4","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: lorlatinib, Cognitive effects, Grade 3-4","Control: 0.000<br />Experimental: 0.013<br />greater: experi<br />event: lorlatinib, Sleep effects, Grade 3-4","Control: 0.021<br />Experimental: 0.027<br />greater: experi<br />event: lorlatinib, Dyspnea, Grade 3-4","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: lorlatinib, Respiratory failure, Grade 3-4","Control: 0.000<br />Experimental: 0.100<br />greater: experi<br />event: lorlatinib, Hypertension, Grade 3-4","Control: 0.007<br />Experimental: 0.013<br />greater: experi<br />event: lorlatinib, Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.007<br />greater: experi<br />event: lorlatinib, Arthralgia, Grade 3-4","Control: 0.000<br />Experimental: 0.007<br />greater: experi<br />event: lorlatinib, Myalgia, Grade 3-4","Control: 0.000<br />Experimental: 0.007<br />greater: experi<br />event: lorlatinib, Back pain, Grade 3-4","Control: 0.014<br />Experimental: 0.040<br />greater: experi<br />event: lorlatinib, Edema, Grade 3-4","Control: 0.021<br />Experimental: 0.170<br />greater: experi<br />event: lorlatinib, Weight gain, Grade 3-4","Control: 0.007<br />Experimental: 0.013<br />greater: experi<br />event: lorlatinib, Chest pain, Grade 3-4","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: lorlatinib, Bronchitis, Grade 3-4","Control: 0.060<br />Experimental: 0.150<br />greater: experi<br />event: cemiplimab-rwlc, Rash, All Grades","Control: 0.080<br />Experimental: 0.110<br />greater: experi<br />event: cemiplimab-rwlc, Cough, All Grades","Control: 0.000<br />Experimental: 0.014<br />greater: experi<br />event: cemiplimab-rwlc, Rash, Grade 3-4","Control: 0.003<br />Experimental: 0.006<br />greater: experi<br />event: cemiplimab-rwlc, Decreased appetite, Grade 3-4","Control: 0.470<br />Experimental: 0.640<br />greater: experi<br />event: nivolumab + cabozantinib, Diarrhea, Grades 1-4","Control: 0.150<br />Experimental: 0.220<br />greater: experi<br />event: nivolumab + cabozantinib, Abdominal pain, Grades 1-4","Control: 0.500<br />Experimental: 0.510<br />greater: experi<br />event: nivolumab + cabozantinib, Fatigue, Grades 1-4","Control: 0.260<br />Experimental: 0.440<br />greater: experi<br />event: nivolumab + cabozantinib, Hepatotoxicity, Grades 1-4","Control: 0.140<br />Experimental: 0.360<br />greater: experi<br />event: nivolumab + cabozantinib, Rash, Grades 1-4","Control: 0.044<br />Experimental: 0.190<br />greater: experi<br />event: nivolumab + cabozantinib, Pruritus, Grades 1-4","Control: 0.300<br />Experimental: 0.340<br />greater: experi<br />event: nivolumab + cabozantinib, Hypothyroidism, Grades 1-4","Control: 0.290<br />Experimental: 0.330<br />greater: experi<br />event: nivolumab + cabozantinib, Musculoskeletal pain, Grades 1-4","Control: 0.090<br />Experimental: 0.180<br />greater: experi<br />event: nivolumab + cabozantinib, Arthralgia, Grades 1-4","Control: 0.200<br />Experimental: 0.280<br />greater: experi<br />event: nivolumab + cabozantinib, Decreased appetite, Grades 1-4","Control: 0.220<br />Experimental: 0.240<br />greater: experi<br />event: nivolumab + cabozantinib, Dysgeusia, Grades 1-4","Control: 0.120<br />Experimental: 0.160<br />greater: experi<br />event: nivolumab + cabozantinib, Headache, Grades 1-4","Control: 0.170<br />Experimental: 0.200<br />greater: experi<br />event: nivolumab + cabozantinib, Cough, Grades 1-4","Control: 0.034<br />Experimental: 0.170<br />greater: experi<br />event: nivolumab + cabozantinib, Dysphonia , Grades 1-4","Control: 0.080<br />Experimental: 0.200<br />greater: experi<br />event: nivolumab + cabozantinib, Upper respiratory tract infection, Grades 1-4","Control: 0.044<br />Experimental: 0.070<br />greater: experi<br />event: nivolumab + cabozantinib, Diarrhea, Grade 3-4","Control: 0.003<br />Experimental: 0.006<br />greater: experi<br />event: nivolumab + cabozantinib, Nausea, Grade 3-4","Control: 0.003<br />Experimental: 0.019<br />greater: experi<br />event: nivolumab + cabozantinib, Abdominal pain, Grade 3-4","Control: 0.003<br />Experimental: 0.019<br />greater: experi<br />event: nivolumab + cabozantinib, Vomiting, Grade 3-4","Control: 0.050<br />Experimental: 0.110<br />greater: experi<br />event: nivolumab + cabozantinib, Hepatotoxicity, Grade 3-4","Control: 0.000<br />Experimental: 0.031<br />greater: experi<br />event: nivolumab + cabozantinib, Rash, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: nivolumab + cabozantinib, Pruritus, Grade 3-4","Control: 0.031<br />Experimental: 0.038<br />greater: experi<br />event: nivolumab + cabozantinib, Musculoskeletal pain, Grade 3-4","Control: 0.013<br />Experimental: 0.019<br />greater: experi<br />event: nivolumab + cabozantinib, Decreased appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: nivolumab + cabozantinib, Cough, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: nivolumab + cabozantinib, Dysphonia , Grade 3-4","Control: 0.210<br />Experimental: 0.400<br />greater: experi<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Upper respiratory tract infection, All Grades","Control: 0.090<br />Experimental: 0.150<br />greater: experi<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Pneumoma, All Grades","Control: 0.300<br />Experimental: 0.360<br />greater: experi<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Diarrhea, All Grades","Control: 0.290<br />Experimental: 0.340<br />greater: experi<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Constipation, All Grades","Control: 0.200<br />Experimental: 0.310<br />greater: experi<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Peripheral sensory neuropathy, All Grades","Control: 0.200<br />Experimental: 0.260<br />greater: experi<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Dyspnea, All Grades","Control: 0.110<br />Experimental: 0.200<br />greater: experi<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Cough, All Grades","Control: 0.060<br />Experimental: 0.120<br />greater: experi<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Back pain, All Grades","Control: 0.050<br />Experimental: 0.100<br />greater: experi<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Arthralgia, All Grades","Control: 0.050<br />Experimental: 0.100<br />greater: experi<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Muscle spasms, All Grades","Control: 0.050<br />Experimental: 0.110<br />greater: experi<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Arrhythmia, All Grades","Control: 0.000<br />Experimental: 0.110<br />greater: experi<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Injection site reactions, All Grades","Control: 0.050<br />Experimental: 0.100<br />greater: experi<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Pneumoma, Grade 3-4","Control: 0.040<br />Experimental: 0.060<br />greater: experi<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Constipation, Grade 3-4","Control: 0.020<br />Experimental: 0.030<br />greater: experi<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Peripheral sensory neuropathy, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Cough, Grade 3-4","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Back pain, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Muscle spasms, Grade 3-4","Control: 0.020<br />Experimental: 0.040<br />greater: experi<br />event: D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Arrhythmia, Grade 3-4","Control: 0.470<br />Experimental: 0.630<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Nausea, All Grades","Control: 0.080<br />Experimental: 0.260<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Vomiting, All Grades","Control: 0.230<br />Experimental: 0.240<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Constipation, All Grades","Control: 0.048<br />Experimental: 0.110<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Stomatitis, All Grades","Control: 0.450<br />Experimental: 0.600<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Decreased appetite, All Grades","Control: 0.032<br />Experimental: 0.060<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Dehydration, All Grades","Control: 0.310<br />Experimental: 0.580<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Anemiac, All Grades","Control: 0.032<br />Experimental: 0.048<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Febrile neutropenia, All Grades","Control: 0.440<br />Experimental: 0.550<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Fatigued, All Grades","Control: 0.160<br />Experimental: 0.240<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Pyrexia, All Grades","Control: 0.000<br />Experimental: 0.100<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Edema peripheral, All Grades","Control: 0.150<br />Experimental: 0.220<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Alopecia, All Grades","Control: 0.000<br />Experimental: 0.100<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Interstitial lung disease, All Grades","Control: 0.016<br />Experimental: 0.080<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Hepatic function abnormal, All Grades","Control: 0.016<br />Experimental: 0.048<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Nausea, Grade 3-4","Control: 0.016<br />Experimental: 0.024<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.016<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Stomatitis, Grade 3-4","Control: 0.130<br />Experimental: 0.170<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Decreased appetite, Grade 3-4","Control: 0.016<br />Experimental: 0.024<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Dehydration, Grade 3-4","Control: 0.230<br />Experimental: 0.380<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Anemiac, Grade 3-4","Control: 0.032<br />Experimental: 0.048<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Febrile neutropenia, Grade 3-4","Control: 0.048<br />Experimental: 0.090<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Fatigued, Grade 3-4","Control: 0.000<br />Experimental: 0.024<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Interstitial lung disease, Grade 3-4","Control: 0.016<br />Experimental: 0.032<br />greater: experi<br />event: fam-trastuzumab deruxtecan-nxki, Hepatic function abnormal, Grade 3-4","Control: 0.520<br />Experimental: 0.540<br />greater: experi<br />event: relugolix, Hot flush, All Grades","Control: 0.290<br />Experimental: 0.300<br />greater: experi<br />event: relugolix, Musculoskeletal pain, All Grades","Control: 0.240<br />Experimental: 0.260<br />greater: experi<br />event: relugolix, Fatigue, All Grades","Control: 0.070<br />Experimental: 0.120<br />greater: experi<br />event: relugolix, Diarrhea, All Grades","Control: 0.100<br />Experimental: 0.120<br />greater: experi<br />event: relugolix, Constipation, All Grades","Control: 0.000<br />Experimental: 0.006<br />greater: experi<br />event: relugolix, Hot flush, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: relugolix, Fatigue, Grade 3-4","Control: 0.000<br />Experimental: 0.002<br />greater: experi<br />event: relugolix, Diarrhea, Grade 3-4","Control: 0.100<br />Experimental: 0.500<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Nausea, All Grades","Control: 0.250<br />Experimental: 0.320<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Diarrhea, All Grades","Control: 0.044<br />Experimental: 0.210<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Vomiting, All Grades","Control: 0.210<br />Experimental: 0.590<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Fatigue, All Grades","Control: 0.110<br />Experimental: 0.150<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Pyrexia, All Grades","Control: 0.050<br />Experimental: 0.350<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Appetite decrease, All Grades","Control: 0.120<br />Experimental: 0.260<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Weight decrease, All Grades","Control: 0.039<br />Experimental: 0.120<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Dizziness, All Grades","Control: 0.220<br />Experimental: 0.290<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Upper respiratory tract infection, All Grades","Control: 0.060<br />Experimental: 0.220<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Cataract, All Grades","Control: 0.060<br />Experimental: 0.130<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Vision blurred, All Grades","Control: 0.000<br />Experimental: 0.080<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Nausea, Grade 3-4","Control: 0.010<br />Experimental: 0.060<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.041<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Vomiting, Grade 3-4","Control: 0.050<br />Experimental: 0.280<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Fatigue, Grade 3-4","Control: 0.010<br />Experimental: 0.015<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Pyrexia, Grade 3-4","Control: 0.000<br />Experimental: 0.036<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Appetite decrease, Grade 3-4","Control: 0.010<br />Experimental: 0.021<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Weight decrease, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Dizziness, Grade 3-4","Control: 0.015<br />Experimental: 0.036<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Upper respiratory tract infection, Grade 3-4","Control: 0.015<br />Experimental: 0.090<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Cataract, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: selinexor + bortezomib + dexamethasone, Vision blurred, Grade 3-4","Control: 0.470<br />Experimental: 0.570<br />greater: experi<br />event: margetuximab + chemotherapy, Fatigue/Asthenia, All Grades","Control: 0.140<br />Experimental: 0.190<br />greater: experi<br />event: margetuximab + chemotherapy, Pyrexia, All Grades","Control: 0.320<br />Experimental: 0.330<br />greater: experi<br />event: margetuximab + chemotherapy, Nausea, All Grades","Control: 0.140<br />Experimental: 0.210<br />greater: experi<br />event: margetuximab + chemotherapy, Vomiting, All Grades","Control: 0.170<br />Experimental: 0.190<br />greater: experi<br />event: margetuximab + chemotherapy, Constipation, All Grades","Control: 0.150<br />Experimental: 0.180<br />greater: experi<br />event: margetuximab + chemotherapy, Alopecia, All Grades","Control: 0.160<br />Experimental: 0.190<br />greater: experi<br />event: margetuximab + chemotherapy, Headache, All Grades","Control: 0.150<br />Experimental: 0.160<br />greater: experi<br />event: margetuximab + chemotherapy, Peripheral neuropathy, All Grades","Control: 0.120<br />Experimental: 0.140<br />greater: experi<br />event: margetuximab + chemotherapy, Cough, All Grades","Control: 0.110<br />Experimental: 0.130<br />greater: experi<br />event: margetuximab + chemotherapy, Dyspnea, All Grades","Control: 0.120<br />Experimental: 0.140<br />greater: experi<br />event: margetuximab + chemotherapy, Arthralgia/Myalgia, All Grades","Control: 0.090<br />Experimental: 0.110<br />greater: experi<br />event: margetuximab + chemotherapy, Extremity pain, All Grades","Control: 0.030<br />Experimental: 0.130<br />greater: experi<br />event: margetuximab + chemotherapy, Infusion-related reaction, All Grades","Control: 0.045<br />Experimental: 0.070<br />greater: experi<br />event: margetuximab + chemotherapy, Fatigue/Asthenia, Grade 3-4","Control: 0.004<br />Experimental: 0.011<br />greater: experi<br />event: margetuximab + chemotherapy, Nausea, Grade 3-4","Control: 0.000<br />Experimental: 0.004<br />greater: experi<br />event: margetuximab + chemotherapy, Cough, Grade 3-4","Control: 0.000<br />Experimental: 0.008<br />greater: experi<br />event: margetuximab + chemotherapy, Extremity pain, Grade 3-4","Control: 0.000<br />Experimental: 0.015<br />greater: experi<br />event: margetuximab + chemotherapy, Infusion-related reaction, Grade 3-4","Control: 0.240<br />Experimental: 0.410<br />greater: experi<br />event: pembrolizumab, Upper respiratory tract infection, All Grades","Control: 0.030<br />Experimental: 0.110<br />greater: experi<br />event: pembrolizumab, Urinary tract infection, All Grades","Control: 0.290<br />Experimental: 0.320<br />greater: experi<br />event: pembrolizumab, Musculoskeletal pain, All Grades","Control: 0.170<br />Experimental: 0.220<br />greater: experi<br />event: pembrolizumab, Diarrhea, All Grades","Control: 0.130<br />Experimental: 0.200<br />greater: experi<br />event: pembrolizumab, pyrexia, All Grades","Control: 0.190<br />Experimental: 0.200<br />greater: experi<br />event: pembrolizumab, Rash, All Grades","Control: 0.120<br />Experimental: 0.180<br />greater: experi<br />event: pembrolizumab, Pruritus, All Grades","Control: 0.140<br />Experimental: 0.200<br />greater: experi<br />event: pembrolizumab, Cough, All Grades","Control: 0.030<br />Experimental: 0.110<br />greater: experi<br />event: pembrolizumab, Pneumonitis, All Grades","Control: 0.070<br />Experimental: 0.110<br />greater: experi<br />event: pembrolizumab, Dyspnea, All Grades","Control: 0.030<br />Experimental: 0.190<br />greater: experi<br />event: pembrolizumab, Hypothyroidism, All Grades","Control: 0.000<br />Experimental: 0.014<br />greater: experi<br />event: pembrolizumab, Upper respiratory tract infection, Grade 3-4","Control: 0.013<br />Experimental: 0.027<br />greater: experi<br />event: pembrolizumab, Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.014<br />greater: experi<br />event: pembrolizumab, Vomiting, Grade 3-4","Control: 0.013<br />Experimental: 0.050<br />greater: experi<br />event: pembrolizumab, Pneumonitis, Grade 3-4","Control: 0.046<br />Experimental: 0.180<br />greater: experi<br />event: nivolumab + ipilimumab, Pyrexia, All Grades","Control: 0.080<br />Experimental: 0.170<br />greater: experi<br />event: nivolumab + ipilimumab, Edema, All Grades","Control: 0.170<br />Experimental: 0.380<br />greater: experi<br />event: nivolumab + ipilimumab, Musculoskeletal pain, All Grades","Control: 0.011<br />Experimental: 0.130<br />greater: experi<br />event: nivolumab + ipilimumab, Arthralgia, All Grades","Control: 0.110<br />Experimental: 0.340<br />greater: experi<br />event: nivolumab + ipilimumab, Rash, All Grades","Control: 0.014<br />Experimental: 0.210<br />greater: experi<br />event: nivolumab + ipilimumab, Pruritus, All Grades","Control: 0.120<br />Experimental: 0.320<br />greater: experi<br />event: nivolumab + ipilimumab, Diarrhea, All Grades","Control: 0.100<br />Experimental: 0.150<br />greater: experi<br />event: nivolumab + ipilimumab, Abdominal pain, All Grades","Control: 0.160<br />Experimental: 0.270<br />greater: experi<br />event: nivolumab + ipilimumab, Dyspnea, All Grades","Control: 0.090<br />Experimental: 0.230<br />greater: experi<br />event: nivolumab + ipilimumab, Cough, All Grades","Control: 0.014<br />Experimental: 0.150<br />greater: experi<br />event: nivolumab + ipilimumab, Hypothyroidism, All Grades","Control: 0.070<br />Experimental: 0.120<br />greater: experi<br />event: nivolumab + ipilimumab, Upper respiratory tract infection, All Grades","Control: 0.042<br />Experimental: 0.100<br />greater: experi<br />event: nivolumab + ipilimumab, Pneumonia, All Grades","Control: 0.007<br />Experimental: 0.013<br />greater: experi<br />event: nivolumab + ipilimumab, Pyrexia, Grade 3-4","Control: 0.011<br />Experimental: 0.033<br />greater: experi<br />event: nivolumab + ipilimumab, Musculoskeletal pain, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: nivolumab + ipilimumab, Arthralgia, Grade 3-4","Control: 0.004<br />Experimental: 0.027<br />greater: experi<br />event: nivolumab + ipilimumab, Rash, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: nivolumab + ipilimumab, Pruritus, Grade 3-4","Control: 0.011<br />Experimental: 0.060<br />greater: experi<br />event: nivolumab + ipilimumab, Diarrhea, Grade 3-4","Control: 0.007<br />Experimental: 0.010<br />greater: experi<br />event: nivolumab + ipilimumab, Abdominal pain, Grade 3-4","Control: 0.000<br />Experimental: 0.007<br />greater: experi<br />event: nivolumab + ipilimumab, Cough, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: nivolumab + ipilimumab, Upper respiratory tract infection, Grade 3-4","Control: 0.021<br />Experimental: 0.040<br />greater: experi<br />event: nivolumab + ipilimumab, Pneumonia, Grade 3-4","Control: 0.280<br />Experimental: 0.410<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Infusion-related reactions, All Grades","Control: 0.280<br />Experimental: 0.320<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Fatigue, All Grades","Control: 0.150<br />Experimental: 0.200<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Pyrexia, All Grades","Control: 0.290<br />Experimental: 0.400<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Respiratory tract infection, All Grades","Control: 0.120<br />Experimental: 0.180<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Pneumonia, All Grades","Control: 0.120<br />Experimental: 0.170<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Bronchitis, All Grades","Control: 0.300<br />Experimental: 0.370<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Thrombocytopenia, All Grades","Control: 0.310<br />Experimental: 0.330<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Anemiae, All Grades","Control: 0.140<br />Experimental: 0.320<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Diarrhea, All Grades","Control: 0.130<br />Experimental: 0.180<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Nausea, All Grades","Control: 0.280<br />Experimental: 0.310<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, HHypertension, All Grades","Control: 0.110<br />Experimental: 0.180<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Insomnia, All Grades","Control: 0.100<br />Experimental: 0.160<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Back pain, All Grades","Control: 0.050<br />Experimental: 0.120<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Infusion-related reactions, Grade 3-4","Control: 0.080<br />Experimental: 0.110<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Fatigue, Grade 3-4","Control: 0.007<br />Experimental: 0.019<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Pyrexia, Grade 3-4","Control: 0.033<br />Experimental: 0.070<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Respiratory tract infection, Grade 3-4","Control: 0.090<br />Experimental: 0.130<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Pneumonia, Grade 3-4","Control: 0.013<br />Experimental: 0.026<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Bronchitis, Grade 3-4","Control: 0.160<br />Experimental: 0.250<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Thrombocytopenia, Grade 3-4","Control: 0.140<br />Experimental: 0.170<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Anemiae, Grade 3-4","Control: 0.007<br />Experimental: 0.039<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Diarrhea, Grade 3-4","Control: 0.130<br />Experimental: 0.180<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, HHypertension, Grade 3-4","Control: 0.026<br />Experimental: 0.039<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Dyspnea, Grade 3-4","Control: 0.020<br />Experimental: 0.039<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Insomnia, Grade 3-4","Control: 0.013<br />Experimental: 0.019<br />greater: experi<br />event: carfilzomib + daratumumab + dexamethasone, Back pain, Grade 3-4","Control: 0.130<br />Experimental: 0.350<br />greater: experi<br />event: avelumab, Fatigue, All Grades","Control: 0.035<br />Experimental: 0.150<br />greater: experi<br />event: avelumab, Pyrexia, All Grades","Control: 0.150<br />Experimental: 0.240<br />greater: experi<br />event: avelumab, Musculoskeletal pain, All Grades","Control: 0.060<br />Experimental: 0.160<br />greater: experi<br />event: avelumab, Arthralgia, All Grades","Control: 0.023<br />Experimental: 0.200<br />greater: experi<br />event: avelumab, Rash, All Grades","Control: 0.017<br />Experimental: 0.170<br />greater: experi<br />event: avelumab, Pruritus, All Grades","Control: 0.110<br />Experimental: 0.200<br />greater: experi<br />event: avelumab, Urinary tract infection, All Grades","Control: 0.049<br />Experimental: 0.170<br />greater: experi<br />event: avelumab, Diarrhea, All Grades","Control: 0.090<br />Experimental: 0.160<br />greater: experi<br />event: avelumab, Constipation, All Grades","Control: 0.060<br />Experimental: 0.160<br />greater: experi<br />event: avelumab, Nausea, All Grades","Control: 0.035<br />Experimental: 0.130<br />greater: experi<br />event: avelumab, Vomiting, All Grades","Control: 0.046<br />Experimental: 0.140<br />greater: experi<br />event: avelumab, Cough, All Grades","Control: 0.070<br />Experimental: 0.140<br />greater: experi<br />event: avelumab, Decreased appetite, All Grades","Control: 0.006<br />Experimental: 0.120<br />greater: experi<br />event: avelumab, Hypothyroidism, All Grades","Control: 0.000<br />Experimental: 0.100<br />greater: experi<br />event: avelumab, Infusion-related reaction , All Grades","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: avelumab, Pyrexia, Grade 3-4","Control: 0.000<br />Experimental: 0.006<br />greater: experi<br />event: avelumab, Arthralgia, Grade 3-4","Control: 0.000<br />Experimental: 0.012<br />greater: experi<br />event: avelumab, Rash, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: avelumab, Pruritus, Grade 3-4","Control: 0.038<br />Experimental: 0.060<br />greater: experi<br />event: avelumab, Urinary tract infection, Grade 3-4","Control: 0.003<br />Experimental: 0.006<br />greater: experi<br />event: avelumab, Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.006<br />greater: experi<br />event: avelumab, Constipation, Grade 3-4","Control: 0.006<br />Experimental: 0.012<br />greater: experi<br />event: avelumab, Vomiting, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: avelumab, Cough, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: avelumab, Hypothyroidism, Grade 3-4","Control: 0.000<br />Experimental: 0.009<br />greater: experi<br />event: avelumab, Infusion-related reaction , Grade 3-4","Control: 0.070<br />Experimental: 0.120<br />greater: experi<br />event: nivolumab, Pruritus, All Grades","Control: 0.170<br />Experimental: 0.180<br />greater: experi<br />event: nivolumab, Diarrhea, All Grades","Control: 0.140<br />Experimental: 0.170<br />greater: experi<br />event: nivolumab, Upper respiratory tract infection, All Grades","Control: 0.140<br />Experimental: 0.160<br />greater: experi<br />event: nivolumab, Cough, All Grades","Control: 0.014<br />Experimental: 0.110<br />greater: experi<br />event: nivolumab, Hypothyroidism, All Grades","Control: 0.010<br />Experimental: 0.019<br />greater: experi<br />event: nivolumab, Rash, Grade 3-4","Control: 0.014<br />Experimental: 0.019<br />greater: experi<br />event: nivolumab, Diarrhea, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: nivolumab, Upper respiratory tract infection, Grade 3-4","Control: 0.240<br />Experimental: 0.300<br />greater: experi<br />event: atezolizumab + bevacizumab, Hypertension, All Grades","Control: 0.100<br />Experimental: 0.180<br />greater: experi<br />event: atezolizumab + bevacizumab, Pyrexia, All Grades","Control: 0.070<br />Experimental: 0.200<br />greater: experi<br />event: atezolizumab + bevacizumab, Proteinuria, All Grades","Control: 0.100<br />Experimental: 0.110<br />greater: experi<br />event: atezolizumab + bevacizumab, Weight Decreased, All Grades","Control: 0.100<br />Experimental: 0.190<br />greater: experi<br />event: atezolizumab + bevacizumab, Pruritus, All Grades","Control: 0.080<br />Experimental: 0.100<br />greater: experi<br />event: atezolizumab + bevacizumab, Vomiting, All Grades","Control: 0.100<br />Experimental: 0.120<br />greater: experi<br />event: atezolizumab + bevacizumab, Cough, All Grades","Control: 0.045<br />Experimental: 0.100<br />greater: experi<br />event: atezolizumab + bevacizumab, Epistaxis, All Grades","Control: 0.000<br />Experimental: 0.110<br />greater: experi<br />event: atezolizumab + bevacizumab, Infusion Related Reaction, All Grades","Control: 0.120<br />Experimental: 0.150<br />greater: experi<br />event: atezolizumab + bevacizumab, Hypertension, Grade 3-4","Control: 0.006<br />Experimental: 0.030<br />greater: experi<br />event: atezolizumab + bevacizumab, Proteinuria, Grade 3-4","Control: 0.000<br />Experimental: 0.024<br />greater: experi<br />event: atezolizumab + bevacizumab, Infusion Related Reaction, Grade 3-4","Control: 0.400<br />Experimental: 0.490<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Fatigue, All Grades","Control: 0.100<br />Experimental: 0.140<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Pyrexia, All Grades","Control: 0.270<br />Experimental: 0.390<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Musculoskeletal pain, All Grades","Control: 0.180<br />Experimental: 0.310<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Diarrhea, All Grades","Control: 0.170<br />Experimental: 0.180<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Vomiting, All Grades","Control: 0.110<br />Experimental: 0.120<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Abdominal pain, All Grades","Control: 0.100<br />Experimental: 0.300<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Rash, All Grades","Control: 0.029<br />Experimental: 0.210<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Pruritus, All Grades","Control: 0.100<br />Experimental: 0.110<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Alopecia, All Grades","Control: 0.220<br />Experimental: 0.280<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Decreased appetite, All Grades","Control: 0.150<br />Experimental: 0.190<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Cough, All Grades","Control: 0.140<br />Experimental: 0.180<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Dyspnea, All Grades","Control: 0.034<br />Experimental: 0.190<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Hypothyroidism, All Grades","Control: 0.070<br />Experimental: 0.110<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Headache, All Grades","Control: 0.060<br />Experimental: 0.110<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Dizziness, All Grades","Control: 0.049<br />Experimental: 0.050<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Fatigue, Grade 3-4","Control: 0.020<br />Experimental: 0.045<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Musculoskeletal pain, Grade 3-4","Control: 0.009<br />Experimental: 0.017<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Nausea, Grade 3-4","Control: 0.017<br />Experimental: 0.060<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Diarrhea, Grade 3-4","Control: 0.014<br />Experimental: 0.020<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Vomiting, Grade 3-4","Control: 0.003<br />Experimental: 0.047<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Rash, Grade 3-4","Control: 0.000<br />Experimental: 0.008<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Pruritus, Grade 3-4","Control: 0.006<br />Experimental: 0.008<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Alopecia, Grade 3-4","Control: 0.017<br />Experimental: 0.020<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Decreased appetite, Grade 3-4","Control: 0.032<br />Experimental: 0.047<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Dyspnea, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Hypothyroidism, Grade 3-4","Control: 0.000<br />Experimental: 0.006<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Headache, Grade 3-4","Control: 0.000<br />Experimental: 0.006<br />greater: experi<br />event: nivolumab + ipilimumab + chemotherapy, Dizziness, Grade 3-4","Control: 0.088<br />Experimental: 0.130<br />greater: experi<br />event: brigatinib, Stomatitis, All Grades","Control: 0.170<br />Experimental: 0.400<br />greater: experi<br />event: brigatinib, Rash, All Grades","Control: 0.058<br />Experimental: 0.200<br />greater: experi<br />event: brigatinib, Pruritus, All Grades","Control: 0.200<br />Experimental: 0.350<br />greater: experi<br />event: brigatinib, Cough, All Grades","Control: 0.220<br />Experimental: 0.250<br />greater: experi<br />event: brigatinib, Dyspnea, All Grades","Control: 0.022<br />Experimental: 0.051<br />greater: experi<br />event: brigatinib, ILD/Pneumonitis, All Grades","Control: 0.080<br />Experimental: 0.320<br />greater: experi<br />event: brigatinib, Hypertension, All Grades","Control: 0.230<br />Experimental: 0.280<br />greater: experi<br />event: brigatinib, Myalgia, All Grades","Control: 0.170<br />Experimental: 0.210<br />greater: experi<br />event: brigatinib, Back pain, All Grades","Control: 0.120<br />Experimental: 0.140<br />greater: experi<br />event: brigatinib, Arthralgia, All Grades","Control: 0.170<br />Experimental: 0.220<br />greater: experi<br />event: brigatinib, Headache, All Grades","Control: 0.007<br />Experimental: 0.130<br />greater: experi<br />event: brigatinib, Increased Blood cholesterol, All Grades","Control: 0.066<br />Experimental: 0.150<br />greater: experi<br />event: brigatinib, Pneumonia, All Grades","Control: 0.100<br />Experimental: 0.120<br />greater: experi<br />event: brigatinib, Upper respiratory tract infection, All Grades","Control: 0.000<br />Experimental: 0.007<br />greater: experi<br />event: brigatinib, Stomatitis, Grade 3-4","Control: 0.000<br />Experimental: 0.029<br />greater: experi<br />event: brigatinib, Rash, Grade 3-4","Control: 0.007<br />Experimental: 0.029<br />greater: experi<br />event: brigatinib, ILD/Pneumonitis, Grade 3-4","Control: 0.029<br />Experimental: 0.130<br />greater: experi<br />event: brigatinib, Hypertension, Grade 3-4","Control: 0.000<br />Experimental: 0.007<br />greater: experi<br />event: brigatinib, Pyrexia, Grade 3-4","Control: 0.000<br />Experimental: 0.022<br />greater: experi<br />event: brigatinib, Headache, Grade 3-4","Control: 0.000<br />Experimental: 0.007<br />greater: experi<br />event: brigatinib, Peripheral neuropathy, Grade 3-4","Control: 0.000<br />Experimental: 0.007<br />greater: experi<br />event: brigatinib, Bradycardia, Grade 3-4","Control: 0.029<br />Experimental: 0.051<br />greater: experi<br />event: brigatinib, Pneumonia, Grade 3-4","Control: 0.150<br />Experimental: 0.460<br />greater: experi<br />event: olaparib, Anemia, Grades 1-4 ","Control: 0.030<br />Experimental: 0.120<br />greater: experi<br />event: olaparib, Thrombocytopenia, Grades 1-4 ","Control: 0.190<br />Experimental: 0.410<br />greater: experi<br />event: olaparib, Nausea, Grades 1-4 ","Control: 0.070<br />Experimental: 0.210<br />greater: experi<br />event: olaparib, Diarrhea, Grades 1-4 ","Control: 0.120<br />Experimental: 0.180<br />greater: experi<br />event: olaparib, Vomiting, Grades 1-4 ","Control: 0.320<br />Experimental: 0.410<br />greater: experi<br />event: olaparib, Fatigue (including asthenia), Grades 1-4 ","Control: 0.180<br />Experimental: 0.300<br />greater: experi<br />event: olaparib, Decreased appetite, Grades 1-4 ","Control: 0.020<br />Experimental: 0.110<br />greater: experi<br />event: olaparib, Cough, Grades 1-4 ","Control: 0.030<br />Experimental: 0.100<br />greater: experi<br />event: olaparib, Dyspnea, Grades 1-4 ","Control: 0.050<br />Experimental: 0.210<br />greater: experi<br />event: olaparib, Anemia, Grade 3-4","Control: 0.000<br />Experimental: 0.040<br />greater: experi<br />event: olaparib, Thrombocytopenia, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: olaparib, Nausea, Grade 3-4","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: olaparib, Diarrhea, Grade 3-4","Control: 0.010<br />Experimental: 0.020<br />greater: experi<br />event: olaparib, Vomiting, Grade 3-4","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: olaparib, Dyspnea, Grade 3-4","Control: 0.090<br />Experimental: 0.140<br />greater: experi<br />event: atezolizumab, Pyrexia, All Grades","Control: 0.100<br />Experimental: 0.140<br />greater: experi<br />event: atezolizumab, Dyspnea, All Grades","Control: 0.100<br />Experimental: 0.120<br />greater: experi<br />event: atezolizumab, Cough, All Grades","Control: 0.008<br />Experimental: 0.010<br />greater: experi<br />event: atezolizumab, Constipation, Grade 3-4","Control: 0.000<br />Experimental: 0.007<br />greater: experi<br />event: atezolizumab, Decreased appetite, Grade 3-4","Control: 0.000<br />Experimental: 0.007<br />greater: experi<br />event: atezolizumab, Dyspnea, Grade 3-4","Control: 0.000<br />Experimental: 0.003<br />greater: experi<br />event: atezolizumab, Cough, Grade 3-4","Control: 0.420<br />Experimental: 0.440<br />greater: experi<br />event: nivolumab + ipilimumab, Fatigue, All Grades","Control: 0.110<br />Experimental: 0.180<br />greater: experi<br />event: nivolumab + ipilimumab, Pyrexia, All Grades","Control: 0.120<br />Experimental: 0.140<br />greater: experi<br />event: nivolumab + ipilimumab, Edema, All Grades","Control: 0.100<br />Experimental: 0.340<br />greater: experi<br />event: nivolumab + ipilimumab, Rash, All Grades","Control: 0.033<br />Experimental: 0.210<br />greater: experi<br />event: nivolumab + ipilimumab, Pruritus, All Grades","Control: 0.260<br />Experimental: 0.310<br />greater: experi<br />event: nivolumab + ipilimumab, Decreased appetite, All Grades","Control: 0.160<br />Experimental: 0.270<br />greater: experi<br />event: nivolumab + ipilimumab, Musculoskeletal pain, All Grades","Control: 0.025<br />Experimental: 0.130<br />greater: experi<br />event: nivolumab + ipilimumab, Arthralgia, All Grades","Control: 0.160<br />Experimental: 0.260<br />greater: experi<br />event: nivolumab + ipilimumab, Diarrhea/colitis, All Grades","Control: 0.090<br />Experimental: 0.100<br />greater: experi<br />event: nivolumab + ipilimumab, Abdominal pain, All Grades","Control: 0.160<br />Experimental: 0.260<br />greater: experi<br />event: nivolumab + ipilimumab, Dyspnea, All Grades","Control: 0.130<br />Experimental: 0.230<br />greater: experi<br />event: nivolumab + ipilimumab, Cough, All Grades","Control: 0.100<br />Experimental: 0.210<br />greater: experi<br />event: nivolumab + ipilimumab, Hepatitis, All Grades","Control: 0.012<br />Experimental: 0.160<br />greater: experi<br />event: nivolumab + ipilimumab, Hypothyroidism, All Grades","Control: 0.005<br />Experimental: 0.100<br />greater: experi<br />event: nivolumab + ipilimumab, Hyperthyroidism, All Grades","Control: 0.080<br />Experimental: 0.130<br />greater: experi<br />event: nivolumab + ipilimumab, Pneumonia, All Grades","Control: 0.060<br />Experimental: 0.110<br />greater: experi<br />event: nivolumab + ipilimumab, Headache, All Grades","Control: 0.044<br />Experimental: 0.060<br />greater: experi<br />event: nivolumab + ipilimumab, Fatigue, Grade 3-4","Control: 0.004<br />Experimental: 0.005<br />greater: experi<br />event: nivolumab + ipilimumab, Pyrexia, Grade 3-4","Control: 0.004<br />Experimental: 0.047<br />greater: experi<br />event: nivolumab + ipilimumab, Rash, Grade 3-4","Control: 0.000<br />Experimental: 0.005<br />greater: experi<br />event: nivolumab + ipilimumab, Pruritus, Grade 3-4","Control: 0.014<br />Experimental: 0.023<br />greater: experi<br />event: nivolumab + ipilimumab, Decreased appetite, Grade 3-4","Control: 0.007<br />Experimental: 0.019<br />greater: experi<br />event: nivolumab + ipilimumab, Musculoskeletal pain, Grade 3-4","Control: 0.002<br />Experimental: 0.009<br />greater: experi<br />event: nivolumab + ipilimumab, Arthralgia, Grade 3-4","Control: 0.009<br />Experimental: 0.036<br />greater: experi<br />event: nivolumab + ipilimumab, Diarrhea/colitis, Grade 3-4","Control: 0.021<br />Experimental: 0.043<br />greater: experi<br />event: nivolumab + ipilimumab, Dyspnea, Grade 3-4","Control: 0.000<br />Experimental: 0.002<br />greater: experi<br />event: nivolumab + ipilimumab, Cough, Grade 3-4","Control: 0.012<br />Experimental: 0.090<br />greater: experi<br />event: nivolumab + ipilimumab, Hepatitis, Grade 3-4","Control: 0.000<br />Experimental: 0.005<br />greater: experi<br />event: nivolumab + ipilimumab, Hypothyroidism, Grade 3-4","Control: 0.040<br />Experimental: 0.070<br />greater: experi<br />event: nivolumab + ipilimumab, Pneumonia, Grade 3-4","Control: 0.000<br />Experimental: 0.005<br />greater: experi<br />event: nivolumab + ipilimumab, Headache, Grade 3-4","Control: 0.780<br />Experimental: 0.800<br />greater: experi<br />event: ibrutinib + rituximab, Fatigue, All Grades","Control: 0.170<br />Experimental: 0.280<br />greater: experi<br />event: ibrutinib + rituximab, Peripheral edema, All Grades","Control: 0.080<br />Experimental: 0.230<br />greater: experi<br />event: ibrutinib + rituximab, Pain, All Grades","Control: 0.350<br />Experimental: 0.610<br />greater: experi<br />event: ibrutinib + rituximab, Musculoskeletal pain, All Grades","Control: 0.100<br />Experimental: 0.410<br />greater: experi<br />event: ibrutinib + rituximab, Arthralgia, All Grades","Control: 0.270<br />Experimental: 0.530<br />greater: experi<br />event: ibrutinib + rituximab, Diarrhea, All Grades","Control: 0.080<br />Experimental: 0.220<br />greater: experi<br />event: ibrutinib + rituximab, Stomatitis, All Grades","Control: 0.100<br />Experimental: 0.190<br />greater: experi<br />event: ibrutinib + rituximab, Abdominal pain, All Grades","Control: 0.290<br />Experimental: 0.490<br />greater: experi<br />event: ibrutinib + rituximab, Rash, All Grades","Control: 0.040<br />Experimental: 0.360<br />greater: experi<br />event: ibrutinib + rituximab, Bruising, All Grades","Control: 0.220<br />Experimental: 0.420<br />greater: experi<br />event: ibrutinib + rituximab, Hypertension, All Grades","Control: 0.080<br />Experimental: 0.310<br />greater: experi<br />event: ibrutinib + rituximab, Hemorrhage, All Grades","Control: 0.270<br />Experimental: 0.400<br />greater: experi<br />event: ibrutinib + rituximab, Headache, All Grades","Control: 0.130<br />Experimental: 0.210<br />greater: experi<br />event: ibrutinib + rituximab, Dizziness, All Grades","Control: 0.130<br />Experimental: 0.190<br />greater: experi<br />event: ibrutinib + rituximab, Peripheral neuropathy, All Grades","Control: 0.250<br />Experimental: 0.320<br />greater: experi<br />event: ibrutinib + rituximab, Cough, All Grades","Control: 0.210<br />Experimental: 0.220<br />greater: experi<br />event: ibrutinib + rituximab, Dyspnea, All Grades","Control: 0.190<br />Experimental: 0.290<br />greater: experi<br />event: ibrutinib + rituximab, Upper respiratory tract infection, All Grades","Control: 0.030<br />Experimental: 0.160<br />greater: experi<br />event: ibrutinib + rituximab, Skin infection, All Grades","Control: 0.040<br />Experimental: 0.190<br />greater: experi<br />event: ibrutinib + rituximab, Hyperuricemia, All Grades","Control: 0.500<br />Experimental: 0.510<br />greater: experi<br />event: encorafenib + cetuximab, Fatigue, All Grades","Control: 0.150<br />Experimental: 0.170<br />greater: experi<br />event: encorafenib + cetuximab, Pyrexia, All Grades","Control: 0.030<br />Experimental: 0.270<br />greater: experi<br />event: encorafenib + cetuximab, Arthralgia, All Grades","Control: 0.040<br />Experimental: 0.150<br />greater: experi<br />event: encorafenib + cetuximab, Myopathy, All Grades","Control: 0.010<br />Experimental: 0.100<br />greater: experi<br />event: encorafenib + cetuximab, Pain in extremity, All Grades","Control: 0.060<br />Experimental: 0.140<br />greater: experi<br />event: encorafenib + cetuximab, Pruritus, All Grades","Control: 0.000<br />Experimental: 0.140<br />greater: experi<br />event: encorafenib + cetuximab, Melanocytic nevus, All Grades","Control: 0.120<br />Experimental: 0.130<br />greater: experi<br />event: encorafenib + cetuximab, Dry skin, All Grades","Control: 0.030<br />Experimental: 0.200<br />greater: experi<br />event: encorafenib + cetuximab, Headache, All Grades","Control: 0.060<br />Experimental: 0.120<br />greater: experi<br />event: encorafenib + cetuximab, Peripheral neuropathy, All Grades","Control: 0.090<br />Experimental: 0.190<br />greater: experi<br />event: encorafenib + cetuximab, Hemorrhage, All Grades","Control: 0.060<br />Experimental: 0.130<br />greater: experi<br />event: encorafenib + cetuximab, Insomnia, All Grades","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: encorafenib + cetuximab, Arthralgia, Grade ≥ 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: encorafenib + cetuximab, Myopathy, Grade ≥ 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: encorafenib + cetuximab, Peripheral neuropathy, Grade ≥ 3","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: encorafenib + cetuximab, Hemorrhage, Grade ≥ 3","Control: 0.090<br />Experimental: 0.150<br />greater: experi<br />event: durvalumab + Etoposide + either Carboplatin or Cisplatin , Cough/Productive Cough, All Grades","Control: 0.004<br />Experimental: 0.100<br />greater: experi<br />event: durvalumab + Etoposide + either Carboplatin or Cisplatin , Hyperthyroidisma, All Grades","Control: 0.060<br />Experimental: 0.110<br />greater: experi<br />event: durvalumab + Etoposide + either Carboplatin or Cisplatin , Rash, All Grades","Control: 0.170<br />Experimental: 0.180<br />greater: experi<br />event: durvalumab + Etoposide + either Carboplatin or Cisplatin , Decreased appetite, All Grades","Control: 0.000<br />Experimental: 0.008<br />greater: experi<br />event: durvalumab + Etoposide + either Carboplatin or Cisplatin , Cough/Productive Cough, Grade 3-4","Control: 0.000<br />Experimental: 0.008<br />greater: experi<br />event: durvalumab + Etoposide + either Carboplatin or Cisplatin , Constipation, Grade 3-4","Control: 0.008<br />Experimental: 0.011<br />greater: experi<br />event: durvalumab + Etoposide + either Carboplatin or Cisplatin , Alopecia, Grade 3-4","Control: 0.023<br />Experimental: 0.034<br />greater: experi<br />event: durvalumab + Etoposide + either Carboplatin or Cisplatin , Fatigue/Asthenia, Grade 3-4","Control: 0.000<br />Experimental: 0.380<br />greater: experi<br />event: isatuximab-irfc, Infusion-related reaction, All grades","Control: 0.230<br />Experimental: 0.310<br />greater: experi<br />event: isatuximab-irfc, Pneumonia, All grades","Control: 0.420<br />Experimental: 0.570<br />greater: experi<br />event: isatuximab-irfc, Upper respiratory tract infection, All grades","Control: 0.020<br />Experimental: 0.120<br />greater: experi<br />event: isatuximab-irfc, Febrile neutropenia, All grades","Control: 0.120<br />Experimental: 0.170<br />greater: experi<br />event: isatuximab-irfc, Dyspnea, All grades","Control: 0.190<br />Experimental: 0.260<br />greater: experi<br />event: isatuximab-irfc, Diarrhea, All grades","Control: 0.090<br />Experimental: 0.150<br />greater: experi<br />event: isatuximab-irfc, Nausea, All grades","Control: 0.034<br />Experimental: 0.120<br />greater: experi<br />event: isatuximab-irfc, Vomiting, All grades","Control: 0.000<br />Experimental: 0.013<br />greater: experi<br />event: isatuximab-irfc, Infusion-related reaction, Grade 3","Control: 0.160<br />Experimental: 0.220<br />greater: experi<br />event: isatuximab-irfc, Pneumonia, Grade 3","Control: 0.034<br />Experimental: 0.090<br />greater: experi<br />event: isatuximab-irfc, Upper respiratory tract infection, Grade 3","Control: 0.013<br />Experimental: 0.110<br />greater: experi<br />event: isatuximab-irfc, Febrile neutropenia, Grade 3","Control: 0.013<br />Experimental: 0.050<br />greater: experi<br />event: isatuximab-irfc, Dyspnea, Grade 3","Control: 0.007<br />Experimental: 0.020<br />greater: experi<br />event: isatuximab-irfc, Diarrhea, Grade 3","Control: 0.000<br />Experimental: 0.013<br />greater: experi<br />event: isatuximab-irfc, Vomiting, Grade 3","Control: 0.000<br />Experimental: 0.013<br />greater: experi<br />event: isatuximab-irfc, Infusion-related reaction, Grade 4","Control: 0.027<br />Experimental: 0.033<br />greater: experi<br />event: isatuximab-irfc, Pneumonia, Grade 4","Control: 0.007<br />Experimental: 0.013<br />greater: experi<br />event: isatuximab-irfc, Febrile neutropenia, Grade 4","Control: 0.660<br />Experimental: 0.830<br />greater: experi<br />event: neratinib +  Capecitabine, Diarrhea, All Grades","Control: 0.420<br />Experimental: 0.530<br />greater: experi<br />event: neratinib +  Capecitabine, Nausea, All Grades","Control: 0.310<br />Experimental: 0.460<br />greater: experi<br />event: neratinib +  Capecitabine, Vomiting, All Grades","Control: 0.130<br />Experimental: 0.310<br />greater: experi<br />event: neratinib +  Capecitabine, Constipation, All Grades","Control: 0.032<br />Experimental: 0.080<br />greater: experi<br />event: neratinib +  Capecitabine, Abdominal distension, All Grades","Control: 0.400<br />Experimental: 0.450<br />greater: experi<br />event: neratinib +  Capecitabine, Fatigue/asthenia, All Grades","Control: 0.023<br />Experimental: 0.043<br />greater: experi<br />event: neratinib +  Capecitabine, Malaise, All Grades","Control: 0.013<br />Experimental: 0.040<br />greater: experi<br />event: neratinib +  Capecitabine, Influenza like illness, All Grades","Control: 0.042<br />Experimental: 0.090<br />greater: experi<br />event: neratinib +  Capecitabine, Urinary tract infection, All Grades","Control: 0.045<br />Experimental: 0.080<br />greater: experi<br />event: neratinib +  Capecitabine, Upper respiratory tract infection, All Grades","Control: 0.220<br />Experimental: 0.350<br />greater: experi<br />event: neratinib +  Capecitabine, Decreased appetite, All Grades","Control: 0.080<br />Experimental: 0.100<br />greater: experi<br />event: neratinib +  Capecitabine, Back Pain, All Grades","Control: 0.060<br />Experimental: 0.100<br />greater: experi<br />event: neratinib +  Capecitabine, Arthralgia, All Grades","Control: 0.019<br />Experimental: 0.050<br />greater: experi<br />event: neratinib +  Capecitabine, Muscle spasms, All Grades","Control: 0.100<br />Experimental: 0.140<br />greater: experi<br />event: neratinib +  Capecitabine, Dizziness, All Grades","Control: 0.010<br />Experimental: 0.070<br />greater: experi<br />event: neratinib +  Capecitabine, Renal impairment, All Grades","Control: 0.019<br />Experimental: 0.046<br />greater: experi<br />event: neratinib +  Capecitabine, Dysuria, All Grades","Control: 0.130<br />Experimental: 0.250<br />greater: experi<br />event: neratinib +  Capecitabine, Diarrhea, Grade 3","Control: 0.029<br />Experimental: 0.043<br />greater: experi<br />event: neratinib +  Capecitabine, Nausea, Grade 3","Control: 0.019<br />Experimental: 0.040<br />greater: experi<br />event: neratinib +  Capecitabine, Vomiting, Grade 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: neratinib +  Capecitabine, Constipation, Grade 3","Control: 0.045<br />Experimental: 0.060<br />greater: experi<br />event: neratinib +  Capecitabine, Fatigue/asthenia, Grade 3","Control: 0.006<br />Experimental: 0.007<br />greater: experi<br />event: neratinib +  Capecitabine, Urinary tract infection, Grade 3","Control: 0.023<br />Experimental: 0.026<br />greater: experi<br />event: neratinib +  Capecitabine, Decreased appetite, Grade 3","Control: 0.000<br />Experimental: 0.020<br />greater: experi<br />event: neratinib +  Capecitabine, Renal impairment, Grade 3","Control: 0.120<br />Experimental: 0.210<br />greater: experi<br />event: pembrolizumab, Pruritus, Grade 1–2","Control: 0.050<br />Experimental: 0.210<br />greater: experi<br />event: pembrolizumab, Hypothyroidism, Grade 1–2","Control: 0.130<br />Experimental: 0.180<br />greater: experi<br />event: pembrolizumab, Arthralgia, Grade 1–2","Control: 0.140<br />Experimental: 0.170<br />greater: experi<br />event: pembrolizumab, Diarrhoea, Grade 1–2","Control: 0.150<br />Experimental: 0.160<br />greater: experi<br />event: pembrolizumab, Fatigue, Grade 1–2","Control: 0.030<br />Experimental: 0.110<br />greater: experi<br />event: pembrolizumab, Hyperthyroidism, Grade 1–2","Control: 0.060<br />Experimental: 0.090<br />greater: experi<br />event: pembrolizumab, Nausea, Grade 1–2","Control: 0.060<br />Experimental: 0.090<br />greater: experi<br />event: pembrolizumab, Nasopharyngitis, Grade 1–2","Control: 0.050<br />Experimental: 0.080<br />greater: experi<br />event: pembrolizumab, Rash, Grade 1–2","Control: 0.050<br />Experimental: 0.070<br />greater: experi<br />event: pembrolizumab, Increased alanine aminotransferase, Grade 1–2","Control: 0.050<br />Experimental: 0.070<br />greater: experi<br />event: pembrolizumab, Asthenia, Grade 1–2","Control: 0.030<br />Experimental: 0.070<br />greater: experi<br />event: pembrolizumab, Maculopapular rash, Grade 1–2","Control: 0.050<br />Experimental: 0.070<br />greater: experi<br />event: pembrolizumab, Increased aspartate aminotransferase, Grade 1–2","Control: 0.040<br />Experimental: 0.070<br />greater: experi<br />event: pembrolizumab, Decreased appetite, Grade 1–2","Control: 0.040<br />Experimental: 0.070<br />greater: experi<br />event: pembrolizumab, Decreased bodyweight, Grade 1–2","Control: 0.060<br />Experimental: 0.070<br />greater: experi<br />event: pembrolizumab, Increased blood creatinine, Grade 1–2","Control: 0.030<br />Experimental: 0.060<br />greater: experi<br />event: pembrolizumab, Myalgia, Grade 1–2","Control: 0.030<br />Experimental: 0.060<br />greater: experi<br />event: pembrolizumab, Productive cough, Grade 1–2","Control: 0.020<br />Experimental: 0.050<br />greater: experi<br />event: pembrolizumab, Pneumonitis, Grade 1–2","Control: 0.040<br />Experimental: 0.050<br />greater: experi<br />event: pembrolizumab, Dry skin, Grade 1–2","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Hypothyroidism, Grade 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Cough, Grade 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Hyperthyroidism, Grade 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Nausea, Grade 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Rash, Grade 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Back pain, Grade 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Maculopapular rash, Grade 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Myalgia, Grade 3","Control: 0.000<br />Experimental: 0.010<br />greater: experi<br />event: pembrolizumab, Pneumonitis, Grade 4"],"key":["talazoparib + enzalutamide, Fatigue, Grades 1-4","talazoparib + enzalutamide, Fatigue, Grade 3","talazoparib + enzalutamide, Nausea, Grades 1-4","talazoparib + enzalutamide, Nausea, Grade 3","talazoparib + enzalutamide, Decreased appetite, Grades 1-4","talazoparib + enzalutamide, Fractures, Grades 1-4","talazoparib + enzalutamide, Fractures, Grade 3","talazoparib + enzalutamide, Dizzy, Grades 1-4","talazoparib + enzalutamide, Dysgeusiae, Grades 1-4","olaparib + abiraterone + prednisone (or prednisolone), Anemia, Grades 1-4","olaparib + abiraterone + prednisone (or prednisolone), Lymphopenia, Grades 1-4","olaparib + abiraterone + prednisone (or prednisolone), Fatigue (includes asthenia), Grades 1-4","olaparib + abiraterone + prednisone (or prednisolone), Nausea, Grades 1-4","olaparib + abiraterone + prednisone (or prednisolone), Diarrhea, Grades 1-4","olaparib + abiraterone + prednisone (or prednisolone), Abdominal pain, Grades 1-4","olaparib + abiraterone + prednisone (or prednisolone), Decreased appetite, Grades 1-4","olaparib + abiraterone + prednisone (or prednisolone), Dizziness, Grades 1-4","olaparib + abiraterone + prednisone (or prednisolone), Anemia, Grade 3-4","olaparib + abiraterone + prednisone (or prednisolone), Lymphopenia, Grade 3-4","olaparib + abiraterone + prednisone (or prednisolone), Fatigue (includes asthenia), Grade 3-4","olaparib + abiraterone + prednisone (or prednisolone), Diarrhea, Grade 3-4","olaparib + abiraterone + prednisone (or prednisolone), Decreased appetite, Grade 3-4","olaparib + abiraterone + prednisone (or prednisolone), Dizziness, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Lymphopenia, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Anemia, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Febrile neutropeniaa, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Creatinine increased, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Aspartate aminotransferase increased, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Alkaline phosphatase increased, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Uric acid increased, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Weight decreased, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Nausea, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Diarrhea, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Mucositis, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Abdominal paind, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Vomiting, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Pyrexia, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Edemae, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Rash, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Upper respiratory tract infection', All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Decreased appetite, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Cough, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Dyspnea, All grades","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Anemia, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Thrombocytopenia, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Febrile neutropeniaa, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Alanine aminotransferase increased, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Uric acid increased, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Weight decreased, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Peripheral neuropathy, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Nausea, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Diarrhea, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Constipation, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Mucositis, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Vomiting, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Pyrexia, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Edemae, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Rash, Grade 3-4","polatuzumab vedotin-piiq + R-CHP (rituximab + cyclophosphamide + doxorubicin + prednisone), Decreased appetite, Grade 3-4","sacituzumab govitecan-hziy, Diarrhea, All grades","sacituzumab govitecan-hziy, Nausea, All grades","sacituzumab govitecan-hziy, Constipation, All grades","sacituzumab govitecan-hziy, Vomiting, All grades","sacituzumab govitecan-hziy, Abdominal Pain, All grades","sacituzumab govitecan-hziy, Dyspepsia, All grades","sacituzumab govitecan-hziy, Fatigue, All grades","sacituzumab govitecan-hziy, Hypokalemia, All grades","sacituzumab govitecan-hziy, Arthralgia, All grades","sacituzumab govitecan-hziy, Headache, All grades","sacituzumab govitecan-hziy, Dyspnea, All grades","sacituzumab govitecan-hziy, Cough, All grades","sacituzumab govitecan-hziy, Alopecia, All grades","sacituzumab govitecan-hziy, Pruritus, All grades","sacituzumab govitecan-hziy, Diarrhea, Grade 3-4","sacituzumab govitecan-hziy, Constipation, Grade 3-4","sacituzumab govitecan-hziy, Fatigue, Grade 3-4","sacituzumab govitecan-hziy, Decreased appetite, Grade 3-4","sacituzumab govitecan-hziy, Hypokalemia, Grade 3-4","elacestrant, Musculoskeletal pain, All grades","elacestrant, Nausea, All grades","elacestrant, Vomiting, All grades","elacestrant, Diarrhea, All grades","elacestrant, Constipation, All grades","elacestrant, Abdominal pain, All grades","elacestrant, Dyspepsia, All grades","elacestrant, Decreased appetite , All grades","elacestrant, Hot flush , All grades","elacestrant, Musculoskeletal pain, Grade 3-4","elacestrant, Nausea, Grade 3-4","elacestrant, Vomiting, Grade 3-4","elacestrant, Abdominal pain, Grade 3-4","elacestrant, Fatigue, Grade 3-4","elacestrant, Decreased appetite , Grade 3-4","elacestrant, Headache, Grade 3-4","zanubrutinib, Musculoskeletal pain, All grades","zanubrutinib, Upper respiratory tract infection, All grades","zanubrutinib, Pneumonia, All grades","zanubrutinib, Hemorrhage, All grades","zanubrutinib, Hypertension, All grades","zanubrutinib, Bruising, All grades","zanubrutinib, Coughe, All grades","zanubrutinib, Diarrhea, All grades","zanubrutinib, Second primary malignancyl, All grades","zanubrutinib, Headache, All grades","zanubrutinib, Dizziness, All grades","zanubrutinib, Musculoskeletal pain, Grade 3-4","zanubrutinib, Upper respiratory tract infection, Grade 3-4","zanubrutinib, Pneumonia, Grade 3-4","zanubrutinib, Hemorrhage, Grade 3-4","zanubrutinib, Hypertension, Grade 3-4","zanubrutinib, Constipation, Grade 3-4","zanubrutinib, Second primary malignancyl, Grade 3-4","zanubrutinib, Dizziness, Grade 3-4","zanubrutinib, Upper respiratory tract infection, All grades","zanubrutinib, COVID-19, All grades","zanubrutinib, Bruising, All grades","zanubrutinib, Dizziness, All grades","zanubrutinib, COVID-19, Grade 3-4","zanubrutinib, Rash, Grade 3-4","zanubrutinib, Diarrhea, Grade 3-4","zanubrutinib, Cough, Grade 3-4","tremelimumab + durvalumab + platinum-based chemotherapy, Cough/Productive Cough/, All grades","tremelimumab + durvalumab + platinum-based chemotherapy, Nausea, All grades","tremelimumab + durvalumab + platinum-based chemotherapy, Diarrhea, All grades","tremelimumab + durvalumab + platinum-based chemotherapy, Vomiting, All grades","tremelimumab + durvalumab + platinum-based chemotherapy, Stomatitis, All grades","tremelimumab + durvalumab + platinum-based chemotherapy, Hypothyroidism, All grades","tremelimumab + durvalumab + platinum-based chemotherapy, Rash, All grades","tremelimumab + durvalumab + platinum-based chemotherapy, Alopecia, All grades","tremelimumab + durvalumab + platinum-based chemotherapy, Pruritus, All grades","tremelimumab + durvalumab + platinum-based chemotherapy, Fatigue/Asthenia, All grades","tremelimumab + durvalumab + platinum-based chemotherapy, Pyrexia, All grades","tremelimumab + durvalumab + platinum-based chemotherapy, Musculoskeletal Pain, All grades","tremelimumab + durvalumab + platinum-based chemotherapy, Decreased appetite, All grades","tremelimumab + durvalumab + platinum-based chemotherapy, Pneumonia, All grades","tremelimumab + durvalumab + platinum-based chemotherapy, Upper respiratory tract infections, All grades","tremelimumab + durvalumab + platinum-based chemotherapy, Headachek, All grades","tremelimumab + durvalumab + platinum-based chemotherapy, Rash, Grade 3-4","tremelimumab + durvalumab + platinum-based chemotherapy, Fatigue/Asthenia, Grade 3-4","tremelimumab + durvalumab + platinum-based chemotherapy, Decreased appetite, Grade 3-4","tremelimumab + durvalumab + platinum-based chemotherapy, Pneumonia, Grade 3-4","cemiplimab-rwlc + platinum-based chemotherapy, Rasha, All grades","cemiplimab-rwlc + platinum-based chemotherapy, Nausea, All grades","cemiplimab-rwlc + platinum-based chemotherapy, Constipation, All grades","cemiplimab-rwlc + platinum-based chemotherapy, Vomiting, All grades","cemiplimab-rwlc + platinum-based chemotherapy, Diarrhea, All grades","cemiplimab-rwlc + platinum-based chemotherapy, Fatigue, All grades","cemiplimab-rwlc + platinum-based chemotherapy, Peripheral neuropath, All grades","cemiplimab-rwlc + platinum-based chemotherapy, Decreased appetite, All grades","cemiplimab-rwlc + platinum-based chemotherapy, Weight decreased, All grades","cemiplimab-rwlc + platinum-based chemotherapy, Dyspneae, All grades","cemiplimab-rwlc + platinum-based chemotherapy, Insomnia, All grades","cemiplimab-rwlc + platinum-based chemotherapy, Rasha, Grade 3-4","cemiplimab-rwlc + platinum-based chemotherapy, Musculoskeletal pain, Grade 3-4","cemiplimab-rwlc + platinum-based chemotherapy, Constipation, Grade 3-4","cemiplimab-rwlc + platinum-based chemotherapy, Diarrhea, Grade 3-4","cemiplimab-rwlc + platinum-based chemotherapy, Fatigue, Grade 3-4","cemiplimab-rwlc + platinum-based chemotherapy, Decreased appetite, Grade 3-4","cemiplimab-rwlc + platinum-based chemotherapy, Weight decreased, Grade 3-4","cemiplimab-rwlc + platinum-based chemotherapy, Dyspneae, Grade 3-4","tremelimumab + durvalumab, Pruritus, All grades","tremelimumab + durvalumab, Pyrexia, All grades","tremelimumab + durvalumab, Insomnia, All grades","tremelimumab + durvalumab, Hypothyroidisml, All grades","tremelimumab + durvalumab, Musculoskeletal pain, All grades","tremelimumab + durvalumab, Diarrhea, Grade 3-4","tremelimumab + durvalumab, Decreased appetite, Grade 3-4","tremelimumab + durvalumab, Insomnia, Grade 3-4","tremelimumab + durvalumab, Musculoskeletal pain, Grade 3-4","durvalumab + gemcitabine + cisplatin, Pyrexia, All grades","durvalumab + gemcitabine + cisplatin, Nausea, All grades","durvalumab + gemcitabine + cisplatin, Constipation, All grades","durvalumab + gemcitabine + cisplatin, Abdominal pain, All grades","durvalumab + gemcitabine + cisplatin, Diarrhea, All grades","durvalumab + gemcitabine + cisplatin, Decreased appetite, All grades","durvalumab + gemcitabine + cisplatin, Rash, All grades","durvalumab + gemcitabine + cisplatin, Pruritus, All grades","durvalumab + gemcitabine + cisplatin, Pyrexia, Grade 3-4","durvalumab + gemcitabine + cisplatin, Constipation, Grade 3-4","durvalumab + gemcitabine + cisplatin, Decreased appetite, Grade 3-4","durvalumab + gemcitabine + cisplatin, Rash, Grade 3-4","darolutamide + docetaxel, Constipation, All grades","darolutamide + docetaxel, Decreased Appetite, All grades","darolutamide + docetaxel, Rash, All grades","darolutamide + docetaxel, Hemorrhage, All grades","darolutamide + docetaxel, Weight Increased, All grades","darolutamide + docetaxel, Hypertension, All grades","darolutamide + docetaxel, Rash, Grade 3-4","darolutamide + docetaxel, Weight Increased, Grade 3-4","darolutamide + docetaxel, Hypertension, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Nausea, All grades","fam-trastuzumab deruxtecan-nxki, Vomiting, All grades","fam-trastuzumab deruxtecan-nxki, Constipation, All grades","fam-trastuzumab deruxtecan-nxki, Diarrhea, All grades","fam-trastuzumab deruxtecan-nxki, Abdominal pain, All grades","fam-trastuzumab deruxtecan-nxki, Stomatitisb, All grades","fam-trastuzumab deruxtecan-nxki, Fatigue, All grades","fam-trastuzumab deruxtecan-nxki, Alopecia, All grades","fam-trastuzumab deruxtecan-nxki, Anemia, All grades","fam-trastuzumab deruxtecan-nxki, Decreased appetite, All grades","fam-trastuzumab deruxtecan-nxki, Musculoskeletal pain, All grades","fam-trastuzumab deruxtecan-nxki, Decreased weight, All grades","fam-trastuzumab deruxtecan-nxki, Hemorrhage, All grades","fam-trastuzumab deruxtecan-nxki, Headache, All grades","fam-trastuzumab deruxtecan-nxki, Dizziness, All grades","fam-trastuzumab deruxtecan-nxki, Upper respiratory tract infection, All grades","fam-trastuzumab deruxtecan-nxki, Interstitial lung disease, All grades","fam-trastuzumab deruxtecan-nxki, Dyspnea, All grades","fam-trastuzumab deruxtecan-nxki, Nausea, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Vomiting, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Constipation, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Abdominal pain, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Fatigue, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Pyrexia, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Anemia, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Decreased appetite, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Musculoskeletal pain, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Decreased weight, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Headache, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Dizziness, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Upper respiratory tract infection, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Interstitial lung disease, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Dyspnea, Grade 3-4","lisocabtagene maraleucel, Neutropenia, Grade 1–2","lisocabtagene maraleucel, Anaemia, Grade 1–2","lisocabtagene maraleucel, Cytokine release syndrome, Grade 1–2","lisocabtagene maraleucel, Headache, Grade 1–2","lisocabtagene maraleucel, Fatigue, Grade 1–2","lisocabtagene maraleucel, Constipation, Grade 1–2","lisocabtagene maraleucel, Pyrexia, Grade 1–2","lisocabtagene maraleucel, Lymphopenia, Grade 1–2","lisocabtagene maraleucel, Dizziness, Grade 1–2","lisocabtagene maraleucel, Insomnia, Grade 1–2","lisocabtagene maraleucel, Hypotension, Grade 1–2","lisocabtagene maraleucel, Leukopenia, Grade 1–2","lisocabtagene maraleucel, Febrile neutropenia, Grade 1–2","lisocabtagene maraleucel, Arthralg ia, Grade 1–2","lisocabtagene maraleucel, Cough, Grade 1–2","lisocabtagene maraleucel, Dyspnoea, Grade 1–2","lisocabtagene maraleucel, Bone pain, Grade 1–2","lisocabtagene maraleucel, Tremor, Grade 1–2","lisocabtagene maraleucel, Myalgia, Grade 1–2","lisocabtagene maraleucel, Asthenia, Grade 1–2","lisocabtagene maraleucel, Hypertension, Grade 1–2","lisocabtagene maraleucel, Neutropenia, Grade ≥ 3","lisocabtagene maraleucel, Cytokine release syndrome, Grade ≥ 3","lisocabtagene maraleucel, Prolonged cytopeniat, Grade ≥ 3","lisocabtagene maraleucel, Headache, Grade ≥ 3","lisocabtagene maraleucel, Constipation, Grade ≥ 3","lisocabtagene maraleucel, Lymphopenia, Grade ≥ 3","lisocabtagene maraleucel, Hypotension, Grade ≥ 3","lisocabtagene maraleucel, Peripheral oedema, Grade ≥ 3","lisocabtagene maraleucel, Leukopenia, Grade ≥ 3","lisocabtagene maraleucel, Abdominal pain, Grade ≥ 3","lisocabtagene maraleucel, Tremor, Grade ≥ 3","lisocabtagene maraleucel, Myalgia, Grade ≥ 3","lisocabtagene maraleucel, Asthenia, Grade ≥ 3","lisocabtagene maraleucel, Hypertension, Grade ≥ 3","ivosidenib + azacitidine, Nausea, All grades","ivosidenib + azacitidine, Vomiting, All grades","ivosidenib + azacitidine, Electrocardiogram QT prolonged, All grades","ivosidenib + azacitidine, Insomnia, All grades","ivosidenib + azacitidine, Differentiation Syndrome, All grades","ivosidenib + azacitidine, Leukocytosis, All grades","ivosidenib + azacitidine, Hematoma, All grades","ivosidenib + azacitidine, Hypertension, All grades","ivosidenib + azacitidine, Arthralgia, All grades","ivosidenib + azacitidine, Dyspnea, All grades","ivosidenib + azacitidine, Headache, All grades","ivosidenib + azacitidine, Electrocardiogram QT prolonged, Grade ≥ 3","ivosidenib + azacitidine, Insomnia, Grade ≥ 3","ivosidenib + azacitidine, Differentiation Syndrome, Grade ≥ 3","ivosidenib + azacitidine, Arthralgia, Grade ≥ 3","olaparib, Nausea, Grades 1-4","olaparib, Vomitin, Grades 1-4","olaparib, Diarrhea, Grades 1-4","olaparib, Stomatitis, Grades 1-4","olaparib, Fatigue (including asthenia) , Grades 1-4","olaparib, Anemia, Grades 1-4","olaparib, Leukopenia, Grades 1-4","olaparib, Neutropenia, Grades 1-4","olaparib, Headache, Grades 1-4","olaparib, Dysgeusia, Grades 1-4","olaparib, Dizziness, Grades 1-4","olaparib, Decreased appetite, Grades 1-4","olaparib, Nausea, Grade 3-4","olaparib, Vomitin, Grade 3-4","olaparib, Stomatitis, Grade 3-4","olaparib, Fatigue (including asthenia) , Grade 3-4","olaparib, Anemia, Grade 3-4","olaparib, Leukopenia, Grade 3-4","olaparib, Neutropenia, Grade 3-4","olaparib, Headache, Grade 3-4","olaparib, Decreased appetite, Grade 3-4","pembrolizumab, Hypothyroidism, All grades","pembrolizumab, Hyperthyroidism, All grades","pembrolizumab, Diarrhoea, All grades","pembrolizumab, Nausea, All grades","pembrolizumab, Fatigue, All grades","pembrolizumab, Asthenia, All grades","pembrolizumab, Arthralgia, All grades","pembrolizumab, Myalgia, All grades","pembrolizumab, Increased alanine aminotransferase, All grades","pembrolizumab, Increased aspartate aminotransferase, All grades","pembrolizumab, Pruritus, All grades","pembrolizumab, Rash, All grades","pembrolizumab, Rash maculopapular, All grades","pembrolizumab, Hyperthyroidism, Grade ≥ 3","pembrolizumab, Fatigue, Grade ≥ 3","pembrolizumab, Asthenia, Grade ≥ 3","pembrolizumab, Arthralgia, Grade ≥ 3","pembrolizumab, Myalgia, Grade ≥ 3","pembrolizumab, Pruritus, Grade ≥ 3","pembrolizumab, Rash maculopapular, Grade ≥ 3","pembrolizumab, Hypothyroidism, Adverse events of interest: Any grade","pembrolizumab, Hyperthyroidism, Adverse events of interest: Any grade","pembrolizumab, Colitis, Adverse events of interest: Any grade","pembrolizumab, Adrenal insufficiency, Adverse events of interest: Any grade","pembrolizumab, Hepatitis, Adverse events of interest: Any grade","pembrolizumab, Hypophysitis, Adverse events of interest: Any grade","pembrolizumab, Myasthenic syndrome, Adverse events of interest: Any grade","pembrolizumab, Myelitis, Adverse events of interest: Any grade","pembrolizumab, Myositis, Adverse events of interest: Any grade","pembrolizumab, Nephritis, Adverse events of interest: Any grade","pembrolizumab, Pancreatitis, Adverse events of interest: Any grade","pembrolizumab, Pneumonitis, Adverse events of interest: Any grade","pembrolizumab, Sarcoidosis, Adverse events of interest: Any grade","pembrolizumab, Severe skin reactions, Adverse events of interest: Any grade","pembrolizumab, Thyroiditis, Adverse events of interest: Any grade","pembrolizumab, Type 1 diabetes, Adverse events of interest: Any grade","pembrolizumab, Uveitis, Adverse events of interest: Any grade","pembrolizumab, Hyperthyroidism, Adverse events of interest: Grade ≥3","pembrolizumab, Colitis, Adverse events of interest: Grade ≥3","pembrolizumab, Adrenal insufficiency, Adverse events of interest: Grade ≥3","pembrolizumab, Hepatitis, Adverse events of interest: Grade ≥3","pembrolizumab, Hypophysitis, Adverse events of interest: Grade ≥3","pembrolizumab, Myasthenic syndrome, Adverse events of interest: Grade ≥3","pembrolizumab, Myelitis, Adverse events of interest: Grade ≥3","pembrolizumab, Myositis, Adverse events of interest: Grade ≥3","pembrolizumab, Nephritis, Adverse events of interest: Grade ≥3","pembrolizumab, Pancreatitis, Adverse events of interest: Grade ≥3","pembrolizumab, Pneumonitis, Adverse events of interest: Grade ≥3","pembrolizumab, Severe skin reactions, Adverse events of interest: Grade ≥3","pembrolizumab, Type 1 diabetes, Adverse events of interest: Grade ≥3","pembrolizumab, Musculoskeletal pain, All grades","pembrolizumab, Fatigue, All grades","pembrolizumab, Rash, All grades","pembrolizumab, Pruritus, All grades","pembrolizumab, Diarrhea, All grades","pembrolizumab, Nausea, All grades","pembrolizumab, Hypothyroidism, All grades","pembrolizumab, Hyperthyroidism , All grades","pembrolizumab, Cough, All grades","pembrolizumab, Headache, All grades","pembrolizumab, Hepatotoxicity, All grades","pembrolizumab, Acute kidney injury, All grades","pembrolizumab, Musculoskeletal pain, Grade 3-4","pembrolizumab, Fatigue, Grade 3-4","pembrolizumab, Rash, Grade 3-4","pembrolizumab, Pruritus, Grade 3-4","pembrolizumab, Diarrhea, Grade 3-4","pembrolizumab, Nausea, Grade 3-4","pembrolizumab, Abdominal, Grade 3-4","pembrolizumab, Hypothyroidism, Grade 3-4","pembrolizumab, Hyperthyroidism , Grade 3-4","pembrolizumab, Headache, Grade 3-4","pembrolizumab, Hepatotoxicity, Grade 3-4","pembrolizumab, Acute kidney injury, Grade 3-4","pembrolizumab + chemotherapy + (bevacizumab?), Peripheral neuropathy, All grades","pembrolizumab + chemotherapy + (bevacizumab?), Rash, All grades","pembrolizumab + chemotherapy + (bevacizumab?), Fatigue, All grades","pembrolizumab + chemotherapy + (bevacizumab?), Diarrhea, All grades","pembrolizumab + chemotherapy + (bevacizumab?), Arthralgia, All grades","pembrolizumab + chemotherapy + (bevacizumab?), Hypertension, All grades","pembrolizumab + chemotherapy + (bevacizumab?), Rash, Grade 3-4","pembrolizumab + chemotherapy + (bevacizumab?), Fatigue, Grade 3-4","pembrolizumab + chemotherapy + (bevacizumab?), Nausea, Grade 3-4","pembrolizumab + chemotherapy + (bevacizumab?), Vomiting, Grade 3-4","pembrolizumab + chemotherapy + (bevacizumab?), Urinary tract infection, Grade 3-4","cabozantinib, Diarrhea, All grades","cabozantinib, Nausea, All grades","cabozantinib, Vomitin, All grades","cabozantinib, Stomatitis, All grades","cabozantinib, Dry mouth, All grades","cabozantinib, Fatigue, All grades","cabozantinib, Decreased appetite, All grades","cabozantinib, Palmar-plantar erythrodysesthesia, All grades","cabozantinib, Hypertension, All grades","cabozantinib, Weight decreased, All grades","cabozantinib, Dysgeusia, All grades","cabozantinib, Headache, All grades","cabozantinib, Dysphonia, All grades","cabozantinib, Pulmonary embolism, All grades","cabozantinib, Proteinuria, All grades","cabozantinib, Diarrhea, Grade 3-4","cabozantinib, Nausea, Grade 3-4","cabozantinib, Vomitin, Grade 3-4","cabozantinib, Stomatitis, Grade 3-4","cabozantinib, Dry mouth, Grade 3-4","cabozantinib, Fatigue, Grade 3-4","cabozantinib, Decreased appetite, Grade 3-4","cabozantinib, Palmar-plantar erythrodysesthesia, Grade 3-4","cabozantinib, Hypertension, Grade 3-4","cabozantinib, Weight decreased, Grade 3-4","cabozantinib, Headache, Grade 3-4","cabozantinib, Pulmonary embolism, Grade 3-4","cabozantinib, Proteinuria, Grade 3-4","ivosidenib, Fatigue, All grades","ivosidenib, Nausea, All grades","ivosidenib, Diarrhea, All grades","ivosidenib, Abdominal pain, All grades","ivosidenib, Ascites, All grades","ivosidenib, Vomiting, All grades","ivosidenib, Cough, All grades","ivosidenib, Decreased appetite, All grades","ivosidenib, Anemia, All grades","ivosidenib, Rash, All grades","ivosidenib, Headache, All grades","ivosidenib, Neuropathy, All grades","ivosidenib, Ascites, Grade ≥ 3","ivosidenib, Vomiting, Grade ≥ 3","ivosidenib, Decreased appetite, Grade ≥ 3","ivosidenib, Anemia, Grade ≥ 3","ivosidenib, Rash, Grade ≥ 3","nivolumab, Rash, All grades","nivolumab, Pruritus, All grades","nivolumab, Fatigue/Asthenia, All grades","nivolumab, Diarrhea, All grades","nivolumab, Nausea, All grades","nivolumab, Musculoskeletal pain, All grades","nivolumab, Hyperthyroidism, All grades","nivolumab, Hypothyroidism, All grades","nivolumab, Renal dysfunction, All grades","nivolumab, Cough, All grades","nivolumab, Dyspnea, All grades","nivolumab, Decreased appetite, All grades","nivolumab, Dizziness, All grades","nivolumab, Hepatitis, All grades","nivolumab, Rash, Grade 3-4","nivolumab, Fatigue/Asthenia, Grade 3-4","nivolumab, Diarrhea, Grade 3-4","nivolumab, Nausea, Grade 3-4","nivolumab, Abdominal pain, Grade 3-4","nivolumab, Arthralgia, Grade 3-4","nivolumab, Renal dysfunction, Grade 3-4","nivolumab, Decreased appetite, Grade 3-4","nivolumab, Dizziness, Grade 3-4","nivolumab, Hepatitis, Grade 3-4","pembrolizumab + chemotherapy, Fatigue, All grades","pembrolizumab + chemotherapy, Pyrexia, All grades","pembrolizumab + chemotherapy, Nausea, All grades","pembrolizumab + chemotherapy, Constipation, All grades","pembrolizumab + chemotherapy, Diarrhea, All grades","pembrolizumab + chemotherapy, Stomatitis, All grades","pembrolizumab + chemotherapy, Vomiting, All grades","pembrolizumab + chemotherapy, Abdominal pain, All grades","pembrolizumab + chemotherapy, Alopecia, All grades","pembrolizumab + chemotherapy, Rash, All grades","pembrolizumab + chemotherapy, Headache, All grades","pembrolizumab + chemotherapy, Myalgia, All grades","pembrolizumab + chemotherapy, Cough, All grades","pembrolizumab + chemotherapy, Decreased appetite , All grades","pembrolizumab + chemotherapy, Insomnia, All grades","pembrolizumab + chemotherapy, Fatigue, Grade 3-4","pembrolizumab + chemotherapy, Pyrexia, Grade 3-4","pembrolizumab + chemotherapy, Nausea, Grade 3-4","pembrolizumab + chemotherapy, Diarrhea, Grade 3-4","pembrolizumab + chemotherapy, Stomatitis, Grade 3-4","pembrolizumab + chemotherapy, Vomiting, Grade 3-4","pembrolizumab + chemotherapy, Rash, Grade 3-4","pembrolizumab + chemotherapy, Peripheral neuropathy, Grade 3-4","pembrolizumab + chemotherapy, Arthralgia , Grade 3-4","pembrolizumab + chemotherapy, Myalgia, Grade 3-4","pembrolizumab + chemotherapy, Cough, Grade 3-4","pembrolizumab + chemotherapy, Decreased appetite , Grade 3-4","pembrolizumab + chemotherapy, Insomnia, Grade 3-4","nivolumab, Nausea, All grades","nivolumab, Fatigue, All grades","nivolumab, Rash, All grades","nivolumab, Pruritus, All grades","nivolumab, Weight decreased, All grades","nivolumab, Musculoskeletal pain, All grades","nivolumab, Arthralgia, All grades","nivolumab, Decreased appetite, All grades","nivolumab, Hypothyroidism, All grades","nivolumab, Diarrhea, Grade 3-4","nivolumab, Nausea, Grade 3-4","nivolumab, Dyspnea, Grade 3-4","nivolumab, Rash, Grade 3-4","nivolumab, Pruritus, Grade 3-4","nivolumab, Weight decreased, Grade 3-4","nivolumab, Arthralgia, Grade 3-4","nivolumab, Decreased appetite, Grade 3-4","pembrolizumab + chemotherapy, Nausea, All grades","pembrolizumab + chemotherapy, Diarrhea, All grades","pembrolizumab + chemotherapy, Vomiting, All grades","pembrolizumab + chemotherapy, Stomatitis, All grades","pembrolizumab + chemotherapy, Fatigue, All grades","pembrolizumab + chemotherapy, Decreased appetite, All grades","pembrolizumab + chemotherapy, Diarrhea, Grade 3-4","pembrolizumab + chemotherapy, Vomiting, Grade 3-4","pembrolizumab + chemotherapy, Stomatitis, Grade 3-4","pembrolizumab + chemotherapy, Fatigue, Grade 3-4","osimertinib, Diarrhea, All grades","osimertinib, Stomatitis, All grades","osimertinib, Abdominal Pain, All grades","osimertinib, Rash, All grades","osimertinib, Nail toxicity, All grades","osimertinib, Dry skin, All grades","osimertinib, Pruritus, All grades","osimertinib, Nasopharyngitis, All grades","osimertinib, Upper respiratory tract infection, All grades","osimertinib, Urinary Tract Infection, All grades","osimertinib, Fatigue, All grades","osimertinib, Dizziness, All grades","osimertinib, Decreased appetite, All grades","osimertinib, Diarrhea, Grade ≥ 3","osimertinib, Stomatitis, Grade ≥ 3","osimertinib, Abdominal Pain, Grade ≥ 3","osimertinib, Rash, Grade ≥ 3","osimertinib, Nail toxicity, Grade ≥ 3","osimertinib, Dry skin, Grade ≥ 3","osimertinib, Upper respiratory tract infection, Grade ≥ 3","osimertinib, Urinary Tract Infection, Grade ≥ 3","osimertinib, Fatigue, Grade ≥ 3","osimertinib, Decreased appetite, Grade ≥ 3","pembrolizumab + chemotherapy, Diarrhea, All grades","pembrolizumab + chemotherapy, Constipation, All grades","pembrolizumab + chemotherapy, Vomiting, All grades","pembrolizumab + chemotherapy, Rash, All grades","pembrolizumab + chemotherapy, Cough, All grades","pembrolizumab + chemotherapy, Decreased appetite, All grades","pembrolizumab + chemotherapy, Fatigue, Grade 3-4","pembrolizumab + chemotherapy, Constipation, Grade 3-4","pembrolizumab + chemotherapy, Rash, Grade 3-4","pembrolizumab + chemotherapy, Decreased appetite, Grade 3-4","venetoclax + azacitidine, Nausea, All grades","venetoclax + azacitidine, Diarrhea, All grades","venetoclax + azacitidine, Vomiting, All grades","venetoclax + azacitidine, Stomatitis, All grades","venetoclax + azacitidine, Abdominal pain, All grades","venetoclax + azacitidine, Febrile neutropenia, All grades","venetoclax + azacitidine, Musculoskeletal pain, All grades","venetoclax + azacitidine, Fatigue, All grades","venetoclax + azacitidine, Edemag, All grades","venetoclax + azacitidine, Hemorrhage, All grades","venetoclax + azacitidine, Hypotension, All grades","venetoclax + azacitidine, Decreased appetite, All grades","venetoclax + azacitidine, Rash, All grades","venetoclax + azacitidine, Sepsis (excluding fungal), All grades","venetoclax + azacitidine, Urinary tract infection, All grades","venetoclax + azacitidine, Dyspnean, All grades","venetoclax + azacitidine, Dizziness, All grades","venetoclax + azacitidine, Nausea, Grade 3-4","venetoclax + azacitidine, Diarrhea, Grade 3-4","venetoclax + azacitidine, Vomiting, Grade 3-4","venetoclax + azacitidine, Stomatitis, Grade 3-4","venetoclax + azacitidine, Abdominal pain, Grade 3-4","venetoclax + azacitidine, Febrile neutropenia, Grade 3-4","venetoclax + azacitidine, Musculoskeletal pain, Grade 3-4","venetoclax + azacitidine, Fatigue, Grade 3-4","venetoclax + azacitidine, Edemag, Grade 3-4","venetoclax + azacitidine, Hemorrhage, Grade 3-4","venetoclax + azacitidine, Hypotension, Grade 3-4","venetoclax + azacitidine, Decreased appetite, Grade 3-4","venetoclax + azacitidine, Rash, Grade 3-4","venetoclax + azacitidine, Sepsis (excluding fungal), Grade 3-4","venetoclax + azacitidine, Dyspnean, Grade 3-4","azacitidine, Nausea, All grades","azacitidine, Vomiting, All grades","azacitidine, Diarrhea, All grades","azacitidine, Constipation, All grades","azacitidine, Abdominal pain, All grades","azacitidine, Fatigue / astheniab, All grades","azacitidine, Pneumoniac, All grades","azacitidine, Arthralgia, All grades","azacitidine, Pain in extremity, All grades","azacitidine, Decreased appetite, All grades","azacitidine, Febrile neutropenia, All grades","azacitidine, Dizziness, All grades","azacitidine, Nausea, TYPO","azacitidine, Vomiting, TYPO","azacitidine, Diarrhea, TYPO","azacitidine, Constipation, TYPO","azacitidine, Abdominal pain, TYPO","azacitidine, Fatigue / astheniab, TYPO","azacitidine, Pneumoniac, TYPO","azacitidine, Pain in extremity, TYPO","azacitidine, Febrile neutropenia, TYPO","atezolizumab +  cobimetinib + vemurafenib, Rash, All grades","atezolizumab +  cobimetinib + vemurafenib, Pruritus, All grades","atezolizumab +  cobimetinib + vemurafenib, Fatigue, All grades","atezolizumab +  cobimetinib + vemurafenib, Pyrexia, All grades","atezolizumab +  cobimetinib + vemurafenib, Edema, All grades","atezolizumab +  cobimetinib + vemurafenib, Hepatotoxicity, All grades","atezolizumab +  cobimetinib + vemurafenib, Stomatitis, All grades","atezolizumab +  cobimetinib + vemurafenib, Musculoskeletal pain, All grades","atezolizumab +  cobimetinib + vemurafenib, Hypothyroidism, All grades","atezolizumab +  cobimetinib + vemurafenib, Hyperthyroidism, All grades","atezolizumab +  cobimetinib + vemurafenib, Infusion related reaction, All grades","atezolizumab +  cobimetinib + vemurafenib, Pneumonitis, All grades","atezolizumab +  cobimetinib + vemurafenib, Rash, Grade 3-4","atezolizumab +  cobimetinib + vemurafenib, Fatigue, Grade 3-4","atezolizumab +  cobimetinib + vemurafenib, Edema, Grade 3-4","atezolizumab +  cobimetinib + vemurafenib, Hepatotoxicity, Grade 3-4","atezolizumab +  cobimetinib + vemurafenib, Stomatitis, Grade 3-4","atezolizumab +  cobimetinib + vemurafenib, Musculoskeletal pain, Grade 3-4","atezolizumab +  cobimetinib + vemurafenib, Hyperthyroidism, Grade 3-4","atezolizumab +  cobimetinib + vemurafenib, Infusion related reaction, Grade 3-4","atezolizumab +  cobimetinib + vemurafenib, Pneumonitis, Grade 3-4","atezolizumab +  cobimetinib + vemurafenib, Hypertension, Grade 3-4","ramucirumab + erlotinib, Infectionsa b, All grades","ramucirumab + erlotinib, Hypertension, All grades","ramucirumab + erlotinib, Stomatitis, All grades","ramucirumab + erlotinib, Gastrointestinal hemorrhage, All grades","ramucirumab + erlotinib, Gingival bleeding, All grades","ramucirumab + erlotinib, Proteinuria, All grades","ramucirumab + erlotinib, Alopecia, All grades","ramucirumab + erlotinib, Epistaxis, All grades","ramucirumab + erlotinib, Pulmonary hemorrhageq, All grades","ramucirumab + erlotinib, Peripheral edema, All grades","ramucirumab + erlotinib, Headache, All grades","ramucirumab + erlotinib, Infectionsa b, Grade ≥ 3","ramucirumab + erlotinib, Hypertension, Grade ≥ 3","ramucirumab + erlotinib, Diarrhea, Grade ≥ 3","ramucirumab + erlotinib, Stomatitis, Grade ≥ 3","ramucirumab + erlotinib, Proteinuria, Grade ≥ 3","ramucirumab + erlotinib, Peripheral edema, Grade ≥ 3","ramucirumab + erlotinib, Headache, Grade ≥ 3","ripretinib, Alopecia, Grades 1-4","ripretinib, Palmar-plantar erythrodysesthesia syndrome, Grades 1-4","ripretinib, Dry skin, Grades 1-4","ripretinib, Pruritus, Grades 1-4","ripretinib, Fatigue, Grades 1-4","ripretinib, Peripheral edema, Grades 1-4","ripretinib, Nausea, Grades 1-4","ripretinib, Abdominal pain, Grades 1-4","ripretinib, Constipation, Grades 1-4","ripretinib, Diarrhea, Grades 1-4","ripretinib, Vomiting, Grades 1-4","ripretinib, Stomatitis, Grades 1-4","ripretinib, Myalgia, Grades 1-4","ripretinib, Arthralgia, Grades 1-4","ripretinib, Muscle spasms, Grades 1-4","ripretinib, Decreased appetite, Grades 1-4","ripretinib, Decreased weight, Grades 1-4","ripretinib, Headache, Grades 1-4","ripretinib, Hypertension, Grades 1-4","ripretinib, Dyspnea, Grades 1-4","ripretinib, Fatigue, Grade 3-4","ripretinib, Peripheral edema, Grade 3-4","ripretinib, Nausea, Grade 3-4","ripretinib, Abdominal pain, Grade 3-4","ripretinib, Constipation, Grade 3-4","ripretinib, Vomiting, Grade 3-4","ripretinib, Myalgia, Grade 3-4","ripretinib, Hypertension, Grade 3-4","olaparib + bevacizumab, Fatigue (including asthenia), Grades 1-4","olaparib + bevacizumab, Nausea, Grades 1-4","olaparib + bevacizumab, Vomiting, Grades 1-4","olaparib + bevacizumab, Anemia, Grades 1-4","olaparib + bevacizumab, Lymphopenia, Grades 1-4","olaparib + bevacizumab, Leukopenia, Grades 1-4","olaparib + bevacizumab, Fatigue (including asthenia), TYPO","olaparib + bevacizumab, Nausea, TYPO","olaparib + bevacizumab, Anemia, TYPO","olaparib + bevacizumab, Lymphopenia, TYPO","olaparib + bevacizumab, Leukopenia, TYPO","niraparib, Thrombocytopenia, Grades 1-4","niraparib, Anemia, Grades 1-4","niraparib, Neutropenia, Grades 1-4","niraparib, Leukopenia, Grades 1-4","niraparib, Nausea, Grades 1-4","niraparib, Constipation, Grades 1-4","niraparib, Vomiting, Grades 1-4","niraparib, Fatigue, Grades 1-4","niraparib, AST/ALT elevation, Grades 1-4","niraparib, Decreased appetite, Grades 1-4","niraparib, Musculoskeletal pain, Grades 1-4","niraparib, Headache, Grades 1-4","niraparib, Dizziness, Grades 1-4","niraparib, Insomnia, Grades 1-4","niraparib, Acute kidney injury, Grades 1-4","niraparib, Dyspnea, Grades 1-4","niraparib, Cough, Grades 1-4","niraparib, Hypertension, Grades 1-4","niraparib, Thrombocytopenia, Grade 3-4","niraparib, Anemia, Grade 3-4","niraparib, Neutropenia, Grade 3-4","niraparib, Leukopenia, Grade 3-4","niraparib, Constipation, Grade 3-4","niraparib, Fatigue, Grade 3-4","niraparib, AST/ALT elevation, Grade 3-4","niraparib, Decreased appetite, Grade 3-4","niraparib, Musculoskeletal pain, Grade 3-4","niraparib, Headache, Grade 3-4","niraparib, Insomnia, Grade 3-4","niraparib, Acute kidney injury, Grade 3-4","niraparib, Hypertension, Grade 3-4","tucatinib + trastuzumab + capecitabine, Diarrhea, All grades","tucatinib + trastuzumab + capecitabine, Nausea, All grades","tucatinib + trastuzumab + capecitabine, Vomiting, All grades","tucatinib + trastuzumab + capecitabine, Stomatitis, All grades","tucatinib + trastuzumab + capecitabine, Palmar-plantar erythrodysesthesia syndrome, All grades","tucatinib + trastuzumab + capecitabine, Rash, All grades","tucatinib + trastuzumab + capecitabine, Hepatotoxicity, All grades","tucatinib + trastuzumab + capecitabine, Decreased appetite, All grades","tucatinib + trastuzumab + capecitabine, Anemia, All grades","tucatinib + trastuzumab + capecitabine, Arthralgia, All grades","tucatinib + trastuzumab + capecitabine, Creatinine increased, All grades","tucatinib + trastuzumab + capecitabine, Weight decreased, All grades","tucatinib + trastuzumab + capecitabine, Peripheral neuropathy, All grades","tucatinib + trastuzumab + capecitabine, Epistaxis, All grades","tucatinib + trastuzumab + capecitabine, Diarrhea, Grade 3","tucatinib + trastuzumab + capecitabine, Nausea, Grade 3","tucatinib + trastuzumab + capecitabine, Stomatitis, Grade 3","tucatinib + trastuzumab + capecitabine, Palmar-plantar erythrodysesthesia syndrome, Grade 3","tucatinib + trastuzumab + capecitabine, Rash, Grade 3","tucatinib + trastuzumab + capecitabine, Hepatotoxicity, Grade 3","tucatinib + trastuzumab + capecitabine, Decreased appetite, Grade 3","tucatinib + trastuzumab + capecitabine, Anemia, Grade 3","tucatinib + trastuzumab + capecitabine, Weight decreased, Grade 3","tucatinib + trastuzumab + capecitabine, Diarrhea, Grade 4","tucatinib + trastuzumab + capecitabine, Hepatotoxicity, Grade 4","nivolumab + chemotherapy, Nausea, All grades","nivolumab + chemotherapy, Constipation, All grades","nivolumab + chemotherapy, Stomatitis, All grades","nivolumab + chemotherapy, Diarrhea, All grades","nivolumab + chemotherapy, Vomiting, All grades","nivolumab + chemotherapy, Dysphagia, All grades","nivolumab + chemotherapy, Abdominal pain, All grades","nivolumab + chemotherapy, Decreased appetite, All grades","nivolumab + chemotherapy, Fatigue, All grades","nivolumab + chemotherapy, Pyrexiad, All grades","nivolumab + chemotherapy, Edemae, All grades","nivolumab + chemotherapy, Peripheral neuropathy, All grades","nivolumab + chemotherapy, Insomnia, All grades","nivolumab + chemotherapy, Rash, All grades","nivolumab + chemotherapy, Pruritus, All grades","nivolumab + chemotherapy, Cough, All grades","nivolumab + chemotherapy, Pneumonial, All grades","nivolumab + chemotherapy, Hypothyroidism, All grades","nivolumab + chemotherapy, Weight decreased, All grades","nivolumab + chemotherapy, Musculoskeletal pain, All grades","nivolumab + chemotherapy, Nausea, Grade 3-4","nivolumab + chemotherapy, Stomatitis, Grade 3-4","nivolumab + chemotherapy, Diarrhea, Grade 3-4","nivolumab + chemotherapy, Dysphagia, Grade 3-4","nivolumab + chemotherapy, Abdominal pain, Grade 3-4","nivolumab + chemotherapy, Decreased appetite, Grade 3-4","nivolumab + chemotherapy, Peripheral neuropathy, Grade 3-4","nivolumab + chemotherapy, Rash, Grade 3-4","nivolumab + chemotherapy, Pneumonial, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Nausea, All grades","fam-trastuzumab deruxtecan-nxki, Vomiting, All grades","fam-trastuzumab deruxtecan-nxki, Constipation, All grades","fam-trastuzumab deruxtecan-nxki, Diarrhea, All grades","fam-trastuzumab deruxtecan-nxki, Abdominal paina, All grades","fam-trastuzumab deruxtecan-nxki, Stomatitisb, All grades","fam-trastuzumab deruxtecan-nxki, Dyspepsia, All grades","fam-trastuzumab deruxtecan-nxki, Fatigue, All grades","fam-trastuzumab deruxtecan-nxki, Anemia, All grades","fam-trastuzumab deruxtecan-nxki, Alopeciae, All grades","fam-trastuzumab deruxtecan-nxki, Musculoskeletal pain, All grades","fam-trastuzumab deruxtecan-nxki, Decreased appetite, All grades","fam-trastuzumab deruxtecan-nxki, Decreased weight, All grades","fam-trastuzumab deruxtecan-nxki, Respiratory infectiong, All grades","fam-trastuzumab deruxtecan-nxki, Cough, All grades","fam-trastuzumab deruxtecan-nxki, Interstitial lung disease, All grades","fam-trastuzumab deruxtecan-nxki, Headache, All grades","fam-trastuzumab deruxtecan-nxki, Dizziness, All grades","fam-trastuzumab deruxtecan-nxki, Nausea, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Vomiting, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Diarrhea, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Abdominal paina, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Stomatitisb, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Fatigue, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Anemia, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Alopeciae, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Musculoskeletal pain, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Decreased appetite, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Decreased weight, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Cough, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Interstitial lung disease, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Headache, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Dizziness, Grade 3-4","lutetium Lu 177 vipivotide tetraxetan + standard of care, Fatigue, All grades","lutetium Lu 177 vipivotide tetraxetan + standard of care, Decreased appetite, All grades","lutetium Lu 177 vipivotide tetraxetan + standard of care, Weight decreased, All grades","lutetium Lu 177 vipivotide tetraxetan + standard of care, Peripheral edema, All grades","lutetium Lu 177 vipivotide tetraxetan + standard of care, Pyrexia, All grades","lutetium Lu 177 vipivotide tetraxetan + standard of care, Dry mouth, All grades","lutetium Lu 177 vipivotide tetraxetan + standard of care, Nausea, All grades","lutetium Lu 177 vipivotide tetraxetan + standard of care, Constipation, All grades","lutetium Lu 177 vipivotide tetraxetan + standard of care, Vomiting, All grades","lutetium Lu 177 vipivotide tetraxetan + standard of care, Diarrhea, All grades","lutetium Lu 177 vipivotide tetraxetan + standard of care, Abdominal pain, All grades","lutetium Lu 177 vipivotide tetraxetan + standard of care, Anemia, All grades","lutetium Lu 177 vipivotide tetraxetan + standard of care, Thrombocytopenia, All grades","lutetium Lu 177 vipivotide tetraxetan + standard of care, Urinary tract infection, All grades","lutetium Lu 177 vipivotide tetraxetan + standard of care, Acute kidney injury, All grades","lutetium Lu 177 vipivotide tetraxetan + standard of care, Dizziness, All grades","lutetium Lu 177 vipivotide tetraxetan + standard of care, Headache, All grades","lutetium Lu 177 vipivotide tetraxetan + standard of care, Dysgeusia, All grades","lutetium Lu 177 vipivotide tetraxetan + standard of care, Fatigue, Grade 3-4","lutetium Lu 177 vipivotide tetraxetan + standard of care, Decreased appetite, Grade 3-4","lutetium Lu 177 vipivotide tetraxetan + standard of care, Weight decreased, Grade 3-4","lutetium Lu 177 vipivotide tetraxetan + standard of care, Pyrexia, Grade 3-4","lutetium Lu 177 vipivotide tetraxetan + standard of care, Nausea, Grade 3-4","lutetium Lu 177 vipivotide tetraxetan + standard of care, Constipation, Grade 3-4","lutetium Lu 177 vipivotide tetraxetan + standard of care, Vomiting, Grade 3-4","lutetium Lu 177 vipivotide tetraxetan + standard of care, Diarrhea, Grade 3-4","lutetium Lu 177 vipivotide tetraxetan + standard of care, Abdominal pain, Grade 3-4","lutetium Lu 177 vipivotide tetraxetan + standard of care, Anemia, Grade 3-4","lutetium Lu 177 vipivotide tetraxetan + standard of care, Thrombocytopenia, Grade 3-4","lutetium Lu 177 vipivotide tetraxetan + standard of care, Urinary tract infection, Grade 3-4","lutetium Lu 177 vipivotide tetraxetan + standard of care, Acute kidney injury, Grade 3-4","lutetium Lu 177 vipivotide tetraxetan + standard of care, Dizziness, Grade 3-4","lutetium Lu 177 vipivotide tetraxetan + standard of care, Headache, Grade 3-4","relatlimab-rmbw +nivolumab, Musculoskeletal pain, All grades","relatlimab-rmbw +nivolumab, Fatigue, All grades","relatlimab-rmbw +nivolumab, Rash, All grades","relatlimab-rmbw +nivolumab, Pruritus, All grades","relatlimab-rmbw +nivolumab, Diarrhea, All grades","relatlimab-rmbw +nivolumab, Nausea, All grades","relatlimab-rmbw +nivolumab, Headache, All grades","relatlimab-rmbw +nivolumab, Hypothyroidisma, All grades","relatlimab-rmbw +nivolumab, Decreased appetite, All grades","relatlimab-rmbw +nivolumab, Cough, All grades","relatlimab-rmbw +nivolumab, Musculoskeletal pain, Grade 3-4","relatlimab-rmbw +nivolumab, Fatigue, Grade 3-4","relatlimab-rmbw +nivolumab, Diarrhea, Grade 3-4","relatlimab-rmbw +nivolumab, Nausea, Grade 3-4","relatlimab-rmbw +nivolumab, Decreased appetite, Grade 3-4","relatlimab-rmbw +nivolumab, Cough, Grade 3-4","nivolumab + platinum-doublet chemotherapy, Constipation, All grades","nivolumab + platinum-doublet chemotherapy, Fatigue, All grades","nivolumab + platinum-doublet chemotherapy, Malaise, All grades","nivolumab + platinum-doublet chemotherapy, Rash, All grades","nivolumab + platinum-doublet chemotherapy, Peripheral neuropathy, All grades","nivolumab + platinum-doublet chemotherapy, Vomiting, Grade 3-4","nivolumab + platinum-doublet chemotherapy, Fatigue, Grade 3-4","nivolumab + platinum-doublet chemotherapy, Rash, Grade 3-4","tebentafusp-tebn, Cytokine release syndrome, All grades","tebentafusp-tebn, Rash, All grades","tebentafusp-tebn, Pruritus, All grades","tebentafusp-tebn, Dry skin, All grades","tebentafusp-tebn, Skin Hypopigmentation, All grades","tebentafusp-tebn, Erythema, All grades","tebentafusp-tebn, Hair color changes, All grades","tebentafusp-tebn, Pyrexia, All grades","tebentafusp-tebn, Fatigue, All grades","tebentafusp-tebn, Chills, All grades","tebentafusp-tebn, Edemab, All grades","tebentafusp-tebn, Nausea, All grades","tebentafusp-tebn, Abdominal pain, All grades","tebentafusp-tebn, Vomiting, All grades","tebentafusp-tebn, Diarrhea, All grades","tebentafusp-tebn, Hypotension, All grades","tebentafusp-tebn, Headache, All grades","tebentafusp-tebn, Arthralgia, All grades","tebentafusp-tebn, Cytokine release syndrome, Grade 3-4","tebentafusp-tebn, Rash, Grade 3-4","tebentafusp-tebn, Pruritus, Grade 3-4","tebentafusp-tebn, Pyrexia, Grade 3-4","tebentafusp-tebn, Fatigue, Grade 3-4","tebentafusp-tebn, Chills, Grade 3-4","tebentafusp-tebn, Nausea, Grade 3-4","tebentafusp-tebn, Vomiting, Grade 3-4","tebentafusp-tebn, Hypotension, Grade 3-4","tebentafusp-tebn, Arthralgia, Grade 3-4","asciminib, Upper respiratory tract infection, All grades","asciminib, Musculoskeletal pain, All grades","asciminib, Arthralgia, All grades","asciminib, Headache, All grades","asciminib, Fatigue, All grades","asciminib, Hypertension, All grades","asciminib, Musculoskeletal pain, Grade 3-4","asciminib, Headache, Grade 3-4","asciminib, Hypertension, Grade 3-4","asciminib, Nausea, Grade 3-4","atezolizumab, Rash, All grades","atezolizumab, Pruritus, All grades","atezolizumab, Hypothyroidism, All grades","atezolizumab, Cough, All grades","atezolizumab, Pyrexia, All grades","atezolizumab, Fatigue, All grades","atezolizumab, Peripheral neuropathy, All grades","atezolizumab, Musculoskeletal pain, All grades","atezolizumab, Arthralgia, All grades","atezolizumab, Rash, Grade 3-4","atezolizumab, Pyrexia, Grade 3-4","atezolizumab, Fatigue, Grade 3-4","atezolizumab, Peripheral neuropathy, Grade 3-4","atezolizumab, Musculoskeletal pain, Grade 3-4","atezolizumab, Arthralgia, Grade 3-4","abemaciclib + endocrine therapy, Diarrhea, All grades","abemaciclib + endocrine therapy, Nausea, All grades","abemaciclib + endocrine therapy, Vomiting, All grades","abemaciclib + endocrine therapy, Stomatitis, All grades","abemaciclib + endocrine therapy, Infections, All grades","abemaciclib + endocrine therapy, Fatigue, All grades","abemaciclib + endocrine therapy, Headache, All grades","abemaciclib + endocrine therapy, Dizziness, All grades","abemaciclib + endocrine therapy, Decreased appetite, All grades","abemaciclib + endocrine therapy, Rash, All grades","abemaciclib + endocrine therapy, Alopecia, All grades","abemaciclib + endocrine therapy, Diarrhea, Grade 3","abemaciclib + endocrine therapy, Nausea, Grade 3","abemaciclib + endocrine therapy, Vomiting, Grade 3","abemaciclib + endocrine therapy, Stomatitis, Grade 3","abemaciclib + endocrine therapy, Infections, Grade 3","abemaciclib + endocrine therapy, Fatigue, Grade 3","abemaciclib + endocrine therapy, Headache, Grade 3","abemaciclib + endocrine therapy, Decreased appetite, Grade 3","abemaciclib + endocrine therapy, Rash, Grade 3","abemaciclib + endocrine therapy, Infections, Grade 4","ruxolitinib, Infections (pathogen not specified), All grades","ruxolitinib, Viral infections, All grades","ruxolitinib, Musculoskeletal pain, All grades","ruxolitinib, Pyrexia, All grades","ruxolitinib, Fatigue, All grades","ruxolitinib, Hypertension, All grades","ruxolitinib, Cough, All grades","ruxolitinib, Dyspnea, All grades","ruxolitinib, Musculoskeletal pain, Grade ≥ 3","ruxolitinib, Pyrexia, Grade ≥ 3","zanubrutinib, Upper respiratory tract infection, All grades","zanubrutinib, Nausea, All grades","zanubrutinib, Constipation, All grades","zanubrutinib, Fatigue, All grades","zanubrutinib, Pyrexia, All grades","zanubrutinib, Pruritus, All grades","zanubrutinib, Musculoskeletal am, All grades","zanubrutinib, Headache, All grades","zanubrutinib, Dizziness, All grades","zanubrutinib, Dyspnea, All grades","zanubrutinib, Diarrhea, Grade 3-4","zanubrutinib, Pyrexia, Grade 3-4","zanubrutinib, Pruritus, Grade 3-4","zanubrutinib, Musculoskeletal am, Grade 3-4","zanubrutinib, Dizziness, Grade 3-4","lenvatinib + pembrolizumab, Fatigue, All Grades","lenvatinib + pembrolizumab, Diarrhea, All Grades","lenvatinib + pembrolizumab, Nausea, All Grades","lenvatinib + pembrolizumab, Abdominal pain, All Grades","lenvatinib + pembrolizumab, Vomiting, All Grades","lenvatinib + pembrolizumab, Constipation, All Grades","lenvatinib + pembrolizumab, Musculoskeletal pain, All Grades","lenvatinib + pembrolizumab, Hypothyroidism, All Grades","lenvatinib + pembrolizumab, Hypertension, All Grades","lenvatinib + pembrolizumab, Hemorrhagic events, All Grades","lenvatinib + pembrolizumab, Decreased appetite, All Grades","lenvatinib + pembrolizumab, Rash, All Grades","lenvatinib + pembrolizumab, Dysphonia, All Grades","lenvatinib + pembrolizumab, Proteinuria, All Grades","lenvatinib + pembrolizumab, Acute kidney injury, All Grades","lenvatinib + pembrolizumab, Weight decreased , All Grades","lenvatinib + pembrolizumab, Hepatotoxicity, All Grades","lenvatinib + pembrolizumab, Headache, All Grades","lenvatinib + pembrolizumab, Fatigue, Grade 3-4","lenvatinib + pembrolizumab, Diarrhea, Grade 3-4","lenvatinib + pembrolizumab, Nausea, Grade 3-4","lenvatinib + pembrolizumab, Abdominal pain, Grade 3-4","lenvatinib + pembrolizumab, Vomiting, Grade 3-4","lenvatinib + pembrolizumab, Constipation, Grade 3-4","lenvatinib + pembrolizumab, Musculoskeletal pain, Grade 3-4","lenvatinib + pembrolizumab, Hypothyroidism, Grade 3-4","lenvatinib + pembrolizumab, Hypertension, Grade 3-4","lenvatinib + pembrolizumab, Hemorrhagic events, Grade 3-4","lenvatinib + pembrolizumab, Decreased appetite, Grade 3-4","lenvatinib + pembrolizumab, Rash, Grade 3-4","lenvatinib + pembrolizumab, Proteinuria, Grade 3-4","lenvatinib + pembrolizumab, Acute kidney injury, Grade 3-4","lenvatinib + pembrolizumab, Weight decreased , Grade 3-4","lenvatinib + pembrolizumab, Hepatotoxicity, Grade 3-4","pembrolizumab + lenvatinib, Hypothyroidism, All Grades","pembrolizumab + lenvatinib, Hypertension, All Grades","pembrolizumab + lenvatinib, Hemorrhagic events, All Grades","pembrolizumab + lenvatinib, Fatigue, All Grades","pembrolizumab + lenvatinib, Diarrhea, All Grades","pembrolizumab + lenvatinib, Nausea, All Grades","pembrolizumab + lenvatinib, Vomiting, All Grades","pembrolizumab + lenvatinib, Stomatitis, All Grades","pembrolizumab + lenvatinib, Abdominal pain, All Grades","pembrolizumab + lenvatinib, Constipation, All Grades","pembrolizumab + lenvatinib, Musculoskeletal disorders, All Grades","pembrolizumab + lenvatinib, Decreased appetite, All Grades","pembrolizumab + lenvatinib, Decreased weight, All Grades","pembrolizumab + lenvatinib, Proteinuria, All Grades","pembrolizumab + lenvatinib, Urinary tract infection, All Grades","pembrolizumab + lenvatinib, Headache, All Grades","pembrolizumab + lenvatinib, Dysphonia, All Grades","pembrolizumab + lenvatinib, Palmar-plantar erythrodysesthesia, All Grades","pembrolizumab + lenvatinib, Rash, All Grades","pembrolizumab + lenvatinib, Hypothyroidism, Grade 3-4","pembrolizumab + lenvatinib, Hypertension, Grade 3-4","pembrolizumab + lenvatinib, Hemorrhagic events, Grade 3-4","pembrolizumab + lenvatinib, Fatigue, Grade 3-4","pembrolizumab + lenvatinib, Diarrhea, Grade 3-4","pembrolizumab + lenvatinib, Nausea, Grade 3-4","pembrolizumab + lenvatinib, Vomiting, Grade 3-4","pembrolizumab + lenvatinib, Stomatitis, Grade 3-4","pembrolizumab + lenvatinib, Abdominal pain, Grade 3-4","pembrolizumab + lenvatinib, Musculoskeletal disorders, Grade 3-4","pembrolizumab + lenvatinib, Decreased appetite, Grade 3-4","pembrolizumab + lenvatinib, Decreased weight, Grade 3-4","pembrolizumab + lenvatinib, Proteinuria, Grade 3-4","pembrolizumab + lenvatinib, Urinary tract infection, Grade 3-4","pembrolizumab + lenvatinib, Headache, Grade 3-4","pembrolizumab + lenvatinib, Palmar-plantar erythrodysesthesia, Grade 3-4","pembrolizumab + lenvatinib, Rash, Grade 3-4","daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Fatigue, All Grades","daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Pyrexia, All Grades","daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Edema peripheral, All Grades","daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Pneumonia, All Grades","daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Upper respiratory infection, All Grades","daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Diarrhea, All Grades","daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Cough, All Grades","daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Fatigue, Grade ≥ 3","daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Pneumonia, Grade ≥ 3","daratumumab + hyaluronidase-fihj + pomalidomide + dexamethasone, Diarrhea, Grade ≥ 3","nivolumab + chemotherapy, Peripheral neuropathy, All Grades","nivolumab + chemotherapy, Headache, All Grades","nivolumab + chemotherapy, Nausea, All Grades","nivolumab + chemotherapy, Diarrhea, All Grades","nivolumab + chemotherapy, Vomiting, All Grades","nivolumab + chemotherapy, Abdominal pain, All Grades","nivolumab + chemotherapy, Constipation, All Grades","nivolumab + chemotherapy, Stomatitisc, All Grades","nivolumab + chemotherapy, Fatigue, All Grades","nivolumab + chemotherapy, Pyrexia, All Grades","nivolumab + chemotherapy, Edema, All Grades","nivolumab + chemotherapy, Decreased appetite, All Grades","nivolumab + chemotherapy, Hypoalbuminemia, All Grades","nivolumab + chemotherapy, Weight decreased, All Grades","nivolumab + chemotherapy, Increased lipase, All Grades","nivolumab + chemotherapy, Increased amylase, All Grades","nivolumab + chemotherapy, Musculoskeletal pain, All Grades","nivolumab + chemotherapy, Rash, All Grades","nivolumab + chemotherapy, Palmar-plantar erythrodysesthesia syndrome, All Grades","nivolumab + chemotherapy, Cough, All Grades","nivolumab + chemotherapy, Upper respiratory tract infection, All Grades","sacituzumab govitecan, Neutropenia, All Grades","sacituzumab govitecan, Anemia, All Grades","sacituzumab govitecan, Leukopenia, All Grades","sacituzumab govitecan, Lymphopenia, All Grades","sacituzumab govitecan, Diarrhea, All Grades","sacituzumab govitecan, Nausea, All Grades","sacituzumab govitecan, Vomiting, All Grades","sacituzumab govitecan, Constipation, All Grades","sacituzumab govitecan, Abdominal Pain, All Grades","sacituzumab govitecan, Stomatitisv, All Grades","sacituzumab govitecan, Fatigue, All Grades","sacituzumab govitecan, Pyrexia, All Grades","sacituzumab govitecan, Urinary tract infection, All Grades","sacituzumab govitecan, Upper respiratory tract infection, All Grades","sacituzumab govitecan, Alanine aminotransferase increased, All Grades","sacituzumab govitecan, Decreased appetite, All Grades","sacituzumab govitecan, Hypokalemia, All Grades","sacituzumab govitecan, Hypomagnesaemia, All Grades","sacituzumab govitecan, Back pain, All Grades","sacituzumab govitecan, Arthralgia, All Grades","sacituzumab govitecan, Headache, All Grades","sacituzumab govitecan, Dizziness, All Grades","sacituzumab govitecan, Insomnia, All Grades","sacituzumab govitecan, Cough, All Grades","sacituzumab govitecan, Alopecia, All Grades","sacituzumab govitecan, Rash, All Grades","sacituzumab govitecan, Pruritus, All Grades","sacituzumab govitecan, Neutropenia, Grade 3-4","sacituzumab govitecan, Anemia, Grade 3-4","sacituzumab govitecan, Leukopenia, Grade 3-4","sacituzumab govitecan, Diarrhea, Grade 3-4","sacituzumab govitecan, Nausea, Grade 3-4","sacituzumab govitecan, Vomiting, Grade 3-4","sacituzumab govitecan, Constipation, Grade 3-4","sacituzumab govitecan, Abdominal Pain, Grade 3-4","sacituzumab govitecan, Stomatitisv, Grade 3-4","sacituzumab govitecan, Decreased appetite, Grade 3-4","sacituzumab govitecan, Hypokalemia, Grade 3-4","sacituzumab govitecan, Arthralgia, Grade 3-4","sacituzumab govitecan, Headache, Grade 3-4","isatuximab-irfc + Carfilzomib + Dexamethasone, Infusion-related reaction, All Grades","isatuximab-irfc + Carfilzomib + Dexamethasone, Upper respiratory tract infection, All Grades","isatuximab-irfc + Carfilzomib + Dexamethasone, Pneumonia, All Grades","isatuximab-irfc + Carfilzomib + Dexamethasone, Bronchitis, All Grades","isatuximab-irfc + Carfilzomib + Dexamethasone, Hypertension, All Grades","isatuximab-irfc + Carfilzomib + Dexamethasone, Dyspnea, All Grades","isatuximab-irfc + Carfilzomib + Dexamethasone, Cough, All Grades","isatuximab-irfc + Carfilzomib + Dexamethasone, Diarrhea, All Grades","isatuximab-irfc + Carfilzomib + Dexamethasone, Vomiting, All Grades","isatuximab-irfc + Carfilzomib + Dexamethasone, Fatigue, All Grades","isatuximab-irfc + Carfilzomib + Dexamethasone, Infusion-related reaction, Grade 3","isatuximab-irfc + Carfilzomib + Dexamethasone, Upper respiratory tract infection, Grade 3","isatuximab-irfc + Carfilzomib + Dexamethasone, Pneumonia, Grade 3","isatuximab-irfc + Carfilzomib + Dexamethasone, Bronchitis, Grade 3","isatuximab-irfc + Carfilzomib + Dexamethasone, Hypertension, Grade 3","isatuximab-irfc + Carfilzomib + Dexamethasone, Dyspnea, Grade 3","isatuximab-irfc + Carfilzomib + Dexamethasone, Diarrhea, Grade 3","isatuximab-irfc + Carfilzomib + Dexamethasone, Vomiting, Grade 3","isatuximab-irfc + Carfilzomib + Dexamethasone, Fatigue, Grade 3","isatuximab-irfc + Carfilzomib + Dexamethasone, Pneumonia, Grade 4","tivozanib, Fatigue, All Grades","tivozanib, Hypertension, All Grades","tivozanib, Bleeding, All Grades","tivozanib, Nausea, All Grades","tivozanib, Vomiting, All Grades","tivozanib, Decreased appetite, All Grades","tivozanib, Dysphonia, All Grades","tivozanib, Cough, All Grades","tivozanib, Dyspnea, All Grades","tivozanib, Hypothyroidism, All Grades","tivozanib, Back pain, All Grades","tivozanib, Fatigue, Grade 3-4","tivozanib, Hypertension, Grade 3-4","tivozanib, Bleeding, Grade 3-4","tivozanib, Decreased appetite, Grade 3-4","tivozanib, Dysphonia, Grade 3-4","tivozanib, Dyspnea, Grade 3-4","tivozanib, Hypothyroidism, Grade 3-4","lorlatinib, Mood effects, All Grades","lorlatinib, Peripheral neuropathy, All Grades","lorlatinib, Cognitive effects, All Grades","lorlatinib, Sleep effects, All Grades","lorlatinib, Dyspnea, All Grades","lorlatinib, Respiratory failure, All Grades","lorlatinib, Hypertension, All Grades","lorlatinib, Arthralgia, All Grades","lorlatinib, Myalgia, All Grades","lorlatinib, Back pain, All Grades","lorlatinib, Pain in extremity, All Grades","lorlatinib, Edema, All Grades","lorlatinib, Weight gain, All Grades","lorlatinib, Pyrexia, All Grades","lorlatinib, Upper respiratory tract infection, All Grades","lorlatinib, Bronchitis, All Grades","lorlatinib, Rash, All Grades","lorlatinib, Mood effects, Grade 3-4","lorlatinib, Peripheral neuropathy, Grade 3-4","lorlatinib, Cognitive effects, Grade 3-4","lorlatinib, Sleep effects, Grade 3-4","lorlatinib, Dyspnea, Grade 3-4","lorlatinib, Respiratory failure, Grade 3-4","lorlatinib, Hypertension, Grade 3-4","lorlatinib, Diarrhea, Grade 3-4","lorlatinib, Arthralgia, Grade 3-4","lorlatinib, Myalgia, Grade 3-4","lorlatinib, Back pain, Grade 3-4","lorlatinib, Edema, Grade 3-4","lorlatinib, Weight gain, Grade 3-4","lorlatinib, Chest pain, Grade 3-4","lorlatinib, Bronchitis, Grade 3-4","cemiplimab-rwlc, Rash, All Grades","cemiplimab-rwlc, Cough, All Grades","cemiplimab-rwlc, Rash, Grade 3-4","cemiplimab-rwlc, Decreased appetite, Grade 3-4","nivolumab + cabozantinib, Diarrhea, Grades 1-4","nivolumab + cabozantinib, Abdominal pain, Grades 1-4","nivolumab + cabozantinib, Fatigue, Grades 1-4","nivolumab + cabozantinib, Hepatotoxicity, Grades 1-4","nivolumab + cabozantinib, Rash, Grades 1-4","nivolumab + cabozantinib, Pruritus, Grades 1-4","nivolumab + cabozantinib, Hypothyroidism, Grades 1-4","nivolumab + cabozantinib, Musculoskeletal pain, Grades 1-4","nivolumab + cabozantinib, Arthralgia, Grades 1-4","nivolumab + cabozantinib, Decreased appetite, Grades 1-4","nivolumab + cabozantinib, Dysgeusia, Grades 1-4","nivolumab + cabozantinib, Headache, Grades 1-4","nivolumab + cabozantinib, Cough, Grades 1-4","nivolumab + cabozantinib, Dysphonia , Grades 1-4","nivolumab + cabozantinib, Upper respiratory tract infection, Grades 1-4","nivolumab + cabozantinib, Diarrhea, Grade 3-4","nivolumab + cabozantinib, Nausea, Grade 3-4","nivolumab + cabozantinib, Abdominal pain, Grade 3-4","nivolumab + cabozantinib, Vomiting, Grade 3-4","nivolumab + cabozantinib, Hepatotoxicity, Grade 3-4","nivolumab + cabozantinib, Rash, Grade 3-4","nivolumab + cabozantinib, Pruritus, Grade 3-4","nivolumab + cabozantinib, Musculoskeletal pain, Grade 3-4","nivolumab + cabozantinib, Decreased appetite, Grade 3-4","nivolumab + cabozantinib, Cough, Grade 3-4","nivolumab + cabozantinib, Dysphonia , Grade 3-4","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Upper respiratory tract infection, All Grades","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Pneumoma, All Grades","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Diarrhea, All Grades","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Constipation, All Grades","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Peripheral sensory neuropathy, All Grades","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Dyspnea, All Grades","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Cough, All Grades","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Back pain, All Grades","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Arthralgia, All Grades","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Muscle spasms, All Grades","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Arrhythmia, All Grades","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Injection site reactions, All Grades","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Pneumoma, Grade 3-4","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Diarrhea, Grade 3-4","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Constipation, Grade 3-4","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Peripheral sensory neuropathy, Grade 3-4","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Cough, Grade 3-4","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Back pain, Grade 3-4","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Muscle spasms, Grade 3-4","D-VCd (daratumumab + hyaluronidase + bortezomib + cyclophosphamide + dexamethasone), Arrhythmia, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Nausea, All Grades","fam-trastuzumab deruxtecan-nxki, Vomiting, All Grades","fam-trastuzumab deruxtecan-nxki, Constipation, All Grades","fam-trastuzumab deruxtecan-nxki, Stomatitis, All Grades","fam-trastuzumab deruxtecan-nxki, Decreased appetite, All Grades","fam-trastuzumab deruxtecan-nxki, Dehydration, All Grades","fam-trastuzumab deruxtecan-nxki, Anemiac, All Grades","fam-trastuzumab deruxtecan-nxki, Febrile neutropenia, All Grades","fam-trastuzumab deruxtecan-nxki, Fatigued, All Grades","fam-trastuzumab deruxtecan-nxki, Pyrexia, All Grades","fam-trastuzumab deruxtecan-nxki, Edema peripheral, All Grades","fam-trastuzumab deruxtecan-nxki, Alopecia, All Grades","fam-trastuzumab deruxtecan-nxki, Interstitial lung disease, All Grades","fam-trastuzumab deruxtecan-nxki, Hepatic function abnormal, All Grades","fam-trastuzumab deruxtecan-nxki, Nausea, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Diarrhea, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Stomatitis, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Decreased appetite, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Dehydration, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Anemiac, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Febrile neutropenia, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Fatigued, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Interstitial lung disease, Grade 3-4","fam-trastuzumab deruxtecan-nxki, Hepatic function abnormal, Grade 3-4","relugolix, Hot flush, All Grades","relugolix, Musculoskeletal pain, All Grades","relugolix, Fatigue, All Grades","relugolix, Diarrhea, All Grades","relugolix, Constipation, All Grades","relugolix, Hot flush, Grade 3-4","relugolix, Fatigue, Grade 3-4","relugolix, Diarrhea, Grade 3-4","selinexor + bortezomib + dexamethasone, Nausea, All Grades","selinexor + bortezomib + dexamethasone, Diarrhea, All Grades","selinexor + bortezomib + dexamethasone, Vomiting, All Grades","selinexor + bortezomib + dexamethasone, Fatigue, All Grades","selinexor + bortezomib + dexamethasone, Pyrexia, All Grades","selinexor + bortezomib + dexamethasone, Appetite decrease, All Grades","selinexor + bortezomib + dexamethasone, Weight decrease, All Grades","selinexor + bortezomib + dexamethasone, Dizziness, All Grades","selinexor + bortezomib + dexamethasone, Upper respiratory tract infection, All Grades","selinexor + bortezomib + dexamethasone, Cataract, All Grades","selinexor + bortezomib + dexamethasone, Vision blurred, All Grades","selinexor + bortezomib + dexamethasone, Nausea, Grade 3-4","selinexor + bortezomib + dexamethasone, Diarrhea, Grade 3-4","selinexor + bortezomib + dexamethasone, Vomiting, Grade 3-4","selinexor + bortezomib + dexamethasone, Fatigue, Grade 3-4","selinexor + bortezomib + dexamethasone, Pyrexia, Grade 3-4","selinexor + bortezomib + dexamethasone, Appetite decrease, Grade 3-4","selinexor + bortezomib + dexamethasone, Weight decrease, Grade 3-4","selinexor + bortezomib + dexamethasone, Dizziness, Grade 3-4","selinexor + bortezomib + dexamethasone, Upper respiratory tract infection, Grade 3-4","selinexor + bortezomib + dexamethasone, Cataract, Grade 3-4","selinexor + bortezomib + dexamethasone, Vision blurred, Grade 3-4","margetuximab + chemotherapy, Fatigue/Asthenia, All Grades","margetuximab + chemotherapy, Pyrexia, All Grades","margetuximab + chemotherapy, Nausea, All Grades","margetuximab + chemotherapy, Vomiting, All Grades","margetuximab + chemotherapy, Constipation, All Grades","margetuximab + chemotherapy, Alopecia, All Grades","margetuximab + chemotherapy, Headache, All Grades","margetuximab + chemotherapy, Peripheral neuropathy, All Grades","margetuximab + chemotherapy, Cough, All Grades","margetuximab + chemotherapy, Dyspnea, All Grades","margetuximab + chemotherapy, Arthralgia/Myalgia, All Grades","margetuximab + chemotherapy, Extremity pain, All Grades","margetuximab + chemotherapy, Infusion-related reaction, All Grades","margetuximab + chemotherapy, Fatigue/Asthenia, Grade 3-4","margetuximab + chemotherapy, Nausea, Grade 3-4","margetuximab + chemotherapy, Cough, Grade 3-4","margetuximab + chemotherapy, Extremity pain, Grade 3-4","margetuximab + chemotherapy, Infusion-related reaction, Grade 3-4","pembrolizumab, Upper respiratory tract infection, All Grades","pembrolizumab, Urinary tract infection, All Grades","pembrolizumab, Musculoskeletal pain, All Grades","pembrolizumab, Diarrhea, All Grades","pembrolizumab, pyrexia, All Grades","pembrolizumab, Rash, All Grades","pembrolizumab, Pruritus, All Grades","pembrolizumab, Cough, All Grades","pembrolizumab, Pneumonitis, All Grades","pembrolizumab, Dyspnea, All Grades","pembrolizumab, Hypothyroidism, All Grades","pembrolizumab, Upper respiratory tract infection, Grade 3-4","pembrolizumab, Diarrhea, Grade 3-4","pembrolizumab, Vomiting, Grade 3-4","pembrolizumab, Pneumonitis, Grade 3-4","nivolumab + ipilimumab, Pyrexia, All Grades","nivolumab + ipilimumab, Edema, All Grades","nivolumab + ipilimumab, Musculoskeletal pain, All Grades","nivolumab + ipilimumab, Arthralgia, All Grades","nivolumab + ipilimumab, Rash, All Grades","nivolumab + ipilimumab, Pruritus, All Grades","nivolumab + ipilimumab, Diarrhea, All Grades","nivolumab + ipilimumab, Abdominal pain, All Grades","nivolumab + ipilimumab, Dyspnea, All Grades","nivolumab + ipilimumab, Cough, All Grades","nivolumab + ipilimumab, Hypothyroidism, All Grades","nivolumab + ipilimumab, Upper respiratory tract infection, All Grades","nivolumab + ipilimumab, Pneumonia, All Grades","nivolumab + ipilimumab, Pyrexia, Grade 3-4","nivolumab + ipilimumab, Musculoskeletal pain, Grade 3-4","nivolumab + ipilimumab, Arthralgia, Grade 3-4","nivolumab + ipilimumab, Rash, Grade 3-4","nivolumab + ipilimumab, Pruritus, Grade 3-4","nivolumab + ipilimumab, Diarrhea, Grade 3-4","nivolumab + ipilimumab, Abdominal pain, Grade 3-4","nivolumab + ipilimumab, Cough, Grade 3-4","nivolumab + ipilimumab, Upper respiratory tract infection, Grade 3-4","nivolumab + ipilimumab, Pneumonia, Grade 3-4","carfilzomib + daratumumab + dexamethasone, Infusion-related reactions, All Grades","carfilzomib + daratumumab + dexamethasone, Fatigue, All Grades","carfilzomib + daratumumab + dexamethasone, Pyrexia, All Grades","carfilzomib + daratumumab + dexamethasone, Respiratory tract infection, All Grades","carfilzomib + daratumumab + dexamethasone, Pneumonia, All Grades","carfilzomib + daratumumab + dexamethasone, Bronchitis, All Grades","carfilzomib + daratumumab + dexamethasone, Thrombocytopenia, All Grades","carfilzomib + daratumumab + dexamethasone, Anemiae, All Grades","carfilzomib + daratumumab + dexamethasone, Diarrhea, All Grades","carfilzomib + daratumumab + dexamethasone, Nausea, All Grades","carfilzomib + daratumumab + dexamethasone, HHypertension, All Grades","carfilzomib + daratumumab + dexamethasone, Insomnia, All Grades","carfilzomib + daratumumab + dexamethasone, Back pain, All Grades","carfilzomib + daratumumab + dexamethasone, Infusion-related reactions, Grade 3-4","carfilzomib + daratumumab + dexamethasone, Fatigue, Grade 3-4","carfilzomib + daratumumab + dexamethasone, Pyrexia, Grade 3-4","carfilzomib + daratumumab + dexamethasone, Respiratory tract infection, Grade 3-4","carfilzomib + daratumumab + dexamethasone, Pneumonia, Grade 3-4","carfilzomib + daratumumab + dexamethasone, Bronchitis, Grade 3-4","carfilzomib + daratumumab + dexamethasone, Thrombocytopenia, Grade 3-4","carfilzomib + daratumumab + dexamethasone, Anemiae, Grade 3-4","carfilzomib + daratumumab + dexamethasone, Diarrhea, Grade 3-4","carfilzomib + daratumumab + dexamethasone, HHypertension, Grade 3-4","carfilzomib + daratumumab + dexamethasone, Dyspnea, Grade 3-4","carfilzomib + daratumumab + dexamethasone, Insomnia, Grade 3-4","carfilzomib + daratumumab + dexamethasone, Back pain, Grade 3-4","avelumab, Fatigue, All Grades","avelumab, Pyrexia, All Grades","avelumab, Musculoskeletal pain, All Grades","avelumab, Arthralgia, All Grades","avelumab, Rash, All Grades","avelumab, Pruritus, All Grades","avelumab, Urinary tract infection, All Grades","avelumab, Diarrhea, All Grades","avelumab, Constipation, All Grades","avelumab, Nausea, All Grades","avelumab, Vomiting, All Grades","avelumab, Cough, All Grades","avelumab, Decreased appetite, All Grades","avelumab, Hypothyroidism, All Grades","avelumab, Infusion-related reaction , All Grades","avelumab, Pyrexia, Grade 3-4","avelumab, Arthralgia, Grade 3-4","avelumab, Rash, Grade 3-4","avelumab, Pruritus, Grade 3-4","avelumab, Urinary tract infection, Grade 3-4","avelumab, Diarrhea, Grade 3-4","avelumab, Constipation, Grade 3-4","avelumab, Vomiting, Grade 3-4","avelumab, Cough, Grade 3-4","avelumab, Hypothyroidism, Grade 3-4","avelumab, Infusion-related reaction , Grade 3-4","nivolumab, Pruritus, All Grades","nivolumab, Diarrhea, All Grades","nivolumab, Upper respiratory tract infection, All Grades","nivolumab, Cough, All Grades","nivolumab, Hypothyroidism, All Grades","nivolumab, Rash, Grade 3-4","nivolumab, Diarrhea, Grade 3-4","nivolumab, Upper respiratory tract infection, Grade 3-4","atezolizumab + bevacizumab, Hypertension, All Grades","atezolizumab + bevacizumab, Pyrexia, All Grades","atezolizumab + bevacizumab, Proteinuria, All Grades","atezolizumab + bevacizumab, Weight Decreased, All Grades","atezolizumab + bevacizumab, Pruritus, All Grades","atezolizumab + bevacizumab, Vomiting, All Grades","atezolizumab + bevacizumab, Cough, All Grades","atezolizumab + bevacizumab, Epistaxis, All Grades","atezolizumab + bevacizumab, Infusion Related Reaction, All Grades","atezolizumab + bevacizumab, Hypertension, Grade 3-4","atezolizumab + bevacizumab, Proteinuria, Grade 3-4","atezolizumab + bevacizumab, Infusion Related Reaction, Grade 3-4","nivolumab + ipilimumab + chemotherapy, Fatigue, All Grades","nivolumab + ipilimumab + chemotherapy, Pyrexia, All Grades","nivolumab + ipilimumab + chemotherapy, Musculoskeletal pain, All Grades","nivolumab + ipilimumab + chemotherapy, Diarrhea, All Grades","nivolumab + ipilimumab + chemotherapy, Vomiting, All Grades","nivolumab + ipilimumab + chemotherapy, Abdominal pain, All Grades","nivolumab + ipilimumab + chemotherapy, Rash, All Grades","nivolumab + ipilimumab + chemotherapy, Pruritus, All Grades","nivolumab + ipilimumab + chemotherapy, Alopecia, All Grades","nivolumab + ipilimumab + chemotherapy, Decreased appetite, All Grades","nivolumab + ipilimumab + chemotherapy, Cough, All Grades","nivolumab + ipilimumab + chemotherapy, Dyspnea, All Grades","nivolumab + ipilimumab + chemotherapy, Hypothyroidism, All Grades","nivolumab + ipilimumab + chemotherapy, Headache, All Grades","nivolumab + ipilimumab + chemotherapy, Dizziness, All Grades","nivolumab + ipilimumab + chemotherapy, Fatigue, Grade 3-4","nivolumab + ipilimumab + chemotherapy, Musculoskeletal pain, Grade 3-4","nivolumab + ipilimumab + chemotherapy, Nausea, Grade 3-4","nivolumab + ipilimumab + chemotherapy, Diarrhea, Grade 3-4","nivolumab + ipilimumab + chemotherapy, Vomiting, Grade 3-4","nivolumab + ipilimumab + chemotherapy, Rash, Grade 3-4","nivolumab + ipilimumab + chemotherapy, Pruritus, Grade 3-4","nivolumab + ipilimumab + chemotherapy, Alopecia, Grade 3-4","nivolumab + ipilimumab + chemotherapy, Decreased appetite, Grade 3-4","nivolumab + ipilimumab + chemotherapy, Dyspnea, Grade 3-4","nivolumab + ipilimumab + chemotherapy, Hypothyroidism, Grade 3-4","nivolumab + ipilimumab + chemotherapy, Headache, Grade 3-4","nivolumab + ipilimumab + chemotherapy, Dizziness, Grade 3-4","brigatinib, Stomatitis, All Grades","brigatinib, Rash, All Grades","brigatinib, Pruritus, All Grades","brigatinib, Cough, All Grades","brigatinib, Dyspnea, All Grades","brigatinib, ILD/Pneumonitis, All Grades","brigatinib, Hypertension, All Grades","brigatinib, Myalgia, All Grades","brigatinib, Back pain, All Grades","brigatinib, Arthralgia, All Grades","brigatinib, Headache, All Grades","brigatinib, Increased Blood cholesterol, All Grades","brigatinib, Pneumonia, All Grades","brigatinib, Upper respiratory tract infection, All Grades","brigatinib, Stomatitis, Grade 3-4","brigatinib, Rash, Grade 3-4","brigatinib, ILD/Pneumonitis, Grade 3-4","brigatinib, Hypertension, Grade 3-4","brigatinib, Pyrexia, Grade 3-4","brigatinib, Headache, Grade 3-4","brigatinib, Peripheral neuropathy, Grade 3-4","brigatinib, Bradycardia, Grade 3-4","brigatinib, Pneumonia, Grade 3-4","olaparib, Anemia, Grades 1-4 ","olaparib, Thrombocytopenia, Grades 1-4 ","olaparib, Nausea, Grades 1-4 ","olaparib, Diarrhea, Grades 1-4 ","olaparib, Vomiting, Grades 1-4 ","olaparib, Fatigue (including asthenia), Grades 1-4 ","olaparib, Decreased appetite, Grades 1-4 ","olaparib, Cough, Grades 1-4 ","olaparib, Dyspnea, Grades 1-4 ","olaparib, Anemia, Grade 3-4","olaparib, Thrombocytopenia, Grade 3-4","olaparib, Nausea, Grade 3-4","olaparib, Diarrhea, Grade 3-4","olaparib, Vomiting, Grade 3-4","olaparib, Dyspnea, Grade 3-4","atezolizumab, Pyrexia, All Grades","atezolizumab, Dyspnea, All Grades","atezolizumab, Cough, All Grades","atezolizumab, Constipation, Grade 3-4","atezolizumab, Decreased appetite, Grade 3-4","atezolizumab, Dyspnea, Grade 3-4","atezolizumab, Cough, Grade 3-4","nivolumab + ipilimumab, Fatigue, All Grades","nivolumab + ipilimumab, Pyrexia, All Grades","nivolumab + ipilimumab, Edema, All Grades","nivolumab + ipilimumab, Rash, All Grades","nivolumab + ipilimumab, Pruritus, All Grades","nivolumab + ipilimumab, Decreased appetite, All Grades","nivolumab + ipilimumab, Musculoskeletal pain, All Grades","nivolumab + ipilimumab, Arthralgia, All Grades","nivolumab + ipilimumab, Diarrhea/colitis, All Grades","nivolumab + ipilimumab, Abdominal pain, All Grades","nivolumab + ipilimumab, Dyspnea, All Grades","nivolumab + ipilimumab, Cough, All Grades","nivolumab + ipilimumab, Hepatitis, All Grades","nivolumab + ipilimumab, Hypothyroidism, All Grades","nivolumab + ipilimumab, Hyperthyroidism, All Grades","nivolumab + ipilimumab, Pneumonia, All Grades","nivolumab + ipilimumab, Headache, All Grades","nivolumab + ipilimumab, Fatigue, Grade 3-4","nivolumab + ipilimumab, Pyrexia, Grade 3-4","nivolumab + ipilimumab, Rash, Grade 3-4","nivolumab + ipilimumab, Pruritus, Grade 3-4","nivolumab + ipilimumab, Decreased appetite, Grade 3-4","nivolumab + ipilimumab, Musculoskeletal pain, Grade 3-4","nivolumab + ipilimumab, Arthralgia, Grade 3-4","nivolumab + ipilimumab, Diarrhea/colitis, Grade 3-4","nivolumab + ipilimumab, Dyspnea, Grade 3-4","nivolumab + ipilimumab, Cough, Grade 3-4","nivolumab + ipilimumab, Hepatitis, Grade 3-4","nivolumab + ipilimumab, Hypothyroidism, Grade 3-4","nivolumab + ipilimumab, Pneumonia, Grade 3-4","nivolumab + ipilimumab, Headache, Grade 3-4","ibrutinib + rituximab, Fatigue, All Grades","ibrutinib + rituximab, Peripheral edema, All Grades","ibrutinib + rituximab, Pain, All Grades","ibrutinib + rituximab, Musculoskeletal pain, All Grades","ibrutinib + rituximab, Arthralgia, All Grades","ibrutinib + rituximab, Diarrhea, All Grades","ibrutinib + rituximab, Stomatitis, All Grades","ibrutinib + rituximab, Abdominal pain, All Grades","ibrutinib + rituximab, Rash, All Grades","ibrutinib + rituximab, Bruising, All Grades","ibrutinib + rituximab, Hypertension, All Grades","ibrutinib + rituximab, Hemorrhage, All Grades","ibrutinib + rituximab, Headache, All Grades","ibrutinib + rituximab, Dizziness, All Grades","ibrutinib + rituximab, Peripheral neuropathy, All Grades","ibrutinib + rituximab, Cough, All Grades","ibrutinib + rituximab, Dyspnea, All Grades","ibrutinib + rituximab, Upper respiratory tract infection, All Grades","ibrutinib + rituximab, Skin infection, All Grades","ibrutinib + rituximab, Hyperuricemia, All Grades","encorafenib + cetuximab, Fatigue, All Grades","encorafenib + cetuximab, Pyrexia, All Grades","encorafenib + cetuximab, Arthralgia, All Grades","encorafenib + cetuximab, Myopathy, All Grades","encorafenib + cetuximab, Pain in extremity, All Grades","encorafenib + cetuximab, Pruritus, All Grades","encorafenib + cetuximab, Melanocytic nevus, All Grades","encorafenib + cetuximab, Dry skin, All Grades","encorafenib + cetuximab, Headache, All Grades","encorafenib + cetuximab, Peripheral neuropathy, All Grades","encorafenib + cetuximab, Hemorrhage, All Grades","encorafenib + cetuximab, Insomnia, All Grades","encorafenib + cetuximab, Arthralgia, Grade ≥ 3","encorafenib + cetuximab, Myopathy, Grade ≥ 3","encorafenib + cetuximab, Peripheral neuropathy, Grade ≥ 3","encorafenib + cetuximab, Hemorrhage, Grade ≥ 3","durvalumab + Etoposide + either Carboplatin or Cisplatin , Cough/Productive Cough, All Grades","durvalumab + Etoposide + either Carboplatin or Cisplatin , Hyperthyroidisma, All Grades","durvalumab + Etoposide + either Carboplatin or Cisplatin , Rash, All Grades","durvalumab + Etoposide + either Carboplatin or Cisplatin , Decreased appetite, All Grades","durvalumab + Etoposide + either Carboplatin or Cisplatin , Cough/Productive Cough, Grade 3-4","durvalumab + Etoposide + either Carboplatin or Cisplatin , Constipation, Grade 3-4","durvalumab + Etoposide + either Carboplatin or Cisplatin , Alopecia, Grade 3-4","durvalumab + Etoposide + either Carboplatin or Cisplatin , Fatigue/Asthenia, Grade 3-4","isatuximab-irfc, Infusion-related reaction, All grades","isatuximab-irfc, Pneumonia, All grades","isatuximab-irfc, Upper respiratory tract infection, All grades","isatuximab-irfc, Febrile neutropenia, All grades","isatuximab-irfc, Dyspnea, All grades","isatuximab-irfc, Diarrhea, All grades","isatuximab-irfc, Nausea, All grades","isatuximab-irfc, Vomiting, All grades","isatuximab-irfc, Infusion-related reaction, Grade 3","isatuximab-irfc, Pneumonia, Grade 3","isatuximab-irfc, Upper respiratory tract infection, Grade 3","isatuximab-irfc, Febrile neutropenia, Grade 3","isatuximab-irfc, Dyspnea, Grade 3","isatuximab-irfc, Diarrhea, Grade 3","isatuximab-irfc, Vomiting, Grade 3","isatuximab-irfc, Infusion-related reaction, Grade 4","isatuximab-irfc, Pneumonia, Grade 4","isatuximab-irfc, Febrile neutropenia, Grade 4","neratinib +  Capecitabine, Diarrhea, All Grades","neratinib +  Capecitabine, Nausea, All Grades","neratinib +  Capecitabine, Vomiting, All Grades","neratinib +  Capecitabine, Constipation, All Grades","neratinib +  Capecitabine, Abdominal distension, All Grades","neratinib +  Capecitabine, Fatigue/asthenia, All Grades","neratinib +  Capecitabine, Malaise, All Grades","neratinib +  Capecitabine, Influenza like illness, All Grades","neratinib +  Capecitabine, Urinary tract infection, All Grades","neratinib +  Capecitabine, Upper respiratory tract infection, All Grades","neratinib +  Capecitabine, Decreased appetite, All Grades","neratinib +  Capecitabine, Back Pain, All Grades","neratinib +  Capecitabine, Arthralgia, All Grades","neratinib +  Capecitabine, Muscle spasms, All Grades","neratinib +  Capecitabine, Dizziness, All Grades","neratinib +  Capecitabine, Renal impairment, All Grades","neratinib +  Capecitabine, Dysuria, All Grades","neratinib +  Capecitabine, Diarrhea, Grade 3","neratinib +  Capecitabine, Nausea, Grade 3","neratinib +  Capecitabine, Vomiting, Grade 3","neratinib +  Capecitabine, Constipation, Grade 3","neratinib +  Capecitabine, Fatigue/asthenia, Grade 3","neratinib +  Capecitabine, Urinary tract infection, Grade 3","neratinib +  Capecitabine, Decreased appetite, Grade 3","neratinib +  Capecitabine, Renal impairment, Grade 3","pembrolizumab, Pruritus, Grade 1–2","pembrolizumab, Hypothyroidism, Grade 1–2","pembrolizumab, Arthralgia, Grade 1–2","pembrolizumab, Diarrhoea, Grade 1–2","pembrolizumab, Fatigue, Grade 1–2","pembrolizumab, Hyperthyroidism, Grade 1–2","pembrolizumab, Nausea, Grade 1–2","pembrolizumab, Nasopharyngitis, Grade 1–2","pembrolizumab, Rash, Grade 1–2","pembrolizumab, Increased alanine aminotransferase, Grade 1–2","pembrolizumab, Asthenia, Grade 1–2","pembrolizumab, Maculopapular rash, Grade 1–2","pembrolizumab, Increased aspartate aminotransferase, Grade 1–2","pembrolizumab, Decreased appetite, Grade 1–2","pembrolizumab, Decreased bodyweight, Grade 1–2","pembrolizumab, Increased blood creatinine, Grade 1–2","pembrolizumab, Myalgia, Grade 1–2","pembrolizumab, Productive cough, Grade 1–2","pembrolizumab, Pneumonitis, Grade 1–2","pembrolizumab, Dry skin, Grade 1–2","pembrolizumab, Hypothyroidism, Grade 3","pembrolizumab, Cough, Grade 3","pembrolizumab, Hyperthyroidism, Grade 3","pembrolizumab, Nausea, Grade 3","pembrolizumab, Rash, Grade 3","pembrolizumab, Back pain, Grade 3","pembrolizumab, Maculopapular rash, Grade 3","pembrolizumab, Myalgia, Grade 3","pembrolizumab, Pneumonitis, Grade 4"],"type":"scatter","mode":"markers","marker":{"autocolorscale":false,"color":"rgba(228,146,115,1)","opacity":0.55,"size":5.66929133858268,"symbol":"circle","line":{"width":1.88976377952756,"color":"rgba(228,146,115,1)"}},"hoveron":"points","name":"experi","legendgroup":"experi","showlegend":true,"xaxis":"x","yaxis":"y","hoverinfo":"text","_isNestedKey":false,"frame":null},{"x":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],"y":[0.22,0.2,0.11,0.22,0.15,0.12,0.1,0.17,0.28,0.23,0.07,0.028,0.08,0.31,0.17,0,0.13,0.14,0.14,0.12,0.14,0.006,0.003,0.006,0.019,0.016,0.05,0.009,0.04,0.025,0.009,0,0,0,0.031,0.009,0,0.003,0.08,0,0.019,0.006,null,null],"text":["Control:    NA<br />Experimental: 0.220<br />greater: NA<br />event: nivolumab + ipilimumab, Nausea, All grades","Control:    NA<br />Experimental: 0.200<br />greater: NA<br />event: nivolumab + ipilimumab, Constipation, All grades","Control:    NA<br />Experimental: 0.110<br />greater: NA<br />event: nivolumab + ipilimumab, Stomatitis, All grades","Control:    NA<br />Experimental: 0.220<br />greater: NA<br />event: nivolumab + ipilimumab, Diarrhea, All grades","Control:    NA<br />Experimental: 0.150<br />greater: NA<br />event: nivolumab + ipilimumab, Vomiting, All grades","Control:    NA<br />Experimental: 0.120<br />greater: NA<br />event: nivolumab + ipilimumab, Dysphagia, All grades","Control:    NA<br />Experimental: 0.100<br />greater: NA<br />event: nivolumab + ipilimumab, Abdominal pain, All grades","Control:    NA<br />Experimental: 0.170<br />greater: NA<br />event: nivolumab + ipilimumab, Decreased appetite, All grades","Control:    NA<br />Experimental: 0.280<br />greater: NA<br />event: nivolumab + ipilimumab, Fatigue, All grades","Control:    NA<br />Experimental: 0.230<br />greater: NA<br />event: nivolumab + ipilimumab, Pyrexiad, All grades","Control:    NA<br />Experimental: 0.070<br />greater: NA<br />event: nivolumab + ipilimumab, Edemae, All grades","Control:    NA<br />Experimental: 0.028<br />greater: NA<br />event: nivolumab + ipilimumab, Peripheral neuropathy, All grades","Control:    NA<br />Experimental: 0.080<br />greater: NA<br />event: nivolumab + ipilimumab, Insomnia, All grades","Control:    NA<br />Experimental: 0.310<br />greater: NA<br />event: nivolumab + ipilimumab, Rash, All grades","Control:    NA<br />Experimental: 0.170<br />greater: NA<br />event: nivolumab + ipilimumab, Pruritus, All grades","Control:    NA<br />Experimental: 0.000<br />greater: NA<br />event: nivolumab + ipilimumab, Alopecia, All grades","Control:    NA<br />Experimental: 0.130<br />greater: NA<br />event: nivolumab + ipilimumab, Cough, All grades","Control:    NA<br />Experimental: 0.140<br />greater: NA<br />event: nivolumab + ipilimumab, Pneumonial, All grades","Control:    NA<br />Experimental: 0.140<br />greater: NA<br />event: nivolumab + ipilimumab, Hypothyroidism, All grades","Control:    NA<br />Experimental: 0.120<br />greater: NA<br />event: nivolumab + ipilimumab, Weight decreased, All grades","Control:    NA<br />Experimental: 0.140<br />greater: NA<br />event: nivolumab + ipilimumab, Musculoskeletal pain, All grades","Control:    NA<br />Experimental: 0.006<br />greater: NA<br />event: nivolumab + ipilimumab, Nausea, Grade 3-4","Control:    NA<br />Experimental: 0.003<br />greater: NA<br />event: nivolumab + ipilimumab, Constipation, Grade 3-4","Control:    NA<br />Experimental: 0.006<br />greater: NA<br />event: nivolumab + ipilimumab, Stomatitis, Grade 3-4","Control:    NA<br />Experimental: 0.019<br />greater: NA<br />event: nivolumab + ipilimumab, Diarrhea, Grade 3-4","Control:    NA<br />Experimental: 0.016<br />greater: NA<br />event: nivolumab + ipilimumab, Vomiting, Grade 3-4","Control:    NA<br />Experimental: 0.050<br />greater: NA<br />event: nivolumab + ipilimumab, Dysphagia, Grade 3-4","Control:    NA<br />Experimental: 0.009<br />greater: NA<br />event: nivolumab + ipilimumab, Abdominal pain, Grade 3-4","Control:    NA<br />Experimental: 0.040<br />greater: NA<br />event: nivolumab + ipilimumab, Decreased appetite, Grade 3-4","Control:    NA<br />Experimental: 0.025<br />greater: NA<br />event: nivolumab + ipilimumab, Fatigue, Grade 3-4","Control:    NA<br />Experimental: 0.009<br />greater: NA<br />event: nivolumab + ipilimumab, Pyrexiad, Grade 3-4","Control:    NA<br />Experimental: 0.000<br />greater: NA<br />event: nivolumab + ipilimumab, Edemae, Grade 3-4","Control:    NA<br />Experimental: 0.000<br />greater: NA<br />event: nivolumab + ipilimumab, Peripheral neuropathy, Grade 3-4","Control:    NA<br />Experimental: 0.000<br />greater: NA<br />event: nivolumab + ipilimumab, Insomnia, Grade 3-4","Control:    NA<br />Experimental: 0.031<br />greater: NA<br />event: nivolumab + ipilimumab, Rash, Grade 3-4","Control:    NA<br />Experimental: 0.009<br />greater: NA<br />event: nivolumab + ipilimumab, Pruritus, Grade 3-4","Control:    NA<br />Experimental: 0.000<br />greater: NA<br />event: nivolumab + ipilimumab, Alopecia, Grade 3-4","Control:    NA<br />Experimental: 0.003<br />greater: NA<br />event: nivolumab + ipilimumab, Cough, Grade 3-4","Control:    NA<br />Experimental: 0.080<br />greater: NA<br />event: nivolumab + ipilimumab, Pneumonial, Grade 3-4","Control:    NA<br />Experimental: 0.000<br />greater: NA<br />event: nivolumab + ipilimumab, Hypothyroidism, Grade 3-4","Control:    NA<br />Experimental: 0.019<br />greater: NA<br />event: nivolumab + ipilimumab, Weight decreased, Grade 3-4","Control:    NA<br />Experimental: 0.006<br />greater: NA<br />event: nivolumab + ipilimumab, Musculoskeletal pain, Grade 3-4","Control:    NA<br />Experimental:    NA<br />greater: NA<br />event: tebentafusp-tebn, Skin Hypopigmentation, Grade 3-4","Control:    NA<br />Experimental:    NA<br />greater: NA<br />event: tebentafusp-tebn, Hair color changes, Grade 3-4"],"key":["nivolumab + ipilimumab, Nausea, All grades","nivolumab + ipilimumab, Constipation, All grades","nivolumab + ipilimumab, Stomatitis, All grades","nivolumab + ipilimumab, Diarrhea, All grades","nivolumab + ipilimumab, Vomiting, All grades","nivolumab + ipilimumab, Dysphagia, All grades","nivolumab + ipilimumab, Abdominal pain, All grades","nivolumab + ipilimumab, Decreased appetite, All grades","nivolumab + ipilimumab, Fatigue, All grades","nivolumab + ipilimumab, Pyrexiad, All grades","nivolumab + ipilimumab, Edemae, All grades","nivolumab + ipilimumab, Peripheral neuropathy, All grades","nivolumab + ipilimumab, Insomnia, All grades","nivolumab + ipilimumab, Rash, All grades","nivolumab + ipilimumab, Pruritus, All grades","nivolumab + ipilimumab, Alopecia, All grades","nivolumab + ipilimumab, Cough, All grades","nivolumab + ipilimumab, Pneumonial, All grades","nivolumab + ipilimumab, Hypothyroidism, All grades","nivolumab + ipilimumab, Weight decreased, All grades","nivolumab + ipilimumab, Musculoskeletal pain, All grades","nivolumab + ipilimumab, Nausea, Grade 3-4","nivolumab + ipilimumab, Constipation, Grade 3-4","nivolumab + ipilimumab, Stomatitis, Grade 3-4","nivolumab + ipilimumab, Diarrhea, Grade 3-4","nivolumab + ipilimumab, Vomiting, Grade 3-4","nivolumab + ipilimumab, Dysphagia, Grade 3-4","nivolumab + ipilimumab, Abdominal pain, Grade 3-4","nivolumab + ipilimumab, Decreased appetite, Grade 3-4","nivolumab + ipilimumab, Fatigue, Grade 3-4","nivolumab + ipilimumab, Pyrexiad, Grade 3-4","nivolumab + ipilimumab, Edemae, Grade 3-4","nivolumab + ipilimumab, Peripheral neuropathy, Grade 3-4","nivolumab + ipilimumab, Insomnia, Grade 3-4","nivolumab + ipilimumab, Rash, Grade 3-4","nivolumab + ipilimumab, Pruritus, Grade 3-4","nivolumab + ipilimumab, Alopecia, Grade 3-4","nivolumab + ipilimumab, Cough, Grade 3-4","nivolumab + ipilimumab, Pneumonial, Grade 3-4","nivolumab + ipilimumab, Hypothyroidism, Grade 3-4","nivolumab + ipilimumab, Weight decreased, Grade 3-4","nivolumab + ipilimumab, Musculoskeletal pain, Grade 3-4","tebentafusp-tebn, Skin Hypopigmentation, Grade 3-4","tebentafusp-tebn, Hair color changes, Grade 3-4"],"type":"scatter","mode":"markers","marker":{"autocolorscale":false,"color":"rgba(127,127,127,1)","opacity":0.55,"size":5.66929133858268,"symbol":"circle","line":{"width":1.88976377952756,"color":"rgba(127,127,127,1)"}},"hoveron":"points","name":"NA","legendgroup":"NA","showlegend":true,"xaxis":"x","yaxis":"y","hoverinfo":"text","_isNestedKey":false,"frame":null}],"layout":{"margin":{"t":43.7625570776256,"r":7.30593607305936,"b":40.1826484018265,"l":48.9497716894977},"font":{"color":"rgba(0,0,0,1)","family":"Roboto Condensed","size":14.6118721461187},"title":{"text":"Adverse Events, all reported","font":{"color":"rgba(0,0,0,1)","family":"Roboto Condensed","size":17.5342465753425},"x":0,"xref":"paper"},"xaxis":{"domain":[0,1],"automargin":true,"type":"linear","autorange":false,"range":[-0.01,1.01],"tickmode":"array","ticktext":["0%","25%","50%","75%","100%"],"tickvals":[0,0.25,0.5,0.75,1],"categoryorder":"array","categoryarray":["0%","25%","50%","75%","100%"],"nticks":null,"ticks":"","tickcolor":null,"ticklen":3.65296803652968,"tickwidth":0,"showticklabels":true,"tickfont":{"color":"rgba(77,77,77,1)","family":"Roboto Condensed","size":11.689497716895},"tickangle":-0,"showline":false,"linecolor":null,"linewidth":0,"showgrid":true,"gridcolor":"rgba(235,235,235,1)","gridwidth":0.66417600664176,"zeroline":false,"anchor":"y","title":{"text":"Control","font":{"color":"rgba(0,0,0,1)","family":"Roboto Condensed","size":14.6118721461187}},"hoverformat":".2f"},"yaxis":{"domain":[0,1],"automargin":true,"type":"linear","autorange":false,"range":[-0.01,1.01],"tickmode":"array","ticktext":["0%","25%","50%","75%","100%"],"tickvals":[0,0.25,0.5,0.75,1],"categoryorder":"array","categoryarray":["0%","25%","50%","75%","100%"],"nticks":null,"ticks":"","tickcolor":null,"ticklen":3.65296803652968,"tickwidth":0,"showticklabels":true,"tickfont":{"color":"rgba(77,77,77,1)","family":"Roboto Condensed","size":11.689497716895},"tickangle":-0,"showline":false,"linecolor":null,"linewidth":0,"showgrid":true,"gridcolor":"rgba(235,235,235,1)","gridwidth":0.66417600664176,"zeroline":false,"anchor":"x","title":{"text":"Experimental","font":{"color":"rgba(0,0,0,1)","family":"Roboto Condensed","size":14.6118721461187}},"hoverformat":".2f"},"shapes":[{"type":"rect","fillcolor":null,"line":{"color":null,"width":0,"linetype":[]},"yref":"paper","xref":"paper","x0":0,"x1":1,"y0":0,"y1":1}],"showlegend":false,"legend":{"bgcolor":null,"bordercolor":null,"borderwidth":0,"font":{"color":"rgba(0,0,0,1)","family":"Roboto Condensed","size":11.689497716895}},"hovermode":"closest","barmode":"relative"},"config":{"doubleClick":"reset","modeBarButtonsToAdd":["hoverclosest","hovercompare"],"showSendToCloud":false},"source":"A","attrs":{"3da8da15af3":{"intercept":{},"slope":{},"type":"scatter"},"3da853bc5dac":{"x":{},"y":{},"colour":{},"key":{}}},"cur_data":"3da8da15af3","visdat":{"3da8da15af3":["function (y) ","x"],"3da853bc5dac":["function (y) ","x"]},"highlight":{"on":"plotly_click","persistent":false,"dynamic":false,"selectize":false,"opacityDim":0.2,"selected":{"opacity":1},"debounce":0},"shinyEvents":["plotly_hover","plotly_click","plotly_selected","plotly_relayout","plotly_brushed","plotly_brushing","plotly_clickannotation","plotly_doubleclick","plotly_deselect","plotly_afterplot","plotly_sunburstclick"],"base_url":"https://plot.ly"},"evals":[],"jsHooks":[]}</script>
</div>
</div>
<div class="cell">

</div>
</section>

</main>
<!-- /main column -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    target: function(trigger) {
      return trigger.previousElementSibling;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn) {
    const config = {
      allowHTML: true,
      content: contentFn,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start'
    };
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
</div> <!-- /content -->



</body></html>